The origin, versatility and distribution of azole fungicide resistance in the banana black Sigatoka pathogen *Pseudocercospora fijiensis*

Pablo A. Chong Aguirre

Thesis committee

Promotors Prof. Dr G.H.J Kema Professor of Tropical Phytopathology Wageningen University

Prof. Dr P.W. Crous Professor of Evolutionary Phytopathology CBS-KNAW Fungal Biodiversity Center, Utrecht

Other members

Dr J.J. Stoorvogel, Wageningen University

Prof. Dr B.J. Zwaan, Wageningen University

DrB.A. Fraaije, Rothamsted Research, Harpenden, United Kingdom

Prof. Dr C.M.J. Pieterse, Utrecht University

This research was conducted under the auspices of the Graduate School of Experimental Plant Sciences.

The origin, versatility and distribution of azole fungicide resistance in the banana black Sigatoka pathogen *Pseudocercospora fijiensis*

Pablo A. Chong Aguirre

Thesis

submitted in fulfilment of the requirements for the degree of doctor at Wageningen University by the authority of the Rector Magnificus Prof. Dr A.P.J. Mol, in the presence of the Thesis Committee appointed by the Academic Board to be defended in public on Monday 31 October 2016 at 4 p.m. in the Aula

Pablo A. Chong Aguirre The origin, versatility and distribution of azole fungicide resistance in the banana black Sigatoka pathogen *Pseudocercospora fijiensis* 290 pages.

PhD thesis, Wageningen University, Wageningen, NL (2016)

With references, with summaries in English, Spanish and Dutch

ISBN: 978-94-6257-879-1 DOI: 10.18174/387237

Contents

Chapter 1	General introduction and outline of the thesis						
Chapter 2	An historical treatise and critical review of black Sigatoka control in banana production						
Chapter 3	Global analysis of reduced sensitivity to azole fungicides in the banana black Sigatoka pathogen <i>Pseudocercospora fijiensis</i>						
Chapter 4	A new resistance mechanism to DMI fungicides in the fungal banana black Sigatoka pathogen <i>Pseudocercospora fijiensis</i> is driven by increased expression of <i>Pfcyp51</i> through multiple promoter repeats	178					
Chapter 5	Genetic mapping of resistance to 14α -demethylase inhibitor fungicides in the banana black Sigatoka pathogen <i>Pseudocercospora fijiensis</i> reveals <i>Pfcyp51</i> as a single explanatory factor	205					
Chapter 6	General discussion	251					
	References	265					
	Summary	275					
	Acknowledgments	284					
	About the author	287					
	List of publications	288					
	Experimental Plant Science (EPS) certificate	289					

Chapter 1

General introduction and outline of the thesis

Black Sigatoka disease of banana, caused by *Pseudocercospora fijiensis*

Banana, the top fruit of the world and an important staple

The genus *Musa* contains banana plants with edible fruits, which are among the oldest domesticated crops. Archaeological studies indicated that the domestication process of bananas and plantains probably started around 7,000 years ago in Southeast Asia (D'Hont *et al.* 2012; Perrier *et al.* 2011). The modern geographical distribution of *Musa* spp. includes the tropical and subtropical areas of the Americas, Africa, the Caribbean Islands, Melanesia, the Pacific islands and Southeast Asia (mainland and islands). Bananas are among the most important crops worldwide and rank highly on the list of valuable agricultural commodities (Ploetz 2000; Ploetz *et al.* 2015). The 2012 – 2013 banana market review from the Food and Agriculture Organization of the United Nations (FAO), stated that the global production of bananas was around 106.7 millions of tons.

The global banana export reached 16.5 million tons with a gross production value of US \$29.7 billion (FAO 2014a, b). Ecuador is the largest exporter in the world, exporting 5.19 million tons (MT) in 2012, followed by the Philippines with 2.6 MT, Guatemala with 1.98 MT, Costa Rica with 1.88 MT and Colombia with 1.83 MT (FAO 2014a, b) (Figure 1). The main importers of banana in 2012 were the United States of America and countries of the European Union with 4.4 MT and 4.3 MT, respectively (FAO 2014a). Other important markets are Russia, Japan and China (FAO 2014b).



Figure 1. Main banana exporting countries in 2012, data taken from FAOSTAT.

The global banana export represents only 15.5% of the total banana production. The remaining 84.5% represents the banana production for domestic markets and local consumption. This underscores the importance of the banana fruit as a major fruit in many tropical and subtropical countries. Cooking bananas are a starchy staple food crop for approximately 500 million people (Collins 2014), such as in Uganda where it is a major staple food as well as an important cash commodity for communities (Shively & Hao 2012). Bananas are also very important in the local markets of Asia. Virtually all banana production from India and China are destined for local markets (Ploetz et al. 2015). Many banana varieties for local consumption are nutritious - rich in minerals and vitamins A, C and B6 - relative cheap and easy to produce (Ekesa et al. 2012; INIBAP 1998). In developing countries in Latin America, the banana trade is an important source of income. For example, in Ecuador, 95% of the total production is exported and represents almost 60% of the agricultural gross domestic product (GDP; US\$ 1.9 billion in 2009). In fact, bananas are the second export product of Ecuador after oil (Vega 2011). They are an important factor in the economy, strengthening the rural communities in the coastal region (Vega 2011). In Ecuador, the majority of producers are smallholders with 71% working on up to 20 hectares. In 2009, 2.5 million Ecuadorians,

representing 17.5% of the population, were directly or indirectly involve in the banana industry (Vega 2011). Different banana and plantain varieties are easy to spot in local markets, where they are cheap and provide an accessible source of energy, minerals and vitamins. A similar pattern emerges in African developing countries. From the total agricultural output of Uganda, 25% of the value concerns bananas and top-ranks the *per capita* consumption in the world (0.70 kg.person⁻¹.day⁻¹) (Shively et al 2012). Comparable developments are observed in the eastern parts of the Democratic Republic of Congo where bananas (plantains and cooking bananas) constitute the second main starchy staple food after cassava, with a consumption rate of around 0.37 - 0.48 kg.person⁻¹.day⁻¹ (Ekesa *et al.* 2012).

Banana plants are monocotyledons of the order Zingiberales. Most edible bananas belong to the Eumusa (Musa) section of the family Musaceae with seedless diploid, triploid or tetraploid genetic configurations derived from two founding species, Musa acuminata (the wild diploid, fertile A-genome donor) and *M. balbisiana* (the wild diploid, fertile B-genome donor), either alone or in various combinations (D'Hont et al. 2012; Perrier et al. 2011). The subgroup Cavendish comprises triploid sterile hybrids (AAA) derived from *M. acuminata* and is the most significant banana group representing 28% of global banana consumption and nearly all of the worldwide banana export. The plantain subgroup (AAB), important in African and Latin America, is accountable for 21% of the global fruit production (Ploetz et al. 2015). Commercial bananas are typically produced in large monocultures, which results in increased disease threats. Smallholders frequently grow different banana cultivars in mixed cropping systems resulting in complicated management, but with significantly lower disease pressure (Ploetz et al. 2015; Zadoks & Schein 1979). Like in any agricultural production system, but particularly in perennial crops, many abiotic and biotic factors as well as managerial activities affect banana production, including soil structure (physical and chemical), irrigation, fertilization, drainage systems, pesticides, fruit bag covering, bunch support, debudding and dehanding. Many 10

smallholders lack the resources to control these factors (Ploetz *et al.* 2015). Despite regional fluctuations, the most important diseases in banana crops are caused by fungi followed by - in descending importance order – bacterial and viral disease, nematode and insect pests (Ploetz *et al.* 2015).

Globally, the most important disease in banana production is the so-called black Sigatoka, or black leaf streak disease, caused by Pseudocercospora fijiensis (Morelet) (Deighton 1976), previously Mycosphaerella fijiensis Morelet (1969) (Churchill 2011b). Other important diseases are Panama disease caused by Fusarium oxysporum f. sp. cubense (FOC), yellow Sigatoka disease caused by Pseudocercospora musae, anthracnose caused by Collectotrichum musae, Banana Streak Virus (BSV) and the burrowing nematode Radopholus similis (Blomme et al. 2011; Ploetz et al. 2015). The relatively rapid, long-distance dissemination of diseases is thought to be associated with anthropogenic movement of infested material, specially by "suckers" (Ploetz et al. 2015). Banana suckers are lateral shoots developing from the rhizome of the mother plant that are used to vegetative propagate the plant by the growers. Before the era of tissue culture, this was the one and only way to reproduce the plant and it greatly contributed to the global dissemination of FOC (Ordoñez et al. 2015). The currently most important re-emerging banana disease is FOC caused by the genetic lineage vegetative compatibility group 01213, colloquially called Tropical Race 4 (TR4). Other emerging diseases are the bacterial diseases, namely Banana Xanthomonas Wilt (BXW) and blood disease caused by Ralstonia haywardii subspecies celebensis. These emerging diseases and some other important diseases like eumusae leaf spot (Mycosphaerella eumusae), freckle (Phyllosticta maculata and allied species) (Wong et al. 2012), banana lesion nematode (Pratylenchus goodeyi) and Banana Bunchy Top Virus (BBTV) have relative narrow geographical distributions, but may incur major losses (Ploetz et al. 2015). For the majority of these diseases, effective quarantine measures and the use of clean seed material are the only available and hence, essential measures to reduce their dispersal. Other diseases - primarily the foliar blights, including the Sigatoka complex - and (insect and nematode) pests are manageable by using pesticides. However, reducing efficacies are a major concern as the major commercial banana varieties - including Cavendish - are (very) susceptible to a plethora of diseases (Ploetz *et al.* 2015).

The importance of black Sigatoka disease

Among the banana diseases, black Sigatoka is by far the major problem in the banana industry, causing serious leaf defoliation and indirect post-harvest fruit quality problems due to premature ripening of the fruit, turning it unacceptable for export (Ploetz 2000). The main control measure involves frequent fungicide applications, which has a very high environmental and economic burden (Risède *et al.* 2010). As such, black Sigatoka has a major effect on subsistence production of banana and plantain since most of the smallholders are unable to afford these fungicides (Ploetz 2000). Meanwhile the public opinion, debating the fungicide usage and the increasing negative environmental impacts, demands safer food and environmental friendly crop management. This justified demand has an increasing impact on global exporting regulations, directing towards reduced pesticide use in commercial banana production (Risède *et al.* 2010), which primarily comprises the highly susceptible Cavendish type monocultures.

Hence, one of the major issues in black Sigatoka control has been the excessive and unplanned fungicide use in many banana farms worldwide. This uncurbed use facilitated resistance development in the pathogen population, thereby reducing the efficacy of disease management and hence, maximizing the number of fungicide applications, such as presently in Costa Rica. In the 1990's, 30 applications per year were sufficient for disease control, but in 2007 the frequency had increased to over 50 treatments. Another example is Cameroon with 12

12

treatments increasing to nearly 50 applications per year between 1990 and 2008 (Lapeyre et al. 2010b). In Ecuador, the average number of applications was 10 - 12 in the 1990's, which increased up to approximately 30 applications per year in 2016 (CIBE, unpublished data). Consequently, these excessive fungicide applications do contribute to negative impacts on the environment and occupational health of workers in banana plantations and rural villages nearby, as mentioned in the World Health Organization report (Beaglehole et al. 2003; van Wendel de Joode et al. 2016). In 2006-2008, the international project 'Pesticide Reduction Program for Bananas (PRPB)' sponsored by the Common Fund for Commodities and coordinated by Wageningen University and Research, analysed global pesticide use in banana producing countries (Risède et al. 2010), which revealed that the majority of the currently applied fungicides is targeting P. fijiensis. In addition, a clear correlation was detected between black Sigatoka incidence, annual rainfall (more rain = more *P. fijiensis* spores = more fungicide applications) and the risk of reduced efficacy of fungicides, which forced farmers to shift to contact fungicides. Since contact fungicides lack a curative effect their application frequency is higher, which increases the chemical load in banana production (Risède et al. 2010). This vicious circle of required intensification of fungicide applications and increasing resistance in P. fijiensis populations towards systemic fungicides threatens fruit production and underscores the need for new molecules and application strategies to sustainably manage black Sigatoka in banana.

Disease symptoms

P. fijiensis symptoms start to appear 14 to 20 days after inoculation with red-brown specks (~0.25 mm diameter) at the lower leaf surface (Long 1979; Marín *et al.* 2003). These specks rapidly enlarge into reddish-brown streaks running parallel to the leaf veins that then develop into larger dark-brown to black composite streaks, which are indeed visible at both leaf

surfaces, but appear larger on the abaxial side (Long 1979). The streaks eventually form fusiform or elliptical spots that coalesce and form a water-soaked border with a yellow halo that eventually merge to cause extensive leaf necrosis (Figure 2). The time period from the first symptom to the streaks and subsequently necrotic spots varies depending on the cultivar and the severity of the infection (Marín *et al.* 2003). The symptom description of *P. fijiensis* infection is summarized in Tables 1 and 2 (Fouré 1985; Marín *et al.* 2003; Meredith & Lawrence 1969).



Figure 2. Banana plant infected with *Pseudocercospora fijiensis* in a greenhouse experiment. The plant shows the typical symptoms of the disease, streaks, elliptical necrotic lesions with water-soaked border and a chlorotic yellow halo and extensive necrosis. Mark in arrows are some of the stage of the disease based on Fouré description (Fouré 1985).

Common name	Stage	Description			
Speck	Stage 1	First visible lesion. Reddish brown specks in the lower surface of the leaf (<0.25 mm). Abundant near the margin of the leaf. Usually first appear in the third, fourth or older leaves.			
First Streak stage	Stage 2	Streaks elongate to form narrow reddish brown streaks up to 20 mm long and 2 mm wide. The long axis is parallel to the leaf venation. Frequently they are densely aggregated in a band several centimetres wide. Specks that overlap, form large, compound streaks.			
Second Streak stage	Stage 3	The streaks may elongate slightly. The colour changes from reddish brown to dark brown or almost black. They are clearly visible in the upper surface of the leaf.			
First Spot stage	Stage 4	The streaks broaden and become fusiform or elliptical. The spot is characterized by the development of a light brown, water- soaked border around the spot.			
Second Spot stage	Stage 5	The dark brown or black central area of the spot becomes depressed and the water-soaked border becomes more pronounced. A slight yellowing of the leaf tissue surrounding the water-soaked border may occur.			
Third Spot stage	Stage 6	The centre of the spot dehydrates, becoming light grey or buff- coloured and further depresses. The spot is bordered by a well define dark brown or black rim. There is a bright yellow transitional zone between the spot and the green healthy leaf tissue. After the leaf collapsed and withered, spots remain clearly visible.			

Table 1. Black Sigatoka symptoms on banana (Meredith & Lawrence 1969).

Table 2. Black Sigatoka symptoms	describe by Fouré tak	cen from Marín et al	2003 (Fouré
1985; Marín et al. 2003).			

Common name	Stage (Fouré)	Description			
Mark	Stage 1a	Depigmentation mark (whitish or yellow). Only on lower surface			
Speck	Stage 1b	Red-brown speak on lower surface of the leaf			
Dash/Lesion	Stage 2	Red-brown streaks on both side of the leaf surface			
Streak Stage 3		Wider streaks. Colour starts changing from red to dark brown.			
Spot Stage 4		Dark brown (lower) to black (upper) spots.			
Burn	Stage 5	Black spot with chlorotic halo. Lesion is slightly depressed.			
Necrosis	Stage 6	Centre of the spot dries out and becomes whitish to grey. Spot is surrounded by a dark brown to black border and further depressed.			

The Pseudocercospora fijiensis life cycle

The life cycle of *P. fijiensis* starts with leaf infection by either ascospores or conidia. After a period of epiphytic growth of two to three days, germ tubes penetrate the leaf through the stomata (Lapeyre *et al.* 2010b). The first symptoms will generally appear 14-20 days after penetration of the leaf. Conidia form at early stages (stage 2 to 4) of the disease development and are splash-dispersed over short-range distances. Ascospores develop at stage 6 and become airborne and show long-range distance dispersal up to an estimated mean distance of 614 meters with a maximum distance of 1000 meters (Lapeyre *et al.* 2010b; Rieux *et al.* 2014).



Figure 3. *Pseudocercospora fijiensis* life cycle reprinted from Agrios (2005) as shown in Churchill (2011).

The first conidiophores of *P. fijiensis* develop on the abaxial surface of the leaf during stage 2 or 3 and continue to develop until stage 5. Conidia production is almost continuous between stage 3 and stage 5. Conidiophores emerge individually or in diverging fascicles of two to eight stalks from the stomata of the abaxial surface of the leaf (within the boundary of the lesion). Few conidiophores emerge from stomata on the adaxial surface of the lesion (Meredith & Lawrence 1969). Conidia are pale greenish or olivaceous in colour and obclavate to cylindro-obclavate in form. Conidia contain one to 10 septae that form a straight or mildly curved propagule, with a short obconically truncate base. Conidia have a visible and slightly thickened hilum 1.5-3 μ m of diameter and an obtuse tip, 20-132 μ m long, of 2.5-5 μ m diameter at the broadest point near to the base, tapering to 1.5-3 μ m diameter at the tip (Meredith & Lawrence 1969).

The sexual reproduction starts with the development of spermogonia at stage 3 or 4 at the lower leaf surface. Spermogonia with spermatia become abundant at stage 4 (Meredith & Lawrence 1969). On the abaxial surface, spermogonia develop frequently in the substomatal cavity of stomata from which one or more conidiophores emerge. Mature spermogonia contain hyaline, rod-shape spermatia that act as gametes in fertilization of the pseudothecia that emerge in stage 5 and 6 (Meredith & Lawrence 1969). Pseudothecia are present at both sides of the lamina, but more frequent on the adaxial surface. The pseudothecia are scattered, immersed, piercing the epidermis by a narrow or moderately thick papillate ostiole, globose with 50-85 μ m of diameter. Their wall is composed of three or more layers of dark brown polygonal cells and they contain numerous asci that are bitunicate, obclavate, and contain eight two-celled hyaline fusoid-clavate ascospores (dimensions 11.5-15.6 x 2.5-5.0 μ m, Figure 4), with the larger cell uppermost in the ascus (Meredith & Lawrence 1969).



Figure 4. *Pseudocercospora fijiensis* ascospores in cryogenic Scanning Electron Microscope (CRY-SEM).

Pseudocercospora fijiensis genetics

Pseudocercospora fijiensis is a haploid, ascomycete fungus, belonging to the family *Mycosphaerellaceae*, order *Capnodiales*, class *Dothideomycetes*, and phylum *Ascomycota*. The fungus has an asexual and sexual reproduction cycle driven by a bipolar heterothallic mating system (Churchill 2011b). The dissemination of *P. fijiensis* most likely started in Southeast Asia and since then has spread to the major tropical and subtropical banana growing areas of the world (Churchill 2011b; Long 1979; Robert *et al.* 2012). This has been supported by a number of population genetic analyses that indicate Southeast Asia, between Papua New Guinea and the Solomon Islands (Carlier *et al.* 1996; Halkett *et al.* 2010; Hayden *et al.* 2003; Rivas *et al.* 2004b) as the centre of origin. Consequently, founder effects and bottleneck phenomena were detected in populations outside Southeast Asia, which are potentially the main determinants of

the global population structure (Carlier *et al.* 1996; Fahleson *et al.* 2009; Halkett *et al.* 2010; Manzo-Sanchez *et al.* 2008; Rivas *et al.* 2004b; Zandjanakou-Tachin *et al.* 2009). This is consistent with the stochastic nature of the disease spreading at continental and local scales in contrast to a steady advance of an epidemic front, although some populations within countries show a continuous range expansion as an epidemic front (Halkett *et al.* 2010).

The underlying mechanism for stochastic disease development at local or continental scale could result from either airborne spores or from the transport of infected plant material (Halkett et al. 2010; Rivas et al. 2004b; Zandjanakou-Tachin et al. 2009). Most of the P. *fijiensis* populations are not in gametic disequilibrium, resulting in high gene diversity levels. This supports the hypothesis that random-mating - in accord with a heterothallic bipolar mating system, similar to the related Zymoseptoria tritici (Conde-Ferraez et al. 2007; Goodwin & Kema 2014; Kema et al. 1996; Waalwijk et al. 2002) exists within the population and underlines the important role of ascospore dissemination (Carlier et al. 1996; Halkett et al. 2010; Rieux et al. 2014; Rivas et al. 2004b). The colonization patterns are also supported by genetic studies from a historical perspective. For example, the first report of *P. fijiensis* in Latin America was in Honduras and Costa Rica (Guzmán et al. 2013), which is congruent with the highest gene diversity levels found in these countries (Rivas et al. 2004b). In other Latin American countries the genetic diversity is considered medium to low in comparison with Costa Rica and Honduras (Perea et al. 2005). In Africa, the point of entry is more ambiguous since the genetic diversity levels are comparable throughout most countries (Fahleson et al. 2009; Rivas et al. 2004b; Zandjanakou-Tachin et al. 2009).

Black Sigatoka disease management relies on fungicides

As mentioned above, black Sigatoka management in banana is difficult as the majority of commercial banana varieties is highly susceptible to *P. fijiensis*. In contrast to a plethora of other crops, plant breeding in banana is also limited and hence, cultivars with improved resistance to *P. fijiensis* hardly enter the market. In any case, the Cavendish subgroup, which is a major constituent of the global banana production, is extremely susceptible to black Sigatoka. Therefore, disease control relies either entirely on fungicides or production moves to suboptimal environments that slow down disease development, such as the high altitude desert area of Piura, Peru.

In the banana industry two groups of fungicides are applied to control *P. fijiensis*. These are categorized according to their phytomobility into the plant tissue and characterized as contact and systemic fungicides. Contact fungicides remain at the leaf surface. Systemic or penetrating fungicides on the other hand are able to penetrate the plant tissue. The most widely applied systemic fungicides for black Sigatoka control are those belonging to the chemical families benzimidazoles, triazoles, morpholines and strobilurins (Pérez 2006).

The benzimidazoles were the first modern site-specific penetrating fungicides used for fungi pathogen control (Latin 2011). This group includes benomyl and thiabendazole.

In the 1980s, triazole (azoles) fungicides were introduced. They belong to the Demethylation Inhibitor fungicides (DMIs) that obstruct the lanosterol 14 α -demethylase which catalyses the removal of a methyl group from lanosterol. This is an essential enzyme of the ergosterol biosynthesis pathway (Cañas *et al.* 2009; Pietila *et al.* 2006). The lanosterol 14 α -demethylase enzyme is encoded by the *cyp51* gene.

Morpholine fungicides are well known by the compound Tridemorph that was first approved in 1969 (Pérez 2006). Tridemorph inhibits the $\Delta 8 - \Delta 7$ isomerase and the C14 reductase in the ergosterol metabolic pathway.

The first strobilurin fungicide was introduced to the global market in 1997 (Knight *et al.* 2002). The quinol oxidation inhibitors (QoIs), or strobilurins, block the respiration pathway by inhibiting the cytochrome bc1 complex in mitochondria (Peres *et al.* 2014). By 2000, resistant *P. fijiensis* isolates emerged on banana production farms in Costa Rica (Amil *et al.* 2007).

The newest compounds introduced in the market are "second generation" carboxamides. These fungicides are classified by the Fungicide Resistance Action Committee (FRAC) as Succinate Dehydrogenase Inhibitors class or SDHIs. Their fungicidal activity is based on the disruption of the mitochondrial tricarboxylic acid cycle (TCA) through inhibition of the Succinate Dehydrogenase enzyme (SDH). At the molecular level, carboxamides inhibit ubiquinone reduction by binding to the ubiquinone binding site (Qp site) of the SDH enzyme (Scalliet *et al.* 2012).

Scope of the thesis

This study aims to elucidate the molecular mechanisms on adaptation to a major class of fungicides, the sterol demethylation-inhibitors (DMIs), that are globally used in the disease management of black Sigatoka caused by *P. fijiensis*.

Chapter 1 provides a general introduction to the subject with a description of the importance of banana as a food and fruit crop, the causal agent of black Sigatoka - *P. fijiensis* - and its lifestyle and the disease expression and management.

Chapter 2 describes the history of black Sigatoka disease management and the role of fungicides and the decline in efficacy with a focus on the situation in Costa Rica, which is exemplary for other important banana growing regions.

Chapter 3 contains a global phenotypic and genotypic analysis of *P. fijiensis* isolates to describe and understand reduced efficacy to DMI fungicides and the relationship with *Pfcyp51* gene and promoter modifications and associated CYP51 protein three-dimensional modifications.

Chapter 4 summarizes a functional analysis of the *Pfcyp51* gene and describes promoter swapping experiments between wild type and resistant *P. fijiensis* isolates to analyse the role of repeat elements - present in the *Pfcyp51* promoters of resistant *P. fijiensis* strains - in the expression of the gene and its relation to reduced efficacy.

Chapter 5 addresses the question whether the *Pfcyp51* gene is the only determining factor in reduced DMI efficacy by an unbiased mapping approach where two resistant isolates are crossed to a sensitive strain resulting in two *P. fijiensis* mapping populations that were genotyped and phenotyped for DMI sensitivity. In both populations, a causal genetic region of 250,660 bp is identified that contains 53 putative genes, including the *Pfcyp51*.

Chapter 6 discusses the experimental outcomes of the preceding chapters, puts these in a broad context and concludes that *Pfcyp51* gene and promoter modulation is largely responsible for the reduced DMI efficacy in black Sigatoka disease management. The impact and implications of these findings are discussed for the development of future sustainable disease control strategies.

Chapter 2

An historical treatise and critical review of black Sigatoka

control in banana production

Pablo Chong, Claudiana Carr, Gilberth Murillo, Mauricio Guzmán, Jorge Sandoval and Gerrit H.J. Kema

Introduction

Bananas are among the most important crops worldwide (Ploetz 2000; Ploetz et al. 2015). The 2012 – 2013 banana market review from the Food and Agriculture Organization of the United Nations (FAO), stated that the global production of bananas was around 106.7 millions of tons. Global export reached 16.5 million tons with a gross production value of US \$29.7 billion (FAO 2014a, b). Nonetheless, global export of banana represents only 15.5% of the total banana production. The remaining 84.5% represents banana production for local consumption. This stresses the importance of the banana fruit as a staple food in many tropical and subtropical developing countries. It is believed that banana is a starchy staple food for approximately 500 million people (Collins 2014). Many banana varieties for local consumption are relative cheap and easy to produce. Sadly, many of these varieties are susceptible to black Sigatoka disease, an important leaf defoliation disease that is caused by the dothideomycete fungus Pseudocercospora fijiensis (previously Mycosphaerella fijiensis) (Arango et al. 2016). The disease causes substantial direct and indirect losses due to defoliation and consequently reduced yields as well as due to premature ripening of the fruit, turning them into an unfit commodity for the export, respectively (Ploetz 2000). The main control measure involves frequent fungicide applications with a very high environmental and economic burden (Chong et al. 2016b; Chong et al. 2016c; Risède et al. 2010). As such, black Sigatoka has a major effect on subsistence production of banana and plantain since most of the smallholders are unable to afford the costs of these fungicides (Ploetz 2000). One of the major issues in black Sigatoka control has been the excessive and unplanned fungicide use in many banana farms worldwide (Lapeyre et al. 2010b). This uncurbed usage promoted resistance development within the pathogen population. Over time, resistance levels increased to such extent that the number of fungicide applications are now near maximum levels (Chong et al. 2016b). This can be well illustrated by the history of the control of the disease in Costa Rica, which is one of the major banana export countries that had to deal with the disease soon after its incursion in Central America (Marín *et al.* 2003). The extent and well documented record of the disease management by the National Banana Corporation (CORBANA) enables a critical review of contemporary black Sigatoka management, further substantiating and underscoring the need for alternative disease management practices and strategic decisions towards sustainable and environmentally friendly banana production.

Black Sigatoka management through time

A historic picture of black Sigatoka management

Black Sigatoka disease was first report in Fiji in 1963 (Rhodes 1964) and arrived to Costa Rica in 1979 (Lapeyre *et al.* 2010b; Rivas *et al.* 2004b). When black Sigatoka arrived another pathogen *Pseudocercospora musae* (previously *Mycosphaerella musicola*), also known as yellow Sigatoka, was already present in the banana farms in Costa Rica (Stover 1962). Much of the strategies for the control for black Sigatoka disease have been adapted from the control of yellow Sigatoka. For example, the use of protectant fungicide begins with the arrival of *P. musae* to Central America in 1934. The United Fruit Company begins applying Bordeaux mixture (CuSO₄ + Ca(OH)₂) for the control (Stover, 1990). In 1941, Leach did a great deal when he identifies that the unfurling heart leaf ("candela or cigar") is the major target for the ascospores of *P. musae* and later *P. fijiensis*. He also probed that it is physically impossible for protectant fungicides to reach ascospores in the hart leaf since this leaf is constantly expanding and exposing under surface of the leaf cylinder. By 1946 Leach published his research on bananas leaf spot diseases in Gross Michel cultivar (Leach 1946). Another important control strategy, the use of oil sprays for the control, was discover by Guille and Guyot in 1956 (Guyot & Guillé 1954; Stover 1990). Table 1 shows a time line history of the chemical control of the so call banana leaf spots diseases, yellow and black Sigatoka. Eventually, black Sigatoka displaced yellow Sigatoka in most of the banana production areas around the world becoming the omnipresent banana pathogen (Guzmán *et al.* 2013).

Since the 1950s the export banana trade has been dominated by the banana "Cavendish" varieties (D'Hont *et al.* 2012; Langhe *et al.* 2009), which are very susceptible to *P. fijiensis.* Hence, fungicides are major disease control agents in addition to a range of cultural practices. The latter includes the application of mineral oil, which has been practiced since the 1950s (Klein 1960)(Marin et al 2003) and slows down disease development (Pérez 2006; Stover 1990). Moreover, mineral oil became an important carrier for many fungicides. In many ways, mineral oil is a main component of conventional control, they protect and reduce the fungicide volume by forming a homogeneous mist that distributes active ingredients on the leaf, prevents evaporation and improves, in the case of many systemic fungicides, the penetration of the plant tissue.

Prior to 1970's, almost all fungicides were protectants (Ma & Michailides 2005). Ethylene bis-dithiocarbamates, such as maneb and mancozeb were introduced in the market in 1950 and 1958, respectively, and have been widely used for black Sigatoka control. Dithiocarbamates have a nonspecific mode of action (moa) with the thiol group blocking respiration and other important metabolic process (Gullino *et al.* 2010; Pérez 2006). Chlorothalonil is another compound that is still frequently used, only with water as oil mixtures are phytotoxic (Pérez 2006). It is a derivate of the phthalimides, which thiol group interferes with the glutathione pathway, A-coenzyme and 2-mercaptoethanol thereby reducing all metabolic activity of the fungal cell.

The benzimidazoles were the first modern site-specific fungicides for disease control (Latin 2011). They include benomyl and thiabendazole that are still being used for the control

of crown rot of the harvested and packed fruit. Benomyl, a methyl benzimidazole carbamate, was introduced in 1968 and inhibits fungal growth by binding to the β -tubulin thereby disrupting fungal cell division (Cañas *et al.* 2006). However, point mutations at positions 198 of the β -tubulin gene lead to one amino acid (aa) change, which provokes complete resistance in *P. fijiensis* populations without any apparent fitness penalty (Cañas *et al.* 2006; Pérez 2006).

The first triazole fungicide, propiconazole, was introduced for black Sigatoka control in 1984 (Stover 1990). It belongs to the group of sterol demethylation-inhibitors (DMIs) that inhibit the lanosterol 14 α -demethylase (CYP51), an essential enzyme of the ergosterol biosynthesis pathway (Cañas *et al.* 2009). This enzyme catalyses the removal of a methyl group from lanosterol in fungi, allowing the sterol metabolism to proceed to the production of ergosterol. Triazoles inhibit the CYP51 function by binding to the heme cofactor in the active site of the enzyme. Henceforth, sterol metabolism is hampered due the accumulation of 14- α methyl-3,6-diol, a toxic sterol produced by the Δ -5,6-desaturase encoded by the gene ERG3, which affect membrane integrity and leads to growth inhibition and cell death (Lupetti *et al.* 2002; Pietila *et al.* 2006; Shapiro *et al.* 2011). Several studies have shown a correlation between the loss of sensitivity to triazoles and point mutations in the *cyp51* gene (Cañas *et al.* 2009; Lepesheva & Waterman 2004). In *P. fijiensis* such mutations are abundant and resistance is also due to overexpression of the *Pfcyp51*, as a result of promoter insertions (Chong *et al.* 2010; Chong *et al.* 2016b; Díaz-Trujillo *et al.* 2016a)

The morpholine fungicides are represented by tridemorph that was approved for black Sigatoka control in 1969. It inhibits the $\Delta 8-\Delta 7$ isomerase and the C14 reductase in the ergosterol metabolic pathway and its translocation is essentially trans-laminar (Pérez 2006). Therefore, it has a limited risk of resistance development in the pathogen population. Despite this advantage, its efficacy for black Sigatoka control is not as good as the azole fungicides (Pérez 2006).

27

The first quinol oxidation inhibitor (QoI), or strobilurin was introduced in 1997 (Amil *et al.* 2007; Knight *et al.* 2002). It blocks the respiration pathway by interfering with the cytochrome bc1 complex in the mitochondria (Pérez 2006; Sierotzki *et al.* 2000). Due to their entirely new chemistry and enormous efficacy, strobilurins quickly became one of the most important agricultural fungicides accounting for >20% of the global fungicide market within the first ten years after their introduction (Fernández *et al.* 2010). However, by 2000, isolates of *P. fijiensis* with resistance to the QoIs were already common on some farms in the production zones of Costa Rica (Amil *et al.* 2007), and in 2008, *P. fijiensis* populations at three commercial plantations in Costa Rica were almost fixed for strobilurin resistance (Arango *et al.* 2016). The resistance to these compounds is mediated by a point mutation in the *Pfcytb* gene that leads to a change of a glycine for an alanine at position 143 (G143A) of the protein (Sierotzki *et al.* 2000).

Finally, the latest fungicides for black Sigatoka management that entered the market are the "second generation" carboxamides or succinate dehydrogenase inhibitors (SDHIs). First generation carboxamides were discovered in the mid 1960's for the control of basidiomycetes. Their fungicidal activity is based on the disruption of the mitochondrial tricarboxylic acid cycle (TCA) through inhibition of the succinate dehydrogenase (SDH) enzyme. At the molecular level, carboxamides inhibit ubiquinone reduction by binding to the ubiquinone binding site (Qp site) of the SDH enzyme (Scalliet *et al.* 2012). New molecules with a wider spectrum of activity were discovered recently (Leroux *et al.* 2010) but are not yet generally applied.

Year	Black Sigatoka strategies evolution and important events	Reference
1934	Arrival of <i>Pseudocercospora musae</i> (<i>Mycosphaerella musicola</i>), also called yellow Sigatoka, to Americas and the beginning of the use of Bordeaux mixture.	Stover 1962
1941	Leach identifies the unfurling cigar (heart) leaf as the major target for the <i>Pseudocercospora musae</i> spores. He also proves that the heart leaf cannot be protected by contact fungicides.	Leach 1946
1946	Leach publishes his discoveries in "Banana leaf spot (<i>Mycosphaerella musicola</i>) on the Gros Michel variety in Jamaica: "Investigations on the aetiology of the disease and the principles of control by spraying".	Leach 1946
1950	The first dithiocarbamate, Maneb, was introduced for yellow Sigatoka control.	Stover 1990
1956	Guille and Guyot discovered oil sprays.	Guyot & Guillé 1954
1958	Introduction of the dithiocarbamate mancozeb (Dithane) for the control of yellow Sigatoka. Maneb successfully controls leaf spot diseases together with copper applications by aircraft.	Stover 1990
1960	Klein publishes the first forecasting method of oil spray in Honduras. He shows that oil controls the streak disease stage and that the stages of the disease can be used as a decision moment for fungicide application.	Klein 1960
1962	Discovery that oil-in-water mixtures are more effective than oil alone.	Stover 1990
1963	First report of black Sigatoka in Fiji.	Rhodes 1964
1967	DuPont sent the first systemic fungicide (the first benzimidazole), compound number 1991 or Benlate (benomyl), to be evaluated in Honduras. In the same year Calixin (tridemorph) was also tested in Honduras.	Stover 1990
1972	 The second forecasting method was developed in Guadalupe by Ganry and Meyer, who divided the disease symptoms in five stages. They correlated disease development with temperature and evaporation rates. This was the first system introducing oil and systemic fungicides (Benlate). Black Sigatoka is discovered in Honduras and from there it dispersed throughout Latin America and the Caribbean. 	Ganry & Meyer 1972 Guzmán <i>et al</i> 2013
1973	First epidemic of black Sigatoka disease in Honduras. Benlate was effectively and extensively used for disease control. First use of in-oil mixtures and later in "cocktails" (different mode of action fungicide mixtures) with Mancozeb.	Stover 1990
1976	First fungicide resistance appeared against Benlate in Honduras, followed by a serious outbreak of black Sigatoka.	Stover 1990
1979	Chlorothalonil was introduced, but was unable to provide adequate control under conductive conditions for the disease (heavy rain promoting abundant ascospore production).	Stover 1990
1980	The Fungicide Resistance Action Committee (FRAC) was founded as an organization designed to discuss resistance problems and to formulate plans for cooperative efforts to avoid or manage fungicide resistance.	http://www.frac.info/about- frac/why-frac-
1981	Dithane, Benlate and Calixin were reintroduced to control black Sigatoka. At that time protectant fungicides were used combined with cocktails during rainy periods and almost exclusively in dry periods.	Stover 1990
1983	First report of black Sigatoka in Cameroon. The symptom development method was modified to six stages by Fouré.	Fouré 1985, Stover 1990
1984	The first triazole fungicide propiconazole belonging to the DMI group was introduced together with a forecasting method to control black Sigatoka.	Stover 1990

Table 1.	Historical	time	line o	of the	evolution	and	important	events	in the	e chemical	control	of
black Sig	atoka						-					

Year	Black Sigatoka strategies evolution and important events	Reference
1986	Flusilazole fungicide is introduced for black Sigatoka control. Propiconazole and flusilazole were extremely effective having curative effect when applied 14 days after the cigar leaf unfurled. Both compounds were extremely persistent in the leaf (up to 60 days after application) and were applied as oil-in-water emulsions. The decision supports system (forecasting) and the use of triazoles reduced the number of application cycles for black Sigatoka control from 35 - 45 to 20.	Stover 1990
1987	Guidelines were established to reduce the development of resistance in <i>Pseudocercospora fijiensis</i> to azoles and included no year-round applications (max. 4 - 8 cycles over six month).	Stover 1990
1988	Fungicide resistance monitoring methods were discussed/described during the first meeting on the use of DMI fungicides.	Stover 1990
1997	The first quinol oxidation inhibitor (QoI) or strobilurin was introduced.	Amil et al 2007
2000	Resistance to the QoIs already common on some farms in the productions zones of Costa Rica.	Amil et al 2007
2003	 Reduced efficacy of DMIs towards <i>P. fijiensis</i> is prevalent in many countries. FRAC Banana Working Group is established. 	Marín <i>et al</i> 2003 http://www.frac.info/about- frac/why-frac-
2004	Anilinopyrimidines are introduced.	Guzmán 2007
2006	DMI sensitivity is not "restored" after refraining from application over a period of four years in Costa Rica.	Guzmán
2008	<i>P. fijiensis</i> populations in Costa Rica are nearly fixed for QoI resistance (92-100%).	Arango et al 2016
2009	 Correlation between reduced efficacy of triazoles and point mutations in the <i>Pfcyp51</i> gene discovered. Overexpression of the <i>Pfcyp51</i> gene is found in Costa Rican samples from 2009. 	Cañas <i>et al</i> 2009 Chong et al 2012, Díaz et al 2016 (Chapter 3 and 4)
2010	 Irrespective of the country of origin in Latin America, the baseline sensitivity for boscalid, fluopyram and isopyrazam is high. Black Sigatoka incursion in Martinique. 	http://www.frac.info/docs/default- source/working-groups/banana- group/group/2010-meeting- minutesenglish.pdf?sfvrsn=4 loos et al 2011
2012	Black Sigatoka incursion in Guadalupe.	Guzmán et al 2013
2016	First genetic mapping of DMI resistance in P. fijiensis.	Chong et al 2016c (Chapter 5)

DMIs as major control agents for black Sigatoka management

Currently, the DMIs are the major control agents for black Sigatoka in banana. The *P. fijiensis* DMI baseline sensitivity in Costa Rica has been continuously rising: In 2003, Marín et al., reported an average EC_{50} for propiconazole of 0.15 mg.L⁻¹ with a maximum value of 0.5 mg.L⁻¹ in Costa Rica populations (Marín *et al.* 2003). Díaz et al., (2016) showed an increase

among four resistant Costa Rican isolates sampled in 2009 to an average of 1.10 mg.L⁻¹ with a maximum value of 1.53 mg.L⁻¹ and recently Chong et al. (2016) determined an EC₅₀ average of 5.8 mg.L⁻¹ and a maximum value of 18.4 mg.L⁻¹ among 107 *P. fijiensis* isolates from 2014 (Chong *et al.* 2016b). This shows that the EC₅₀ between 2003 and 2014 gradually increased with an average of 1.4 fold per year. For example, based on 2009 the measured average was 1.1 mg.L⁻¹ and predicted by calculation, is 1.12 mg.L⁻¹. Therefore, the increment is predictable and it is currently 38 times higher than in 2003. Evidently, one can argue that the locations and sample numbers need to be considered but the sensitivity shift is clear.

As mentioned above, Costa Rica has a long history of black Sigatoka control with a high number of fungicides applications per year (Lapeyre *et al.* 2010a; Marín *et al.* 2003). The observed DMI baseline sensitivity shift correlates with the increasing amounts of applied fungicides, which increased from 30 in the 1990's up to 50 treatments by 2007 and up to 53 in 2015 on the San Pablo plantation (Figure 1). In a global survey for DMI efficacy, Chong et al., (2016) recently reported that EC_{50} values among Costa Rican *P. fijiensis* isolates are representative for the selective pressure exerted by DMIs fungicides on the pathogen population. Interestingly, at least for the case of "San Pablo", the actual number of DMI cycles reduced over time from seven to four applications per year in 1998 and 2014, respectively, but overall the number of DMI cycles was approximately 10 between 2003 and 2010. From 2014 to 2015, there was a sudden rise in the number of DMI cycles (from four to seven; Figure 2) that maybe a consequence of the frequency of less sensitive isolates with high EC_{50} values in the "San Pablo" population (sample taken in 2014, Figure 3) (Chong *et al.* 2016b). This suggests that the selective pressure in previous years was sufficient to turn the major part of the population into resistant strains by 2014.



Figure 1. An overview of different chemicals used to control black Sigatoka at the San Pablo plantation in Limon, Costa Rica, in 1998 and during the period 2003-2015. Numbers over the coloured bars indicate the annual frequency of applications per chemical group. The numbered diamonds over the bars indicate the total number of fungicide cycles per year (One cycle can include several fungicides in mixtures).



Figure 2. An overview of the number of DMI applications for the control black Sigatoka at the San Pablo plantation in Limon, Costa Rica, in 1998 and during the period 2003-2015.



Figure 3. The average sensitivity, measured as EC_{50} , of 49 randomly collected monoascosporic *Pseudocercospora fijiensis* strains from the San Pablo - Limon, Costa Rica population to three DMI fungicides in 2014. Strains with an EC_{50} values >1 mg.L⁻¹ are considered resistant (Chapter 3) (Chong *et al.* 2016b).

It is important to mention that the aforementioned reduction of DMI cycles at "San Pablo" between 2011 to 2014 was driven by forecast information (weather and disease development) and economic considerations, but not by the reduced efficacy of the compounds. In addition, ceasing DMI applications for a period of four years hardly changed the frequency of resistant strains in the population. This suggests no fitness penalty for reverting to sensitivity. Previous studies in P. fijiensis have not shown significant differences in incubation period, latency period, conidial sporulation and severity between DMI sensitive and resistant isolates (Romero 1999). Hence, the use of DMI free periods will likely not contribute to population shifts towards sensitivity. On the contrary, by the end of the four years without DMIs fungicides the frequency of DMI resistant strains increased in both treatments (Figure 4), which might, however, also result from the immigration/gene flow from the DMI experimental plots (plots of 50 ha with 200 ha borders between experimental plots) since the airborne P. fijiensis ascospores can travel at least hundreds of meters (Guzmán 2007; Lapeyre et al. 2010b; Rieux et al. 2014). The increased use of mancozeb, azoxystrobin and tridemorph compensated for reduced cycles with DMIs, but exerted – of course – significant selective pressure for these fungicides (azoxystrobin and tridemorph), and has resulted in *P. fijiensis* populations that are nearly fixed for strobilurin resistance, surely compared to the wild type (wt) population of San Carlos (Arango et al., 2016).

The historical records (2001 - 2015) for DMI sensitivity monitoring (discriminatory dose 0.1 mg.L⁻¹) of ascospores germ tube lengths from different Costa Rican banana regions enable a comparison of wt site San Carlos with commercial banana plantations (Figure 5). In general, the loss of sensitivity curve fluctuates, but seems to stabilize in the last 5 years, which can be explained by the implementation of better control (with mixtures of different target-site specific and protectant fungicides) and management strategies during recent years.

Nonetheless, germ tube lengths monitoring experiments have unequivocally shown the reduced efficacy of DMIs for Costa Rican *P. fijiensis* populations (Chong *et al.* 2016b).



Figure 4. The infection index of *Pseudocercospora fijiensis* on Cavendish banana at the San Pablo plantation – Limón, Costa Rica - in plots that were either treated with DMIs or that underwent alternative treatments without DMIs from 1998 to 2001 (Guzmán 2007).

Evidently, it is possible that the contrast in sensitivity levels is determined by the two monitoring procedures - EC_{50} based on mycelial growth in 96-well plates vs. ascospores germ tube lengths - or by the physiological differences of the tested tissues (mycelium vs. ascospores). For example, ascospore monitoring procedures are evaluated with two or three doses at 48 hours with a considerable number of samples (on average 100 spores per treatment with more than three repetitions). However, only three doses preclude observing accurate response levels, despite the representative number of ascospores per population. Alternatively, some fungicidal effects might be expressed at stages after 48 hours. Calvo et al. (1997) showed that the germ tube of propiconazole resistant ascospores continued growing after 48 hours, while those of some sensitive ascospores stopped growing after 48 hours (Calvo *et al.* 1997). In contrast, mono-ascosporic colonies are evaluated with eight different doses and after five to 34

10 days incubation with mycelium pieces in 96-well microtiter tests (Chong et al. 2016b), a method that is very common for other fungi, such as the related Zymoseptoria tritici where thousands of isolates are monitored on an annual basis by various laboratories (http://www.frac.info/monitoring-methods). Hence, this method is more precise to determine overall sensitivity of an individual strain, but requires a range of preliminary experiments for standardization and statistical analyses as well as sufficient samples to represent a given population. Despite the different levels, however, the shift of base line sensitivity is recorded independent of these two methodologies, which is also apparent by analysing the *P. fijiensis* populations in commercial farms with the wt population at San Carlos (Figure 6; Chong et al., 2016). In the commercial banana farms the percentage of inhibited ascospores tends to decrease. Ascospore germ tubes inhibition in the range of 50-70% (Figure 6) might result individuals with moderate sensitivity to DMIs or to tolerance, as defined by normal development despite substantial abiotic stress. Interestingly, we noticed that there is always a very low percentage of isolates from the control population with high levels of DMI resistance as well as very sensitive ascospores from overall resistant populations at commercial farms. This supports the hypothesis that there are always sensitive isolates that escape disease control or resistant isolates that are able to survive and reproduce in a non-selective environment (Latin 2011; Vincellin 2014). We have not observed such blurred classes for strobilurin resistance in the same populations (Arango et al., 2016).




Figure 6. Comparison of the inhibition of *Pseudocercospora fijiensis* ascospore germ-tube lengths at 0.1 mg.L⁻¹ as a measure of sensitivity to the DMI fungicides propiconazole, difenoconazole and epoxiconazole in either control sites at commercial Cavendish plantations in the main producing area in Limón (red bars) and San Carlos (green bars) Costa Rica. Populations with >70% inhibited ascospores are considered as sensitive, whereas those with inhibition percentage between 50% and 70% are supposed to be tolerant and <50% inhibited ascospores populations are presumably resistant.

Clearly, one of the most important questions about the selection pressure that DMI fungicide exerts on *P. fijiensis* populations is about the actual doses that reach the fungus. The translation from laboratory efficacy trails to field conditions is difficult and hardly tested. However, we have performed inoculation trails with *P. fijiensis* isolates of various resistance levels – as determined in the laboratory - and showed that some resistant strains were equally fit in greenhouse trials using field doses of DMIs (DMI doses of 400 mg.L⁻¹ Figure 7).



Figure 7. Phenotyping DMI sensitive and resistant *Pseudocercospora fijiensis* strains on Cavendish (var. Grand Naine) under greenhouse conditions. Plants were treated prior inoculation with two DMIs (propiconazole, Tilt, and difenoconazole, Sico) or with the water control (no fungicide application). Plots show a rapid development of infected leaf area by the resistant strain R2. Resistant strain R1 developed much slower but caused significantly more disease than the sensitive control (S2), Disease development was monitored between 7 and 49 days after inoculation (dai).

In general, most farmers follow the technical instructions of the manufacturers as printed on the label of the commercial fungicides, but the effective dose also depends on the "carrier", mineral oil or oil in water emulsions with different emulsifiers. Fischer (1991) reported that a mix of propiconazole in emulsion has a foliar level recovery of 90% compared to just 43% in mineral oil, although the latter had a significantly better leaf coverage than emulsions, particularly under moderate dew conditions.

Details on final DMI doses under field conditions are available in the - rare - Ciba-Geigy Tilt technical dossier from 1991. It provides one of the most complete descriptions of the application, leaf penetration and inside leaf degradation of the product. This important information should be available for each fungicide that is commercialized for black Sigatoka control. For example, oil in water emulsion was the best combination for leaf penetration from 13 mg.L⁻¹ of fungicide inside the leaf at the first hour down to a final dose of 2 mg.L⁻¹ at 96 hours after application. However, the most stable application was the mix with oil that despite a relatively low leaf penetration - at the first hour after application 5 mg.L⁻¹ – maintained a concentration of 6 mg.L⁻¹ for the next 11 hours and finally of 4 mg.L⁻¹ between 24 and 96 hours. Finally, a water formulation showed a penetration of 6 mg L^{-1} at the first hour, which dropped to only 0.5 mg.L⁻¹ at 96 hours. In general, the major fungicide part that penetrated the lamina disappears within 12 hours (biological degradation, dilution), but a residual low level of the active ingredient remains in the tissue for more than four days (Ciba-Geigy 1991). Still, it is worth mentioning that doses on the leaf are usually 1 to 1.5 times higher during the first 12 hours (the persistence of the fungicide on the leaf highly depends of the type of carrier) (Ciba-Geigy 1991). Hence, considering these results, the actual propiconazole doses that most pathogen spores and colonies face will be 1-5 mg.L⁻¹ at least for some days (Ciba-Geigy 1991), provided an appropriate distribution on/in the leaf. We, therefore, conclude that the empiric

dose of 1 mg.L⁻¹ as a threshold for propiconazole resistance in laboratory efficacy trials has a solid support from leaf penetration experiments.

Cultural practices to reduce black Sigatoka impact

The control of the critical levels of black Sigatoka in banana plantations is driven by reducing direct costs- such as reduced yield potential - and indirect costs, due to reduced quality. The latter is far more important as the disease triggers early ripening, which makes the fruit unfit for export (Ploetz et al. 2015). Hence, the extraordinary control measures are required to deliver a marketable product that survives the demanding logistic chain (Guzmán et al. 2013; Ploetz et al. 2015). The favourable weather conditions for black Sigatoka development include high relative humidity (95 - 100%) with temperatures around 27°C and intermittent rain fall (Long 1979; Marín et al. 2003). The common agronomic factors that affect disease development include production site selection, banana variety selection, planting date, soil fertility and acidity, plant spacing, irrigation practices and field drainage (Vincellin 2014). As mentioned above, the underlying issues of black Sigatoka management is the fact that 95% of the export trade comprises highly susceptible "Cavendish" clones that essentially form one big monoculture around the globe (Ploetz et al. 2015). Hence, the reduction of on-farm inoculum is one of the most important cultural practices, which can be achieved by removing leaf tissue with mature pseudothecia that release ascospores. This practice is known as "deleafing", "detipping" or "surgery" (Marín et al. 2003). The detached foliage will rapidly decompose on the plantation floor, but still may provide inoculum. Therefore, decomposition is stimulated by adding products, such as urea, which altogether can reduce the infectiousness by 50% (Marín et al. 2003). Water logging is a potential threat to banana plantations under tropical conditions and, hence, appropriate drainage, plant spacing or drip-irrigation are crucial for optimal plant

development and to reduce excessive humidity that supports disease development (Marín *et al.* 2003).

The commonest fungicides and spraying programs for black Sigatoka management

Overall, the international banana industry just uses two kinds of fungicides for black Sigatoka management that are categorized according to their phytomobility, either contact or penetrant fungicides (Table 2). Contact fungicides remain on the surface of the leaf and they are only redistributed by precipitation, irrigation and dew. Penetrant fungicides, on the other hand are absorbed into the plant tissue and can be subdivided into acropetal, local penetrant or systemic penetrants (Latin 2011). In acropetal penetration compounds are moving between cells along with the water potential gradient. They are xylem mobile and therefore translocated upward towards the leaf tips and margins. Local penetrants diffuse into the wax/cuticle layer where they are bound and immobilized. Systemic penetrants move inter- and intracellularly with the live protoplast and follow a sugar density gradient (Latin 2011). The main contemporary compounds currently used for black Sigatoka management are contact fungicides such as mancozeb and chlorothalonil, and the acropetal penetrant fungicides such as the DMIs propiconazole, epoxiconazole, difenoconazole and tebuconazole. Despite the overall resistance development strobilurins such as azoxystrobin, pyraclostrobin and trifloxystrobin are still in use, likely due to their "greening effect" (Bennett & Arneson 2003; Pérez 2006). Finally, tridemorph (amine) has been also very important for the control of black Sigatoka, particularly in mixtures with protectants or systemic fungicides. Table 2 describes all the fungicides that have been recommended by the Fungicide Resistance Action Committee (FRAC) for the control of black Sigatoka. Usually, several fungicides are prepared as "cocktails" that are

composed of two or three fungicides with different modes of action. Generally, a mix is composed by one or two systemic fungicides and a protectant, for instance a DMI, an amine and mancozeb. Occasionally, QoIs (depending of the level of resistance in the population) or SDHIs are used instead of DMIs. QoIs are most of the time mix with amines or pyrimidines. Due to the epidemiology of the disease, with an almost continuum of ascospore production (Lapeyre *et al.* 2010b; Marín *et al.* 2003), contact fungicides remain a very important component of the tank mixes, sometimes combined with new or specialty products such as vegetable wax and various biologicals (Table S1).

At present, weekly spray schedules are required with around four applications per month (depending of the rain fall). This is significant more than e.g. the San Pablo applications schedule in 1998 that comprised three applications per month in general and two applications from May to August. At that time, most fungicides were applied alone and systemic fungicides were applied in a six-month period, alternating weekly with another moa or contact fungicide. In 2003, applications were raised to five per month in some periods and most fungicides were mixed in "cocktails"; either systemic/protectant or protectant/protectant tank mixtures, although these protectants were also applied alone. Then, from 2008 onwards, spray schedules were more or less the same with four applications per months using systemic fungicides applied in mixtures and alternating moa's over a six-month period. The number of applications was increased to five per month in 2009 which is unaltered since then. A summary of the application cycles and the specific systemic groups being applied is shown in Figure 1. Table S1 provides the actual San Pablo fungicide application schedule during 2015. **Table 2.** Fungicides used in black Sigatoka control ordered by their chemical classifications (FRAC 2013, 2015).

Chemical class		Fungicide use in banana	Fungicide trade name*	Description				
Contact	Benzene derivatives	chlorothalonil	Bravo, Bronco, Daconil	This compound interferes with the glutathione pathway, a coenzyme and 2-mercaptoethanol reducing thiol-group based metabolism in the cell.				
fungicides	Carbamates	Mancozeb	Dithane	Mancozeb is placed in the subclass of carbamate pesticides called dithiocarbamates. As a cholinesterase inhibitor, it affects the nervous system.				
		bitertanol	Baycor					
		difenoconazole	Score, Sico					
		epoxiconazole	Opus					
		fenbuconazole	Indar					
	Demethylation inhibitors (DMI)	myclobutanil	Rally, Sisthane	I hese compounds inhibit the lanosterol 14α-demethylase, an essential enzyme of the ergosterol biosynthesis nathway				
		propiconazole	Tilt, Bumper					
		lebuconazole	Silvacui					
		tetraconazole	Eminente					
		triadimenol	Bulldock, Caporal.					
		spiroxamine	Impulse					
		fenpropimorph	Volley	Amines are ergosterol synthesis inhibitions. Tridemorph				
Systemic fungicides	Amine fungicides	fenpropidin	Seeker 750	inhibits the $\Delta 8 - \Delta 7$ isomerase and the C14 reductase in the ergosterol metabolic pathway.				
		tridemorph	Calixin, Musaclean					
	Qo inhibitors (Qol)	azoxystrobin	Amistar, Bankit	Quind quidefine inhibiters (Qala) as starbilizing black the				
		pyraclostrobin	Comet	respiration pathway by inhibiting the cytochrome bc1				
		trifloxystrobin	Tega	complex in millochondria.				
	Anilinopyrimidines (AP)	pyrimethanil	Siganex	AP's inhibit the methionine biosynthesis. It should only be used in mixtures and in full alternation. To reduce selection pressure, the total number of applications is limited to eight per year and these should not represent more than 50% of total number of sprays.				
		benomyl	Benlate					
		carbendazim	Curacarb					
	Benzimidazoles	thiophanate	Cycosin	Fungicides with high systemic and curative activity that allow long intervals between applications. Resistant <i>P. fijiensis</i>				
	(DOW)	thiabendazole	Mertect	strains were detected two years after first application.				
		thiophanate- methyl	Nucilate, Thiophol, Topsin.					
	N- Phenylcarbamates	dietofencarb,	Powmyl	No sensitivity data are yet available. A maximum of 33% of the total number of sprays can be applied with N- Phenylcarbamates.				
		boscalid	Cumora	Irrespective of the country of origin in Latin America, the				
	SDHI fungicides	fluopyram	Luna	baseline sensitivity for boscalid, fluopyram and isopyrazam is high.				
		isopyrazam	Reflect					
	Guanidines	dodine	Syllit	Irrespective of the country of origin in Latin America, the baseline sensitivity for dodine is variable. However, in Ecuador baseline sensitivity did not significantly change after two vears of applications.				

*Some trade names also include mixes with other active ingredients.

Molecular analyses of fungicide resistance in *P. fijiensis*

One of the main adaptations to environmental changes or selection pressure is the genetic variation of the target organism, which modulates and complicates sustainable disease control. Site-specific compounds often select for total resistance due to point mutations - often referred as "major gene" resistance or "monogenic" resistance - that renders these compounds ineffective (Latin 2011), including the mechanisms for resistance to benzimidazoles and strobilurins. Eventually, mutant alleles will dissipate in the population conferring partial or total resistance to a particular fungicide (Grünwald et al. 2003), whereby the epidemiology of the organism can amplify the effect and rate of dissemination (Aouini et al., 2016). The target of DMIs is lanosterol 14 α -demethylase that is encoded by *Pfcyp51* (Cañas *et al.* 2009). Recent studies revealed a correlation between propiconazole resistance and point mutations in the Pfcyp51 gene (Cañas et al. 2009; Chong et al. 2010; Lepesheva & Waterman 2004). The effect of point mutations in the *Pfcyp51* gene was also related with cross resistance to epoxiconazole and difenoconazole (Chong et al. 2016b). The plethora of Pfcyp51 mutations has resulted in a total of 28 aa substitutions (Chong et al. 2016b). From this 28 aa substitutions, positions 136, 313, 380, 381 and 460 – 463 have been associated with loss of sensibility to DMI (Cañas et al. 2009; Chong et al. 2016b). These amino acid changes are nearby central positions of the lanosterol 14α-demethylase, surrounding the Substrate Recognition Site (SRS) (e.g. positions Y136, A313, 381) and inside a loop close to the L α helix (e.g. Y460 to Y463) (Cañas *et al.* 2009; Chong et al. 2016b; Lepesheva & Waterman 2004). The large variation in genetic isoforms complicates the analysis of the enzyme and the corresponding degrees of resistance. *Pfcyp51* promoter insertions were recently discovered as a driving mechanism for *Pfcyp51* expression contributing to quantitative variation for reduced DMI sensitivity (Chong et al., 2016a, 2016b; Diaz et al., 2016). Similar mechanisms were identified in Aspergillus fumigatus isolates that are resistant to medical azole fungicides (Mellado et al. 2007; Snelders et al. 2012; Verweij *et al.* 2013). Interestingly, none of the DMI sensitive strains found in a global survey contained promoter insertions, while they were very common in tolerant and resistant strains and correlated with the levels of resistance to DMIs (Chong *et al.* 2016b). Overexpression of *cyp51* also correlated with promoter insertions in *Venturia inaequalis* and *Blumeriella jaapii* (Schnabel and Jones 2000, Ma et al. 2006), but their frequency in *P. fijiensis* is unparalleled. In *B. jaapii*, the overexpression results from upstream insertions of various truncated derivatives of LINE-like retrotransposons (Ma *et al.* 2006). However, the underlying mechanism and function of these repeated elements remains to be deciphered (Schnabel and Jones 2000, Ma et al. 2006; Diaz et al., 2016) and might involve blocking proper binding of expression reducing components or generate binding sites for positive regulators that enhance the promoter.

Supervised black Sigatoka control aided by disease forecasting systems

Forecasting systems have been essential tools for the control of black Sigatoka by using climatic and biological descriptors for the prediction of the severity of the disease (Guzmán 2007; Lapeyre *et al.* 2010b; Marín *et al.* 2003). These severity predictions are used for the timely application of the fungicide (Guzmán 2007; Lapeyre *et al.* 2010b). This allows a supervised rather than a calendar driven application, which supports efficient use of fungicides and modulates their application depending on necessary doses or frequencies. As mention above, most of the control strategies in black Sigatoka have been adapted from control programs that were developed for the milder yellow Sigatoka, which is caused by the fungus *P. musae*. The first forecasting for oil sprays was determined by symptom severity of controls that were only treated with oil (Stover 1990). Later, weather variables, such as temperature and evaporation rates, were additionally used to optimize fungicide applications by Ganry and Meyer (1972), including the use of oil and systemic fungicides (benomyl) and using a 0-5 scale

for symptom severity classes for yellow Sigatoka (Ganry & Meyer 1972; Stover 1990). After the incursion of black Sigatoka in Cameroon in 1983 the symptom development score was extended by Fouré with an additional severity class (stage 6) (Fouré 1985; Stover 1990).

Despite the overall success of these forecasting programs in a more supervised control of black Sigatoka for many years, they never took into account the cost of fungicide resistance. Since they only can be used with highly curative systemic fungicides (single target) the development of fungicide resistance interfered with their efficacy, leading to progressive abandoning of this rational strategy in favour of the systematic use of contact fungicides that must be applied every week (Lapeyre *et al.* 2010b). Hence, notwithstanding the fact that forecasting programs are still being used – in oil mixtures and based on different chemistries - as a decision making tool, there is a need for optimized and modernized programs to further fungicide efficiency in black Sigatoka control (Lapeyre *et al.* 2010b).

The way forward: integrating molecular DMI resistance parameters in disease management

Biological parameters such as the 'Stage of Evolution of Disease' (SED), the 'Youngest Leaf bearing Streaks' (YLSt), The 'Youngest Leaf Spotted' (YLS) and the 'Number of Functional Leaves at Harvest' (NLH) are very important for decision making and the evaluation of the efficacy of control strategies (Lapeyre *et al.* 2010b). Sensitivity monitoring procedures of the ascospores germ-tube inhibition have also been use for decision making, especially for the evaluation of the efficacy of control. Nonetheless, the information retrieved by this methodology is too superficial. Since is not possible to recover any molecular information from this method the information about the mechanism behind the resistance is lost. A more professional methodology has to be implemented integrating the molecular 46 information to understand the origin of the resistance. The currently available molecular information on modulation of the Pfcyp51 gene, which seems the main driver for reduced sensitivity (Chong et al., 2016c), is a potential add-on for optimizing forecasting programs and hence, disease control. Quantitative information on overall P. fijiensis population characteristics (EC₅₀ values, number of promoter inserts that can be monitored by simple PCR, but also cross resistance, multi drug resistance, fitness and virulence) in the target and neighbouring plantations - immigration and gene flow - can be used to predict the success of spraying cycles. The costs of generating these data is substantial due to sample/material preparation, but it provides a much broader view on the evolution of P. fijiensis populations that can be monitored and used to alert potential problems with reduced efficacy and hence inherent and increasing direct and indirect costs. With the continuously reducing costs for genome-based information, the use of this type of detailed information will positively contribute to optimize disease control. Governments and research institutes need to prepare themselves for advancing black Sigatoka management through interdisciplinary approaches using the latest technologies and alternative products to diversify and innovate control strategies. It is rather disturbing that monitoring of fungicide sensitivity in e.g. wheat is highly professionalized and entirely sequence based, but that black Sigatoka management is still using old-fashioned worn-out procedures that do not provide any insight in underlying mechanisms and thus prevent modernizing and rationalizing disease control. For instance, the lack of cross resistance between pyraclostrobin and azoxystrobin in *P. fijiensis* is nicely supported by a simple PCR test with specific molecular markers for the G143A substitution in the *Pfcytb* gene (Sepúlveda & Torres 2016). Such a quick scan is also possible for DMIs as we determined that aa changes at positions 313, 136 and 463 (or even combinations of these substitutions) are the most important substitutions causing reduced efficacy. In addition, promoter insertions can be visualized by a simple PCR and are important alerts for reduced efficacy of DMIs as recently

demonstrated for Costa Rica (Figure 8) (Diaz et al., 2016). Ideally, qPCR tests should be run directly on DNA preps from infected leaves to rapidly quantify and type DMI resistance in pathogen populations (Singh & Mustapha 2013). Eventually and evidently, sequence based technologies will revolutionize the discovery of underlying mechanisms of reduced sensitivities of disease control agents and will contribute to modern and optimized disease management.



Figure 8. Example of PCR amplification of the *Pfcyp51* promoter in *Pseudocercospora fijiensis* isolates from different populations. Isolate CIRAD86 (C86) was used as indicative control for the presence of one promoter element, and isolates Z8.12 and CA5_16 as controls with three and six repeat elements, respectively. The number of repeat elements in each control sample is showed over the corresponding band. The other strains originate from banana plantations under fungicide disease management and represent various promoter length variants.

Comparing the use of DMI sensitivity data in the control of the fungal wheat pathogen *Zymoseptoria tritici* and *Pseudocercospora fijiensis*

P. fijiensis and *Z. tritici* are two of the most economically important pathogens of banana and wheat, respectively (Cook *et al.* 2013; Dean *et al.* 2012; Kema 2009). The analogy between these related dothideomycetes (Arango *et al.* 2016) is key to the use of *Z. tritici* as a model for the molecular studies in *P. fijiensis* (Kema 2009; Stergiopoulos *et al.* 2014). There are also striking similarities and dissimilarities with regard to the evolution of DMI resistance in both species, which will increase the understanding of the phenomenon and how to deal with

it under practical conditions. Both diseases are foliar blights caused by species with striking similarities in lifestyle: a heterothallic bipolar mating system with both asexual and sexual reproduction that enables these pathogens to complete several sexual cycles per year, resulting in genetically very diverse and versatile populations (Arzanlou *et al.* 2010). Yet, despite numerous speculations, recent data have shown that the basis on the plant pathogen interaction is a classic gene-for-gene model with avirulence effectors and host receptors (Aouini 2016; Arango *et al.* 2016; Stergiopoulos *et al.* 2010). For both diseases, DMIs are the cornerstone of disease management (Cools & Fraaije 2013). The evolution of DMI sensitivity in *Z. tritici* is a continuous threat to growers and the agrochemical industry and therefore represents the best studied system in agriculturally important plant pathogenic fungi (Cools & Fraaije 2013). Similar to *P. fijiensis*, shifts in DMI sensitivity in *Z. tritici* populations have been gradual by nature and are therefore commonly attributed to polygenic mechanisms, including (i) alteration in the *cyp51* sequence, (ii) overexpression of the *cyp51*gene and (iii) ATP-binding cassette transporters and major facilitators, resulting in fungicide efflux (Chong *et al.* 2016; Cools & Fraaije 2013; Cools *et al.* 2013; Cowen 2008).

With regard to modulation of the *cyp51* gene, many - similar - mutations have been identified for *P. fijiensis* and *Z. tritici* (Cañas *et al.* 2009; Chong *et al.* 2016b; Cools & Fraaije 2013). In the *cyp51* gene for 36 amino aa substitutions were identified in *Z. tritici* and 28 aa in *P. fijiensis*. Some of these, identical, substitutions have been instrumental for DMI resistance (Chong *et al.* 2016b; Cools & Fraaije 2013). For example, the substitution Y136F in *P. fijiensis* is equivalent to Y137F in *Z. tritici*, and both are also linked with reduced DMI sensitivity in *Penicillium italicum, Uncinula necator* and *Blumeria graminis* f. sp. *hordei* (Albertini *et al.* 2003; Cools & Fraaije 2013; Délye *et al.* 1997). A substitution at Y136, or its equivalent in other species, is the most frequently observed modification of CYP51 in pathogenic fungi

(Cools et al. 2013). Interestingly, the equivalent position in Z. tritici, Y137F, although common in strain from the 1990s, has now virtually disappeared from the population. Cools and Fraaije (2013) associate this phenomenon with the disappearance of triadimenol, a fungicide that was commonly used in 1970s (Cools & Fraaije 2013). Substitution Y136F in P. fijiensis represents a 17.47% share in a recent global survey among 269 isolates and is primarily present in Costa Rica (2014) and Colombia (2012) (Chong et al. 2016b). It was also identified in two isolates from the Dominican Republic and in one strain from Cameroon (2014), but is absent in Ecuadoran isolates (2011) as well as strains from Martinique and Guadalupe (2013) (Chong et al. 2016b). Given the example of Z. tritici, it is of interest to study whether these differences can also be attributed to the use of particular fungicides in these countries. Substitutions V136A and I381V are correlated with reduced sensitivities to tebuconazole in Z. tritici (Cools et al. 2013). Positional changes at 380 and 381 in P. fijiensis tend to be rare, and were most prevalent in strains from Costa Rica and the Dominican Republic (Chong et al. 2016b). It would be of interest to test such isolates for sensitivity towards tebuconazole, but thereby considering that isolates that overexpress *Pfcyp51* are less susceptible and show reduced variation in their response (overexpression is not selected for based on specific DMI fungicides) (Cools & Fraaije 2013). Hence, any phenotypic test with tebuconazole should be conducted with a strain carrying substitutions at position 380 or 381, but with a wild type promoter.

Other similitudes are found in substitutions around positions 313 and 460 to 463 (Cools *et al.* 2013). In *Z. tritici* modulation of position 312 is rare, but as changes at position 313 are ubiquitous in *P. fijiensis* (Chong *et al.* 2016b; Cools & Fraaije 2013). In both species we have identified numerous as changes that do not have any apparent relation with DMI sensitivity and could either result from compensating mutation events, contingent evolution or exert pressure for the selection of important substitutions (Chong *et al.* 2016b; Cools & Fraaije

2013). CYP51 complementation experiments in *Saccharomyces cerevisiae* or *P. fijiensis* transformation experiments can be used to analyse the importance of these substitutions (Cools & Fraaije 2013; Díaz-Trujillo *et al.* 2016a). The collected data in both species clearly indicate that accumulation of mutations in the *cyp51* gene in drive reduced sensitivity to DMI fungicides (Cools *et al.* 2013). The environmental exposure of other fungi, including the human pathogen *A. fumigatus*, and the reduced efficacy of (medical) DMIs is a worrying situation with far reaching consequences for patients and potential risks for occupational health of workers in the agricultural sector (Risède *et al.* 2010; Snelders *et al.* 2012; Verweij *et al.* 2009).

Overexpression of the *cyp51* gene has been also reported in both species (Chong *et al.* 2010; Cools *et al.* 2012; Díaz-Trujillo *et al.* 2016a). In *Z. tritici* a 120 bp insertion in the promoter region correlates with a 10 to 40-fold overexpression of the *cyp51* gene (Cools *et al.* 2012). Similarly, promoter insertions in *Pfcyp51* cause an overexpression resulting in decreased sensitivity to DMIs (Díaz-Trujillo *et al.* 2016a). However, promoter insertions are very rare in *Z. tritici* but, contrastingly, common in *P. fijiensis* where the actual insertion is a repeat of a normal *Pfcyp51* promoter element of 19 bp that is repeated many times at position 103, upstream of the coding region of the *Pfcyp51* gene (Chong *et al.* 2016b; Díaz-Trujillo *et al.* 2016a). A similar tandem repeat associated reduction of DMI sensitiveness was observed in *A. fumigatus* (Mellado *et al.* 2007; Snelders *et al.* 2012; Verweij *et al.* 2013). The size, nature and location of the promoter inserts in *Z. tritici* and *P. fijiensis* are distinct and unique and therefore likely not related or due to a similar mechanism. Nevertheless, the fact that promoter insertions arose in three fungi that are commonly treated with DMIs raises important questions on their origin and role in order to improve their management both in agriculture as well as the clinical practice.

Finally, the role of transporters– either major facilitators (MFS) or ATP-binding cassette (ABC) transporters – in reduced efficacy due to increased efflux of active ingredients of fungicides has been reported in several plant and human pathogens, including *Candida albicans, A. fumigatus* and *Z. tritici* (Cools *et al.* 2013; Cowen 2008; Stergiopoulos *et al.* 2002; Zwiers 2002). Until now there is no report on increased expression of membrane transporters in *P. fijiensis*. All current evidence points to *cyp51* as the major regulator of DMI sensitivity (Chong *et al.* 2016c). Recently, Chong et al. (2016b) followed an unbiased genetic mapping approach to identify genomic regions involved in DMI sensitivity, which identified one major genetic window containing *Pfcyp51* on putative chromosome 7. However, the aforementioned genetic window contained at least 52 other genes, including a putative ABC transporter that cannot be ruled out to affect DMI sensitivity and await functional analysis (Chong *et al.* 2016c).

The *P. fijiensis* – banana interaction and its epidemiology impact on black Sigatoka disease

As pointed out above, recent studies have shown that the *P. fijiensis* homologue of the *Cladosporium fulvum Avr4* effector is recognized by the tomato *Cf4* resistance gene (Stergiopoulos et al., 2010; Arango et al., 2016). Moreover, the allelic variation at this *PfAvr4* locus is limited to just six variants (Stergiopoulos et al., 2014). Since Calcutta 4 (*M. acuminata* ssp. *burmannica*, a wild diploid banana) showed a typical hypersensitive response to *P. fijiensis* isolates carrying *PfAvr4*, it is considered that wild banana germplasm carries homologues of *Cf4* that can be used in either classical breeding or genetic engineering approaches (Arango et al., 2016). Similar to the situation in *Z. tritici*, a basic understanding of the pathosystem will eventually lead to enhanced breeding efforts that will lead to the discovery of new resistance genes for black Sigatoka management. Thus far, this is not seriously addressed and hence, all 52

breeding efforts rely on just natural infection. A more targeted approach taking into account the achievements in other similar pathosystems, such as the wheat-*Z. tritici* pathosystem (Mirzadi Gohari *et al.* 2015), will greatly advance breeding output and efficiency, which eventually will exploit natural host resistance as a major factor for disease control. Surprisingly, this is hitherto virtually neglected as a breeding target in banana.

The long road to a sound black Sigatoka disease management

First of all, it is important to note that black Sigatoka is primarily a problem in large monoculture export plantations that are dominated by "Cavendish" clones. However, the disease is definitely also of importance for non-export countries such as India and Brazil that either grow increasing volumes of "Cavendish" clones, or a suite of different varieties with greater appreciation by the consumer, respectively. Backyard farmers' crops may be affected by the disease as well, but need a completely different approach through targeted small-holder oriented programs. These are increasingly driven by commercial breeding companies, as for other tropical including cucurbits crops, potatoes, and peppers, see also http://www.accesstoseeds.org. In any case, host resistance is a cornerstone for appropriate, effective disease management and this philosophy is absent in the global banana industry, where black Sigatoka is considered as a disease one can deal with due to the fungicide solution, despite the enormous costs (on average at least 1,000 - 1,500 USD.ha⁻¹.year⁻¹). However, any political decision or consumer preference to reduce the chemical load in banana production or a legal abandonment of aerial spraying will directly affect the industry and call for more sustainable ways to control the disease. Instead of short-sightedness, the industry needs strategy and vision. This warrants increased efforts to professionalize breeding programs supported by sound

scientific data. The recent suite of papers on black Sigatoka disease management and biology contribute to this raising awareness (Chong *et al.* 2016b; Chong *et al.* 2016c; Díaz-Trujillo *et al.* 2016a).

The current review and the research referred to clearly indicate that the ceiling of chemical control of black Sigatoka is approaching or has been reached in some cases. One can simply not spray banana crops on a daily basis. Hence, alternative products with different moa's and broader, multisite targets are indispensable for continued disease control. Meanwhile, sensitivity monitoring has to undergo a major shift towards scientifically oriented strategies using the latest technologies rather than old-fashioned worn-out methodologies that exist purely at the expense of production zones in the developing world. The continuously increasing resistance to systemic fungicides in the field is a clear wake-up call for the industry that now progressively falls back on protectants that are both environmentally unfriendly and threaten occupational health of farm workers, employees and surrounding villagers (van Wendel de Joode et al. 2016). Hence, governments, industry and the logistic chain players have to acknowledge and consider their responsibilities and undertake actions to ensure the trialling and release of new systemic fungicides and their integration with appropriate control strategies. In addition, the power of the retail sector and eventually of primarily Western consumers has to be leveraged with programs that constructively connect actors in banana production and the trade and simultaneously dovetails programs to support sound and sustainable banana production with justified wages for all chain participants. A low price in Western supermarkets at the expense of low wage countries is old fashioned, unjustified and conflicts with the current view on the distribution of wealth and harmonized good agricultural practice. However, strategic changes and solutions - such as diversified resistant banana germplasm - will only slowly surface, simply because these will take time and require substantial budgets to

materialize. Technically, major improvements of disease control methods can rapidly be achieved by (enabling the) adoption of new discoveries and using these in overall decision support systems as outlined above (Lapeyre, 2010; Risède et al., 2010). For instance, disease forecasting programs will work appropriately under suboptimal conditions for black Sigatoka disease development such as the dry tropics (Lapeyre, 2010). The challenge is to translate these to the wet tropics where *P. fijiensis* thrives and continuously undergoes sexual reproduction turning it into an extremely versatile pathogen. There, continuous monitoring of the fungicide sensitivity is one of the major tools for the timely and accurate modulation of forecasting and control strategies, which can be aided by the application of accurate and rapid molecular monitoring tools such as PCR-based technologies that will extend the timeframe for an adequate supervised response. Lessons from other crops should be learned in banana cropping thereby assuring a continued and justified access to food and fruit.

Supporting information

Table S1.- Example of fungicide application data sheet for the San Pablo plantation in Costa

 Rica.

DIRECCIÓN DE INVESTIGACIONES-CORBANA ASISTENCIA TÉCNICA EN EL MANEJO DE LA SIGATOKA NEGRA REGISTRO DE ASPERSIONES											
Farm: San Pablo Este Year: 2015											
		Program	Оре	ration	Oil	Oil	Cycle		\$ (Irrigation)		
Week	Date	Fungicide Mix	Date	Mix	L/ha	Mz	Nu.	D.C.	ha cycle	/ha/pdo	Observatio ns
52/14					142.5	26.0	50				System. aplic.: Triaz.= 7, Aminas= 13, Benz.= 0
											Pyri.= 4, Carboxa= 1 y Estrob.= 2. Total= 13
1	28-Dec	Dithane 1,75+3+NF	Dec 28	D1,75+N F	3	0.92	1	6			MaxiBoost (0,6) / 161 ha
1	3-Jan	Dithane 1,75+4+NF	Jan 3	D1,75+N F	4	0.92	2	6			TechnoZn (1) / 157 ha
3	12-Jan	CSiCa2+9 (Calixin + Sico)	12	CSiCa2	9	1.00	3	9			155 ha
4	21-Jan	Volley (fenpropimorph) + Dithane 1+1,9+8	22	CVo(1)1, 9	8	1.00	4	10			152 ha
5	27-Jan	Dithane 1,75+3+NF	27	D1,75+N F	3	0.92	5	5			TecnokZn (1) / 147 ha (renov c. 14- 19)
5	31-Jan	Dithane 1,75+3+NF	31	D1,75+N F	2	0.92	6	4			Phytocrop (1) / 147 ha
7	9-Feb	Opus (epoxiconazole) Impulse (Spiroxamide) Dithane 1,9+9	Feb. 8	COplm1, 9	9	1.00	7	8			Adel x progr / 148 ha
8	18-Feb	Impulse(Spiroxamide) Siganex (AP) Dithane 1,9+9	18	ClmSx1, 9	9	1.00	8	10			147 ha
9	24-Feb	Dithane 1,75+3+NF	24	D1,75+N F	3	0.92	9	6			TecnokZn (1)
10	1-Mar	Dithane 1,75+3+NF	Mar. 3	D1,75+N F	4	0.92	10	7			Atra x clima / MaxiBoost (0,6)
11	10-Mar	CVo 0,85+1,9+6 (fenpropimorph + mancozeb)	10	CVo0,85 +1,9	7	1.00	11	7			
11	14-Mar	Dithane 1,75+2+NF	14	D1,75+N F	2	0.92	12	4			TecnokZn (1)
12	21-Mar	CSx1,9+6 (pyrimethanil + mancozeb)	21	CSx1,9	6	1.00	13	7			
13	26-Mar	Dithane 1,75+3+NF	26	D1,75+N F	3	0.92	14	5			NutriProtect or (0,51)
14	31-Mar	Dithane 1,75+3+NF	31	D1,75+N F	2	0.92	15	5			Psac (1)
15	9-Apr	CTiCa1,9+7 (mancozeb +tilt +tridemorph)	Apr. 9- 12	CTiCa1, 9	7.5	1.00	16	9			Ti= Tilt / Atra x clima / Día 12, aceite 8

DIRECCIÓN DE INVESTIGACIONES-CORBANA ASISTENCIA TÉCNICA EN EL MANEJO DE LA SIGATOKA NEGRA REGISTRO DE ASPERSIONES											
Farm: San Pablo Este Year: 2015											
		Program	Ope	ration	Oil	Oil	Cycle		\$ (Irrigation)		
Week	Date	Fungicide Mix	Date	Mix	L/ha	Mz	Nu.	D.C.	ha cycle	/ha/pdo	Observatio ns
16	15-Apr	Dithane 1,75+2+NF (Mancozeb)	18	ClmSx1, 9	8	1.00	17	9			Reprog x atra y clima
17	23-Apr	Dithane 1,75+2+NF (Mancozeb)	23	D1,75+N F	2	0.92	18	5			Día 25 renov 2014: Sx+5 (19,5 ha) / FolivFe (1)
18	28-Apr	DBg1,5+1 (Mancozeb)	28	DBg1,5+ 1	0	0.79	19	5			Psac (1)=\$4,80
19	3-May	D43Br1,35+0,5 (Dithane + Bravo)	May 3	D43Br	0	0.10	20	5	5		1,35+0,5 / TecnoZn (1)
20	8-May	Br1,2 (Chlorothalonil)	10	D1,75+N F	2	0.92	21	7			Atra y reprog x clima
21	20-May	Regnum Calixin Dithane 1,9 + 9	21	CRgCa1 ,9	9	1.00	22	11			Atra x clima
22	30-May	Impulse Siganex Dithane 1,9+8	30	ClmSx1, 9	8	1.00	23	9			
23	4-Jun	Dithane 1,75+2+NF	Jun. 4	D1,75+N F	2	0.92	24	5			Psac (1)
24	9-Jun	Dithane 1,75+2+NF	9	D1,75+N F	2	0.92	25	5			
25	14-Jun	Dithane 1,75+2+NF	14	Po1,35+ NF	2	0.00	26	5			x falta de Dith 60 /
27	20-Jun	Dithane 1,75+2+NF	28	CSvlm1, 9	9	1.00	27	14			Banazeb/Re prog x clima/Rep espec 16-17 S (Sx0,25, 19 ha)
29	9-Jul	Cumora Siganex Banazeb 2+9	Jul. 14	CCuSx2	9	1.00	28	16		1 - 5	Atra x clima
29	13-Jul	Bb1,75+2+NF (Mancozeb)	18	Bb1,75+ NF	2	0.92	29	4			Bb=Banazeb (mancozeb)/ MaxiB+Psac (0,5+0,56)
30	23-Jul	BbNTZn1,5+1,5+4+NF (Mancozeb)	24	BbNZn+ NF	4	0.92	30	6	3 92		NZnP (cera) (1,5) / Atra x clima
31	1-Aug	Volley (1) Banaz 2+9	Agu. 1	CVo1+1, 9	9	1.00	31	8	;		
33	10-Aug	Sico Calixin Banaz 1,9+9	11	CSiCa1, 9	9	1.00	32	10		5 - 12	
33	16-Aug	BbNZn1,5+2+3+NF	17	BbNZn+ NF	4	0.86	33	6			Atra x clima/NZn:1 v x proveedor/B bNF1,75+0, 3:1 v
34	22-Aug	Dithane 1,75+3+NF	22	Bb1,75+ NF	3	0.92	34	5			Psac (1)
35	26-Aug	Dithane 1,75+3+NF	26	Bb1,75+ NF	2	0.92	35	4			TechnoCa (1)

DIRECCIÓN DE INVESTIGACIONES-CORBANA ASISTENCIA TÉCNICA EN EL MANEJO DE LA SIGATOKA NEGRA REGISTRO DE ASPERSIONES											
Farm: San Pablo Este Year: 2015											
		Program	Оре	ration	Oil	Oil	Cycle		\$ (Irrigation)		
Week	Date	Fungicide Mix	Date	Mix	L/ha	Mz	Nu.	D.C.	ha cycle	/ha/pdo	Observatio ns
36	3-Sep	Impulse Siganex Banaz 1,9+8	Set. 3	ClmSx1, 9	8	1.00	36	8			
37	8-Sep	BbNZn1,5+2+3+NF	10	BbNZn+ NF	5	0.79	37	7	7		NTZnP (2) / Sin Mist Control
38	17-Sep	Volley Banaz 1,9+7	17	CVo1,9	7	1.00	38	7		14	
39	22-Sep	Bb1,75+3+NF	22	BbPhCu	3	0.26	39	5			0,50 + PhCu 0,53
39	27-Sep	Bb1,75+3+NF	27	Bb1,75+ NF	3	0.79	40	5			Tecamin (1)
41	5-Oct	Tilt Calixin Banaz 1,9 +8	Oct. 6	CTiCa1, 9	8	0.92	41	9		6 - 15	
41	10-Oct	BbNZn1,5+2+3+NF	10	BbNZn+ NF	2	0.79	42	4			
42	15-Oct	Bb1,75+3+NF	15	Bb1,75+ NF	3	0.92	43	5			FolCa+Ever est
43	23-Oct	Volley Banaz 1,9+7	23	CVo1,9	7	1.00	44	8	8		Naturamin (150 g)
44	29-Oct	BbNZn1,5+2+3+NF	29	BbNZn+ NF	2	0.79	45	6			
45	4-Nov	Bb2+2 (Macozeb)	Nov. 4- 5	Bb2	2	0.92	46	6			Prueba con fruta sin bolsa y agua de reuso
46	10-Nov	Bb1,75+3+NF	10-12	Bb1,75+ NF	2	0.92	47	6			TechnoCa+ NitK (1+1) / Atra x clima / 12: aceite 3
48	16-Nov	Bb1,75+3+NF	17	Bb1,75+ NF	4	0.92	48	6			
48	25-Nov	Regnum Siganex Banaz 1,9 + 8	26	CRgSx1, 9	8	1.00	49	9			Atra x clima
49	5-Dec	Opus Impulse Banaz 1,9+8	Dec. 4	COplm1, 9	8	1.00	50	9			
50	11-Dec	Bb1,75+2+NF	10	Bb1,75+ NF	2	0.92	51	6			
51	15-Dec	BbNZn1,5+1,5+2+MC	15	BbNZn+ MC	2	0.79	52	5			
52	20-Dec	Bb1,75+2+NF (0,20)	23-24	ClmSx1, 9	8	1.00	53	8			Reprog x clima y atraso
CCa=Cal Br=Bravo	ixin + Dithano	ə, Rg= Regnum, CSx=Siganex +	Dithane,							Sistém. aplic.:Triaz.= 7, Aminas= 18, Benz.= 0	
				Subtotal :	251.5	47.1	53				Pyri.= 6, Carboxa= 1 y Estrob.= 2. Total= 21
			Total:	298.6							

Chapter 3

Global analysis of reduced sensitivity to azole fungicides in the banana black Sigatoka pathogen *Pseudocercospora fijiensis*

Pablo Chong^{1,11}, Josué Ngando Essoh^{2,10}, Rafael Arango³, L. C. Paul Keizer⁴, Ioannis Stergiopoulos⁵, Michael F. Seidl⁶, Mauricio Guzman⁷, Jorge Sandoval⁷, Paul E. Verweij⁸, Gabriel Scalliet⁹, Helge Sierotzski⁹, Luc de Lapeyre de Bellaire¹⁰, Pedro W. Crous^{6,12}, Jean Carlier¹¹, Sandrine Cros¹⁰, Harold J. G. Meijer¹³, Esther Lilia Peralta¹ and Gert H. J. Kema^{6,13}

Abstract

Pseudocercospora fijiensis is the causal agent of black Sigatoka or black leaf streak disease of bananas and plantains. Due to the overall susceptibility of the main export Cavendish bananas, black Sigatoka management largely relies on fungicides, predominantly on multisite inhibitors and azoles, which belong to the sterol demethylation-inhibitors (DMIs) that target the lanosterol 14 α -demethylase enzyme CYP51. We examined the azole sensitivity of 592 field isolates of P. fijiensis collected from various banana production zones in Colombia, Costa Rica, the Dominican Republic, Ecuador, the Philippines, Guadalupe, Martinique and Cameroon. Continuous sensitivity ranges towards the DMIs fungicides difenoconazole, epoxiconazole and propiconazole was observed with clear patterns of cross-sensitivity. Genotyping by sequencing was applied to study the overall genetic diversity in a geographical subset of 155 P. fijiensis strains, which revealed a distinct clustering based on the geographical origins of the isolates, with clear subclades for African, Latin American and the Caribbean isolates. Finally, sequence analyses of the CYP51 encoding gene *Pfcyp51* in 266 isolates showed a wide suite of mutations. Twenty-eight independent point mutations result in amino acid (aa) substitutions with nine of them correlating with reduced sensitivity to DMIs. Moreover, we identified nine novels regionally disseminated as substitutions. The majority of the substitutions correlated with reduced sensitivity to DMIs are in the proximity or affect the putative substrate-binding site based on in silico predictions of the CYP51 protein models. In addition, up to six – sometimes unique - insertions in the Pfcyp51 promoter could be found in strains displaying reduced azole sensitivity. Such promoter insertions correlate with reduced DMI sensitivity and, frequently contain repeated elements with a palindromic core. Wild type strains from unsprayed bananas in Ecuador, Colombia and Cameroon did not contain any promoter insertions. Our study is the first global analysis of fungicide resistance in *P. fijiensis*,

and provides a lead to understand DMI sensitivity reduction, and enables the development of better black Sigatoka management strategies, but also calls for the deployment of a wider range of solutions for a sustainable control of this unparalleled banana threat.

Introduction

Banana is an important staple food (plantain AAB, 2n=3x=33; cooking banana ABB, 2n=3x=33)(D'Hont et al. 2012; Perrier et al. 2011) and the most popular fruit (dessert banana usually AA or AAA, 2n=2x=22 and 3n=3x=33, respectively)(Ploetz et al. 2015) around the world. Commercial banana production is dominated by "Cavendish" cultivars that almost exclusively comprise the export trade (95%), but that are also increasingly important for domestic markets in many countries, such as India and China (Ploetz et al. 2015). Moreover, Cavendish plantations are actively developed in the Middle-East and East Africa as an important cash crop (Shively & Hao 2012; Zeitoun et al. 2012). The success of Cavendish clones is largely explained by their resistance to Panama disease that wiped out "Gros Michel" banana cultivar in Central America in the previous century. However, banana production using "Cavendish" clones also facilitates the dissemination of a new Panama disease causing strain of the soil-borne Fusarium oxysporum f.sp. cubense (the so-called Tropical Race 4 strain, (Ordoñez et al. 2015)) that threatens global banana production. A major foliar blight affecting global banana and plantain production is black Sigatoka or black leaf streak disease, which is caused by the dothideomycete fungus Pseudocercospora fijiensis (previously Mycosphaerella fijiensis). Contrary to Panama disease, P. fijiensis colonizes and destroys the foliage by developing characteristic necrotic spots that eventually coalesce in large blotches that destroy the leaves (Figure S1), thereby initiating physiological adaptations that results in premature

fruit ripening, which is a major secondary post-harvest loss (Stover & Simmonds 1987). Due to the extreme susceptibility of "Cavendish" bananas, black Sigatoka is considered as the costliest banana disease requiring extraordinary fungicide input that threatens the environment and affects the occupational health of plantation workers (Risède et al. 2010; van Wendel de Joode et al. 2016). The increasing fungicide applications (Chong et al. 2016a; de Lapeyre de Bellaire 2009) exert an enormous selection pressure on *P. fijiensis* populations that gradually affect the efficacy of the applied fungicides. Sterol demethylation-inhibitors (DMIs) are the commonest applied systemic fungicides for black Sigatoka management (Cañas et al. 2009). These fungicides interfere with the catalytic site of the lanosterol 14 α -demethylase enzyme, also known as CYP51 (Cañas et al. 2009), which is a key player in ergosterol biosynthesis by catalysing the demethylation of lanosterol via its heme bound iron atom in the substrate recognition site (SRS) (Akins & Sobel 2009; Lepesheva & Waterman 2004; Warrilow et al. 2013). The continuous and massive use of DMI fungicides has contributed to the selection of reduced sensitivity and eventual resistance in P. fijiensis populations (Cañas et al. 2009; Chong et al. 2016a; Churchill 2011a; Guzmán et al. 2013; Marín et al. 2003; Ploetz 2000). Selection and concurrent spread into and across P. fijiensis populations highly depends on the applied fungicides and the properties of the pathogen population (Lapeyre et al. 2010b; Robert et al. 2012; Vincellin 2014). The link between DMI fungicides overuse and the occurrence of reduced efficacy and concurring genetic variation at the target site has been demonstrated in many fungal species (Becher & Wirsel 2012; Cools et al. 2013; Villani et al. 2016; Warrilow et al. 2013). The commonest observed genetic mechanisms of DMI resistance are nonsynonymous point mutations in the coding region of the cyp51 gene resulting in modified versions of the CYP51 protein, and changes in the *cyp51* gene promoter resulting in elevated expression levels (Akins & Sobel 2009; Albarrag et al. 2011; Albertini et al. 2003; Bean et al. 2009; Bolton et al. 2016; Cools et al. 2012; Cools et al. 2013; Délye et al. 1997; Díaz-Trujillo

et al. 2016a; Dyer *et al.* 2000; Eddouzi *et al.* 2013; Hamamoto *et al.* 2000; Ma *et al.* 2006; Mellado *et al.* 2007; Schnabel & Jones 2000; Verweij *et al.* 2013). Point mutations in the *cyp51* coding region mostly result in amino acid (aa) changes within the six SRS (SRS1-6) regions (Cañas *et al.* 2009; Lepesheva & Waterman 2004), which are peptide chains regions at the protein core that interact with the target substrate. The mentioned substitutions do not inactivate the enzyme but compromise fungicide binding affinity (Cools *et al.* 2012; Lepesheva & Waterman 2004). The most common substitutions in the *P. fijiensis cyp51* gene (*Pfcyp51*) are at positions Y136 and A313, inside the putative SRS1 and SRS4 respectively, and substitutions Y461 and Y463 (Cañas *et al.* 2009; Chong *et al.* 2010). Interestingly, *P. fijiensis* isolates from Costa Rica with an accumulated number of mutations in the *Pfcyp51* gene also contain promoter insertions (Díaz-Trujillo *et al.* 2016a). The insertions in the *Pfcyp51* promoter are composed of repeated elements. Promoter replacement analysis showed that these repeats alone are responsible for increased EC₅₀ values (Díaz-Trujillo *et al.* 2016a).

Although there is information regarding the genetic variation of *P. fijiensis* at specific geographical locations (Halkett *et al.* 2010; Hayden *et al.* 2003; Robert *et al.* 2012), the relationship between genetic diversity with DMI usage is currently lacking. Here, we analyse the molecular effects underlying reduced sensitivity and resistance towards DMI fungicides by phenotyping the azole sensitivity of 592 isolates. These data are further supported by sequencing the *Pfcyp51* gene and promoter region of a 266 isolate subset, collected worldwide from major banana producing countries. Furthermore, we show a positive correlation between increased DMI applications, the presence of specific genetic modifications in the promoter and coding region mutations of *Pfcyp51* and reduced azole sensitivity. We also modelled the impact of amino acid changes at the substrate recognition site of the PfCYP51 protein, indicating which mutations possibly contribute significantly to azole resistance. Our findings

support the hypothesis that DMIs exert a stringent selective pressure on *P. fijiensis* in banana plantations globally.

Materials and methods

Pseudocercospora fijiensis strains and inoculum

A suite of 592 *P. fijiensis* strains from major banana producing and indigenous regions in Africa, Asia and Latin America was collected and analysed in this study (Table 1). A random set of strains from this global collection was tested for confirm their specie identity based on the elongation factor-1 α sequence, which was amplified with primers EF1-728F (5'-CATCGAGAA GTTCGAGAAGG-3') and EF1-986R (5'-TACTTGAAGGAACCCTTACC-3') (Carbone & Kohn 1999) and analysed using the NCBI genome database and the *P.(Mycosphaerella) fijiensis* v2.0, JGI genome portal.

Originally, 612 isolate were collected but we were unable to recover 20 *P. fijiensis* isolates from the collection preserved (Preserving solution: 50% of potato dextrose broth and 30% glycerol) at -80°C, and hence 592 *P. fijiensis* isolates were available for subsequent phenotyping. From this set 266 isolates were selected based in their DNA quality and their phenotyping for genotypic analyses, including strains from which we had genomic DNA (gDNA) or *Pfcyp51* sequences available. Five sensitive isolates (X845, X846, X847, X849 and X851) were used to compare the sequence variation among *Pfcyp51* wild type genes but were not phenotype in this study. We regarded these strains as DMIs sensitive, based on available information for their response to propiconazole (Díaz-Trujillo *et al.* 2016a).

Country / collection	Year of collection	lsolates DMI sensitivity tested	<i>Pfcyp51</i> Sequenced	Population characteristics	DMI and total fungicide application per year of collection
Colombia CIB UBALMED	late 2012	98	34	Treated farms and a subset of 13 isolates from non-treated zones	DIM estimated application: 7 cycles from a total of 32 cycles
Costa Rica CORBANA	early 2014	107	33	Treated farms	DIM estimated application: 7 cycles from a total of 56 cycles
Dominican Republic CIRAD	early 2013	25	23	Treated farms	Data undetermined
Ecuador CIBE-ESPOL	early 2011	101	40	Treated farms and a subset of 25 isolates from non-treated zones	DIM estimated application: 13 cycles from a total of 30 cycles
Philippines PRI-WUR	early 2013	98	28	Treated farms	DIM estimated application: 12 cycles from a total of 54 cycles
Guadalupe CIRAD	early 2013	30	3	Non-treated (low exposure)	DIM estimated application: 6 cycles from a total of 10 cycles
Martinique CIRAD	early 2013	42	5	Non-treated (low exposure)	DIM estimated application: 9 cycles from a total of 11 cycles
Cameroon CIRAD	midst 2014	90	94	Treated farms and a subset of 25 isolates from non-treated zones	DIM estimated application: 7 cycles from a total of 45 cycles
Individual sensitive isolates* WUR	2009	1	6	Non-treated	Non-treated zones
Total:	8 collections	592	266		

Table 1. Origins and characteristics of the *Pseudocercospora fijiensis* isolates used in this study.

*(Indonesia, Gabon, Burundi, Taiwan, Philippines and Cameroon)

Inoculum preparation

Inocula were prepared by using the protocol of Peláez et al. (Peláez *et al.* 2006) with modifications. In short, a piece of mycelium (~0.5 cm²) from a 3-4 weeks old *P. fijiensis* colony grown on potato dextrose agar (PDA) medium was blended for 20 sec. at 6,000 rpm in an Ultra Turrax Tube Drive homogenizer (IKA, Staufen, Germany) using a sterile DT-20 tube (IKA, Staufen, Germany) in 15 ml of distilled water. Mycelial pieces were filtered through the Steriflip Vacuum-driven Filter System (Sterile 100 μ m; Merck Millipore, Billerica, USA) and quantified in a Kova glasstic slide 10 with a grids coverslip microscope slide (Kova,

California, USA). The mycelial fragment concentration was adjusted to approximately 5×10^5 .ml⁻¹.

Fungicide testing

Syngenta Crop Protection AG, Basel, Switzerland, provided technical grade quality fungicide samples of propiconazole and difenoconazole. Epoxiconazole was obtained from Sigma (Sigma Aldrich, Missouri, USA). The propiconazole and difenoconazol azoles were maintained as 50.000x stock solutions and epoxiconazole as a 20.000x stock solution in DMSO. Fifty µl of mycelium solution was mixed with 200 µl PDB medium supplemented with antifungal compounds in flat bottom transparent polystyrene non-coated 96-wells microtiter plates (Corning, New York, USA).

Each strain was initially tested in duplicate, against seven concentrations (0.004, 0.016, 0.04, 0.16, 0.64, 2.56 and 10.24 mg.L⁻¹) for each fungicide and a water control. In a secondary screening, a selected subset - based on their geographical origin and sensitivity response - of 212 isolates was re-evaluated in at least three biological repetitions. Finally, a third test was performed for 21 DMI resistant *P. fijiensis* isolates (>10 mg.L⁻¹ in the initial test) against extended final concentrations using 0, 0.64, 2.56, 10.24, 15.36, 20.48, 30.72, 40.96 mg.L⁻¹. In all experiments, the final concentration of DMSO was kept at 1% (v/v) and plates were incubated in the dark at 27°C for 10 days. Mycelium growth was determined after removing the cover of the plates using a micro plate reader Infinite® 200 PRO machine, TECAN, Switzerland, which was calibrated at room temperature (wavelength 690 nm, multiple reads per well in a 5x5 circle-filled form, bandwidth 9 μ m, number of flashes 5 and 1 mm exclusion from well walls). The concentration that resulted in 50% growth inhibition

(EC₅₀) was determined by plotting the growth profiles from the OD readings, adjusted for the background. Monotone regression spline functions (Ramsay 1988) were applied to fit the curve profiles using GenStat 18th Edition software (VSN International, Hemel Hempstead, UK). The EC₅₀ sensitivity threshold ranges for all fungicides were arbitrary chosen based on the clustering analyses of the ²log EC₅₀ means standard error of the differences and the genetic information of the *Pfcyp51* gene. The EC₅₀ sensitivity thresholds selected for the strains grouping were: resistant >1 mg.L⁻¹, tolerant from 0.1 to 0.99 mg.L⁻¹ and sensitive <0.1 mg.L⁻¹.

Pfcyp51 sequencing

The coding region of the *Pfcyp51* gene and its promoter were amplified using the specific primers CYP51 Pfijien F1 (5'-AAGGTCATATCGCAGG-3') and CYP51 Pfijien R1 (5'-GAATGTTATCGTGTGACA-3'). The PCR program consisted of an initial denaturation step at 94°C for 5 min, followed by 34 cycles of denaturation at 94°C for 30 seconds, annealing at 55°C for 30 seconds and an extension at 68°C for 90 sec. A final extension step was performed at 72°C for 7 min. The expected amplicons ranged from 2 to 2,2 Kb and were directly sequenced by Macrogen (Seoul, Korea) using the amplification primers and additional sequencing primers: CYP51_Pfijien_F2 (5'-ACAGAAACATCACCTCC-3', CYP51 Pfijien F3 (5'-ATTGCTTCACTTTCATCC-3'), CYP51 Pfijien F4 (5'-CTCTACCAC GATCTCGAC-3') and CYP51_Pfijien_R2 (5'-GATATGGATATAGTTGT-3'). For each strain the sequences were assembled using SeqMan (Lasergene v8 software from DNASTAR®). Contigs were aligned and analysed using CLC Genomic software version 7.5.2 from Qiagen (Hilden, Germany). The wild type P. fijiensis strain CIRAD86 was used as reference to determine the number and type of mutations in each isolate. We used MEME (Bailey & Elkan 1994), GLAM2 (Frith *et al.* 2008) and ESEfinder 3.0 (Cartegni *et al.* 2003) software to analyse the promoter region of *Pfcyp51*.

Model building and docking studies

The three-dimensional structures of seven PfCYP51 proteins (hybrid models) were predicted using YASARA software (http://www.yasara.org). The hybrid models, were predicted using a three-dimensional template of the CYP51 proteins from Aspergillus fumigatus (PDB code: 4UYM) (Hargrove et al. 2015), Saccharomyces cerevisiae (PDB code: 4LXJ and 4K0F) (Monk et al. 2013), Homo sapiens (PDB code: 3JUS) (Strushkevich et al. To be publish) and Mycobacterium tuberculosis (PDB code: 2W0B) (Chen et al. 2009). From each template five variant models were generated. Each variant model was scored with the Zscores calculated from molecular dynamics force field energies. The variants with the best Zscores were selected to build the final hybrid models. The crystal structure of the lanosterol 14α -demethylase (CYP51b) from A. fumigatus in complex with voriconazole was used as main template. The same software package was applied for simulating the docking of propiconazole in the SRSs of CYP51. The chemical structure of the tested fungicide propiconazole (PubChem retrieved PubChem code 43234), was from (http://pubchem.ncbi.nlm.nih.gov/compound/propiconazole). The global distance test was performed using default settings. Active side residues were defined as those within 7Å (Chen et al. 2010) of the substrate closest atom. The selected modelled genotypes are listed in Table S3.

DArTseq markers generation

A set of 155 *P. fijiensis* isolates were selected based on origin and DNA quality and genotyped using DArTseq sequencing technology (www.diversityarrays.com/). DNA samples were processed in digestion/ligation reactions as described before (Kilian *et al.* 2012). The technology was optimized for *P. fijiensis* by replacing a single *Pst*I-compatible adaptor with two separate adaptors corresponding to two different Restriction Enzyme (RE) overhangs. The *Pst*I-compatible adapter was designed to include the Illumina flow cell attachment sequence, a sequencing primer sequence and a "staggered" varying length barcode region (Elshire *et al.* 2011). The reverse adapter contained the flow cell attachment region and a *Mse*I-compatible overhang sequence so that only "mixed fragments" (*PstI-MseI*) amplify effectively by PCR.

Equimolar amounts of amplification products from each sample of the 96-well microtiter plate were bulked and applied to c-Bot (Illumina) bridge PCR followed by sequencing on an Illumina Hiseq2000 apparatus. Sequences generated from each lane were processed using proprietary DArT analytical pipelines (Kilian *et al.* 2012). In the primary pipeline, the fastq files were first processed to filter for poor quality sequences, applying more stringent selection criteria to the barcode region compared to the rest of the sequence resulting in reliable assignments of the sequences to specific samples. Approximately 2,000,000 sequences per barcode/sample were identified and used in marker calling. Identical sequences were collapsed into "fastqcoll files" and subjected to a second pipeline for further quality selection criteria (Kilian *et al.* 2012). Finally, the score markers (presence/absence of restriction fragments) were represented in a 0/1 binary matrix for usage in the genetic similarity calculation.

Population clustering analyses

To determine the genetic diversity of *P. fijiensis*, we utilized the DArTseq markers of the 155 isolates that originated from eight distinct geographical locations. DArTseq markers were quality filtered (Qpmr >2.7, Reproducibility =1, CallRate >0.66), resulting in 6,586 polymorphic DArTseq markers. Based on the presence or absence profiles of these markers, the Jaccard-distance between isolates was determined using R (<u>http://www.R-project.org</u>) (R-Development-Core-Team 2008). Subsequently, complete hierarchical clustering analysis was performed, as implemented in R (R-Development-Core-Team 2008).

Analyses of *P. fijiensis* strains with the sensitivity trait

For practical reasons, not all 592 isolates could be tested on three fungicides in replication, as is described above. A single estimate on all fungicides was made for 294 isolates, while for 253 isolates the EC_{50} was estimated in triplicate (for the majority). Only 45 isolates did not give a proper EC_{50} estimate to all fungicides. The data was first analysed with a full factorial ANOVA model comparing main effects and interactions for experimental factors isolates and fungicides. Prior to analysis the data were ²log-transformed to obtain homogeneity of variance and a better approximation by the normal distribution. The interaction space of this ANOVA with (3-1).(592-1) parameters, if significant, can be described with more succinct models.

The Finlay-Wilkinson model (FW) (Eberhart & Russell 1966; Finlay & Wilkinson 1963) describes the interaction between two factors in a more parsimonious nonlinear form. It models one of the factors as a product with a linear relation to the other. This relation can depend either on the fungicide or isolate with EC_{50} ; $y_{iik} = Fungicide_i + b_i x Isolate_i + \varepsilon_{iik}$ or y_{iik}

= Isolate_i + b_i x Fungicide_j + ε_{ijk} . This results in 'sensitivities' (b_i) for fungicides or isolates indicated by the steepness of the slope. For isolates this results in nearly 600 lines as sensitivities of each isolate independently, while for fungicides it uses only three lines to describe the general sensitivity response towards each fungicide. Sensitivity above 1 means more sensitive and vice versa.

Analyses of the sensitivity trait with Pfcyp51 mutations

From a subset of 266 isolates, 23 substitutions, binary variables, were established and a promoter palindromic factor with 6 levels (*Pfcyp51* sequencing). Included are the fungicide treatment and country as explanatory factors, with 3 and 8 levels. The FW estimates of the EC50 sensitivities were taken as the response or dependent variable in a regression model, with the mutations and promoter, country and fungicide are explanatory. To analyse main effects of the substitutions alone, these were first fitted with a step-forward approach to select the most explanatory ones without the expected moderating and/or confounded effect of the promoter or the other factors. These selected substitutions were subsequently subjected to an all-subset selection procedure, where we can decide which subset of significant substitutions forms the most stable combination. These most explanatory substitutions variables were used to refit the model, now with the promoter and fungicide factor added as main effects. In the next three steps, possible first order interaction terms with the mutations were added with forward selection followed by backward elimination. Each of these rounds tries iteratively to include subsequent interaction terms based on a forward inclusion ratio and overall significance and retains only the best fitting combinations. First among the mutations themselves, then mutations with promoter and finally mutations with fungicide and country. The model resulting from this process is refitted to arrive at a final model with backward

elimination to see if any previously included interaction terms have become superfluous. The 23 mutations were pairwise tested for interaction with Fischer's Exact test on independence, which can be used to judge the plausibility to accept or discard certain results from the subsequent model fitting.

Results

Pseudocercospora fijiensis specie confirmation

Different species of the fungal genus *Pseudocercospora* cause very similar symptoms on banana. Moreover, these species also morphologically resemble *P. fijiensis* and can coexist in the same leaf (Arzanlou *et al.* 2008; Churchill 2011a), the so-called black Sigatoka complex. We assessed the potential occurrence of other *Pseudocercospora* species in our global collection of isolates. We selected 28 strains from the collection on the basis of their colony morphology to sequence the elongation factor-1 α gene to confirm their identification. PCR amplification resulted in fragments for all strains and, based on blast analyses we identified these strains as *P. fijiensis*, suggesting that most of the strains in the global collection were correctly identified based on morphology and ascospore germination patterns (data not shown).

Fungicide sensitivity of the *P. fijiensis* collection to DMIs

The *Pseudocercospora fijiensis* collection was tested for sensitivity against three DMI fungicides; difenoconazole, epoxiconazole and propiconazole (Table S1). In general, we observed cross-resistance among all strains for these three compounds. In Figure S2a the raw
$^{2}\log$ (EC₅₀) versus fitted estimates illustrates this as a positive band. Fitting the full factorial model revealed that there was a modest interaction between isolate and fungicide (p=0.027) at the cost of a huge number of parameters. A simpler model is the FW model, which describes the interaction variation together with one of the main effects as a linear product. If this factor was the isolate, the angle of the relation, expressed the sensitivity for of each isolate towards the fungicide compared to 1. These sensitivities were not significant (p=0.24), instead used for the fungicides it expressed the sensitivity of each fungicide toward all isolates and had much more explanatory power (p < 0.001). Figure S2b shows this FW model with 3 lines, based on the isolate means, shows clearly the interaction by the difenoconazole sensitivity line crossing the other two fungicides sensitivities which are nearly parallel, so behave additive. For that reason, the structure of the populations bases on their sensitivity response (resistant, tolerant or sensitive) might differ between products (Figure S2b and S3). In countries where banana production requires black Sigatoka management through frequent fungicide applications, viz. Costa Rica, Colombia and the Philippines, isolates with reduced sensitivity were clearly dominant, in decreasing and distinct order (Figure 1, Tables 2 and S1, S2). In countries such as Cameroon, the Dominican Republic and Ecuador where the use of DMIs is still relatively limited a majority of tolerant P. fijiensis isolates, was found (Tables 2 and S2). In contrast, all P. fijiensis isolates from Guadalupe and Martinique were sensitive (Tables 2 and S2). DMIs are used for disease control in both islands but since P. fijiensis recently arrived, the time of the exposure of the population to the DMIs have been short. The DMI sensitivity levels among P. fijiensis isolates found in Costa Rica are the lowest across all isolates, with no isolates classified in the sensitive category and isolates classified in the tolerant category ranging from one percent for propiconazole, two percent for difenoconazole and three percent for epoxiconazole with the rest of the isolates been resistant (Table S2).

Country	mean ² log (EC ₅₀)	hom. group	Isolate count
Guadalupe	-6.015	a	30
Martinique	-5.833	а	42
Ecuador	-2.655	b	101
Cameroon	-2.655	b	90
Dominican R.	-0.924	с	25
Colombia	0.220	d	95
Philippines	0.388	e	98
Costa Rica	2.010	f	111

Table 2. Fisher's protected least significant difference test showing the difference in sensitivity from *Pseudocercospora fijiensis* populations by origin.



Figure 1. Observed sensitivity differences to three DMI fungicide (difenoconazole, epoxiconazole and propiconazole) among *Pseudocercospora fijiensis* strains from varying countries. Data are presented as the frequency of individual EC_{50} data that match against the EC_{50} means for the combined response to the tested DMIs (²Log).

The EC₅₀ values for Costa Rican *P. fijiensis* isolates for the three DMIs were the highest. The majority of isolates in Philippines and Colombia were also resistant. Isolates from Ecuador, Dominican Republic and Cameroon were mostly tolerant. Nonetheless, sensitive and resistant strains were also represented (Figure 1 and Table S2). The lowest values were found in isolates originating from Guadalupe, Martinique and Cameroon. All isolates from untreated areas from Cameroon, Colombia and Ecuador were also sensitive. (Figure 1 and Table S2). Interestingly, Costa Rica population (one of the main banana exporting countries) and the populations from Guadalupe and Martinique (with low fungicide exposure) perfectly fit with the chosen thresholds for DMI resistance and sensitive, respectively (Figure 1 and Tables 2 and S2). Other countries as Cameroon, Colombia and Ecuador have an almost continue set of values (Figure 1 and Table S2). The overall response of the global population is shown in Figure S2 and S3. The additional sensitivity analyses on 21 resistant strains with high fungicide dose (up to 40.96 mg.L⁻¹, Figure S4) revealed that CaM10_6, CaM1_5 and CaM3_1 from Costa Rica had extremely high EC₅₀ values, especially in their response to difenoconazole and propiconazole (Figure S4).

DArTseq genotyping

We analysed the genetic variation among 155 isolates of *P. fijiensis* (Figure 2) using hierarchical clustering based on 6,586 polymorphic DArTseq markers. We detected a clear clustering pattern reflecting the geographical origin of the samples. For example, most isolates from Cameroon cluster together in one group. The majority of isolates from Latin America and the Caribbean are genetically close, but also show the tendency to cluster together by country with some exceptions. The highest genetic diversity, demonstrated by many individual clusters, was detected in the Philippines, whereas the lowest genetic diversity was found in the

Dominican Republic. No clear pattern between the genetic variation and the degree of sensitivity to DMIs was found (Figure 2).



Figure 2. Genetic diversity of 155 selected *Pseudocercospora fijiensis* isolates. a) Hierarchical clustering of 155 *P. fijiensis* isolates based on 6,586 polymorphic DArTseq markers (Jaccard distance; complete linkage clustering). Classification of individual isolates based on b) the country of origin of individual isolates and by c) DMI sensitivity.

The Pfcyp51 diversity and genetic support for reduced sensitivity

Based on dissimilarities in fungicide sensitivity patterns, 266 isolates were selected for amplification and sequencing of the *Pfcyp51* gene, including the promoter region. Six wild type isolates were included as controls to determine the natural variation in *Pfcyp51* sequences irrespective of fungicide sensitivity. We identified 60 unique genotypes with a total number of 28 mutations in the coding region of the *Pfcyp51* gene (Figure 3 and Table S3) taking the sensitive strain CIRAD86 as a reference (Arango *et al.* 2016). The aa changes were dispersed over 20 positions. Strikingly, all isolates shared a nonsynonymous mutation resulting in the amino acid change V106D (Figure 3). The number of mutations per position per country is summarized in Table 3.

Country/ aa subst.	Colombia	Costa Rica	Cameroon	Dom. Republic	Ecuador	Guadalupe	Philippines	Martinique	Individual Isolates	TOTAL
(n)	34	33	94	23	40	3	28	5	6	266
Promoter Insertion	24 (70.6%)	26 (78.8%)	62 (66%)	17 (74%)	5 (12%)	0	8 (28.60%)	0	0	142 (52.79%)
T18I*	34 (100%)	33 (100%)	0	23 (100%)	40 (100%)	3 (100%)	15 (53.60%)	5 (100%)	2 (33.3%)	156 (57.99%)
A19E*	1 (2.9%)	0	0	0	1 (2.5%)	0	0	0	0	2 (0.74%)
Y58F*	0	0	0	0	0	0	0	0	1 (16.6%)	1 (0.37%)
170M	0	0	0	0	0	0	2 (7.1%)	0	0	2 (0.74%)
D71E	0	0	0	0	0	0	2 (7.1%)	0	0	2 (0.74%)
V106D*	34 (100%)	33 (100%)	94 (100%)	23 (100%)	40 (100%)	3 (100%)	28 (100%)	5 (100%)	5 (83.3%)	268 (99.63%)
V116L*	0	0	0	0	0	0	0	0	1 (16.6%)	1 (0.37%)
Y136F	21 (61.8%)	19 (57.6%)	1 (1.06%)	2 (8.70%)	0	0	4 (14.3%)	0	0	47 (17.47%)
K171R*	0	0	0	0	0	0	4 (14.3%)	0	1 (16.6%)	5 (1.86%)
V260L	0	2 (6.1%)	0	0	0	0	0	0	0	2 (0.74%)
I264T*	0	0	0	0	0	0	0	1 (20%)	0	1 (0.37%)
A313G	9 (26.5%)	19 (57.6%)	64 (68.1%)	19 (82.6%)	33 (82.5%)	0	27 (96.4%)	0	0	172 (63.94%)
H380N	0	3 (9.1%)	0	0	0	0	0	0	0	3 (1.12%)
A381G	1 (2.9%)	7 (21.2%)	0	3 (13%)	0	0	0	0	0	11 (4.09%)
R418G*	0	0	0	1 (4.3%)	0	0	0	0	0	1 (0.37%)
A446S*	0	0	0	0	0	0	22 (78.6%)	0	1 (16.7%)	23 (8.55%)
D460E	0	0	0	0	0	0	15 (53.6%)	0	0	15 (5.58%)
D460V	0	0	49 (52.1%)	0	0	0	0	0	0	49 (18.22%)
ΔY461	0	0	0	0	0	0	2 (7.1%)	0	0	2 (0.74%)
Y461D	2 (5.9%)	2 (6%)	0	0	2 (5%)	0	2 (7.1%)	0	0	8 (2.97%)
Y461N	2 (5.9%)	0	0	0	0	0	15 (53.6%)	0	0	17 (6.32%)
Y461S	0	0	0	0	0	0	2 (7.1%)	0	0	2 (0.74%)
G462A	0	1 (3%)	0	0	0	0	0	0	0	1 (0.37%)
G462D	0	0	4 (4.3%)	0	0	0	0	0	0	4 (1.49%)
Y463D	21 (61.8%)	22 (66.7%)	6 (6.4%)	14 (60.9%)	1 (2.5%)	0	6 (21.4%)	0	0	70 (26.02%)
Y463H	3 (8.8%)	1 (3%)	0	2 (8.7%)	10 (25%)	0	0	0	0	16 (5.95%)
Y463N	0	2 (6.1%)	5 (5.3%)	3 (13%)	20 (50%)	0	0	0	0	31 (11.52%)
Y463S	0	4 (12.1%)	0	2 (8.7%)	0	0	0	0	0	6 (2.23%)

Table 3. Changes in the CYP51 protein sequences of *Pseudocercospora fijiensis* isolates per country.

*Amino acid substitutions found in sensitive isolates



Figure 3. Amino acid (aa) substitutions identified in the *Pseudocercospora fijiensis* 14α demethylase enzyme. In total 28 aa changes were observed, located at 20 positions in the sequence of *Pfcyp51*. The substitutions with red labels are in the vicinity of the substrate recognizing site (SRS).

With the exception of Y136F, all amino acid substitutions derived from single base nonsynonymous mutations (Table S4). In Y136F, the wild type codon is TAC at position 405 bp and the altered codons are TTC and TTT, which are present in 29 isolates from different populations (Costa Rica, Cameroon, Colombia and Philippines) and in 11 isolates from Costa Rica, respectively. This may suggest that codon TTT occurred from a consecutive mutation that emerged from the pre-existing codon variant TTC. The list of the codons for each substitution is summarized in Table S4.

At a global scale, the most frequently observed aa changes are V106D (268), A313G (172), T18I (156), Y463D (70), Y136F (47) and Y461D (8) (Table 3). The largest number of specific mutations was present among Philippine isolates. Mutations resulting in I70M, D71E, D460E, Δ Y461 and Y461S were unique for the Philippine population, whereas mutations leading to K171R and A446S were shared with a strain from Taiwan. However, unique mutations were also observed in other countries. For instance, V260L, H380N and G462A were exclusive for Costa Rica, whereas aa changes D460V and G462D were only found in Cameroon. Just a few mutations leading to aa changes were only found once, such as I264T in an isolate from Martinique and R418G in a strain from the Dominican Republic (Table 3). In contrast, other mutations are ubiquitous such as T18I, present in all isolates from Latin America and the Caribbean and in 15 out of 28 Philippine isolates. The same mutation existed in two sensitive wild type strains from the Philippines and Indonesia (Table 3), but was absent among African isolates.

The number of aa changes per individual genotype varied from one to seven substitutions (Table S3). Most of the none sensitive analysed isolates gained four aa changes when compared with the reference strain. The most common combination was T18I/V106D/A313G/Y463D, present in genotypes G29 to G32, identified in 24 isolates from Colombia (2), Philippines (2), Ecuador (1), Costa Rica (5) and the Dominican Republic (14). Genotype G25, represented by one isolate from Cameroon, contained the modification Y136F (Table S3). Thirty-five isolates share only a single substitution (V106D), when compared with the CIRAD86 reference. The two and three-way combinations T18I + V106D, T18I + A19E + V106D, T18I + Y58F + V106D; T18I + V106D + I264T, T18I + V106D + R418G, T18I + V106D + A446S and, V106D + V116L + A446S were all present in P. fijiensis isolates sensitive to DMIs. In contrast, substitutions Y136F, A313G, H380N, D460E, D460V, ΔY461, Y461D, Y461N, Y461S, G462A, G462D, Y463D, Y463H, Y463N and Y463S were only present in strains with reduced sensitivity to DMIs. Interestingly, genotypes G8, G12, G13, G14, G18, G19, G36, G41, G49, G52, G53, G57, G58 and G60 show a differential impact on the sensitivity for the three fungicide with EC_{50} values higher on propiconazole (Table S3).

The chemical properties of the detected aa substitutions in the different genotypes are compared in Table S5. Most substitutions affect the hydrophobic or hydrophilic interactions, particularly T18I, A19E, V106D Y136F, I264T, A313G, A381G, R418G, A446S, D460V and

79

those at positions 461 and 463, which modulate hydrophobic or hydrophilic properties that are expected to influence the three-dimensional conformation of the protein.

Protein models and docking studies

In order to understand the conformational effect of sensitivity related substitutions on the PfCYP51 protein, seven in silico models were built (template base on A. fumigatus, S. cerevisiae, H. sapiens and M. tuberculosis). The quality model Z-scores are summarized in Table S6. The Z-score of a protein is defined as the energy separation between the native fold and the average of an ensemble of misfolds in the units of the standard deviation of the ensemble (Zhang & Skolnick 1998). Figure 4 shows the secondary structure of the protein model based on the CYP51 of genotype G1 (reference strain CIRAD86). The model was compared with an early *in silico* model of *P. fijiensis* and the crystal structures of the CYP51 from Trypanosoma cruzi and T. brucei (Cañas et al. 2009; Chen et al. 2010). Most of the structural CYP51 family protein elements: alpha helixes, beta sheets and the SRSs, were well conserved in the model. The exceptions are the absence of alpha helix F' and F" and the presence of an extra alpha helix predicted from aa positions 452-458. Most importantly, the SRSs were recognizable in the *in silico* PfCYP51 model and suggest an open substrate channel between the alpha helix A', the loop between alpha helix F and G (loop FG), and the loop between beta sheet 2 3 and beta sheet 2 2 (details of the active site and the channel in the model are visualized in Figure S5 and S6).



Figure 4. Schematic representations of CYP51. (A) Three-dimensional model based on *Pseudocercospora fijiensis* CIRAD86 (genotype G1). (B) PfCYP51 secondary structure model annotated based on Cañas et al. (2009) and Chen et al. (2010) (variation in nomenclature between authors is show in parentheses). Helix structures are shown as blue cylinders, β sheets are indicated in red, turns in green and random coils in cyan. Main α helixes are depicted in capital letters and the putative substrate recognition sites (SRS) indicated as boxes. The changes in amino acids identified in *Pfcyp51* are depicted as: (^) only in DMIs sensitive isolates, (*) only in resistant strains and (+) present in both. Residues that potentially locate within 7Å of the propiconazole docking site are labelled with blue triangles.

A global distance test was performed to measure the superposition similarity between two proteins by calculating the number of structurally equivalent pairs of C-alpha atoms that are within the specified distance. This revealed that the most similar model to the PfCYP51 wild type was from the sensitive Bo_1 strain, originating from the indigenous *P. fijiensis* population in Bohol, Philippines (DMIs sensitive, genotype G10) with 85.61% of similarity, while the most dissimilar model was derived from strain CaM10_6, originating from the frequently sprayed Cartagena population in Costa Rica, (DMIs resistant, genotype G44) with 76.95% of similarity (Table S7).

Docking experiments

In silico docking experiments show that propiconazole probably binds to the PfCYP51 active site by positioning the triazole ring close to the porphyrin plane with a nitrogen atom aligned to the iron atom in the heme group (Figures 5A and S5). Based on 3D modelling putative aa positions were identified that are located less than 7Å to the nearest propiconazole atom for the docked compound. The potential interacting aa's are marked in Figure 4 and Table S7. Out of the 21 putative aa's interacting with propiconazole, 19 are located inside the proposed SRSs (Cañas *et al.* 2009). Particularly, positions 136, 313, 380 and 381 found in field isolates with reduce DMI sensitivity were predicted to be in direct interaction with propiconazole (Figure 5A). In the model of the sensitive strain Bo_1 although the amino acid substitutions were positioned outside the docking area, they induced three remarkable spatial changes in the active site chamber of the PfCYP51 (Table S7 and Figure 5B). The models of strains with reduced sensitivities revealed specific changes in the active site conformation including direct changes to some of the propiconazole interacting aa's.

All resistant models have five to eight positions with altered spatial locations and angles compared to the reference model, affecting DMI binding. Notably, the deletion at position 461 (Δ 461) in model M52_10 (genotype G60, Figure 5e) results in the shift of three aa's near the docking area at positions, 524, 525 and 526. As a result, L523 is introduced into the docking site and pushes S526 to a distance of 8.13Å versus 4.05 Å in the model of sensitive strains, a distance not included in the putative range of interaction with the fungicide (Table S7). Sensitive strain Bo_1 has three positions with modulated spatial distance and angles in the PfCYP51 active site chamber (125, 380 and 384; Figure 5b).

A particular orientational variation exist at position 125, which is present in all PfCYP51 models of resistant strains, and that harbours the entrance of the channel facilitating the entry to the enzyme core that comprises the active site (Figure S6). Contrary to this conformation, the model of the sensitive strain Bo_1 has a more exposed entrance at this position while the models of the resistant strains CaM10_6, M52_10 and M52_22 have a narrow access (Figure 5b, c and f). Other major changes are situated for position 383 (reference 1.85Å close to propiconazole) and position 313. In the former case, positional changes seem to be due to aa substitutions at other positions. All predicted changes in the relative distance of aa's near the docking area (reference <7Å) are summarized in Table S7.



Figure 5. Models of the active site of the PfCYP51 protein with amino acid modulations due to mutations. A) Reference model of the PfCYP51 of the reference *Pseudocercospora fijiensis* CIRAD86 showing the location of amino acids (aa) in the vicinity of the propiconazole docking area. With the exception of tyrosine at position 136, aa's with a distance farther than 5.4 Å from the docking area are removed for better visualization. The heme group is depicted in red, the propiconazole fungicide in blue and aa residues in green. B) Active site of *P. fijiensis* strain Bo_1 (in cyan) superimposed on the CIRAD86 reference. Active sites of CYP51 resistant models (C) CaM10_6, (D) CaM10_21, (E) M52_10, (F) M52_22 and (G) Z4_16 (in magenta) superimposed on the CIRAD86 reference. In (D) position 381 was also included. Significant variations in distance, position or angle of the aa residuals are highlighted with light red or yellow discs.

Promoter Insertions

From the 266 sequenced isolates, we found 142 isolates that have an insertion in the *Pfcyp51* promoter (Tables 3 and S4), which have been correlated with reduced sensitivity to DMIs (Díaz-Trujillo *et al.* 2016a). For instance, the 25 *P. fijiensis* strains with the combination T18I + V106D + Y136F + Y463D (genotypes G22, G23 and G24) differed in DMI sensitivity, clearly reflected by the number of insertions in the promoters. Similarly, genotypes G35 and G36 (T18I + V106D + A313G + Y463N) do not differ in *Pfcyp51* substitutions, nonetheless, the three G36 isolates with promoter insertions have higher EC₅₀ values, which maximizes in those with three insertions (Table S3).

A more detailed analysis of the promoter of the resistant strains identify a region of high variation, with insertions starting at position 2,121,774 of scaffold 7 in the genome sequence of the reference strain (*Pseudocercospora fijiensis* v2.0, JGI), ~103 bp upstream of the start codon of *Pfcyp51* (antisense direction). In 98 isolates, the insertions substitute a stretch of 8 to 27 bp starting at position 103 or 102 bp upstream of the start codon, e.g. in the Philippine isolate T52_22 an 8 bp region is substituted by an insertion of 123 bp at position - 102 bp.

Others have gained multiple substitutions, such as isolate CaM3_3 from Costa Rica, which has one 16 bp exchange for a 9 bp fragment at position -103 bp and a second substitution of 7 bp with a 76 bp fragment, localized at –94 bp (Table S8). In addition, 38 isolates contain an insertion at position 94 bp. Two isolates from Cameroon, strain P2S20 and P4S19, have a substitution followed by an insertion at position 157 bp upstream of the start codon. The Philippine isolates (M52_4, M52_9, M52_23 and U22_3) show a deletion of 8 bp, "CATGGACC", in the promoter region beginning 97 bp upstream of the start codon. Generally, the majority of insertions at the -103 region comprise one or more copies or partial

copies of a 19 bp genomic element, "TAAATCTCGTACGATAGCA". This element is present as a single element in the CIRAD86 reference and originally located a few nucleotides downstream in the promoter MYCFIscaffold_7:2121794 – 2121813, (-122 bp upstream of the *Pfcyp51* start codon), indicated as element "A" in Figures 6 and 7.



Figure 6. Logo made in MEME (Bailey & Elkan 1994) of the repeated inserts elements found in the promoter region of 142 *Pseudocercospora fijiensis* strains. Element "A" is common in all repeat candidates that were identified by the software.

Despite the geographical differences of many isolates, we identified very similar insertions in the *Pfcyp51* gene promoter. Overall, a limited number of substitutions and insertions were observed although at variable positions (Figure S7). Element "A" contains a core sequence of an eight base pair palindromic DNA fragment "TCGTACGA", which is present in all variants, and at least twice in all isolates that contain an insertion (Figure 7; green arrows, Figure S7) and up to six copies in the *Pfcyp51* promoter of resistant strains. Some isolates contain a partial construction of element "A" in their insertions, while others have a modified "A" element due to a few additional nucleotides. For example, Philippine isolate T52_22 possesses three copies of element "A" and one partial copy, resulting in four copies of the palindrome. In a similar way, the Ecuadorian isolates RCQS_3 and RCQS_16 possess one copy of the "A" element, but three of the palindromic sequences, two of them in partial stretches of "A" (Figure S7, Table S8). In total, the palindrome sequence is present up to six

times in resistant *Pfcyp51* genotypes (Table S3). The smallest insertion, in isolate POS9 from Cameroon, encodes a single "A" element, but two copies of the palindrome (Figure 8).

The presence of two or more palindromic insertions (three or more copies in total) correlates with strongly reduced DMI sensitivity (Tables S4 and S9). Interestingly, mutation Y136F only occurred in isolates with multiple promoter insertions (at least four or more palindromes "TCGTACGA" insertions). The detailed gene configurations of representative strains with reduced sensitivity are presented in Table S3 and Figure 8.

Although geographically different isolates show very similar insertions in the *Pfcyp51* gene promoter, we found an additional big and unique insertion in Philippine isolates. This 39 bp insertion, "TTCACCACCCTCGCATTCTTGGTCA-*GTATAC*-ATAGACCT", indicated as the "B" element, is present in eight Philippine isolates (Figures 7, 8 and S5). The "B" element also encompasses a palindromic 6 bp DNA fragment "GTATAC" that, however, is not correlated with reduced sensitivity to DMIs.



Figure 7. Analysis of the insertions in the promoter region of the *Pfcyp51* gene in *Pseudocercospora fijiensis* strains from various countries. Insertions are generally located from 94 to 103 bp upstream of the start codon of the gene. Element "A" is marked with blue together with the palindromic arrangement TCGTACGA marked in green. Alterations of element "A" are marked with red and partial constructions of the element with purple. Part of the novel insertion merely identified in Philippines isolates, element "B", is marked with light yellow. Negative values at the right represent the position from the beginning of the insertion related to the start codon of the gene.



Figure 8. Representation of the *Pseudocercospora fijiensis Pfcyp51* gene. Genomic configuration of elements of the most representative resistant genotypes are shown with insertions in the promoter region of the *Pfcyp51* gene. Vertical lines in the coding domain of the *Pfcyp51* gene represent the different CYP51 codon position substitutions: 1) Reference genotype G1. 2) Resistant genotype G24. 3) Resistant genotype G23. 4) Resistant genotype G43 (Philippines). 5) Resistant genotype G42. 6) Resistant genotype G13. 7) Resistant genotype G25 and 8) Resistant genotype G18.

The effect of *Pfcyp51* mutations and fungicide sensitivity

Substitutions A313G, Y136F, H380N, Y463D and D460V gave the main explanatory changes related to increasing EC₅₀ values (Table 4) as the reference genotype was a susceptible one. Additional mutation candidates for a main effect were A381G, A446S, T18I, Y463N and D460E based on a ratio of 20 for inclusion compared to the mean square error (\sim p<0.00001). However, these were less consistent, so a combination among the substitutions could be more plausible. Retaining the first 5 mutations and adding the main effect of the *Pfcyp51* promoter and the fungicide treatment resulted in even higher EC₅₀ predictive power. Figure 9 shows that the number of insertions in the *Pfcyp51* promoter corresponds with reduced fungicide

sensitivity, indicated by the number after the 5 binary position representing the mutational main effect and before the fungicide letter (P). The inclusion of the fungicide factor demonstrates the main effect of the treatment but not shown in Figure 9 as the difference were too small.

Next all first order interactions were evaluated and added if significant. Followed by backward selection to check out the specific combinations that had most predictive power. Substitutions T18I, A381G, A446S are again indicated but now in combination with one or the other and a new mutation V106D is put forward in this context. Also the interaction Y136F with A313G, which are both already in the model as main effect, is still assessed as important. This combination increases again the sensitivity to the DMIs as can be seen from the parameter estimate, and seemingly this is attributed to Y136F as is also in the combination with A318G more sensitive. Finally, the addition of the promoter interaction with a mutation was all checked, however none was found to be very specific. This means that either the interaction with fungicide is already covered by a mutation or there was no specific mutation involved with the difenoconazole interaction. This last explanation is supported by the lack of significance for the alternative FW-model with sensitivities per isolate. Country is not there because the mutations are confounded with it, so country is included as last and the sensibility did not incur much from it. Figure 9 represents the effect of the accumulation of these crucial mutations by x-axis on propiconazole. In the left bottom is the sensitive reference 'without' mutation and the 'simplest' promoter of the *Pfcyp5*. The upper right has the most accumulated mutations as an additive effect together with the most insertions in the promoter that was present in the set of isolates. It shows the additive magnitude of the specific mutation combinations that was present on the $^{2}\log$ (EC₅₀).

Table 4. Regression analyses of *Pseudocercospora fijiensis Pfcyp51* mutations on azole efficacy. This table shows the fitted model with the relevant factors (amino acid substitutions and promoter insertions, F-test <0.001) that remains from 23 factors evaluated. Factors are in descendant order of importance base on the accumulated analyses of the variance ratio (v.r.). The threshold of including a variable was heuristically set to a v.r. ratio of 10, which gave 11 factors as predictor for the loss of sensitivity to DMIs. This final model was checked by backward elimination to see if any previously included terms became superfluous. Table shows the degrees of freedom (d.f.), the sum of the squares (s.s), mean squares (m.s.) and variance ratio (v.r.).

Accumulated analysis of variance											
Substitution change	d.f.	S.S.	m.s.	v.r.							
+ A313G	1	1876.24	1876.24	2489.04							
+ Y136F	1	2268.64	2268.64	3009.60							
+ H380N	1	508.66	508.66	674.79							
+ Y463D	1	116.14	116.14	154.07							
+ D460V	1	110.48	110.48	146.57							
+ Prom	5	205.53	41.11	54.53							
+ Fungi	2	64.44	32.22	42.74							
+ T18I.A381G	1	51.55	51.55	68.39							
+ V106D.A446S	1	148.27	148.27	196.70							
+ Y136F.A313G	1	222.94	222.94	295.75							
+ Y136F.A381G	1	44.60	44.60	59.17							
Residual	627	472.63	0.75								
Total	643	6090.13	9.47								



Model: A313G-Y136F-H380N-Y463D-D460V-Prom-Fungi-T18I-A381G-V106D-A446S

Figure 9. Predicted interaction of the accumulation of specific CYP51 substitutions with the sensitivity response on propiconazole fungicide. The genotype number codes are represented by the presence/absence of substitutions (1/0 matrix) with the exception of the *Pfcyp51* palindromic promoter insertions that have six levels. The 11 number codes follow the chosen fungicide correlated model: 1) A313G, 2) Y136F, 3) H380N, 4) Y463D, 5) D460V, 6) Promoter insert numbers, 7) Fungicide, 8) T18I, 9) A381G, 10) V106D, and 11) A446S. The substitutions are placed from left to right in order of importance where the first one is the most interactive and the last one the least interactive. For practical reasons number code 7 has been labelled for the fungicide (P for propiconazole). For example, model resistant genotype code 001106P1110 (marked in light red) has five substitutions: H380N, Y463D, T18I, A381G and V106D with six promoter palindromic inserts and it has been predicted as resistant (²LogEC⁵⁰ >0) in the interaction with the fungicide propiconazole.

Discussion

The use of antibacterial therapies and anti-fungal is common in human and veterinary medicine to complement the host immune response and restore well-being and health (Boogaerts et al. 2001). Therefore, antibiotics resistance raised global awareness (Unno et al. 2010; Yang et al. 2014), as it threatens the lives of many patients and animals due to failing antibiotic treatments, resulting in the return or severity of many bacterial infections (Brauner et al. 2016). Reduced sensitivities to fungicides equally threaten lives of patients (Eddouzi *et al.* 2013; Mitka 2011; Unno *et al.* 2010; Verweij *et al.* 2013) and animals, such as upon *Aspergillus fumigatus* infections causing aspergillosis, a lethal inflammatory disease without adequate antifungal treatment (Chowdhary *et al.* 2013; Verweij *et al.* 2013). The reduced effect of such treatments is mostly due to *cyp51* mutations (Becher & Wirsel 2012; Cools *et al.* 2013).

The control of plant pathogens also strongly relies on a limited set of fungicides, with mostly similar active ingredients (Cools *et al.* 2013). Azole fungicides are the cornerstone of contemporary managements strategies for many plant pathogens (Cools *et al.* 2013). In this paper we describe the occurrence and mechanisms of the reduced sensitivity of azole fungicides to the plant pathogenic fungus *P. fijiensis*, which may be one of the factors that leads to the increase of fungicide applications for black Sigatoka control in banana cultivation. The dispersal and magnitude of DMI fungicide resistance in *P. fijiensis* urges for an understanding of the underlying mechanisms in order to develop new control strategies. Here, we analysed an unparalleled set of *P. fijiensis* isolates obtained from populations in countries with varying practices (among them four of the top ten largest producers and exporters of banana), hence intensities of black Sigatoka management. This enables a global analysis and comparison of fungicide application and the occurrence of reduced DMI sensitivity in *P. fijiensis* and the prime genetic dynamics. The distribution of EC₅₀'s for all isolates revealed a wide range of DMI

sensitivity, parallel for the tested fungicides, which can be considered as a continuous set of values (Figure S3). This disallowed clear cut-off values to discern statistically significantly different groups. Therefore, we introduced EC_{50} criteria to form three sensitivity groups. This permitted analyses based on the non-synonymous mutations in the *Pfcyp51* gene, the promoter characteristics and the origin of the samples. Nonetheless, the result show differences in the structure of the populations based on their sensitivity response to each specific fungicide (although not significant), especially for difenoconazole. These differences may suggest the need for a better grouping criteria and differential thresholds levels choice per individual fungicide. All fungicide resistant strains were exclusively identified in commercial banana farms, especially from Costa Rica, Colombia and the Philippines, where banana production is economically very important and the number of fungicide applications per season is high (Figure 1 and Table S2).

DMI sensitivity differences are associated with fungicide application practices

Costa Rica has a long history of Sigatoka control associated with a continuously increasing number of fungicides applications per year (Chong *et al.* 2016a; Marín *et al.* 2003). For example, observed DMI baseline sensitivity shift correlates with the increasing amounts of applied fungicides, which raised from 30 in the 90's up to 50 treatments by 2007 and up to 53 in 2015 in San Pablo's farm in Costa Rica (Chong *et al.* 2016a). In this case the actual number of DMI cycles reduced over time from seven to four applications per year in 1998 and 2014, respectively, but overall the number of DMI cycles was approximately 10 between 2003 and 2010. In 2015, there was a sudden rise in the number of DMI cycles. This rise might be resulted by the frequency of strains with high EC_{50} values in the "San Pablo" population. This event

suggests that the selective pressure in previous years was sufficient to turn the major part of the population into resistant strains by 2014. In parallel, we isolated the most resistant strains from this country and have recently proven the association between their genetic constitution and DMI sensitivity (Díaz-Trujillo *et al.* 2016a). Hence, fungicide application intensity results in the recovery of resistant strains, e.g. 99% of the Costa Rican isolates had EC₅₀ values higher than 1 mg.L⁻¹ for propiconazole. In contrast, the majority of strains were sensitive in remote areas nearly secluded from fungicide applications. The resistant strains always carried *Pfcyp51* gene mutations. Recent findings for strobilurins suggested that these remote areas are genetically isolated from large commercial banana plantations, as indicated by their population genetic parameters (Arango *et al.* 2016). For DMIs, similar mechanisms seem to be operational. Hence, the rare occurrence of reduced sensitivity in overall sensitive populations seems to be largely due to genetic drift.

Although the actual number of DMI applications per location from which the strains were collected is in most cases untraceable it seems that the number of resistant isolates increases parallel with the number of fungicide applications (Figure 1 and Table S2) underpinning the selective pressure exerted by the intensive applications of DMIs. The relatively low percentage of resistant strains from Ecuador (difenoconazole 16.83%, epoxiconazole 8.91%, and propiconazole 21.78%) might reflect the particular climatic situation with long dry seasons at the coast, reducing black Sigatoka development and hence favouring control due to lower inoculum production. Therefore, the frequency of fungicide applications is lower (Marín *et al.* 2003), albeit that the number of applications is increasing since the sampling of the isolates in our study (2009-2010; Enrique Donoso, personal communication; CIBE, unpublished data). Hence, it would be worth monitoring the current population of *P. fijiensis* in Ecuador.

P. fijiensis incursions into Martinique and Guadalupe, two islands of the Caribbean close to the northern-east part of South America, happened only in 2010 and 2012, respectively (Guzmán *et al.* 2013; Ioos *et al.* 2011). For that reason, the exposure to the fungicide have been too short, hence the selective pressure is low, which accords with our results, as all *P. fijiensis* isolates are sensitive to DMIs. It has been found that these two populations are sensitive to other mode of action fungicide (data not shown). Thus, the favoured origin hypothesis is that these islands were colonized by wild-type *P. fijiensis* isolates. We can exclude the alternative hypothesis that the absence of continuous DMI selective pressure results in the loss of resistance alleles, due to apparent fitness costs of these alleles, which consequently reverts the population back to sensitivity. This effect was shown for *Magnaporthe oryzae* and *Cercospora beticola*, but remained unnoticed for many other fungi (Hollomon 2015), and we, therefore, consider it unlikely for *P. fijiensis*, particularly since we have identified wild-type strains in other non-sprayed areas such as San Carlos in Costa Rica and Bohol in the Philippines (data not show) and in Cameroon, Colombia and Ecuador.

P. fijiensis colonized Latin America and the Caribbean during multiple events, likely beginning around 40 years ago from Honduras and/or Costa Rica (Halkett *et al.* 2010; Lapeyre *et al.* 2010b; Rivas *et al.* 2004a). Such events are consequently accompanied by a reduction of genetic diversity through founder effects and bottleneck events (Carlier *et al.* 1996; Halkett *et al.* 2010; Hayden *et al.* 2003; Rivas *et al.* 2004b). Our results show that most isolates from Latin America and the Caribbean share the same genetic background (Figure 2). Since *P. fijiensis* ascospores cannot travel beyond a few hundred of meters, long distance dispersal is considered to be solely due to anthropogenic movement of contaminated material (Arango *et al.* 2016; Halkett *et al.* 2010; Marín *et al.* 2003; Ploetz *et al.* 2015; Rieux *et al.* 2014), which unveils

unparalleled risks for the banana sector as was also recently shown for the dissemination of the Tropical Race 4 strain of Panama disease (Ordoñez *et al.* 2015).

The genetic structure of P. fijiensis populations and the wild type Pfcyp51 gene

As indicated above, most Latin American and the Caribbean *P. fijiensis* isolates cluster in the genetic analysis, while isolates from Cameroon form a distinct clade (Figure 2). Interestingly, Philippine strains show the highest diversity. This is consistent with the current understanding of the genetic structure of *P. fijiensis* populations, showing that African and American populations originate from separated colonization events and that South East Asia – here represented by the Philippines – is the centre of origin (Carlier *et al.* 1996; Halkett *et al.* 2010; Hayden *et al.* 2003; Rivas *et al.* 2004b). Intriguingly, this pattern continues at the *Pfcyp51* sequence level. For example, the substitution leading to T18I is present in all Latin American and the Caribbean and in 15 out of 34 Philippine strains, but lacks in the Cameroon population.

Our sequencing data of the Pfcyp51 gene across all populations highlights a particularity of the CIRAD86 – originating from Cameroon - reference strain, which was selected for the first genetic linkage map and genome sequencing (Manzo-Sanchez *et al.* 2008). We now actually question the representativeness of this strain for the species as it encodes V106 in *Pfcyp51*, whereas the sequences of all 268 genotyped isolates encode D106. With the suggested centre of origin in Southeast Asia, we propose that the wild-type genotype is D106 rather than V106. In retrospect, this may indicate that the proposed additive role of V106D for DMI resistance is an artefact, based on a mutation in the hitherto reference CIRAD86. This underscores the need for more genomic information from strains that are selected in the centre of origin.

The selective pressure of DMI fungicides on P. fijiensis

The genetic effects of the DMI application on *P. fijiensis* populations are solely targeted on modifications of the *Pfcyp51* gene (Chong *et al.* 2016c). Most *Pfcyp51* modulations paralleled with the DMI fungicide resistance response and are comparable to those identified in other organisms. Substitutions V136A and I381V are correlated with reduced sensitivities to triadimenol in *Erysiphe necator* and to tebuconazole in *Zymoceptoria. tritici*, respectively (Cools *et al.* 2013). The accumulation of mutations tend to confer increased resistance to DMI fungicides (Cools *et al.* 2013). Here, we were unable to determine such specific substitutions for any of the tested fungicides, which might be due to the high number of factors analysed (individual mutations, mutation combination and seven levels of promoter insertions) and hence, further studies may identify unique mutation/efficacy interactions.

Sensitive strains also show variation in *Pfcyp51* with a maximum of three mutations resulting in three aa changes. Overall, the maximum of aa substitutions was found in the Philippines population where some isolates accumulated up to seven aa substitutions in the coding region of the *Pfcyp51* gene. Such a high degree of polymorphism in the *cyp51* gene was previously reported for *Oculimacula (Tapesia) acuformis* and *Oculimacula yallundae* (Albertini *et al.* 2003). The substitutions resulting in A19E, I70M, D71E, V260L, I264T, H380N, R418G, D460E, D460V, Y461N, Y461S, Δ Y461 and G462D were hitherto unknown in *P. fijiensis*, although other changes in positions 461 and 462 were reported to affect DMI sensitivity (Cañas *et al.* 2009; Chong *et al.* 2010; Díaz-Trujillo *et al.* 2016a). Substitutions A19E, Y58F, V116L, and R418G were solely detected in DMI sensitive isolates, suggesting that these represent natural random variation, which is uncorrelated with DMI sensitivity. Notably, substitution I264T although also detected in a DMI sensitive isolate (EC₅₀ slightly above sensitive mean) - was correlated with additive effects of reduced efficacy of the evaluated DMIs. Similarly, substitutions T18I and A446S are present in both sensitive and resistant isolates, but also correlated with additive effects in strains with reduced sensitivity. These observed additive effects might be explained as compensatory substitutions for azole sensitivity as illustrated by aa changes at positions 459 to 461 in ZtCYP51, compensating the I381V substitution that was, by itself, enzymatically lethal as corroborated by complementation experiments in *S. cerevisiae* (Becher & Wirsel 2012). Nevertheless, these modifications urge for additional studies to elucidate their contribution to *P. fijiensis* survival.

Substitutions A313G, Y136F, H380N, Y463D, and D460V are directly correlated with resistance (Table 4 and Figure 9). Similar substitutions were also found in Z. tritici (Cools et al. 2013) and Y136F was linked with azole resistance in *Penicillium italicum, Uncinula necator* and Blumeria graminis f. sp. hordei (Albertini et al. 2003; Délye et al. 1997). A substitution at Y136, or its equivalent in other species, is the most frequently observed modification of CYP51 in pathogenic fungi (Cools et al. 2013). Interestingly, Y136F originated from two sequential codons. The original codon is TAC while the modified codons are TTC and TTT. The latter is unique for the Costa Rican population and might arose from a consecutive mutation emerging from the pre-existing TTC codon. This consecutive selection might result from prolonged DMI pressure and may represent a bias event towards optimized codon usage. Nonetheless it is worth to mention that P. fijiensis codon usage shows a relative preference for codon TTC (http://www.kazusa.or.jp/codon/). Codon usage in genes have been long investigated in Echericha coli, Sacharomices cerevisiae and Aspergillus nidulans where it correlated with highly expressed genes and more efficient translation (Dilucca et al. 2015; Lloyd & Sharp 1991; Trotta 2013). The Pfcyp51 gene overexpression in Costa Rican isolations (Chong et al. 2010) (Díaz-Trujillo et al. 2016a) might supports this hypothesis, however additional studies are needed to strengthen this hypothesis.

The importance of substitutions at positions 136, 313, 380, 381 and 460 to 463 are strengthened by PfCYP51 modelling. Everything is located in the SRS with the exception of positions 460 to 463. Changes in these aa positions however compromise the three-dimensional structure of the protein resulting in an affinity change. For example, models with the setting Δ Y461, Y461N, G462A and Y463D, revealed significant distance and angle changes around position 524 to 526 (SRS6) (Figure 4, 5c - g, Table S7). The deletion of Δ Y461 itself provoked a shift in positions 523 to 526 introducing the S523 into the active site and pushing S526 out of the selected range (>7Å).

Position 125, at the entrance of the channel to the active site of the protein, was modified in all resistant strains (Figure S6). However, based on modelling, the effect is limited. Additional studies are required to elucidate how these changes affect fungicide entry or the catalytic centre structure.

Promoter insertions

The presence of repeated elements and insertions in the promoter region of *Pfcyp51* explains the overexpression of the gene (Díaz-Trujillo *et al.* 2016a). None of the sensitive strains contained insertions while they were very common in tolerant and resistant strains. In the current survey, promoter insertions positively correlated with the resistance to DMIs (Table 4 and Figure 9). Also in *A. fumigatus, cyp51* promoter insertions explain resistance to azole fungicides (Mellado *et al.* 2007). Interestingly, these insertions were also associated with non-synonymous mutations in the coding region (Mellado *et al.* 2007). Snelders et al. (2012) observed that an *A. fumigatus* isolate with two copies of a tandem repeat acquired an additional repeat during DMI treatment, supporting the hypothesis that genomic changes in the *cyp51* gene are inducible

(Snelders et al. 2012). Analogously, in P. digitatum promoter insertions drive the expression of the cyp51 gene; a 126 bp insertion comprising five repeat elements is present in resistant strains while sensitive isolates only carry one repeat element (Hamamoto *et al.* 2000). Similarly, *cyp51* gene overexpression is also reported in Z. tritici, a close relative of P. fijiensis, where a 120 bp insertion in the promoter region correlates with a 10 to 40-fold overexpression (Cools et al. 2012) as well as in Venturia inaequalis and Blumeriella jaapii where the presence of upstream derivatives of LINE-like retrotransposons correlated with overexpression of the cyp51 gene (Ma et al. 2006; Schnabel & Jones 2000). All these discussed inserts vary in size and nature across species and are not located at equal positions and clearly result from independent events, which raise the question about their origin. They might be remains of transposable element activity, some of which contain powerful promoters (Cools et al. 2013). In P. digitatum the effect of a transposon element in the promoter region has been described to confer resistance to DMIs (Sun et al. 2013). In P. fijiensis three independent promoter insertions exist, at -103 bp, at -94 bp and at -157 bp from the start codon. The latter was only present in two isolates from Cameroon. However, all isolates with insertion contain tandem copies (or partial copies) of the "A" element and were at least DMIs "tolerant" (>0.1 mg.L⁻¹) (Table S3 and Figure S7).

The central core of the repeats are the palindromic arrangements. These motifs constitute an important group of regulatory elements in eukaryotes in which they act as ciselements (Knox & Keller 2015). Many transcription factors (TF) bind palindromic sequences with high affinity (Narlikar & Hartemink 2006; Qian *et al.* 2006). For example, the TF ADR1 binds as a monomer to palindromic sequences to regulate the expression of *S. cerevisiae ADH2* gene (Thurkral *et al.* 1991). In *Cercospora nicotianae* the TF CRG1 binds to a palindrome sequence present in genes that confer resistance to cercosporin (Chung *et al.* 2003). The group of bZIP TFs target palindromic DNA sequences as dimers, thereby regulating e.g. secondary metabolism (Knox & Keller 2015). The importance of the palindromic sequences might explain

the existence of isolates with few full repeats and a partial "A" element insertion in *Pfcyp51* while they are categorized as DMI resistant (Figure 7 and S5).

A second palindromic sequence, inserted in element B, was present in the Pfcyp51 promoter of Philippine isolates. Due to the absence of intermediate strains, only containing the B element, the correlation with Pfcyp51 gene expression is not resolved. However, there was no significant expression difference of Pfcyp51 when compared with strains merely containing the A element (data not shown).

In summary, element "A" and particularly its palindromic core is important for regulation of gene expression, most likely as a transcriptional enhancer (Bolton *et al.* 2016; Schnabel & Jones 2000). The mechanism and the components involved, however, remain to be elucidated. Future work will aim at the characterization of the mechanism and identification of the involved TFs and additional determinants (Bolton *et al.* 2016). Promoter insertions of element A tend to confer higher EC_{50} regardless of the fungicide and might be the reason why we were unable to determine specific substitutions for the tested fungicides. This might suggest that the effect of the promoter insertion can mascaraed the specific interaction between a substitution and a particular fungicide and induce at some degree cross-resistance among DMI fungicides. Interestingly, only tolerant or resistant strains show insertions in the promoter region. This suggest that the selection for overexpression only occur after the emergence of point mutations. Transformation studies have demonstrated that insertions alone do not increase the DMI resistant significantly (Díaz-Trujillo *et al.* 2016a). For this reason, we conclude that the main resistant factors are the mutations in the *Pfcyp51* and that the insertions in the promoter region acts as an additive effect.

Three isolates from Costa Rica, CaM10_6, CaM1_5 and CaM3_1, revealed extraordinary high EC₅₀ values that remain unexplained solely by the *Pfcyp51* promoter

102

configuration similar to those in other, less resistant isolates from Costa Rica. This suggests the presence of additional quantitative genetic components that directly or indirectly modulate resistance as observed in *O. yallundae* (Dyer *et al.* 2000). The construction of a genetic map of *P. fijiensis* based on crosses between fungicide resistant and sensitive isolates facilitates an unbiased identification of additional genes contributing to DMI fungicide resistance (Chong *et al.* 2016c) and provides insight into the recombination frequency of mutant alleles and the possible distribution mechanism of resistance alleles in populations. The current and associated studies (Chong *et al.* 2016a; Chong *et al.* 2016c; Díaz-Trujillo *et al.* 2016a) significantly contribute to the understanding of the origin and dissemination of DMI resistance mechanisms in *P. fijiensis* and facilitates the prediction of the efficacy of new generations of fungicides.

Acknowledgements

This work was supported by the Ecuadorian government through the "Secretaría de Educación Superior, Ciencia, Tecnología e Innovación", SENESCYT, The Ecuadorian University, "Escuela Superior Politécnica del Litoral" (ESPOL), the "Centro de Investigaciones Biotecnológicas del Ecuador CIBE" that belongs to ESPOL university and Syngenta AG. We also acknowledge the support of CORBANA, CIRAD, UNALMED, and Wageningen University & Research, Plant Research International. Special thanks to María Isabel Jiménez, María Jama and Rufino Meza for their invaluable help to collect and provide the Ecuadorian samples, and to Vicente Rey from AUGURA-Cenibanano for help in collecting Colombian Isolates. Finally, we want to acknowledge Caucasella Díaz, Tatiana Chavez, Carla Maté Goldar and Aikaterini Vichou for their contribution in the laboratory work and Pieter Vereijken for his support in data analyses. This project was partially funded through a donation of the Dutch Dioraphte Foundation.

Supporting information

Table S1. EC₅₀ mean values per *Pseudocercospora fijiensis* isolate. Columns show: Country, isolate code, fungicide, 2 Logarithmic mean, lower and upper error of the difference values (Lsed and Used), observations (number of independent EC₅₀ calculated values), standard error of the measurement (Sem), lower and upper confident intervals of the means and the back-transformed EC₅₀ mean values in mg.L⁻¹. Strains with EC₅₀ values lower than 0.1 mg.L⁻¹ are indicated with a green background, values from 0.1 to 0.9 mg.L⁻¹are shown in light yellow background and values higher than 1 mg.L⁻¹ are shown in light red background.

-		1	a				-			
Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Dominican Rep.	A_10	Difenoconazole	-3.525	-5.567	-1.482	3	0.520	-4.546	-2.504	0.087
Dominican Rep.	A_10	Epoxiconazole	-4.238	-6.280	-2.195	3	0.520	-5.259	-3.217	0.053
Dominican Rep.	A_10	Propiconazole	-2.484	-4.527	-0.442	3	0.520	-3.506	-1.463	0.179
Dominican Rep.	A_11	Difenoconazole	0.437	-1.606	2.479	3	0.520	-0.584	1.458	1.354
Dominican Rep.	A_11	Epoxiconazole	-0.057	-2.100	1.985	3	0.520	-1.079	0.964	0.961
Dominican Rep.	A_11	Propiconazole	0.309	-1.733	2.352	3	0.520	-0.712	1.330	1.239
Dominican Rep.	A_12	Difenoconazole	-7.164	-9.207	-5.122	3	0.520	-8.185	-6.143	0.007
Dominican Rep.	A_12	Epoxiconazole	-6.334	-8.376	-4.292	3	0.520	-7.355	-5.313	0.012
Dominican Rep.	A_12	Propiconazole	-5.956	-7.999	-3.914	3	0.520	-6.978	-4.935	0.016
Dominican Rep.	A_13	Difenoconazole	1.082	-0.960	3.124	3	0.520	0.061	2.103	2.117
Dominican Rep.	A_13	Epoxiconazole	-0.107	-2.149	1.936	3	0.520	-1.128	0.915	0.929
Dominican Rep.	A_13	Propiconazole	0.153	-1.889	2.196	3	0.520	-0.868	1.174	1.112
Dominican Rep.	A_14	Difenoconazole	-1.781	-3.824	0.261	3	0.520	-2.802	-0.760	0.291
Dominican Rep.	A_14	Epoxiconazole	-2.274	-4.317	-0.232	3	0.520	-3.295	-1.253	0.207
Dominican Rep.	A_14	Propiconazole	-1.780	-3.822	0.262	3	0.520	-2.801	-0.759	0.291
Dominican Rep.	A_15	Difenoconazole	0.877	-1.165	2.920	3	0.520	-0.144	1.899	1.837
Dominican Rep.	A_15	Epoxiconazole	0.221	-1.822	2.263	3	0.520	-0.801	1.242	1.165
Dominican Rep.	A_15	Propiconazole	0.650	-1.393	2.692	3	0.520	-0.372	1.671	1.569
Dominican Rep.	A_16	Difenoconazole	-4.152	-6.194	-2.110	3	0.520	-5.173	-3.131	0.056
Dominican Rep.	A_16	Epoxiconazole	-2.032	-4.074	0.011	3	0.520	-3.053	-1.010	0.245
Dominican Rep.	A_16	Propiconazole	-1.632	-3.674	0.410	3	0.520	-2.653	-0.611	0.323
Dominican Rep.	A_7	Difenoconazole	-2.646	-4.689	-0.604	3	0.520	-3.667	-1.625	0.160
Dominican Rep.	A_7	Epoxiconazole	-4.329	-6.371	-2.287	3	0.520	-5.350	-3.308	0.050
Dominican Rep.	A_7	Propiconazole	-1.882	-3.924	0.160	3	0.520	-2.903	-0.861	0.271
Dominican Rep.	A_8	Difenoconazole	-2.057	-4.100	-0.015	3	0.520	-3.079	-1.036	0.240
Dominican Rep.	A_8	Epoxiconazole	-3.478	-5.521	-1.436	3	0.520	-4.500	-2.457	0.090
Dominican Rep.	A_8	Propiconazole	-1.459	-3.501	0.583	3	0.520	-2.480	-0.438	0.364
Dominican Rep.	A_9	Difenoconazole	-1.630	-3.672	0.412	3	0.520	-2.651	-0.609	0.323
Dominican Rep.	A_9	Epoxiconazole	-2.694	-4.736	-0.651	3	0.520	-3.715	-1.673	0.155
Dominican Rep.	A_9	Propiconazole	-1.278	-3.321	0.764	3	0.520	-2.300	-0.257	0.412

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Colombia	Almendros_1	Difenoconazole	0.809	-1.233	2.852	1	0.901	-0.959	2.578	1.752
Colombia	Almendros_1	Epoxiconazole	-0.412	-2.454	1.630	1	0.901	-2.181	1.357	0.752
Colombia	Almendros_1	Propiconazole	1.061	-0.982	3.103	1	0.901	-0.708	2.830	2.086
Colombia	Almendros_2	Difenoconazole	2.569	0.527	4.612	1	0.901	0.801	4.338	5.936
Colombia	Almendros_2	Epoxiconazole	0.237	-1.806	2.279	1	0.901	-1.532	2.006	1.178
Colombia	Almendros_2	Propiconazole	1.581	-0.461	3.624	1	0.901	-0.187	3.350	2.993
Colombia	Almendros_3	Difenoconazole	-0.173	-2.215	1.869	1	0.901	-1.942	1.596	0.887
Colombia	Almendros_3	Epoxiconazole	-0.896	-2.939	1.146	1	0.901	-2.665	0.872	0.537
Colombia	Almendros_3	Propiconazole	-0.267	-2.310	1.775	1	0.901	-2.036	1.502	0.831
Colombia	Almendros_4	Difenoconazole	-1.589	-3.632	0.453	1	0.901	-3.358	0.180	0.332
Colombia	Almendros_4	Epoxiconazole	-1.093	-3.135	0.949	1	0.901	-2.862	0.676	0.469
Colombia	Almendros_4	Propiconazole	-0.406	-2.448	1.637	1	0.901	-2.174	1.363	0.755
Colombia	Almendros_8	Difenoconazole	2.898	0.855	4.940	1	0.901	1.129	4.666	7.452
Colombia	Almendros_8	Epoxiconazole	2.672	0.630	4.715	1	0.901	0.904	4.441	6.375
Colombia	Almendros_8	Propiconazole	2.759	0.716	4.801	1	0.901	0.990	4.528	6.768
Philippines	B11_10	Difenoconazole	0.645	-1.397	2.688	1	0.901	-1.123	2.414	1.564
Philippines	B11_10	Epoxiconazole	1.071	-0.972	3.113	1	0.901	-0.698	2.839	2.100
Philippines	B11_10	Propiconazole	1.600	-0.442	3.642	1	0.901	-0.169	3.369	3.031
Philippines	B11_11	Difenoconazole	-0.976	-3.018	1.066	3	0.520	-1.997	0.045	0.508
Philippines	B11_11	Epoxiconazole	-2.089	-4.131	-0.046	3	0.520	-3.110	-1.067	0.235
Philippines	B11_11	Propiconazole	-0.542	-2.585	1.500	3	0.520	-1.564	0.479	0.687
Philippines	B11_12	Difenoconazole	-0.836	-2.878	1.207	3	0.520	-1.857	0.186	0.560
Philippines	B11_12	Epoxiconazole	-1.531	-3.574	0.511	3	0.520	-2.552	-0.510	0.346
Philippines	B11_12	Propiconazole	-0.264	-2.306	1.778	3	0.520	-1.285	0.757	0.833
Philippines	B11_13	Difenoconazole	-1.458	-3.501	0.584	3	0.520	-2.480	-0.437	0.364
Philippines	B11_13	Epoxiconazole	-1.909	-3.952	0.133	3	0.520	-2.930	-0.888	0.266
Philippines	B11_13	Propiconazole	0.187	-1.856	2.229	3	0.520	-0.835	1.208	1.138
Philippines	B11_14	Difenoconazole	-1.566	-3.609	0.476	1	0.901	-3.335	0.202	0.338
Philippines	B11_14	Epoxiconazole	-1.599	-3.641	0.444	1	0.901	-3.367	0.170	0.330
Philippines	B11_14	Propiconazole	-0.067	-2.110	1.975	1	0.901	-1.836	1.701	0.954
Philippines	B11_15	Difenoconazole	1.128	-0.914	3.170	1	0.901	-0.641	2.897	2.186
Philippines	B11_15	Epoxiconazole	0.639	-1.403	2.682	1	0.901	-1.129	2.408	1.558
Philippines	B11_15	Propiconazole	0.952	-1.091	2.994	1	0.901	-0.817	2.720	1.934
Philippines	B11_16	Difenoconazole	0.325	-1.718	2.367	1	0.901	-1.444	2.094	1.252
Philippines	B11_16	Epoxiconazole	-1.187	-3.229	0.856	1	0.901	-2.955	0.582	0.439
Philippines	B11_16	Propiconazole	1.260	-0.782	3.302	1	0.901	-0.509	3.029	2.395
Philippines	B11_2	Difenoconazole	1.317	-0.725	3.360	1	0.901	-0.452	3.086	2.492
Philippines	B11_2	Epoxiconazole	1.781	-0.262	3.823	1	0.901	0.012	3.550	3.436

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Philippines	B11_2	Propiconazole	2.175	0.132	4.217	1	0.901	0.406	3.943	4.514
Philippines	B11_5	Difenoconazole	2.456	0.414	4.498	3	0.520	1.435	3.477	5.487
Philippines	B11_5	Epoxiconazole	2.184	0.142	4.227	3	0.520	1.163	3.205	4.545
Philippines	B11_5	Propiconazole	2.122	0.080	4.164	3	0.520	1.101	3.143	4.353
Philippines	B11_7	Difenoconazole	-0.487	-2.530	1.555	3	0.520	-1.508	0.534	0.713
Philippines	B11_7	Epoxiconazole	-1.627	-3.669	0.416	3	0.520	-2.648	-0.606	0.324
Philippines	B11_7	Propiconazole	0.121	-1.922	2.163	3	0.520	-0.901	1.142	1.087
Philippines	B11_8	Difenoconazole	1.506	-0.536	3.549	1	0.901	-0.262	3.275	2.841
Philippines	B11_8	Epoxiconazole	1.355	-0.688	3.397	1	0.901	-0.414	3.124	2.558
Philippines	B11_8	Propiconazole	1.355	-0.687	3.397	1	0.901	-0.414	3.124	2.558
Philippines	B11_9	Difenoconazole	0.571	-1.471	2.613	1	0.901	-1.198	2.340	1.486
Philippines	B11_9	Epoxiconazole	-0.401	-2.444	1.641	1	0.901	-2.170	1.367	0.757
Philippines	B11_9	Propiconazole	0.218	-1.825	2.260	1	0.901	-1.551	1.987	1.163
Philippines	B21_1	Difenoconazole	-0.795	-2.837	1.248	1	0.901	-2.564	0.974	0.576
Philippines	B21_1	Epoxiconazole	-0.480	-2.522	1.563	1	0.901	-2.248	1.289	0.717
Philippines	B21_1	Propiconazole	1.335	-0.708	3.377	1	0.901	-0.434	3.103	2.522
Philippines	B21_10	Difenoconazole	0.410	-1.633	2.452	1	0.901	-1.359	2.179	1.328
Philippines	B21_10	Epoxiconazole	-0.132	-2.175	1.910	1	0.901	-1.901	1.637	0.912
Philippines	B21_10	Propiconazole	1.586	-0.456	3.628	1	0.901	-0.183	3.355	3.002
Philippines	B21_11	Difenoconazole	1.088	-0.954	3.131	1	0.901	-0.680	2.857	2.126
Philippines	B21_11	Epoxiconazole	0.598	-1.444	2.641	1	0.901	-1.171	2.367	1.514
Philippines	B21_11	Propiconazole	0.974	-1.068	3.017	1	0.901	-0.795	2.743	1.965
Philippines	B21_12	Difenoconazole	0.855	-1.187	2.897	1	0.901	-0.914	2.624	1.809
Philippines	B21_12	Epoxiconazole	1.847	-0.195	3.889	1	0.901	0.078	3.616	3.598
Philippines	B21_12	Propiconazole	-1.016	-3.058	1.027	1	0.901	-2.785	0.753	0.495
Philippines	B21_13	Difenoconazole	-1.097	-3.139	0.945	1	0.901	-2.866	0.672	0.467
Philippines	B21_13	Epoxiconazole	-3.184	-5.227	-1.142	1	0.901	-4.953	-1.415	0.110
Philippines	B21_13	Propiconazole	0.204	-1.838	2.246	1	0.901	-1.565	1.973	1.152
Philippines	B21_2	Difenoconazole	0.041	-2.001	2.084	1	0.901	-1.727	1.810	1.029
Philippines	B21_2	Epoxiconazole	0.317	-1.726	2.359	1	0.901	-1.452	2.086	1.246
Philippines	B21_2	Propiconazole	1.185	-0.858	3.227	1	0.901	-0.584	2.953	2.273
Philippines	B21_3	Difenoconazole	-0.213	-2.255	1.830	1	0.901	-1.981	1.556	0.863
Philippines	B21_3	Epoxiconazole	-0.838	-2.880	1.204	1	0.901	-2.607	0.931	0.559
Philippines	B21_3	Propiconazole	0.664	-1.379	2.706	1	0.901	-1.105	2.432	1.584
Philippines	B21_4	Difenoconazole	2.864	0.821	4.906	1	0.901	1.095	4.633	7.279
Philippines	B21_4	Epoxiconazole	2.970	0.928	5.012	1	0.901	1.201	4.739	7.836
Philippines	B21_4	Propiconazole	0.592	-1.451	2.634	1	0.901	-1.177	2.360	1.507
Philippines	B21_5	Difenoconazole	-2.006	-4.049	0.036	1	0.901	-3.775	-0.237	0.249

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Philippines	B21_5	Epoxiconazole	-1.278	-3.321	0.764	1	0.901	-3.047	0.490	0.412
Philippines	B21_5	Propiconazole	-0.108	-2.150	1.935	1	0.901	-1.877	1.661	0.928
Philippines	B21_6	Difenoconazole	-0.241	-2.283	1.802	1	0.901	-2.009	1.528	0.846
Philippines	B21_6	Epoxiconazole	1.012	-1.031	3.054	1	0.901	-0.757	2.780	2.016
Philippines	B21_6	Propiconazole	-0.207	-2.250	1.835	1	0.901	-1.976	1.561	0.866
Philippines	B21_7	Difenoconazole	1.021	-1.022	3.063	1	0.901	-0.748	2.789	2.029
Philippines	B21_7	Epoxiconazole	1.025	-1.017	3.068	1	0.901	-0.743	2.794	2.036
Philippines	B21_7	Propiconazole	-0.068	-2.111	1.974	1	0.901	-1.837	1.700	0.954
Philippines	B21_8	Difenoconazole	1.965	-0.077	4.008	1	0.901	0.196	3.734	3.905
Philippines	B21_8	Epoxiconazole	2.255	0.213	4.298	1	0.901	0.486	4.024	4.774
Philippines	B21_8	Propiconazole	0.747	-1.296	2.789	1	0.901	-1.022	2.515	1.678
Philippines	B21_9	Difenoconazole	2.421	0.378	4.463	1	0.901	0.652	4.190	5.354
Philippines	B21_9	Epoxiconazole	1.236	-0.806	3.279	1	0.901	-0.533	3.005	2.356
Philippines	B21_9	Propiconazole	2.528	0.486	4.570	1	0.901	0.759	4.297	5.768
Colombia	Bananal_1	Difenoconazole	0.703	-1.340	2.745	1	0.901	-1.066	2.472	1.628
Colombia	Bananal_1	Epoxiconazole	0.660	-1.382	2.703	1	0.901	-1.108	2.429	1.580
Colombia	Bananal_1	Propiconazole	1.185	-0.857	3.228	1	0.901	-0.584	2.954	2.274
Colombia	Bejuquillo_1	Difenoconazole	-6.750	-8.792	-4.707	1	0.901	-8.519	-4.981	0.009
Colombia	Bejuquillo_1	Epoxiconazole	-6.087	-8.130	-4.045	1	0.901	-7.856	-4.318	0.015
Colombia	Bejuquillo_1	Propiconazole	-5.946	-7.989	-3.904	1	0.901	-7.715	-4.177	0.016
Colombia	Bejuquillo_2	Difenoconazole	-6.561	-8.603	-4.518	3	0.520	-7.582	-5.539	0.011
Colombia	Bejuquillo_2	Epoxiconazole	-6.057	-8.099	-4.015	3	0.520	-7.078	-5.036	0.015
Colombia	Bejuquillo_2	Propiconazole	-5.236	-7.278	-3.194	3	0.520	-6.257	-4.215	0.027
Colombia	Bejuquillo_3	Difenoconazole	-5.921	-7.963	-3.878	1	0.901	-7.689	-4.152	0.017
Colombia	Bejuquillo_3	Epoxiconazole	-5.129	-7.172	-3.087	1	0.901	-6.898	-3.360	0.029
Colombia	Bejuquillo_3	Propiconazole	-3.874	-5.916	-1.832	1	0.901	-5.643	-2.105	0.068
Colombia	Bejuquillo_4	Difenoconazole	-7.447	-9.490	-5.405	1	0.901	-9.216	-5.679	0.006
Colombia	Bejuquillo_4	Epoxiconazole	-6.075	-8.118	-4.033	1	0.901	-7.844	-4.307	0.015
Colombia	Bejuquillo_4	Propiconazole	-5.606	-7.648	-3.564	1	0.901	-7.375	-3.837	0.021
Colombia	Bejuquillo_5	Difenoconazole	-6.075	-8.117	-4.032	1	0.901	-7.843	-4.306	0.015
Colombia	Bejuquillo_5	Epoxiconazole	-5.805	-7.847	-3.763	1	0.901	-7.574	-4.036	0.018
Colombia	Bejuquillo_5	Propiconazole	-4.304	-6.346	-2.262	1	0.901	-6.073	-2.535	0.051
Colombia	Bejuquillo_6	Difenoconazole	-6.266	-8.308	-4.224	1	0.901	-8.035	-4.497	0.013
Colombia	Bejuquillo_6	Epoxiconazole	-5.937	-7.980	-3.895	1	0.901	-7.706	-4.168	0.016
Colombia	Bejuquillo_6	Propiconazole	-4.865	-6.907	-2.822	1	0.901	-6.634	-3.096	0.034
Colombia	Bejuquillo_7	Difenoconazole	-6.158	-8.200	-4.116	1	0.901	-7.927	-4.389	0.014
Colombia	Bejuquillo_7	Epoxiconazole	-5.323	-7.366	-3.281	1	0.901	-7.092	-3.554	0.025
Colombia	Bejuquillo_7	Propiconazole	-4.963	-7.005	-2.920	1	0.901	-6.731	-3.194	0.032
Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
-------------	----------	----------------	---------------------	--------	--------	-----	-------	--------	--------	------------------
Philippines	Bo_1	Difenoconazole	-7.483	-9.525	-5.441	3	0.520	-8.504	-6.462	0.006
Philippines	Bo_1	Epoxiconazole	-6.447	-8.490	-4.405	3	0.520	-7.468	-5.426	0.011
Philippines	Bo_1	Propiconazole	-5.851	-7.893	-3.808	3	0.520	-6.872	-4.829	0.017
Colombia	Bonita_2	Difenoconazole	-2.089	-4.131	-0.047	3	0.520	-3.110	-1.068	0.235
Colombia	Bonita_2	Epoxiconazole	-2.749	-4.791	-0.706	3	0.520	-3.770	-1.727	0.149
Colombia	Bonita_2	Propiconazole	-1.796	-3.839	0.246	3	0.520	-2.817	-0.775	0.288
Colombia	C080910	Difenoconazole	-3.023	-5.066	-0.981	3	0.520	-4.044	-2.002	0.123
Colombia	C080910	Epoxiconazole	-3.082	-5.125	-1.040	3	0.520	-4.103	-2.061	0.118
Colombia	C080910	Propiconazole	-1.178	-3.221	0.864	3	0.520	-2.199	-0.157	0.442
Colombia	C120901	Difenoconazole	-1.591	-3.633	0.452	1	0.901	-3.359	0.178	0.332
Colombia	C120901	Epoxiconazole	-2.594	-4.636	-0.552	1	0.901	-4.363	-0.825	0.166
Colombia	C120901	Propiconazole	-1.061	-3.104	0.981	1	0.901	-2.830	0.708	0.479
Colombia	C120906	Difenoconazole	2.761	0.719	4.804	1	0.901	0.993	4.530	6.781
Colombia	C120906	Epoxiconazole	3.072	1.030	5.115	1	0.901	1.304	4.841	8.411
Colombia	C120906	Propiconazole	2.924	0.881	4.966	1	0.901	1.155	4.692	7.587
Colombia	C120908	Difenoconazole	2.764	0.722	4.807	1	0.901	0.995	4.533	6.794
Colombia	C120908	Epoxiconazole	1.580	-0.462	3.623	1	0.901	-0.189	3.349	2.990
Colombia	C120908	Propiconazole	1.313	-0.729	3.355	1	0.901	-0.456	3.082	2.485
Colombia	C120909	Difenoconazole	2.568	0.525	4.610	1	0.901	0.799	4.336	5.928
Colombia	C120909	Epoxiconazole	0.394	-1.648	2.437	1	0.901	-1.375	2.163	1.314
Colombia	C120909	Propiconazole	2.464	0.422	4.507	1	0.901	0.696	4.233	5.519
Colombia	C120910	Difenoconazole				0				>10.24
Colombia	C120910	Epoxiconazole				0				>10.24
Colombia	C120910	Propiconazole				0				>10.24
Colombia	C120912	Difenoconazole	2.585	0.543	4.628	1	0.901	0.816	4.354	6.001
Colombia	C120912	Epoxiconazole	-0.191	-2.234	1.851	1	0.901	-1.960	1.578	0.876
Colombia	C120912	Propiconazole	1.799	-0.244	3.841	1	0.901	0.030	3.568	3.479
Colombia	C120913	Difenoconazole				0				>10.24
Colombia	C120913	Epoxiconazole	2.597	0.555	4.640	1	0.901	0.828	4.366	6.051
Colombia	C120913	Propiconazole				0				>10.24
Colombia	C139	Difenoconazole	-6.430	-8.473	-4.388	2	0.637	-7.681	-5.179	0.012
Colombia	C139	Epoxiconazole	-6.116	-8.158	-4.074	2	0.637	-7.367	-4.865	0.014
Colombia	C139	Propiconazole	-5.387	-7.429	-3.344	2	0.637	-6.638	-4.136	0.024
Cameroon	C86	Difenoconazole	-7.862	-9.905	-5.820	2	0.637	-9.113	-6.612	0.004
Cameroon	C86	Epoxiconazole	-7.217	-9.259	-5.175	2	0.637	-8.468	-5.966	0.007
Cameroon	C86	Propiconazole	-6.681	-8.723	-4.638	2	0.637	-7.932	-5.430	0.010
Costa Rica	Ca10_13	Difenoconazole	2.486	0.444	4.529	2	0.637	1.236	3.737	5.604
Costa Rica	Ca10_13	Epoxiconazole	1.759	-0.283	3.801	2	0.637	0.508	3.010	3.385

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Costa Rica	Ca10_13	Propiconazole	1.990	-0.053	4.032	2	0.637	0.739	3.240	3.971
Costa Rica	Ca5_16	Difenoconazole	2.489	0.446	4.531	2	0.637	1.238	3.739	5.613
Costa Rica	Ca5_16	Epoxiconazole	0.328	-1.715	2.370	2	0.637	-0.923	1.578	1.255
Costa Rica	Ca5_16	Propiconazole	1.473	-0.569	3.515	2	0.637	0.222	2.724	2.776
Costa Rica	CaM1_1	Difenoconazole	2.583	0.541	4.625	7	0.341	1.914	3.252	5.992
Costa Rica	CaM1_1	Epoxiconazole	0.890	-1.153	2.932	6	0.368	0.168	1.612	1.853
Costa Rica	CaM1_1	Propiconazole	1.443	-0.600	3.485	7	0.341	0.774	2.111	2.718
Costa Rica	CaM1_10	Difenoconazole	2.263	0.221	4.305	4	0.451	1.379	3.147	4.800
Costa Rica	CaM1_10	Epoxiconazole	2.155	0.112	4.197	4	0.451	1.270	3.039	4.453
Costa Rica	CaM1_10	Propiconazole	1.974	-0.069	4.016	3	0.520	0.953	2.995	3.928
Costa Rica	CaM1_11	Difenoconazole	1.472	-0.571	3.514	2	0.637	0.221	2.722	2.774
Costa Rica	CaM1_11	Epoxiconazole	2.144	0.101	4.186	2	0.637	0.893	3.395	4.419
Costa Rica	CaM1_11	Propiconazole	1.702	-0.341	3.744	2	0.637	0.451	2.952	3.253
Costa Rica	CaM1_12	Difenoconazole	3.296	1.253	5.338	1	0.901	1.527	5.064	9.819
Costa Rica	CaM1_12	Epoxiconazole	1.695	-0.348	3.737	1	0.901	-0.074	3.464	3.237
Costa Rica	CaM1_12	Propiconazole	2.357	0.315	4.399	2	0.637	1.106	3.608	5.123
Costa Rica	CaM1_13	Difenoconazole				0				>10.24
Costa Rica	CaM1_13	Epoxiconazole				0				>10.24
Costa Rica	CaM1_13	Propiconazole				0				>10.24
Costa Rica	CaM1_14	Difenoconazole	2.732	0.690	4.775	1	0.901	0.964	4.501	6.645
Costa Rica	CaM1_14	Epoxiconazole	1.758	-0.285	3.800	1	0.901	-0.011	3.527	3.382
Costa Rica	CaM1_14	Propiconazole	1.966	-0.076	4.008	1	0.901	0.197	3.735	3.907
Costa Rica	CaM1_15	Difenoconazole				0				>10.24
Costa Rica	CaM1_15	Epoxiconazole	1.904	-0.138	3.947	1	0.901	0.135	3.673	3.743
Costa Rica	CaM1_15	Propiconazole				0				>10.24
Costa Rica	CaM1_16	Difenoconazole				0				>10.24
Costa Rica	CaM1_16	Epoxiconazole	3.002	0.960	5.044	2	0.637	1.751	4.253	8.012
Costa Rica	CaM1_16	Propiconazole	2.952	0.910	4.995	1	0.901	1.183	4.721	7.739
Costa Rica	CaM1_2	Difenoconazole	2.031	-0.011	4.074	5	0.403	1.240	2.822	4.088
Costa Rica	CaM1_2	Epoxiconazole	1.515	-0.527	3.558	7	0.341	0.847	2.184	2.859
Costa Rica	CaM1_2	Propiconazole	2.503	0.460	4.545	5	0.403	1.712	3.294	5.668
Costa Rica	CaM1_3	Difenoconazole	2.429	0.386	4.471	6	0.368	1.707	3.151	5.384
Costa Rica	CaM1_3	Epoxiconazole	1.896	-0.146	3.938	7	0.341	1.228	2.565	3.722
Costa Rica	CaM1_3	Propiconazole	1.793	-0.250	3.835	7	0.341	1.124	2.461	3.464
Costa Rica	CaM1_4	Difenoconazole	1.646	-0.397	3.688	7	0.341	0.977	2.314	3.129
Costa Rica	CaM1_4	Epoxiconazole	1.957	-0.085	4.000	6	0.368	1.235	2.679	3.883
Costa Rica	CaM1_4	Propiconazole	2.215	0.173	4.258	6	0.368	1.493	2.937	4.644
Costa Rica	CaM1_5	Difenoconazole	3.706	1.664	5.749	3	0.520	2.685	4.728	13.054
	1	1								

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Costa Rica	CaM1_5	Epoxiconazole	2.372	0.329	4.414	4	0.451	1.487	3.256	5.176
Costa Rica	CaM1_5	Propiconazole	2.630	0.588	4.673	5	0.403	1.839	3.421	6.191
Costa Rica	CaM1_6	Difenoconazole	2.256	0.214	4.299	5	0.403	1.465	3.047	4.778
Costa Rica	CaM1_6	Epoxiconazole	2.225	0.182	4.267	5	0.403	1.434	3.016	4.675
Costa Rica	CaM1_6	Propiconazole	2.609	0.567	4.652	5	0.403	1.818	3.400	6.103
Costa Rica	CaM1_7	Difenoconazole	2.348	0.305	4.390	6	0.368	1.626	3.070	5.091
Costa Rica	CaM1_7	Epoxiconazole	2.654	0.612	4.697	6	0.368	1.932	3.376	6.296
Costa Rica	CaM1_7	Propiconazole	2.550	0.508	4.592	5	0.403	1.759	3.341	5.856
Costa Rica	CaM1_8	Difenoconazole	1.479	-0.563	3.522	6	0.368	0.757	2.201	2.788
Costa Rica	CaM1_8	Epoxiconazole	2.151	0.108	4.193	6	0.368	1.429	2.873	4.440
Costa Rica	CaM1_8	Propiconazole	0.949	-1.093	2.992	6	0.368	0.227	1.671	1.931
Costa Rica	CaM1_9	Difenoconazole	1.943	-0.099	3.986	2	0.637	0.693	3.194	3.846
Costa Rica	CaM1_9	Epoxiconazole	1.616	-0.427	3.658	1	0.901	-0.153	3.385	3.065
Costa Rica	CaM1_9	Propiconazole	2.568	0.526	4.611	2	0.637	1.318	3.819	5.931
Costa Rica	CaM10_16	Difenoconazole	2.588	0.546	4.631	3	0.520	1.567	3.610	6.014
Costa Rica	CaM10_16	Epoxiconazole	1.215	-0.828	3.257	3	0.520	0.193	2.236	2.321
Costa Rica	CaM10_16	Propiconazole	2.488	0.445	4.530	3	0.520	1.467	3.509	5.609
Costa Rica	CaM10_21	Difenoconazole	2.961	0.919	5.003	3	0.520	1.940	3.982	7.787
Costa Rica	CaM10_21	Epoxiconazole	3.330	1.287	5.372	1	0.901	1.561	5.098	10.054
Costa Rica	CaM10_21	Propiconazole	2.655	0.613	4.697	3	0.520	1.634	3.676	6.299
Costa Rica	CaM10_6	Difenoconazole	4.387	2.345	6.430	3	0.520	3.366	5.408	20.925
Costa Rica	CaM10_6	Epoxiconazole	2.655	0.613	4.697	6	0.368	1.933	3.377	6.298
Costa Rica	CaM10_6	Propiconazole	4.203	2.160	6.245	1	0.901	2.434	5.971	18.414
Costa Rica	CaM2_1	Difenoconazole	2.400	0.357	4.442	3	0.520	1.378	3.421	5.277
Costa Rica	CaM2_1	Epoxiconazole	1.324	-0.719	3.366	2	0.637	0.073	2.574	2.503
Costa Rica	CaM2_1	Propiconazole	1.264	-0.779	3.306	4	0.451	0.379	2.148	2.401
Costa Rica	CaM2_10	Difenoconazole				0				>10.24
Costa Rica	CaM2_10	Epoxiconazole	2.759	0.717	4.802	2	0.637	1.509	4.010	6.770
Costa Rica	CaM2_10	Propiconazole	2.874	0.832	4.917	2	0.637	1.624	4.125	7.333
Costa Rica	CaM2_11	Difenoconazole				0				>10.24
Costa Rica	CaM2_11	Epoxiconazole				0				>10.24
Costa Rica	CaM2_11	Propiconazole				0				>10.24
Costa Rica	CaM2_12	Difenoconazole				0				>10.24
Costa Rica	CaM2_12	Epoxiconazole				0				>10.24
Costa Rica	CaM2_12	Propiconazole				0				>10.24
Costa Rica	CaM2_13	Difenoconazole				0				>10.24
Costa Rica	CaM2_13	Epoxiconazole				0				>10.24
Costa Rica	CaM2_13	Propiconazole				0				>10.24

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Costa Rica	CaM2_14	Difenoconazole				0				>10.24
Costa Rica	CaM2_14	Epoxiconazole	2.784	0.742	4.827	2	0.637	1.534	4.035	6.889
Costa Rica	CaM2_14	Propiconazole	3.004	0.961	5.046	2	0.637	1.753	4.254	8.020
Costa Rica	CaM2_15	Difenoconazole	2.072	0.029	4.114	1	0.901	0.303	3.840	4.204
Costa Rica	CaM2_15	Epoxiconazole	1.939	-0.104	3.981	2	0.637	0.688	3.190	3.834
Costa Rica	CaM2_15	Propiconazole	2.337	0.294	4.379	2	0.637	1.086	3.587	5.051
Costa Rica	CaM2_16	Difenoconazole	3.255	1.213	5.298	1	0.901	1.487	5.024	9.549
Costa Rica	CaM2_16	Epoxiconazole	2.785	0.743	4.827	2	0.637	1.534	4.036	6.892
Costa Rica	CaM2_16	Propiconazole	2.737	0.694	4.779	2	0.637	1.486	3.988	6.666
Costa Rica	CaM2_2	Difenoconazole	3.015	0.972	5.057	2	0.637	1.764	4.265	8.082
Costa Rica	CaM2_2	Epoxiconazole	2.072	0.030	4.115	2	0.637	0.822	3.323	4.205
Costa Rica	CaM2_2	Propiconazole	2.022	-0.020	4.065	3	0.520	1.001	3.044	4.063
Costa Rica	CaM2_3	Difenoconazole	2.315	0.273	4.358	2	0.637	1.065	3.566	4.977
Costa Rica	CaM2_3	Epoxiconazole	2.349	0.306	4.391	3	0.520	1.328	3.370	5.094
Costa Rica	CaM2_3	Propiconazole	2.046	0.004	4.088	4	0.451	1.162	2.930	4.130
Costa Rica	CaM2_4	Difenoconazole	2.839	0.796	4.881	3	0.520	1.817	3.860	7.153
Costa Rica	CaM2_4	Epoxiconazole	2.204	0.161	4.246	3	0.520	1.183	3.225	4.607
Costa Rica	CaM2_4	Propiconazole	2.678	0.636	4.720	3	0.520	1.657	3.699	6.400
Costa Rica	CaM2_5	Difenoconazole				0				>10.24
Costa Rica	CaM2_5	Epoxiconazole	2.843	0.800	4.885	1	0.901	1.074	4.611	7.173
Costa Rica	CaM2_5	Propiconazole	2.915	0.872	4.957	1	0.901	1.146	4.684	7.541
Costa Rica	CaM2_6	Difenoconazole				0				>10.24
Costa Rica	CaM2_6	Epoxiconazole	2.402	0.359	4.444	1	0.901	0.633	4.171	5.285
Costa Rica	CaM2_6	Propiconazole	2.765	0.723	4.807	1	0.901	0.996	4.534	6.797
Costa Rica	CaM2_7	Difenoconazole	1.905	-0.138	3.947	1	0.901	0.136	3.674	3.745
Costa Rica	CaM2_7	Epoxiconazole	1.798	-0.245	3.840	2	0.637	0.547	3.048	3.476
Costa Rica	CaM2_7	Propiconazole	1.990	-0.052	4.033	2	0.637	0.740	3.241	3.974
Costa Rica	CaM2_8	Difenoconazole				0				>10.24
Costa Rica	CaM2_8	Epoxiconazole				0				>10.24
Costa Rica	CaM2_8	Propiconazole				0				>10.24
Costa Rica	CaM2_9	Difenoconazole	2.632	0.590	4.674	2	0.637	1.381	3.883	6.199
Costa Rica	CaM2_9	Epoxiconazole	2.138	0.095	4.180	2	0.637	0.887	3.388	4.401
Costa Rica	CaM2_9	Propiconazole	2.946	0.903	4.988	2	0.637	1.695	4.197	7.705
Costa Rica	CaM3_1	Difenoconazole	4.228	2.186	6.270	3	0.520	3.207	5.249	18.741
Costa Rica	CaM3_1	Epoxiconazole	1.941	-0.101	3.983	6	0.368	1.219	2.663	3.840
Costa Rica	CaM3_1	Propiconazole	3.050	1.007	5.092	5	0.403	2.259	3.841	8.280
Costa Rica	CaM3_10	Difenoconazole				0				>10.24
Costa Rica	CaM3_10	Epoxiconazole	2.611	0.568	4.653	1	0.901	0.842	4.379	6.108

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Costa Rica	CaM3_10	Propiconazole	3.302	1.260	5.345	1	0.901	1.533	5.071	9.864
Costa Rica	CaM3_11	Difenoconazole	2.236	0.194	4.279	2	0.637	0.986	3.487	4.712
Costa Rica	CaM3_11	Epoxiconazole	1.216	-0.827	3.258	2	0.637	-0.035	2.466	2.322
Costa Rica	CaM3_11	Propiconazole	2.764	0.722	4.807	2	0.637	1.514	4.015	6.794
Costa Rica	CaM3_12	Difenoconazole	2.739	0.697	4.782	1	0.901	0.971	4.508	6.678
Costa Rica	CaM3_12	Epoxiconazole	0.716	-1.326	2.759	2	0.637	-0.534	1.967	1.643
Costa Rica	CaM3_12	Propiconazole	2.179	0.137	4.222	2	0.637	0.929	3.430	4.529
Costa Rica	CaM3_13	Difenoconazole	2.831	0.788	4.873	1	0.901	1.062	4.599	7.114
Costa Rica	CaM3_13	Epoxiconazole	2.801	0.758	4.843	2	0.637	1.550	4.051	6.967
Costa Rica	CaM3_13	Propiconazole	3.057	1.014	5.099	1	0.901	1.288	4.825	8.320
Costa Rica	CaM3_14	Difenoconazole	1.248	-0.794	3.291	1	0.901	-0.520	3.017	2.376
Costa Rica	CaM3_14	Epoxiconazole	2.289	0.246	4.331	2	0.637	1.038	3.539	4.886
Costa Rica	CaM3_14	Propiconazole	2.215	0.172	4.257	1	0.901	0.446	3.983	4.642
Costa Rica	CaM3_15	Difenoconazole				0				>10.24
Costa Rica	CaM3_15	Epoxiconazole	1.692	-0.350	3.735	2	0.637	0.441	2.943	3.231
Costa Rica	CaM3_15	Propiconazole				0				>10.24
Costa Rica	CaM3_16	Difenoconazole	2.869	0.827	4.911	2	0.637	1.618	4.120	7.305
Costa Rica	CaM3_16	Epoxiconazole	2.133	0.090	4.175	2	0.637	0.882	3.383	4.386
Costa Rica	CaM3_16	Propiconazole	2.627	0.585	4.670	2	0.637	1.377	3.878	6.179
Costa Rica	CaM3_2	Difenoconazole	2.392	0.350	4.435	2	0.637	1.142	3.643	5.250
Costa Rica	CaM3_2	Epoxiconazole	1.526	-0.516	3.569	3	0.520	0.505	2.547	2.880
Costa Rica	CaM3_2	Propiconazole	2.092	0.049	4.134	4	0.451	1.207	2.976	4.263
Costa Rica	CaM3_3	Difenoconazole	1.679	-0.364	3.721	3	0.520	0.658	2.700	3.202
Costa Rica	CaM3_3	Epoxiconazole	0.022	-2.020	2.065	4	0.451	-0.862	0.907	1.016
Costa Rica	CaM3_3	Propiconazole	1.477	-0.566	3.519	4	0.451	0.592	2.361	2.783
Costa Rica	CaM3_4	Difenoconazole	3.145	1.103	5.188	1	0.901	1.376	4.914	8.847
Costa Rica	CaM3_4	Epoxiconazole	1.705	-0.337	3.747	4	0.451	0.821	2.589	3.261
Costa Rica	CaM3_4	Propiconazole	3.126	1.084	5.169	3	0.520	2.105	4.148	8.732
Costa Rica	CaM3_5	Difenoconazole				0				>10.24
Costa Rica	CaM3_5	Epoxiconazole	2.075	0.033	4.118	2	0.637	0.824	3.326	4.214
Costa Rica	CaM3_5	Propiconazole	3.190	1.147	5.232	1	0.901	1.421	4.958	9.123
Costa Rica	CaM3_6	Difenoconazole				0				>10.24
Costa Rica	CaM3_6	Epoxiconazole	3.095	1.052	5.137	1	0.901	1.326	4.864	8.543
Costa Rica	CaM3_6	Propiconazole				0				>10.24
Costa Rica	CaM3_7	Difenoconazole	1.739	-0.303	3.781	2	0.637	0.488	2.990	3.338
Costa Rica	CaM3_7	Epoxiconazole	1.467	-0.576	3.509	2	0.637	0.216	2.717	2.764
Costa Rica	CaM3_7	Propiconazole	0.726	-1.316	2.769	2	0.637	-0.525	1.977	1.654
Costa Rica	CaM3_8	Difenoconazole	2.078	0.036	4.121	2	0.637	0.828	3.329	4.223

Country	Isolato	Eungicido	² l og(m)	Lood	Llead	(n)	Som	LMCI	LIMCI	EC
Country	isuidle	r ungicide	Log(III)	Laeu	0380	(1)	Jelli	LIVICI	UNICI	LU50
Costa Rica	CaM3_8	Epoxiconazole	1.687	-0.355	3.730	2	0.637	0.437	2.938	3.221
Costa Rica	CaM3_8	Propiconazole	1.583	-0.459	3.626	2	0.637	0.333	2.834	2.997
Costa Rica	CaM3_9	Difenoconazole	1.729	-0.313	3.771	2	0.637	0.478	2.980	3.315
Costa Rica	CaM3_9	Epoxiconazole	0.329	-1.714	2.371	2	0.637	-0.922	1.579	1.256
Costa Rica	CaM3_9	Propiconazole	0.931	-1.111	2.974	2	0.637	-0.320	2.182	1.907
Costa Rica	CaM7_10	Difenoconazole	2.833	0.791	4.875	3	0.520	1.812	3.854	7.126
Costa Rica	CaM7_10	Epoxiconazole	2.284	0.242	4.327	3	0.520	1.263	3.305	4.871
Costa Rica	CaM7_10	Propiconazole	1.114	-0.929	3.156	3	0.520	0.092	2.135	2.164
Costa Rica	CaM7_19	Difenoconazole	2.595	0.553	4.638	2	0.637	1.344	3.846	6.042
Costa Rica	CaM7_19	Epoxiconazole	2.141	0.098	4.183	3	0.520	1.119	3.162	4.410
Costa Rica	CaM7_19	Propiconazole	2.342	0.299	4.384	3	0.520	1.320	3.363	5.069
Colombia	Caribe_1	Difenoconazole	2.901	0.858	4.943	1	0.901	1.132	4.670	7.468
Colombia	Caribe_1	Epoxiconazole	2.435	0.393	4.478	1	0.901	0.667	4.204	5.409
Colombia	Caribe_1	Propiconazole	2.774	0.731	4.816	1	0.901	1.005	4.543	6.839
Colombia	Caribe_2	Difenoconazole	1.603	-0.439	3.646	3	0.520	0.582	2.624	3.038
Colombia	Caribe_2	Epoxiconazole	0.771	-1.272	2.813	3	0.520	-0.250	1.792	1.706
Colombia	Caribe_2	Propiconazole	0.195	-1.847	2.237	3	0.520	-0.826	1.216	1.145
Colombia	Caribe_3	Difenoconazole	2.510	0.467	4.552	3	0.520	1.488	3.531	5.694
Colombia	Caribe_3	Epoxiconazole	1.322	-0.720	3.364	3	0.520	0.301	2.343	2.500
Colombia	Caribe_3	Propiconazole	1.669	-0.373	3.712	3	0.520	0.648	2.690	3.181
Colombia	Caribe_4	Difenoconazole	0.205	-1.838	2.247	1	0.901	-1.564	1.973	1.152
Colombia	Caribe_4	Epoxiconazole	-1.105	-3.147	0.938	1	0.901	-2.873	0.664	0.465
Colombia	Caribe_4	Propiconazole	-0.271	-2.313	1.772	1	0.901	-2.039	1.498	0.829
Dominican Rep.	Dom_1	Difenoconazole	-3.777	-5.820	-1.735	3	0.520	-4.799	-2.756	0.073
Dominican Rep.	Dom_1	Epoxiconazole	-5.681	-7.723	-3.638	3	0.520	-6.702	-4.660	0.019
Dominican Rep.	Dom_1	Propiconazole	-2.374	-4.417	-0.332	3	0.520	-3.396	-1.353	0.193
Dominican Rep.	Dom_10	Difenoconazole	0.779	-1.264	2.821	3	0.520	-0.243	1.800	1.716
Dominican Rep.	Dom_10	Epoxiconazole	0.863	-1.179	2.905	3	0.520	-0.158	1.884	1.819
Dominican Rep.	Dom_10	Propiconazole	1.242	-0.801	3.284	3	0.520	0.221	2.263	2.365
Dominican Rep.	Dom_12	Difenoconazole	-2.578	-4.620	-0.535	3	0.520	-3.599	-1.557	0.168
Dominican Rep.	Dom_12	Epoxiconazole	-2.366	-4.408	-0.324	3	0.520	-3.387	-1.345	0.194
Dominican Rep.	Dom_12	Propiconazole	-0.324	-2.366	1.718	3	0.520	-1.345	0.697	0.799
Dominican Rep.	Dom_2	Difenoconazole	0.068	-1.975	2.110	3	0.520	-0.953	1.089	1.048
Dominican Rep.	Dom_2	Epoxiconazole	-0.024	-2.067	2.018	3	0.520	-1.045	0.997	0.983
Dominican Rep.	Dom_2	Propiconazole	-0.207	-2.249	1.835	3	0.520	-1.228	0.814	0.866
Dominican Rep.	Dom_3	Difenoconazole	-0.151	-2.194	1.891	3	0.520	-1.172	0.870	0.901
Dominican Rep.	Dom_3	Epoxiconazole	-0.250	-2.293	1.792	3	0.520	-1.272	0.771	0.841
Dominican Rep.	Dom_3	Propiconazole	0.403	-1.639	2.445	3	0.520	-0.618	1.424	1.322

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Dominican Rep.	Dom_4	Difenoconazole	0.325	-1.718	2.367	3	0.520	-0.697	1.346	1.252
Dominican Rep.	Dom_4	Epoxiconazole	0.346	-1.696	2.389	3	0.520	-0.675	1.367	1.271
Dominican Rep.	Dom_4	Propiconazole	0.855	-1.188	2.897	3	0.520	-0.166	1.876	1.808
Dominican Rep.	Dom_6	Difenoconazole	-0.950	-2.992	1.093	3	0.520	-1.971	0.072	0.518
Dominican Rep.	Dom_6	Epoxiconazole	-0.615	-2.657	1.428	3	0.520	-1.636	0.406	0.653
Dominican Rep.	Dom_6	Propiconazole	0.053	-1.989	2.095	3	0.520	-0.968	1.074	1.037
Dominican Rep.	Dom_7	Difenoconazole	0.264	-1.778	2.307	3	0.520	-0.757	1.285	1.201
Dominican Rep.	Dom_7	Epoxiconazole	0.277	-1.766	2.319	3	0.520	-0.745	1.298	1.211
Dominican Rep.	Dom_7	Propiconazole	0.561	-1.482	2.603	3	0.520	-0.460	1.582	1.475
Dominican Rep.	Dom_8	Difenoconazole	-1.161	-3.204	0.881	3	0.520	-2.183	-0.140	0.447
Dominican Rep.	Dom_8	Epoxiconazole	-0.824	-2.866	1.218	3	0.520	-1.845	0.197	0.565
Dominican Rep.	Dom_8	Propiconazole	-0.009	-2.052	2.033	3	0.520	-1.030	1.012	0.994
Dominican Rep.	Dom_9	Difenoconazole	-0.163	-2.206	1.879	3	0.520	-1.184	0.858	0.893
Dominican Rep.	Dom_9	Epoxiconazole	-0.542	-2.585	1.500	3	0.520	-1.564	0.479	0.687
Dominican Rep.	Dom_9	Propiconazole	0.180	-1.862	2.222	3	0.520	-0.841	1.201	1.133
Ecuador	E_22	Difenoconazole	-7.618	-9.660	-5.575	4	0.451	-8.502	-6.733	0.005
Ecuador	E_22	Epoxiconazole	-6.926	-8.968	-4.883	3	0.520	-7.947	-5.904	0.008
Ecuador	E_22	Propiconazole	-6.565	-8.608	-4.523	5	0.403	-7.356	-5.774	0.011
Ecuador	EC_1	Difenoconazole	-7.756	-9.798	-5.714	4	0.451	-8.640	-6.872	0.005
Ecuador	EC_1	Epoxiconazole	-6.993	-9.036	-4.951	3	0.520	-8.014	-5.972	0.008
Ecuador	EC_1	Propiconazole	-6.062	-8.104	-4.020	4	0.451	-6.946	-5.178	0.015
Ecuador	EC_21	Difenoconazole	-7.897	-9.940	-5.855	1	0.901	-9.666	-6.128	0.004
Ecuador	EC_21	Epoxiconazole	-7.651	-9.694	-5.609	1	0.901	-9.420	-5.882	0.005
Ecuador	EC_21	Propiconazole	-6.748	-8.790	-4.706	1	0.901	-8.517	-4.979	0.009
Ecuador	EC_5	Difenoconazole	-7.084	-9.126	-5.041	4	0.451	-7.968	-6.199	0.007
Ecuador	EC_5	Epoxiconazole	-6.813	-8.855	-4.771	4	0.451	-7.697	-5.929	0.009
Ecuador	EC_5	Propiconazole	-6.470	-8.513	-4.428	4	0.451	-7.355	-5.586	0.011
Ecuador	ECM_1	Difenoconazole	0.528	-1.514	2.571	1	0.901	-1.240	2.297	1.442
Ecuador	ECM_1	Epoxiconazole	-0.805	-2.847	1.237	1	0.901	-2.574	0.964	0.572
Ecuador	ECM_1	Propiconazole	-0.372	-2.415	1.670	1	0.901	-2.141	1.397	0.773
Ecuador	ECQ_10	Difenoconazole	-4.473	-6.515	-2.430	2	0.637	-5.723	-3.222	0.045
Ecuador	ECQ_10	Epoxiconazole	-4.464	-6.506	-2.421	2	0.637	-5.714	-3.213	0.045
Ecuador	ECQ_10	Propiconazole	-3.046	-5.089	-1.004	2	0.637	-4.297	-1.796	0.121
Ecuador	ECQ_20	Difenoconazole	-5.572	-7.615	-3.530	2	0.637	-6.823	-4.322	0.021
Ecuador	ECQ_20	Epoxiconazole	-5.624	-7.666	-3.581	2	0.637	-6.874	-4.373	0.020
Ecuador	ECQ_20	Propiconazole	-4.753	-6.795	-2.710	2	0.637	-6.003	-3.502	0.037
Ecuador	ECU_18	Difenoconazole	-3.258	-5.300	-1.215	1	0.901	-5.027	-1.489	0.105
Ecuador	ECU_18	Epoxiconazole	-3.842	-5.884	-1.799	1	0.901	-5.610	-2.073	0.070

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Ecuador	ECU_18	Propiconazole	-2.211	-4.253	-0.168	1	0.901	-3.979	-0.442	0.216
Ecuador	ECU_2	Difenoconazole	-2.318	-4.360	-0.276	2	0.637	-3.569	-1.067	0.201
Ecuador	ECU_2	Epoxiconazole	-3.238	-5.280	-1.195	2	0.637	-4.488	-1.987	0.106
Ecuador	ECU_2	Propiconazole	-1.784	-3.826	0.259	2	0.637	-3.034	-0.533	0.290
Ecuador	EN_12	Difenoconazole	-5.773	-7.816	-3.731	1	0.901	-7.542	-4.005	0.018
Ecuador	EN_12	Epoxiconazole	-6.091	-8.134	-4.049	1	0.901	-7.860	-4.323	0.015
Ecuador	EN_12	Propiconazole	-5.193	-7.235	-3.150	1	0.901	-6.962	-3.424	0.027
Ecuador	EN_2	Difenoconazole	-7.012	-9.055	-4.970	2	0.637	-8.263	-5.762	0.008
Ecuador	EN_2	Epoxiconazole	-6.420	-8.462	-4.377	2	0.637	-7.671	-5.169	0.012
Ecuador	EN_2	Propiconazole	-5.695	-7.737	-3.652	2	0.637	-6.945	-4.444	0.019
Ecuador	ENB_52	Difenoconazole	-7.302	-9.344	-5.259	2	0.637	-8.552	-6.051	0.006
Ecuador	ENB_52	Epoxiconazole	-6.964	-9.006	-4.921	2	0.637	-8.215	-5.713	0.008
Ecuador	ENB_52	Propiconazole	-6.283	-8.325	-4.241	3	0.520	-7.304	-5.262	0.013
Ecuador	ENB_6	Difenoconazole	-5.503	-7.546	-3.461	1	0.901	-7.272	-3.734	0.022
Ecuador	ENB_6	Epoxiconazole	-5.915	-7.957	-3.872	1	0.901	-7.683	-4.146	0.017
Ecuador	ENB_6	Propiconazole	-4.623	-6.665	-2.580	1	0.901	-6.391	-2.854	0.041
Ecuador	ENB_7	Difenoconazole	-3.890	-5.933	-1.848	1	0.901	-5.659	-2.122	0.067
Ecuador	ENB_7	Epoxiconazole	-3.963	-6.005	-1.921	1	0.901	-5.732	-2.194	0.064
Ecuador	ENB_7	Propiconazole	-4.075	-6.118	-2.033	1	0.901	-5.844	-2.307	0.059
Ecuador	ENP_8	Difenoconazole	-6.269	-8.311	-4.226	1	0.901	-8.037	-4.500	0.013
Ecuador	ENP_8	Epoxiconazole	-5.505	-7.547	-3.462	1	0.901	-7.273	-3.736	0.022
Ecuador	ENP_8	Propiconazole	-4.712	-6.754	-2.670	1	0.901	-6.481	-2.943	0.038
Ecuador	ENR_4	Difenoconazole	-7.240	-9.283	-5.198	1	0.901	-9.009	-5.471	0.007
Ecuador	ENR_4	Epoxiconazole	-5.865	-7.907	-3.823	1	0.901	-7.634	-4.096	0.017
Ecuador	ENR_4	Propiconazole	-5.714	-7.756	-3.672	1	0.901	-7.483	-3.945	0.019
Ecuador	ENV_5	Difenoconazole	-7.481	-9.523	-5.438	1	0.901	-9.249	-5.712	0.006
Ecuador	ENV_5	Epoxiconazole	-7.223	-9.265	-5.180	1	0.901	-8.992	-5.454	0.007
Ecuador	ENV_5	Propiconazole	-6.054	-8.096	-4.011	1	0.901	-7.823	-4.285	0.015
Ecuador	ENV_9	Difenoconazole	-7.966	-10.008	-5.923	1	0.901	-9.734	-6.197	<0.004
Ecuador	ENV_9	Epoxiconazole	-7.332	-9.375	-5.290	3	0.520	-8.354	-6.311	0.006
Ecuador	ENV_9	Propiconazole	-6.701	-8.743	-4.658	3	0.520	-7.722	-5.680	0.010
Ecuador	ESM_2	Difenoconazole	-5.556	-7.599	-3.514	2	0.637	-6.807	-4.306	0.021
Ecuador	ESM_2	Epoxiconazole	-5.125	-7.167	-3.082	2	0.637	-6.375	-3.874	0.029
Ecuador	ESM_2	Propiconazole	-4.539	-6.581	-2.496	2	0.637	-5.789	-3.288	0.043
Ecuador	ESM_3	Difenoconazole	-5.867	-7.910	-3.825	2	0.637	-7.118	-4.617	0.017
Ecuador	ESM_3	Epoxiconazole	-5.596	-7.638	-3.553	2	0.637	-6.847	-4.345	0.021
Ecuador	ESM_3	Propiconazole	-5.257	-7.300	-3.215	2	0.637	-6.508	-4.007	0.026
Ecuador	ESM_4	Difenoconazole	-4.121	-6.163	-2.078	1	0.901	-5.889	-2.352	0.057

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Ecuador	ESM_4	Epoxiconazole	-4.240	-6.282	-2.198	1	0.901	-6.009	-2.471	0.053
Ecuador	ESM_4	Propiconazole	-4.205	-6.247	-2.162	1	0.901	-5.973	-2.436	0.054
Colombia	Esmeraldas_1	Difenoconazole	2.596	0.553	4.638	3	0.520	1.575	3.617	6.046
Colombia	Esmeraldas_1	Epoxiconazole	1.475	-0.567	3.517	3	0.520	0.454	2.496	2.780
Colombia	Esmeraldas_1	Propiconazole	2.080	0.037	4.122	3	0.520	1.058	3.101	4.227
Colombia	Esmeraldas_2	Difenoconazole	2.896	0.853	4.938	1	0.901	1.127	4.664	7.442
Colombia	Esmeraldas_2	Epoxiconazole	1.028	-1.014	3.070	1	0.901	-0.741	2.797	2.039
Colombia	Esmeraldas_2	Propiconazole	1.725	-0.317	3.768	1	0.901	-0.043	3.494	3.307
Colombia	Esmeraldas_3	Difenoconazole	1.650	-0.392	3.692	3	0.520	0.629	2.671	3.139
Colombia	Esmeraldas_3	Epoxiconazole	1.103	-0.939	3.145	3	0.520	0.082	2.124	2.148
Colombia	Esmeraldas_3	Propiconazole	1.067	-0.975	3.110	3	0.520	0.046	2.088	2.095
Colombia	Esmeraldas_4	Difenoconazole	0.626	-1.416	2.669	1	0.901	-1.142	2.395	1.544
Colombia	Esmeraldas_4	Epoxiconazole	-0.231	-2.274	1.811	1	0.901	-2.000	1.537	0.852
Colombia	Esmeraldas_4	Propiconazole	1.048	-0.995	3.090	1	0.901	-0.721	2.816	2.067
Colombia	Esmeraldas_5	Difenoconazole	2.355	0.313	4.398	1	0.901	0.586	4.124	5.116
Colombia	Esmeraldas_5	Epoxiconazole	0.556	-1.486	2.598	1	0.901	-1.213	2.325	1.470
Colombia	Esmeraldas_5	Propiconazole	1.542	-0.500	3.585	1	0.901	-0.226	3.311	2.913
Colombia	Esperanza_4	Difenoconazole	2.331	0.288	4.373	1	0.901	0.562	4.099	5.031
Colombia	Esperanza_4	Epoxiconazole	2.067	0.025	4.110	1	0.901	0.299	3.836	4.191
Colombia	Esperanza 4	Propiconazole	3 047	1.004	5.089	1	0.901	1.278	4.815	8,263
	Esperanza_4	riopiconazoio	0.011							
Ecuador	ESS_2	Difenoconazole	-6.654	-8.696	-4.611	2	0.637	-7.904	-5.403	0.010
Ecuador	ESS_2 ESS_2	Difenoconazole	-6.654 -6.077	-8.696 -8.119	-4.611 -4.034	2	0.637	-7.904 -7.327	-5.403 -4.826	0.010
Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_2	Difenoconazole Epoxiconazole Propiconazole	-6.654 -6.077 -5.952	-8.696 -8.119 -7.994	-4.611 -4.034 -3.909	2 2 2	0.637 0.637 0.637	-7.904 -7.327 -7.202	-5.403 -4.826 -4.701	0.010 0.015 0.016
Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_2 ESS_4	Difenoconazole Epoxiconazole Propiconazole Difenoconazole	-6.654 -6.077 -5.952 -3.932	-8.696 -8.119 -7.994 -5.975	-4.611 -4.034 -3.909 -1.890	2 2 2 1	0.637 0.637 0.637 0.901	-7.904 -7.327 -7.202 -5.701	-5.403 -4.826 -4.701 -2.164	0.010 0.015 0.016 0.065
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_2 ESS_4 ESS_4	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole	-6.654 -6.077 -5.952 -3.932 -4.594	-8.696 -8.119 -7.994 -5.975 -6.636	-4.611 -4.034 -3.909 -1.890 -2.551	2 2 2 1	0.637 0.637 0.637 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362	-5.403 -4.826 -4.701 -2.164 -2.825	0.010 0.015 0.016 0.065 0.041
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_4	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418	2 2 2 1 1 1	0.637 0.637 0.637 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692	0.010 0.015 0.016 0.065 0.041 0.023
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_4 ESS_6	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752	2 2 2 1 1 1 1	0.637 0.637 0.637 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026	0.010 0.015 0.016 0.065 0.041 0.023 0.009
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Difenoconazole Difenoconazole Epoxiconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470	2 2 2 1 1 1 1 1 1	0.637 0.637 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743	0.010 0.015 0.015 0.065 0.065 0.041 0.023 0.009 0.022
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Epoxiconazole Propiconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295	2 2 1 1 1 1 1 1 1 1	0.637 0.637 0.901 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_7	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Propiconazole Difenoconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416	2 2 1 1 1 1 1 1 1 1 1	0.637 0.637 0.901 0.901 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569 -5.690	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012 0.006
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_6 ESS_6 ESS_7 ESS_7	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole Difenoconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459 -6.274	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501 -8.316	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416 -4.231	2 2 1 1 1 1 1 1 1 1 1 1	0.637 0.637 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228 -8.043	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569 -5.690 -4.505	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012 0.012 0.013
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_6 ESS_7 ESS_7 ESS_7 ESS_7	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Epoxiconazole Epoxiconazole Propiconazole Difenoconazole Difenoconazole Propiconazole Epoxiconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459 -6.274 -6.466	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501 -8.316 -8.509	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416 -4.231 -4.424	2 2 1 1 1 1 1 1 1 1 1 1	0.637 0.637 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228 -8.043 -8.235	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569 -5.690 -4.505 -4.697	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012 0.006 0.013 0.011
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador	ESS_1 ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_6 ESS_6 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole Propiconazole Difenoconazole Epoxiconazole Difenoconazole Propiconazole Difenoconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459 -6.274 -6.466	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501 -8.316 -8.509	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416 -4.231 -4.424	2 2 1 1 1 1 1 1 1 1 1 0	0.637 0.637 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228 -8.043 -8.235	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569 -5.690 -4.505 -4.697	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012 0.012 0.013 0.011 >10.24
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Colombia	ESS_1 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_6 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Difenoconazole Epoxiconazole Epoxiconazole Propiconazole Epoxiconazole Difenoconazole Epoxiconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459 -6.274 -6.466 -2.392	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501 -8.316 -8.509 0.349	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416 -4.231 -4.231 -4.424 4.434	2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.637 0.637 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228 -8.043 -8.235 0.623	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569 -5.690 -4.505 -4.697 -4.160	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012 0.012 0.006 0.013 0.011 >10.24 5.248
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Colombia Colombia	ESPORTE_T ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_6 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Difenoconazole Propiconazole Difenoconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459 -6.274 -6.466 2.392	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501 -8.316 -8.509 0.349	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416 -4.231 -4.424 4.434	2 2 2 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0	0.637 0.637 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228 -8.043 -8.235 0.623	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569 -4.505 -4.697 -4.697 -4.160	0.010 0.015 0.015 0.065 0.041 0.023 0.009 0.022 0.012 0.006 0.013 0.011 >10.24 5.248 >10.24
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Colombia Colombia Colombia	ESPARATE_T ESS_2 ESS_2 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_6 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Difenoconazole Difenoconazole Difenoconazole Epoxiconazole Epoxiconazole Epoxiconazole Difenoconazole Difenoconazole Epoxiconazole Difenoconazole Epoxiconazole Difenoconazole Propiconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459 -6.274 -6.466 -2.392 1.380	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501 -8.316 -8.509 0.349 -0.663	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416 -4.231 -4.231 -4.424 4.434 3.422	2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.637 0.637 0.637 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901 0.901	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228 -8.043 -8.235 0.623 0.359	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569 -4.505 -4.505 -4.697 -4.697 -4.160 2.401	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012 0.012 0.013 0.011 >10.24 5.248 >10.24 2.602
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Colombia Colombia Colombia	ESPORTE_T ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_7 ES	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Difenoconazole Propiconazole Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Difenoconazole Epoxiconazole Difenoconazole Difenoconazole Difenoconazole Epoxiconazole Epoxiconazole Epoxiconazole Difenoconazole Epoxiconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459 -6.274 -6.466 2.392 2.392 1.380 0.025	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501 -8.316 -8.509 0.349 -0.663 -2.017	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416 -4.231 -4.424 4.434 4.434 3.422 2.068	2 2 1 1 1 1 1 1 1 1 1 1 1 1 0 1 0 3 3	0.637 0.637 0.637 0.901 0.902 0.520 0.	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228 -8.043 -8.235 0.623 0.359 -0.996	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.509 -4.505 -4.697 -4.697 -4.160 2.401 1.047	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012 0.006 0.013 0.011 >10.24 5.248 >10.24 2.602 1.018
Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Ecuador Colombia Colombia Colombia Colombia	ESPARATE_T ESS_2 ESS_2 ESS_2 ESS_4 ESS_4 ESS_6 ESS_6 ESS_6 ESS_6 ESS_7 ESS_7 ESS_7 ESS_7 ESS_7 Estadero_1 Estadero_1 Estadero_2 Estadero_2 Estadero_2 Estadero_2 Estadero_2	Difenoconazole Epoxiconazole Propiconazole Difenoconazole Epoxiconazole Difenoconazole Difenoconazole Difenoconazole Epoxiconazole Epoxiconazole Epoxiconazole Epoxiconazole Difenoconazole Epoxiconazole Epoxiconazole Propiconazole Difenoconazole Propiconazole Propiconazole Epoxiconazole	-6.654 -6.077 -5.952 -3.932 -4.594 -5.460 -6.794 -5.512 -6.337 -7.459 -6.274 -6.466 -2.392 -1.380 0.025 0.110	-8.696 -8.119 -7.994 -5.975 -6.636 -7.503 -8.837 -7.554 -8.380 -9.501 -8.316 -8.509 0.349 -0.663 -2.017 -1.932	-4.611 -4.034 -3.909 -1.890 -2.551 -3.418 -4.752 -3.470 -4.295 -5.416 -4.231 -4.231 -4.424 4.434 -3.422 2.068 2.152	2 2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	0.637 0.637 0.901 0.902 0.901 0.902 0.	-7.904 -7.327 -7.202 -5.701 -6.362 -7.229 -8.563 -7.281 -8.106 -9.228 -8.043 -8.235 0.623 0.359 -0.996 -0.911	-5.403 -4.826 -4.701 -2.164 -2.825 -3.692 -5.026 -3.743 -4.569 -4.505 -4.505 -4.697 -4.697 -4.160 2.401 1.047 1.131	0.010 0.015 0.016 0.065 0.041 0.023 0.009 0.022 0.012 0.012 0.006 0.013 0.011 >10.24 5.248 >10.24 2.602 1.018 1.079

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Colombia	Estadero_3	Difenoconazole	1.469	-0.573	3.512	3	0.520	0.448	2.490	2.769
Colombia	Estadero_3	Epoxiconazole	-0.903	-2.945	1.139	3	0.520	-1.924	0.118	0.535
Colombia	Estadero_3	Propiconazole	1.155	-0.887	3.197	3	0.520	0.134	2.176	2.227
Colombia	Estadero_4	Difenoconazole	-0.090	-2.132	1.953	3	0.520	-1.111	0.931	0.940
Colombia	Estadero_4	Epoxiconazole	-0.763	-2.805	1.280	3	0.520	-1.784	0.259	0.589
Colombia	Estadero_4	Propiconazole	-0.025	-2.068	2.017	3	0.520	-1.047	0.996	0.983
Colombia	Estadero_5	Difenoconazole	2.144	0.101	4.186	3	0.520	1.123	3.165	4.419
Colombia	Estadero_5	Epoxiconazole	-0.424	-2.466	1.619	3	0.520	-1.445	0.597	0.745
Colombia	Estadero_5	Propiconazole	2.208	0.166	4.251	3	0.520	1.187	3.229	4.621
Colombia	Frontera_2	Difenoconazole	0.955	-1.087	2.998	3	0.520	-0.066	1.976	1.939
Colombia	Frontera_2	Epoxiconazole	-0.659	-2.701	1.383	3	0.520	-1.680	0.362	0.633
Colombia	Frontera_2	Propiconazole	1.230	-0.812	3.273	3	0.520	0.209	2.252	2.346
Colombia	Frontera_3	Difenoconazole	0.512	-1.530	2.555	3	0.520	-0.509	1.533	1.426
Colombia	Frontera_3	Epoxiconazole	-0.642	-2.685	1.400	3	0.520	-1.663	0.379	0.641
Colombia	Frontera_3	Propiconazole	0.278	-1.764	2.320	3	0.520	-0.743	1.299	1.213
Colombia	Frontera_5	Difenoconazole	0.747	-1.296	2.789	1	0.901	-1.022	2.515	1.678
Colombia	Frontera_5	Epoxiconazole	0.152	-1.891	2.194	2	0.637	-1.099	1.402	1.111
Colombia	Frontera_5	Propiconazole	1.967	-0.075	4.009	3	0.520	0.946	2.988	3.910
Colombia	Frontera_6	Difenoconazole	2.499	0.456	4.541	1	0.901	0.730	4.268	5.652
Colombia	Frontera_6	Epoxiconazole	-0.075	-2.117	1.968	1	0.901	-1.844	1.694	0.949
Colombia	Frontera_6	Propiconazole	2.444	0.401	4.486	1	0.901	0.675	4.212	5.440
Colombia	Frontera_7	Difenoconazole	2.316	0.274	4.358	1	0.901	0.547	4.085	4.979
Colombia	Frontera_7	Epoxiconazole	2.358	0.315	4.400	1	0.901	0.589	4.126	5.125
Colombia	Frontera_7	Propiconazole	2.724	0.682	4.767	1	0.901	0.955	4.493	6.608
Colombia	Galvis_1	Difenoconazole	-0.852	-2.894	1.191	1	0.901	-2.620	0.917	0.554
Colombia	Galvis_1	Epoxiconazole	-0.768	-2.810	1.275	1	0.901	-2.537	1.001	0.587
Colombia	Galvis_1	Propiconazole	1.397	-0.645	3.439	1	0.901	-0.372	3.166	2.633
Colombia	Galvis_2	Difenoconazole	-1.426	-3.468	0.617	3	0.520	-2.447	-0.404	0.372
Colombia	Galvis_2	Epoxiconazole	-2.364	-4.406	-0.321	3	0.520	-3.385	-1.342	0.194
Colombia	Galvis_2	Propiconazole	-0.099	-2.141	1.944	3	0.520	-1.120	0.922	0.934
Ecuador	GCB_28	Difenoconazole	-1.058	-3.100	0.984	2	0.637	-2.309	0.193	0.480
Ecuador	GCB_28	Epoxiconazole	-2.424	-4.467	-0.382	2	0.637	-3.675	-1.173	0.186
Ecuador	GCB_28	Propiconazole	-1.146	-3.188	0.897	2	0.637	-2.397	0.105	0.452
Ecuador	GCB_30	Difenoconazole	-1.424	-3.467	0.618	2	0.637	-2.675	-0.173	0.373
Ecuador	GCB_30	Epoxiconazole	-2.457	-4.499	-0.414	2	0.637	-3.708	-1.206	0.182
Ecuador	GCB_30	Propiconazole	-2.207	-4.249	-0.165	2	0.637	-3.458	-0.956	0.217
Ecuador	GCB_7	Difenoconazole	-2.888	-4.930	-0.845	2	0.637	-4.138	-1.637	0.135
Ecuador	GCB_7	Epoxiconazole	-3.861	-5.903	-1.819	2	0.637	-5.112	-2.610	0.069

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Ecuador	GCB_7	Propiconazole	-2.827	-4.870	-0.785	2	0.637	-4.078	-1.576	0.141
Ecuador	GCLg_18	Difenoconazole	-1.025	-3.068	1.017	2	0.637	-2.276	0.225	0.491
Ecuador	GCLg_18	Epoxiconazole	-2.233	-4.275	-0.190	2	0.637	-3.483	-0.982	0.213
Ecuador	GCLg_18	Propiconazole	-1.202	-3.245	0.840	2	0.637	-2.453	0.048	0.435
Ecuador	GCMA_4	Difenoconazole	-4.023	-6.065	-1.980	4	0.451	-4.907	-3.138	0.062
Ecuador	GCMA_4	Epoxiconazole	-3.845	-5.887	-1.802	4	0.451	-4.729	-2.960	0.070
Ecuador	GCMA_4	Propiconazole	-3.277	-5.320	-1.235	4	0.451	-4.162	-2.393	0.103
Ecuador	GCMS_7	Difenoconazole	-3.138	-5.181	-1.096	3	0.520	-4.160	-2.117	0.114
Ecuador	GCMS_7	Epoxiconazole	-3.859	-5.901	-1.816	3	0.520	-4.880	-2.838	0.069
Ecuador	GCMS_7	Propiconazole	-2.636	-4.679	-0.594	3	0.520	-3.658	-1.615	0.161
Ecuador	GCSB_13	Difenoconazole	-2.480	-4.522	-0.438	3	0.520	-3.501	-1.459	0.179
Ecuador	GCSB_13	Epoxiconazole	-3.076	-5.119	-1.034	3	0.520	-4.097	-2.055	0.119
Ecuador	GCSB_13	Propiconazole	-1.882	-3.924	0.161	3	0.520	-2.903	-0.861	0.271
Ecuador	GNA_1	Difenoconazole	-0.349	-2.391	1.694	2	0.637	-1.599	0.902	0.785
Ecuador	GNA_1	Epoxiconazole	-1.905	-3.947	0.138	2	0.637	-3.155	-0.654	0.267
Ecuador	GNA_1	Propiconazole	0.340	-1.702	2.383	2	0.637	-0.910	1.591	1.266
Ecuador	GNA_6	Difenoconazole	0.110	-1.932	2.153	2	0.637	-1.141	1.361	1.079
Ecuador	GNA_6	Epoxiconazole	-2.038	-4.080	0.004	2	0.637	-3.289	-0.787	0.243
Ecuador	GNA_6	Propiconazole	-1.388	-3.431	0.654	2	0.637	-2.639	-0.138	0.382
Ecuador	GND_18	Difenoconazole	0.460	-1.582	2.503	3	0.520	-0.561	1.482	1.376
Ecuador	GND_18	Epoxiconazole	0.179	-1.864	2.221	3	0.520	-0.843	1.200	1.132
Ecuador	GND_18	Propiconazole	1.497	-0.545	3.540	3	0.520	0.476	2.519	2.823
Ecuador	GNM_1	Difenoconazole	0.637	-1.406	2.679	1	0.901	-1.132	2.406	1.555
Ecuador	GNM_1	Epoxiconazole	-0.992	-3.035	1.050	1	0.901	-2.761	0.776	0.503
Ecuador	GNM_1	Propiconazole	-1.204	-3.246	0.839	1	0.901	-2.973	0.565	0.434
Ecuador	GNMe_1	Difenoconazole	-1.155	-3.197	0.888	1	0.901	-2.923	0.614	0.449
Ecuador	GNMe_1	Epoxiconazole	-0.849	-2.891	1.194	1	0.901	-2.618	0.920	0.555
Ecuador	GNMe_1	Propiconazole	-1.607	-3.650	0.435	1	0.901	-3.376	0.161	0.328
Ecuador	GNP_3	Difenoconazole	1.438	-0.604	3.480	5	0.403	0.647	2.229	2.709
Ecuador	GNP_3	Epoxiconazole	0.668	-1.375	2.710	5	0.403	-0.123	1.459	1.589
Ecuador	GNP_3	Propiconazole	2.420	0.377	4.462	4	0.451	1.535	3.304	5.351
Ecuador	GSa_10	Difenoconazole	-2.520	-4.562	-0.477	2	0.637	-3.771	-1.269	0.174
Ecuador	GSa_10	Epoxiconazole	-3.154	-5.196	-1.111	2	0.637	-4.404	-1.903	0.112
Ecuador	GSa_10	Propiconazole	-2.429	-4.471	-0.386	2	0.637	-3.679	-1.178	0.186
Ecuador	GSa_13	Difenoconazole	-2.283	-4.326	-0.241	3	0.520	-3.305	-1.262	0.205
Ecuador	GSa_13	Epoxiconazole	-3.177	-5.219	-1.134	3	0.520	-4.198	-2.155	0.111
Ecuador	GSa_13	Propiconazole	-1.786	-3.828	0.257	3	0.520	-2.807	-0.765	0.290
Ecuador	GSa_2	Difenoconazole	-2.639	-4.682	-0.597	2	0.637	-3.890	-1.389	0.160

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Ecuador	GSa_2	Epoxiconazole	-2.945	-4.987	-0.902	2	0.637	-4.196	-1.694	0.130
Ecuador	GSa_2	Propiconazole	-1.458	-3.500	0.584	2	0.637	-2.709	-0.207	0.364
Ecuador	GSa_4	Difenoconazole	-3.568	-5.610	-1.526	1	0.901	-5.337	-1.799	0.084
Ecuador	GSa_4	Epoxiconazole	-4.515	-6.557	-2.473	1	0.901	-6.284	-2.746	0.044
Ecuador	GSa_4	Propiconazole	-2.394	-4.437	-0.352	1	0.901	-4.163	-0.626	0.190
Ecuador	GSaN_12	Difenoconazole	-2.752	-4.794	-0.709	2	0.637	-4.003	-1.501	0.148
Ecuador	GSaN_12	Epoxiconazole	-3.485	-5.528	-1.443	2	0.637	-4.736	-2.234	0.089
Ecuador	GSaN_12	Propiconazole	-2.233	-4.276	-0.191	2	0.637	-3.484	-0.983	0.213
Ecuador	GSaN_83	Difenoconazole				0				<0.004
Ecuador	GSaN_83	Epoxiconazole				0				<0.004
Ecuador	GSaN_83	Propiconazole				0				<0.004
Ecuador	GSB_11	Difenoconazole	-4.317	-6.359	-2.274	3	0.520	-5.338	-3.296	0.050
Ecuador	GSB_11	Epoxiconazole	-4.309	-6.351	-2.266	3	0.520	-5.330	-3.287	0.050
Ecuador	GSB_11	Propiconazole	-2.382	-4.425	-0.340	3	0.520	-3.403	-1.361	0.192
Ecuador	GSB_5	Difenoconazole	-2.109	-4.152	-0.067	3	0.520	-3.130	-1.088	0.232
Ecuador	GSB_5	Epoxiconazole	-2.795	-4.837	-0.752	3	0.520	-3.816	-1.773	0.144
Ecuador	GSB_5	Propiconazole	-1.939	-3.981	0.103	3	0.520	-2.960	-0.918	0.261
Ecuador	GSB_7	Difenoconazole	-0.308	-2.351	1.734	4	0.451	-1.193	0.576	0.808
Ecuador	GSB_7	Epoxiconazole	-1.276	-3.318	0.767	4	0.451	-2.160	-0.391	0.413
Ecuador	GSB_7	Propiconazole	0.008	-2.034	2.051	4	0.451	-0.876	0.893	1.006
Ecuador	GSB_9	Difenoconazole	-2.388	-4.430	-0.345	1	0.901	-4.157	-0.619	0.191
Ecuador	GSB_9	Epoxiconazole	-3.401	-5.444	-1.359	1	0.901	-5.170	-1.632	0.095
Ecuador	GSB_9	Propiconazole	-1.823	-3.866	0.219	1	0.901	-3.592	-0.054	0.283
Ecuador	GSN_1	Difenoconazole	-1.368	-3.411	0.674	3	0.520	-2.389	-0.347	0.387
Ecuador	GSN_1	Epoxiconazole	-2.376	-4.419	-0.334	3	0.520	-3.398	-1.355	0.193
Ecuador	GSN_1	Propiconazole	-1.504	-3.547	0.538	3	0.520	-2.525	-0.483	0.353
Ecuador	GSN_19	Difenoconazole	-3.582	-5.625	-1.540	1	0.901	-5.351	-1.813	0.083
Ecuador	GSN_19	Epoxiconazole	-4.012	-6.055	-1.970	1	0.901	-5.781	-2.244	0.062
Ecuador	GSN_19	Propiconazole	-2.069	-4.111	-0.027	1	0.901	-3.838	-0.300	0.238
Colombia	Guata_1	Difenoconazole	0.568	-1.474	2.611	2	0.637	-0.682	1.819	1.483
Colombia	Guata_1	Epoxiconazole	-1.201	-3.244	0.841	2	0.637	-2.452	0.049	0.435
Colombia	Guata_1	Propiconazole	-0.092	-2.134	1.951	2	0.637	-1.342	1.159	0.938
Guadalupe	GW_1	Difenoconazole	-7.843	-9.885	-5.801	1	0.901	-9.612	-6.074	0.004
Guadalupe	GW_1	Epoxiconazole	-7.688	-9.730	-5.645	1	0.901	-9.456	-5.919	0.005
Guadalupe	GW_1	Propiconazole	-4.551	-6.593	-2.508	1	0.901	-6.320	-2.782	0.043
Guadalupe	GW_10	Difenoconazole	-6.297	-8.339	-4.254	1	0.901	-8.065	-4.528	0.013
Guadalupe	GW_10	Epoxiconazole	-5.262	-7.305	-3.220	1	0.901	-7.031	-3.494	0.026
Guadalupe	GW_10	Propiconazole	-4.729	-6.772	-2.687	1	0.901	-6.498	-2.960	0.038

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Guadalupe	GW_11	Difenoconazole	-7.367	-9.409	-5.325	1	0.901	-9.136	-5.598	0.006
Guadalupe	GW_11	Epoxiconazole	-5.965	-8.007	-3.923	1	0.901	-7.734	-4.196	0.016
Guadalupe	GW_11	Propiconazole	-5.523	-7.565	-3.480	1	0.901	-7.291	-3.754	0.022
Guadalupe	GW_12	Difenoconazole	-5.574	-7.616	-3.531	1	0.901	-7.343	-3.805	0.021
Guadalupe	GW_12	Epoxiconazole	-4.715	-6.758	-2.673	1	0.901	-6.484	-2.947	0.038
Guadalupe	GW_12	Propiconazole	-4.447	-6.489	-2.405	1	0.901	-6.216	-2.678	0.046
Guadalupe	GW_14	Difenoconazole	-7.475	-9.518	-5.433	1	0.901	-9.244	-5.706	0.006
Guadalupe	GW_14	Epoxiconazole	-7.176	-9.219	-5.134	1	0.901	-8.945	-5.408	0.007
Guadalupe	GW_14	Propiconazole	-6.277	-8.319	-4.234	1	0.901	-8.045	-4.508	0.013
Guadalupe	GW_15	Difenoconazole	-7.554	-9.596	-5.511	1	0.901	-9.323	-5.785	0.005
Guadalupe	GW_15	Epoxiconazole	-6.347	-8.390	-4.305	1	0.901	-8.116	-4.579	0.012
Guadalupe	GW_15	Propiconazole	-6.279	-8.321	-4.237	1	0.901	-8.048	-4.510	0.013
Guadalupe	GW_16_8	Difenoconazole	-7.067	-9.109	-5.024	1	0.901	-8.835	-5.298	0.007
Guadalupe	GW_16_8	Epoxiconazole	-6.887	-8.930	-4.845	1	0.901	-8.656	-5.119	0.008
Guadalupe	GW_16_8	Propiconazole	-6.260	-8.302	-4.217	1	0.901	-8.028	-4.491	0.013
Guadalupe	GW_16_9	Difenoconazole	-6.098	-8.141	-4.056	1	0.901	-7.867	-4.330	0.015
Guadalupe	GW_16_9	Epoxiconazole	-6.102	-8.145	-4.060	1	0.901	-7.871	-4.333	0.015
Guadalupe	GW_16_9	Propiconazole	-5.195	-7.237	-3.152	1	0.901	-6.964	-3.426	0.027
Guadalupe	GW_2	Difenoconazole	-7.575	-9.618	-5.533	1	0.901	-9.344	-5.807	0.005
Guadalupe	GW_2	Epoxiconazole				0				<0.004
Guadalupe	GW_2	Propiconazole	-4.108	-6.151	-2.066	1	0.901	-5.877	-2.340	0.058
Guadalupe	GW_26	Difenoconazole	-5.925	-7.968	-3.883	1	0.901	-7.694	-4.156	0.016
Guadalupe	GW_26	Epoxiconazole	-5.795	-7.837	-3.752	1	0.901	-7.563	-4.026	0.018
Guadalupe	GW_26	Propiconazole	-4.398	-6.440	-2.355	1	0.901	-6.166	-2.629	0.047
Guadalupe	GW_28	Difenoconazole	-5.791	-7.834	-3.749	1	0.901	-7.560	-4.023	0.018
Guadalupe	GW_28	Epoxiconazole	-6.090	-8.132	-4.048	1	0.901	-7.859	-4.321	0.015
Guadalupe	GW_28	Propiconazole	-7.843	-9.885	-5.801	1	0.901	-9.612	-6.074	0.004
Guadalupe	GW_29	Difenoconazole	-6.107	-8.149	-4.064	1	0.901	-7.876	-4.338	0.015
Guadalupe	GW_29	Epoxiconazole	-6.169	-8.211	-4.126	1	0.901	-7.938	-4.400	0.014
Guadalupe	GW_29	Propiconazole	-7.575	-9.618	-5.533	1	0.901	-9.344	-5.807	0.005
Guadalupe	GW_3	Difenoconazole	-7.519	-9.562	-5.477	1	0.901	-9.288	-5.751	0.005
Guadalupe	GW_3	Epoxiconazole	-6.206	-8.248	-4.163	1	0.901	-7.974	-4.437	0.014
Guadalupe	GW_3	Propiconazole	-4.344	-6.387	-2.302	1	0.901	-6.113	-2.575	0.049
Guadalupe	GW_30	Difenoconazole	-7.519	-9.561	-5.476	1	0.901	-9.288	-5.750	0.005
Guadalupe	GW_30	Epoxiconazole	-6.755	-8.797	-4.712	1	0.901	-8.523	-4.986	0.009
Guadalupe	GW_30	Propiconazole	-7.519	-9.562	-5.477	1	0.901	-9.288	-5.751	0.005
Guadalupe	GW_31	Difenoconazole	-7.507	-9.549	-5.464	1	0.901	-9.276	-5.738	0.005
Guadalupe	GW_31	Epoxiconazole	-6.478	-8.520	-4.435	1	0.901	-8.247	-4.709	0.011
		1	1					1	I	

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Guadalupe	GW_31	Propiconazole	-6.105	-8.148	-4.063	1	0.901	-7.874	-4.337	0.015
Guadalupe	GW_33	Difenoconazole	-7.581	-9.624	-5.539	1	0.901	-9.350	-5.812	0.005
Guadalupe	GW_33	Epoxiconazole	-6.537	-8.579	-4.494	1	0.901	-8.306	-4.768	0.011
Guadalupe	GW_33	Propiconazole	-5.219	-7.261	-3.177	1	0.901	-6.988	-3.450	0.027
Guadalupe	GW_34	Difenoconazole	-5.128	-7.170	-3.085	1	0.901	-6.896	-3.359	0.029
Guadalupe	GW_34	Epoxiconazole	-4.150	-6.193	-2.108	1	0.901	-5.919	-2.381	0.056
Guadalupe	GW_34	Propiconazole	-5.362	-7.405	-3.320	1	0.901	-7.131	-3.594	0.024
Guadalupe	GW_35	Difenoconazole	-6.356	-8.399	-4.314	1	0.901	-8.125	-4.588	0.012
Guadalupe	GW_35	Epoxiconazole	-6.407	-8.449	-4.365	1	0.901	-8.176	-4.638	0.012
Guadalupe	GW_35	Propiconazole	-5.285	-7.328	-3.243	1	0.901	-7.054	-3.517	0.026
Guadalupe	GW_36	Difenoconazole	-5.652	-7.694	-3.610	1	0.901	-7.421	-3.883	0.020
Guadalupe	GW_36	Epoxiconazole	-5.835	-7.878	-3.793	1	0.901	-7.604	-4.066	0.018
Guadalupe	GW_36	Propiconazole	-6.412	-8.454	-4.369	1	0.901	-8.180	-4.643	0.012
Guadalupe	GW_39	Difenoconazole	-6.131	-8.173	-4.088	1	0.901	-7.899	-4.362	0.014
Guadalupe	GW_39	Epoxiconazole	-6.216	-8.258	-4.173	1	0.901	-7.984	-4.447	0.013
Guadalupe	GW_39	Propiconazole	-6.297	-8.339	-4.254	1	0.901	-8.065	-4.528	0.013
Guadalupe	GW_4	Difenoconazole	-6.105	-8.148	-4.063	1	0.901	-7.874	-4.337	0.015
Guadalupe	GW_4	Epoxiconazole	-6.219	-8.262	-4.177	1	0.901	-7.988	-4.451	0.013
Guadalupe	GW_4	Propiconazole	-5.335	-7.377	-3.292	1	0.901	-7.103	-3.566	0.025
Guadalupe	GW_41	Difenoconazole	-5.188	-7.231	-3.146	1	0.901	-6.957	-3.419	0.027
Guadalupe	GW_41	Epoxiconazole	-5.440	-7.483	-3.398	1	0.901	-7.209	-3.672	0.023
Guadalupe	GW_41	Propiconazole	-7.367	-9.409	-5.325	1	0.901	-9.136	-5.598	0.006
Guadalupe	GW_42	Difenoconazole	-4.383	-6.426	-2.341	1	0.901	-6.152	-2.614	0.048
Guadalupe	GW_42	Epoxiconazole	-6.083	-8.125	-4.041	1	0.901	-7.852	-4.314	0.015
Guadalupe	GW_42	Propiconazole	-5.574	-7.616	-3.531	1	0.901	-7.343	-3.805	0.021
Guadalupe	GW_43	Difenoconazole	-5.224	-7.266	-3.181	1	0.901	-6.993	-3.455	0.027
Guadalupe	GW_43	Epoxiconazole	-5.074	-7.116	-3.032	1	0.901	-6.843	-3.305	0.030
Guadalupe	GW_43	Propiconazole	-7.475	-9.518	-5.433	1	0.901	-9.244	-5.706	0.006
Guadalupe	GW_44	Difenoconazole	-5.930	-7.972	-3.887	1	0.901	-7.699	-4.161	0.016
Guadalupe	GW_44	Epoxiconazole	-5.755	-7.798	-3.713	1	0.901	-7.524	-3.987	0.019
Guadalupe	GW_44	Propiconazole	-7.554	-9.596	-5.511	1	0.901	-9.323	-5.785	0.005
Guadalupe	GW_46	Difenoconazole	-4.042	-6.084	-2.000	1	0.901	-5.811	-2.273	0.061
Guadalupe	GW_46	Epoxiconazole	-3.598	-5.640	-1.555	1	0.901	-5.367	-1.829	0.083
Guadalupe	GW_46	Propiconazole	-7.067	-9.109	-5.024	1	0.901	-8.835	-5.298	0.007
Guadalupe	GW_5	Difenoconazole	-5.219	-7.261	-3.177	1	0.901	-6.988	-3.450	0.027
Guadalupe	GW_5	Epoxiconazole	-5.808	-7.850	-3.766	1	0.901	-7.577	-4.039	0.018
Guadalupe	GW_5	Propiconazole	-5.354	-7.396	-3.311	1	0.901	-7.122	-3.585	0.024
Guadalupe	GW_6	Difenoconazole	-5.362	-7.405	-3.320	1	0.901	-7.131	-3.594	0.024

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Guadalupe	GW_6	Epoxiconazole	-4.458	-6.501	-2.416	1	0.901	-6.227	-2.690	0.045
Guadalupe	GW_6	Propiconazole	-5.284	-7.326	-3.241	1	0.901	-7.053	-3.515	0.026
Guadalupe	GW_7	Difenoconazole	-5.285	-7.328	-3.243	1	0.901	-7.054	-3.517	0.026
Guadalupe	GW_7	Epoxiconazole	-6.257	-8.300	-4.215	1	0.901	-8.026	-4.489	0.013
Guadalupe	GW_7	Propiconazole	-5.640	-7.682	-3.598	1	0.901	-7.409	-3.871	0.020
Guadalupe	GW_8	Difenoconazole	-6.412	-8.454	-4.369	1	0.901	-8.180	-4.643	0.012
Guadalupe	GW_8	Epoxiconazole	-6.216	-8.258	-4.174	1	0.901	-7.985	-4.447	0.013
Guadalupe	GW_8	Propiconazole	-5.607	-7.649	-3.565	1	0.901	-7.376	-3.838	0.021
Colombia	Horizonte_1	Difenoconazole	-0.207	-2.250	1.835	1	0.901	-1.976	1.561	0.866
Colombia	Horizonte_1	Epoxiconazole	-1.262	-3.305	0.780	1	0.901	-3.031	0.506	0.417
Colombia	Horizonte_1	Propiconazole	-0.978	-3.020	1.065	1	0.901	-2.747	0.791	0.508
Colombia	Horizonte_3	Difenoconazole	2.822	0.780	4.865	1	0.901	1.054	4.591	7.074
Colombia	Horizonte_3	Epoxiconazole	1.677	-0.365	3.719	3	0.520	0.656	2.698	3.198
Colombia	Horizonte_3	Propiconazole	3.025	0.983	5.067	3	0.520	2.004	4.046	8.139
Colombia	Horizonte_4	Difenoconazole	1.691	-0.351	3.733	5	0.403	0.900	2.482	3.229
Colombia	Horizonte_4	Epoxiconazole	-0.712	-2.754	1.331	6	0.368	-1.434	0.011	0.611
Colombia	Horizonte_4	Propiconazole	1.623	-0.419	3.665	6	0.368	0.901	2.345	3.080
Colombia	Llorona_1	Difenoconazole	-7.529	-9.571	-5.487	1	0.901	-9.298	-5.760	0.005
Colombia	Llorona_1	Epoxiconazole	-5.891	-7.933	-3.849	1	0.901	-7.660	-4.122	0.017
Colombia	Llorona_1	Propiconazole	-5.690	-7.732	-3.648	1	0.901	-7.459	-3.921	0.019
Colombia	Llorona_2	Difenoconazole	-7.355	-9.398	-5.313	1	0.901	-9.124	-5.587	0.006
Colombia	Llorona_2	Epoxiconazole	-6.152	-8.195	-4.110	1	0.901	-7.921	-4.383	0.014
Colombia	Llorona_2	Propiconazole	-5.827	-7.869	-3.785	1	0.901	-7.596	-4.058	0.018
Colombia	Luisa Fernanda_1	Difenoconazole	3.310	1.268	5.352	1	0.901	1.541	5.079	9.917
Colombia	Luisa Fernanda_1	Epoxiconazole	2.524	0.481	4.566	1	0.901	0.755	4.293	5.751
Colombia	Luisa Fernanda_1	Propiconazole	3.070	1.027	5.112	1	0.901	1.301	4.839	8.396
Colombia	Luisa Fernanda_10	Difenoconazole	0.624	-1.419	2.666	1	0.901	-1.145	2.393	1.541
Colombia	Luisa Fernanda_10	Epoxiconazole	-1.036	-3.079	1.006	1	0.901	-2.805	0.733	0.488
Colombia	Luisa Fernanda_10	Propiconazole	1.150	-0.892	3.193	1	0.901	-0.619	2.919	2.220
Colombia	Luisa Fernanda_2	Difenoconazole	2.656	0.614	4.699	1	0.901	0.888	4.425	6.305
Colombia	Luisa Fernanda_2	Epoxiconazole	0.261	-1.781	2.304	1	0.901	-1.507	2.030	1.199
Colombia	Luisa Fernanda_2	Propiconazole	1.594	-0.449	3.636	1	0.901	-0.175	3.362	3.018
Colombia	Luisa Fernanda_4	Difenoconazole	2.793	0.751	4.836	1	0.901	1.025	4.562	6.932
Colombia	Luisa Fernanda_4	Epoxiconazole	1.032	-1.011	3.074	1	0.901	-0.737	2.800	2.044
Colombia	Luisa Fernanda_4	Propiconazole	2.688	0.645	4.730	1	0.901	0.919	4.456	6.442
Colombia	Luisa Fernanda_5	Difenoconazole	2.160	0.117	4.202	1	0.901	0.391	3.929	4.469
Colombia	Luisa Fernanda_5	Epoxiconazole	0.320	-1.723	2.362	1	0.901	-1.449	2.088	1.248
Colombia	Luisa Fernanda_5	Propiconazole	0.996	-1.046	3.038	1	0.901	-0.773	2.765	1.995

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Philippines	M52_1	Difenoconazole	-1.608	-3.651	0.434	3	0.520	-2.630	-0.587	0.328
Philippines	M52_1	Epoxiconazole	-2.494	-4.536	-0.452	3	0.520	-3.515	-1.473	0.177
Philippines	M52_1	Propiconazole	-0.366	-2.408	1.676	3	0.520	-1.387	0.655	0.776
Philippines	M52_10	Difenoconazole	-1.375	-3.417	0.668	3	0.520	-2.396	-0.354	0.386
Philippines	M52_10	Epoxiconazole	-2.045	-4.087	-0.002	3	0.520	-3.066	-1.024	0.242
Philippines	M52_10	Propiconazole	0.189	-1.853	2.231	3	0.520	-0.832	1.210	1.140
Philippines	M52_11	Difenoconazole	-0.860	-2.903	1.182	1	0.901	-2.629	0.908	0.551
Philippines	M52_11	Epoxiconazole	-1.940	-3.982	0.102	1	0.901	-3.709	-0.171	0.261
Philippines	M52_11	Propiconazole	1.021	-1.022	3.063	1	0.901	-0.748	2.789	2.029
Philippines	M52_12	Difenoconazole	-0.940	-2.982	1.103	1	0.901	-2.709	0.829	0.521
Philippines	M52_12	Epoxiconazole	-0.249	-2.292	1.793	1	0.901	-2.018	1.519	0.841
Philippines	M52_12	Propiconazole	1.965	-0.077	4.008	1	0.901	0.196	3.734	3.905
Philippines	M52_13	Difenoconazole	1.302	-0.741	3.344	1	0.901	-0.467	3.071	2.465
Philippines	M52_13	Epoxiconazole	-0.020	-2.063	2.022	1	0.901	-1.789	1.748	0.986
Philippines	M52_13	Propiconazole	2.421	0.378	4.463	1	0.901	0.652	4.190	5.354
Philippines	M52_14	Difenoconazole	-0.389	-2.431	1.654	3	0.520	-1.410	0.632	0.764
Philippines	M52_14	Epoxiconazole	-0.536	-2.579	1.506	3	0.520	-1.557	0.485	0.690
Philippines	M52_14	Propiconazole	-0.707	-2.750	1.335	3	0.520	-1.729	0.314	0.612
Philippines	M52_15	Difenoconazole	0.965	-1.077	3.007	1	0.901	-0.804	2.734	1.952
Philippines	M52_15	Epoxiconazole	1.924	-0.118	3.966	1	0.901	0.155	3.693	3.795
Philippines	M52_15	Propiconazole	1.088	-0.954	3.131	1	0.901	-0.680	2.857	2.126
Philippines	M52_16	Difenoconazole	1.192	-0.850	3.235	1	0.901	-0.576	2.961	2.285
Philippines	M52_16	Epoxiconazole	1.605	-0.437	3.647	1	0.901	-0.164	3.374	3.042
Philippines	M52_16	Propiconazole	0.855	-1.187	2.897	1	0.901	-0.914	2.624	1.809
Philippines	M52_17	Difenoconazole	-1.720	-3.763	0.322	1	0.901	-3.489	0.048	0.303
Philippines	M52_17	Epoxiconazole	-1.059	-3.101	0.984	1	0.901	-2.828	0.710	0.480
Philippines	M52_17	Propiconazole	-0.750	-2.792	1.292	1	0.901	-2.519	1.019	0.595
Philippines	M52_18	Difenoconazole	-1.716	-3.758	0.327	1	0.901	-3.484	0.053	0.304
Philippines	M52_18	Epoxiconazole	-0.885	-2.927	1.157	1	0.901	-2.654	0.884	0.542
Philippines	M52_18	Propiconazole	0.295	-1.748	2.337	1	0.901	-1.474	2.064	1.227
Philippines	M52_19	Difenoconazole	-2.285	-4.328	-0.243	1	0.901	-4.054	-0.517	0.205
Philippines	M52_19	Epoxiconazole	-1.321	-3.363	0.722	1	0.901	-3.089	0.448	0.400
Philippines	M52_19	Propiconazole	-0.390	-2.433	1.652	1	0.901	-2.159	1.378	0.763
Philippines	M52_2	Difenoconazole	-0.187	-2.230	1.855	1	0.901	-1.956	1.582	0.878
Philippines	M52_2	Epoxiconazole	0.526	-1.516	2.568	1	0.901	-1.243	2.295	1.440
Philippines	M52_2	Propiconazole	0.374	-1.668	2.416	1	0.901	-1.395	2.143	1.296
Philippines	M52_20	Difenoconazole	-1.552	-3.595	0.490	1	0.901	-3.321	0.217	0.341
Philippines	M52_20	Epoxiconazole	-0.052	-2.094	1.991	1	0.901	-1.821	1.717	0.965

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Philippines	M52_20	Propiconazole	-2.591	-4.634	-0.549	1	0.901	-4.360	-0.823	0.166
Philippines	M52_21	Difenoconazole	-1.144	-3.187	0.898	1	0.901	-2.913	0.624	0.452
Philippines	M52_21	Epoxiconazole	-2.409	-4.451	-0.366	1	0.901	-4.177	-0.640	0.188
Philippines	M52_21	Propiconazole	-3.341	-5.384	-1.299	1	0.901	-5.110	-1.573	0.099
Philippines	M52_22	Difenoconazole	0.853	-1.190	2.895	4	0.451	-0.032	1.737	1.806
Philippines	M52_22	Epoxiconazole	-0.309	-2.351	1.734	4	0.451	-1.193	0.576	0.807
Philippines	M52_22	Propiconazole	0.428	-1.614	2.470	4	0.451	-0.456	1.312	1.345
Philippines	M52_23	Difenoconazole	-0.972	-3.015	1.070	1	0.901	-2.741	0.797	0.510
Philippines	M52_23	Epoxiconazole	-1.187	-3.230	0.855	1	0.901	-2.956	0.581	0.439
Philippines	M52_23	Propiconazole	1.488	-0.555	3.530	1	0.901	-0.281	3.256	2.804
Philippines	M52_24	Difenoconazole	-2.185	-4.227	-0.142	3	0.520	-3.206	-1.163	0.220
Philippines	M52_24	Epoxiconazole	-2.978	-5.020	-0.935	3	0.520	-3.999	-1.957	0.127
Philippines	M52_24	Propiconazole	0.297	-1.746	2.339	3	0.520	-0.725	1.318	1.228
Philippines	M52_25	Difenoconazole	-3.422	-5.465	-1.380	1	0.901	-5.191	-1.653	0.093
Philippines	M52_25	Epoxiconazole	-2.997	-5.039	-0.954	1	0.901	-4.765	-1.228	0.125
Philippines	M52_25	Propiconazole	-0.749	-2.792	1.293	1	0.901	-2.518	1.019	0.595
Philippines	M52_3	Difenoconazole	-0.147	-2.190	1.895	3	0.520	-1.168	0.874	0.903
Philippines	M52_3	Epoxiconazole	-1.199	-3.242	0.843	3	0.520	-2.221	-0.178	0.435
Philippines	M52_3	Propiconazole	1.194	-0.849	3.236	3	0.520	0.172	2.215	2.287
Philippines	M52_35	Difenoconazole	-1.329	-3.372	0.713	1	0.901	-3.098	0.439	0.398
Philippines	M52_35	Epoxiconazole	-1.409	-3.452	0.633	1	0.901	-3.178	0.360	0.377
Philippines	M52_35	Propiconazole	-0.418	-2.460	1.624	1	0.901	-2.187	1.351	0.748
Philippines	M52_37	Difenoconazole	-0.516	-2.559	1.526	1	0.901	-2.285	1.252	0.699
Philippines	M52_37	Epoxiconazole	-1.499	-3.541	0.544	1	0.901	-3.267	0.270	0.354
Philippines	M52_37	Propiconazole	1.280	-0.762	3.323	1	0.901	-0.488	3.049	2.429
Philippines	M52_4	Difenoconazole	-2.077	-4.119	-0.034	3	0.520	-3.098	-1.055	0.237
Philippines	M52_4	Epoxiconazole	-2.745	-4.787	-0.702	3	0.520	-3.766	-1.723	0.149
Philippines	M52_4	Propiconazole	-0.703	-2.746	1.339	3	0.520	-1.725	0.318	0.614
Philippines	M52_5	Difenoconazole	-3.341	-5.384	-1.299	1	0.901	-5.110	-1.573	0.099
Philippines	M52_5	Epoxiconazole	-2.482	-4.525	-0.440	1	0.901	-4.251	-0.714	0.179
Philippines	M52_5	Propiconazole	-0.795	-2.837	1.248	1	0.901	-2.564	0.974	0.576
Philippines	M52_6	Difenoconazole	-2.575	-4.618	-0.533	1	0.901	-4.344	-0.807	0.168
Philippines	M52_6	Epoxiconazole	-2.368	-4.411	-0.326	1	0.901	-4.137	-0.599	0.194
Philippines	M52_6	Propiconazole	0.041	-2.001	2.084	1	0.901	-1.727	1.810	1.029
Philippines	M52_7	Difenoconazole	1.488	-0.555	3.530	1	0.901	-0.281	3.256	2.804
Philippines	M52_7	Epoxiconazole	1.259	-0.783	3.301	1	0.901	-0.510	3.028	2.393
Philippines	M52_7	Propiconazole	-0.213	-2.255	1.830	1	0.901	-1.981	1.556	0.863
Philippines	M52_8	Difenoconazole	2.918	0.875	4.960	1	0.901	1.149	4.686	7.556

-			<u>.</u>				_			
Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Philippines	M52_8	Epoxiconazole	3.036	0.993	5.078	1	0.901	1.267	4.804	8.200
Philippines	M52_8	Propiconazole	2.864	0.821	4.906	1	0.901	1.095	4.633	7.279
Philippines	M52_9	Difenoconazole	-0.936	-2.978	1.107	3	0.520	-1.957	0.086	0.523
Philippines	M52_9	Epoxiconazole	-1.572	-3.615	0.470	3	0.520	-2.593	-0.551	0.336
Philippines	M52_9	Propiconazole	-0.578	-2.620	1.465	3	0.520	-1.599	0.443	0.670
Martinique	Ma26_10	Difenoconazole	-6.217	-8.260	-4.175	1	0.901	-7.986	-4.449	0.013
Martinique	Ma26_10	Epoxiconazole	-5.364	-7.407	-3.322	1	0.901	-7.133	-3.595	0.024
Martinique	Ma26_10	Propiconazole	-7.507	-9.549	-5.464	1	0.901	-9.276	-5.738	0.005
Martinique	Ma26_11	Difenoconazole	-4.795	-6.837	-2.752	1	0.901	-6.563	-3.026	0.036
Martinique	Ma26_11	Epoxiconazole	-4.482	-6.524	-2.439	1	0.901	-6.251	-2.713	0.045
Martinique	Ma26_11	Propiconazole	-7.581	-9.624	-5.539	1	0.901	-9.350	-5.812	0.005
Martinique	Ma26_13	Difenoconazole	-5.904	-7.946	-3.861	1	0.901	-7.673	-4.135	0.017
Martinique	Ma26_13	Epoxiconazole	-4.239	-6.282	-2.197	1	0.901	-6.008	-2.470	0.053
Martinique	Ma26_13	Propiconazole	-5.128	-7.170	-3.085	1	0.901	-6.896	-3.359	0.029
Martinique	Ma26_14	Difenoconazole	-4.665	-6.707	-2.623	1	0.901	-6.434	-2.896	0.039
Martinique	Ma26_14	Epoxiconazole	-4.324	-6.367	-2.282	1	0.901	-6.093	-2.556	0.050
Martinique	Ma26_14	Propiconazole	-6.356	-8.399	-4.314	1	0.901	-8.125	-4.588	0.012
Martinique	Ma26_16	Difenoconazole	-5.119	-7.162	-3.077	1	0.901	-6.888	-3.350	0.029
Martinique	Ma26_16	Epoxiconazole	-5.117	-7.159	-3.075	1	0.901	-6.886	-3.348	0.029
Martinique	Ma26_16	Propiconazole	-5.652	-7.694	-3.610	1	0.901	-7.421	-3.883	0.020
Martinique	Ma26_17	Difenoconazole	-6.059	-8.101	-4.016	1	0.901	-7.828	-4.290	0.015
Martinique	Ma26_17	Epoxiconazole	-5.941	-7.983	-3.898	1	0.901	-7.709	-4.172	0.016
Martinique	Ma26_17	Propiconazole	-6.131	-8.173	-4.088	1	0.901	-7.899	-4.362	0.014
Martinique	Ma26_18	Difenoconazole	-3.792	-5.834	-1.750	1	0.901	-5.561	-2.023	0.072
Martinique	Ma26_18	Epoxiconazole	-4.828	-6.870	-2.785	1	0.901	-6.596	-3.059	0.035
Martinique	Ma26_18	Propiconazole	-5.188	-7.231	-3.146	1	0.901	-6.957	-3.419	0.027
Martinique	Ma26_19	Difenoconazole	-4.073	-6.115	-2.030	1	0.901	-5.841	-2.304	0.059
Martinique	Ma26_19	Epoxiconazole	-4.368	-6.410	-2.326	1	0.901	-6.137	-2.599	0.048
Martinique	Ma26_19	Propiconazole	-4.383	-6.426	-2.341	1	0.901	-6.152	-2.614	0.048
Martinique	Ma26_2	Difenoconazole	-4.538	-6.580	-2.495	1	0.901	-6.307	-2.769	0.043
Martinique	Ma26_2	Epoxiconazole	-5.349	-7.392	-3.307	1	0.901	-7.118	-3.581	0.025
Martinique	Ma26_2	Propiconazole	-6.098	-8.141	-4.056	1	0.901	-7.867	-4.330	0.015
Martinique	Ma26_20	Difenoconazole	-5.952	-7.994	-3.910	1	0.901	-7.721	-4.183	0.016
Martinique	Ma26_20	Epoxiconazole	-4.913	-6.955	-2.870	1	0.901	-6.681	-3.144	0.033
Martinique	Ma26_20	Propiconazole	-5.224	-7.266	-3.181	1	0.901	-6.993	-3.455	0.027
Martinique	Ma26_22	Difenoconazole	-6.368	-8.410	-4.326	1	0.901	-8.137	-4.599	0.012
Martinique	Ma26_22	Epoxiconazole	-4.713	-6.756	-2.671	1	0.901	-6.482	-2.944	0.038
Martinique	Ma26_22	Propiconazole	-5.930	-7.972	-3.887	1	0.901	-7.699	-4.161	0.016

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Martinique	Ma26_23	Difenoconazole	-7.622	-9.664	-5.579	1	0.901	-9.391	-5.853	0.005
Martinique	Ma26_23	Epoxiconazole	-5.524	-7.566	-3.481	1	0.901	-7.292	-3.755	0.022
Martinique	Ma26_23	Propiconazole	-4.042	-6.084	-2.000	1	0.901	-5.811	-2.273	0.061
Martinique	Ma26_24	Difenoconazole	-6.088	-8.130	-4.045	1	0.901	-7.856	-4.319	0.015
Martinique	Ma26_24	Epoxiconazole	-4.480	-6.522	-2.438	1	0.901	-6.249	-2.711	0.045
Martinique	Ma26_24	Propiconazole	-4.538	-6.580	-2.495	1	0.901	-6.307	-2.769	0.043
Martinique	Ma26_25	Difenoconazole	-5.510	-7.552	-3.467	1	0.901	-7.279	-3.741	0.022
Martinique	Ma26_25	Epoxiconazole	-3.878	-5.921	-1.836	1	0.901	-5.647	-2.110	0.068
Martinique	Ma26_25	Propiconazole	-3.544	-5.587	-1.502	1	0.901	-5.313	-1.775	0.086
Martinique	Ma26_26	Difenoconazole	-5.309	-7.351	-3.267	1	0.901	-7.078	-3.540	0.025
Martinique	Ma26_26	Epoxiconazole	-5.619	-7.661	-3.576	1	0.901	-7.387	-3.850	0.020
Martinique	Ma26_26	Propiconazole	-6.273	-8.316	-4.231	1	0.901	-8.042	-4.505	0.013
Martinique	Ma26_27	Difenoconazole	-4.498	-6.540	-2.455	1	0.901	-6.267	-2.729	0.044
Martinique	Ma26_27	Epoxiconazole	-4.282	-6.324	-2.240	1	0.901	-6.051	-2.513	0.051
Martinique	Ma26_27	Propiconazole				0				<0.004
Martinique	Ma26_28	Difenoconazole	-4.061	-6.104	-2.019	1	0.901	-5.830	-2.293	0.060
Martinique	Ma26_28	Epoxiconazole	-4.760	-6.803	-2.718	1	0.901	-6.529	-2.992	0.037
Martinique	Ma26_28	Propiconazole	-4.918	-6.961	-2.876	1	0.901	-6.687	-3.150	0.033
Martinique	Ma26_29	Difenoconazole	-7.167	-9.209	-5.124	1	0.901	-8.936	-5.398	0.007
Martinique	Ma26_29	Epoxiconazole	-6.262	-8.305	-4.220	1	0.901	-8.031	-4.493	0.013
Martinique	Ma26_29	Propiconazole	-6.217	-8.260	-4.175	1	0.901	-7.986	-4.449	0.013
Martinique	Ma26_3	Difenoconazole	-3.544	-5.587	-1.502	1	0.901	-5.313	-1.775	0.086
Martinique	Ma26_3	Epoxiconazole	-3.572	-5.614	-1.529	1	0.901	-5.340	-1.803	0.084
Martinique	Ma26_3	Propiconazole	-5.925	-7.968	-3.883	1	0.901	-7.694	-4.156	0.016
Martinique	Ma26_30	Difenoconazole	-7.535	-9.577	-5.492	1	0.901	-9.304	-5.766	0.005
Martinique	Ma26_30	Epoxiconazole	-7.014	-9.057	-4.972	1	0.901	-8.783	-5.246	0.008
Martinique	Ma26_30	Propiconazole	-6.888	-8.930	-4.845	1	0.901	-8.657	-5.119	0.008
Martinique	Ma26_32	Difenoconazole	-7.695	-9.737	-5.653	1	0.901	-9.464	-5.926	0.005
Martinique	Ma26_32	Epoxiconazole	-7.626	-9.668	-5.583	1	0.901	-9.394	-5.857	0.005
Martinique	Ma26_32	Propiconazole	-6.320	-8.362	-4.277	1	0.901	-8.088	-4.551	0.013
Martinique	Ma26_33	Difenoconazole	-6.134	-8.177	-4.092	1	0.901	-7.903	-4.366	0.014
Martinique	Ma26_33	Epoxiconazole	-3.337	-5.380	-1.295	1	0.901	-5.106	-1.568	0.099
Martinique	Ma26_33	Propiconazole	-5.193	-7.235	-3.151	1	0.901	-6.962	-3.424	0.027
Martinique	Ma26_35	Difenoconazole	-6.077	-8.120	-4.035	1	0.901	-7.846	-4.308	0.015
Martinique	Ma26_35	Epoxiconazole	-4.648	-6.691	-2.606	1	0.901	-6.417	-2.880	0.040
Martinique	Ma26_35	Propiconazole	-6.640	-8.682	-4.597	1	0.901	-8.409	-4.871	0.010
Martinique	Ma26_36	Difenoconazole	-4.120	-6.163	-2.078	1	0.901	-5.889	-2.352	0.057
Martinique	Ma26_36	Epoxiconazole	-4.333	-6.376	-2.291	1	0.901	-6.102	-2.565	0.050

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Martinique	Ma26_36	Propiconazole	-4.521	-6.564	-2.479	1	0.901	-6.290	-2.752	0.044
Martinique	Ma26_37	Difenoconazole	-6.129	-8.172	-4.087	1	0.901	-7.898	-4.360	0.014
Martinique	Ma26_37	Epoxiconazole	-5.831	-7.873	-3.788	1	0.901	-7.600	-4.062	0.018
Martinique	Ma26_37	Propiconazole	-5.406	-7.449	-3.364	1	0.901	-7.175	-3.637	0.024
Martinique	Ma26_40	Difenoconazole	-7.507	-9.549	-5.465	1	0.901	-9.276	-5.738	0.005
Martinique	Ma26_40	Epoxiconazole	-7.264	-9.307	-5.222	1	0.901	-9.033	-5.496	0.007
Martinique	Ma26_40	Propiconazole	-6.197	-8.240	-4.155	1	0.901	-7.966	-4.428	0.014
Martinique	Ma26_5	Difenoconazole	-6.273	-8.316	-4.231	1	0.901	-8.042	-4.505	0.013
Martinique	Ma26_5	Epoxiconazole	-6.122	-8.165	-4.080	1	0.901	-7.891	-4.354	0.014
Martinique	Ma26_5	Propiconazole	-5.791	-7.834	-3.749	1	0.901	-7.560	-4.023	0.018
Martinique	Ma26_7	Difenoconazole				0				<0.004
Martinique	Ma26_7	Epoxiconazole				0				<0.004
Martinique	Ma26_7	Propiconazole	-6.107	-8.149	-4.064	1	0.901	-7.876	-4.338	0.015
Martinique	Ma26_9	Difenoconazole	-4.918	-6.961	-2.876	1	0.901	-6.687	-3.150	0.033
Martinique	Ma26_9	Epoxiconazole	-4.460	-6.502	-2.417	1	0.901	-6.228	-2.691	0.045
Martinique	Ma26_9	Propiconazole	-7.519	-9.561	-5.476	1	0.901	-9.288	-5.750	0.005
Martinique	Ma27_1	Difenoconazole	-7.695	-9.737	-5.652	1	0.901	-9.464	-5.926	0.005
Martinique	Ma27_1	Epoxiconazole	-6.193	-8.235	-4.150	1	0.901	-7.962	-4.424	0.014
Martinique	Ma27_1	Propiconazole	-6.314	-8.356	-4.272	1	0.901	-8.083	-4.545	0.013
Martinique	Ma27_11	Difenoconazole	-7.594	-9.636	-5.551	1	0.901	-9.362	-5.825	0.005
Martinique	Ma27_11	Epoxiconazole	-6.857	-8.899	-4.814	1	0.901	-8.626	-5.088	0.009
Martinique	Ma27_11	Propiconazole	-6.070	-8.113	-4.028	1	0.901	-7.839	-4.301	0.015
Martinique	Ma27_12	Difenoconazole	-7.602	-9.645	-5.560	1	0.901	-9.371	-5.834	0.005
Martinique	Ma27_12	Epoxiconazole	-6.785	-8.827	-4.742	1	0.901	-8.553	-5.016	0.009
Martinique	Ma27_12	Propiconazole	-6.624	-8.666	-4.581	1	0.901	-8.392	-4.855	0.010
Martinique	Ma27_13	Difenoconazole	-5.488	-7.530	-3.445	1	0.901	-7.257	-3.719	0.022
Martinique	Ma27_13	Epoxiconazole	-5.134	-7.177	-3.092	1	0.901	-6.903	-3.365	0.028
Martinique	Ma27_13	Propiconazole	-5.471	-7.513	-3.429	1	0.901	-7.240	-3.702	0.023
Martinique	Ma27_14	Difenoconazole	-6.011	-8.053	-3.968	1	0.901	-7.780	-4.242	0.016
Martinique	Ma27_14	Epoxiconazole	-5.749	-7.792	-3.707	1	0.901	-7.518	-3.981	0.019
Martinique	Ma27_14	Propiconazole	-5.589	-7.632	-3.547	1	0.901	-7.358	-3.821	0.021
Martinique	Ma27_16	Difenoconazole	-7.286	-9.328	-5.244	1	0.901	-9.055	-5.517	0.006
Martinique	Ma27_16	Epoxiconazole	-6.910	-8.952	-4.868	1	0.901	-8.679	-5.141	0.008
Martinique	Ma27_16	Propiconazole	-6.484	-8.527	-4.442	1	0.901	-8.253	-4.716	0.011
Martinique	Ma27_17	Difenoconazole	-7.813	-9.856	-5.771	1	0.901	-9.582	-6.044	0.004
Martinique	Ma27_17	Epoxiconazole	-7.459	-9.501	-5.416	1	0.901	-9.227	-5.690	0.006
Martinique	Ma27_17	Propiconazole	-6.124	-8.166	-4.081	1	0.901	-7.893	-4.355	0.014
Martinique	Ma27_19	Difenoconazole	-7.733	-9.775	-5.690	1	0.901	-9.501	-5.964	0.005

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	ECeo
·····,			- 317							- 00
Martinique	Ma27_19	Epoxiconazole	-7.207	-9.250	-5.165	1	0.901	-8.976	-5.438	0.007
Martinique	Ma27_19	Propiconazole	-6.192	-8.234	-4.149	1	0.901	-7.960	-4.423	0.014
Martinique	Ma27_22	Difenoconazole				0				<0.004
Martinique	Ma27_22	Epoxiconazole	-7.821	-9.864	-5.779	1	0.901	-9.590	-6.053	0.004
Martinique	Ma27_22	Propiconazole	-7.775	-9.817	-5.733	1	0.901	-9.544	-6.006	0.005
Martinique	Ma27_5	Difenoconazole	-6.055	-8.097	-4.012	1	0.901	-7.824	-4.286	0.015
Martinique	Ma27_5	Epoxiconazole	-6.189	-8.231	-4.146	1	0.901	-7.958	-4.420	0.014
Martinique	Ma27_5	Propiconazole	-4.731	-6.773	-2.688	1	0.901	-6.499	-2.962	0.038
Martinique	Ma27_6	Difenoconazole	-7.795	-9.837	-5.753	1	0.901	-9.564	-6.026	0.005
Martinique	Ma27_6	Epoxiconazole	-7.510	-9.553	-5.468	2	0.637	-8.761	-6.260	0.005
Martinique	Ma27_6	Propiconazole	-6.764	-8.806	-4.722	2	0.637	-8.015	-5.513	0.009
Martinique	Ma27_7	Difenoconazole	-5.848	-7.890	-3.805	1	0.901	-7.616	-4.079	0.017
Martinique	Ma27_7	Epoxiconazole	-5.484	-7.526	-3.441	1	0.901	-7.253	-3.715	0.022
Martinique	Ma27_7	Propiconazole	-5.933	-7.976	-3.891	1	0.901	-7.702	-4.165	0.016
Martinique	Ma27_9	Difenoconazole	-5.000	-7.042	-2.957	1	0.901	-6.769	-3.231	0.031
Martinique	Ma27_9	Epoxiconazole	-4.451	-6.493	-2.408	1	0.901	-6.220	-2.682	0.046
Martinique	Ma27_9	Propiconazole	-4.642	-6.684	-2.600	1	0.901	-6.411	-2.873	0.040
Colombia	Montecristo_3	Difenoconazole	2.065	0.023	4.108	1	0.901	0.296	3.834	4.185
Colombia	Montecristo_3	Epoxiconazole	-0.109	-2.151	1.934	1	0.901	-1.877	1.660	0.927
Colombia	Montecristo_3	Propiconazole	1.152	-0.890	3.195	1	0.901	-0.616	2.921	2.223
Colombia	Montecristo_4	Difenoconazole	2.295	0.253	4.338	3	0.520	1.274	3.317	4.909
Colombia	Montecristo_4	Epoxiconazole	0.779	-1.263	2.822	3	0.520	-0.242	1.801	1.716
Colombia	Montecristo_4	Propiconazole	1.843	-0.199	3.886	3	0.520	0.822	2.865	3.589
Colombia	Montecristo_5	Difenoconazole	2.396	0.353	4.438	3	0.520	1.374	3.417	5.262
Colombia	Montecristo_5	Epoxiconazole	1.260	-0.783	3.302	3	0.520	0.239	2.281	2.394
Colombia	Montecristo_5	Propiconazole	2.194	0.151	4.236	3	0.520	1.172	3.215	4.575
Colombia	Montecristo_7	Difenoconazole	2.949	0.907	4.992	1	0.901	1.181	4.718	7.724
Colombia	Montecristo_7	Epoxiconazole	0.963	-1.080	3.005	1	0.901	-0.806	2.731	1.949
Colombia	Montecristo_7	Propiconazole	1.452	-0.590	3.495	1	0.901	-0.316	3.221	2.737
Dominican Rep.	0_1	Difenoconazole	1.518	-0.525	3.560	3	0.520	0.496	2.539	2.863
Dominican Rep.	0_1	Epoxiconazole	0.651	-1.392	2.693	3	0.520	-0.371	1.672	1.570
Dominican Rep.	0_1	Propiconazole	1.587	-0.455	3.629	3	0.520	0.566	2.608	3.004
Dominican Rep.	0_2	Difenoconazole	0.497	-1.546	2.539	3	0.520	-0.524	1.518	1.411
Dominican Rep.	0_2	Epoxiconazole	-0.347	-2.390	1.695	3	0.520	-1.369	0.674	0.786
Dominican Rep.	O_2	Propiconazole	0.427	-1.616	2.469	3	0.520	-0.594	1.448	1.344
Dominican Rep.	O_3	Difenoconazole	0.694	-1.349	2.736	3	0.520	-0.328	1.715	1.617
Dominican Rep.	O_3	Epoxiconazole	0.365	-1.677	2.408	3	0.520	-0.656	1.387	1.288
Dominican Rep.	O_3	Propiconazole	1.732	-0.311	3.774	3	0.520	0.710	2.753	3.321

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Dominican Rep.	O_4	Difenoconazole	1.125	-0.918	3.167	3	0.520	0.104	2.146	2.181
Dominican Rep.	O_4	Epoxiconazole	0.577	-1.465	2.620	3	0.520	-0.444	1.599	1.492
Dominican Rep.	O_4	Propiconazole	0.702	-1.341	2.744	3	0.520	-0.320	1.723	1.626
Dominican Rep.	O_5	Difenoconazole	-0.790	-2.832	1.253	3	0.520	-1.811	0.231	0.578
Dominican Rep.	O_5	Epoxiconazole	-0.819	-2.861	1.223	3	0.520	-1.840	0.202	0.567
Dominican Rep.	O_5	Propiconazole	-0.168	-2.211	1.874	3	0.520	-1.189	0.853	0.890
Ecuador	OCM_11	Difenoconazole	-2.367	-4.409	-0.325	4	0.451	-3.251	-1.483	0.194
Ecuador	OCM_11	Epoxiconazole	-3.530	-5.572	-1.487	4	0.451	-4.414	-2.645	0.087
Ecuador	OCM_11	Propiconazole	-1.846	-3.889	0.196	4	0.451	-2.731	-0.962	0.278
Ecuador	OCM_12	Difenoconazole	-0.234	-2.277	1.808	4	0.451	-1.119	0.650	0.850
Ecuador	OCM_12	Epoxiconazole	-1.808	-3.850	0.234	4	0.451	-2.692	-0.924	0.286
Ecuador	OCM_12	Propiconazole	0.458	-1.584	2.501	4	0.451	-0.426	1.343	1.374
Ecuador	OCM_15	Difenoconazole	0.361	-1.681	2.403	1	0.901	-1.408	2.130	1.284
Ecuador	OCM_15	Epoxiconazole	-0.463	-2.505	1.580	1	0.901	-2.231	1.306	0.726
Ecuador	OCM_15	Propiconazole	0.519	-1.523	2.562	1	0.901	-1.249	2.288	1.433
Ecuador	OCM_20	Difenoconazole	-1.296	-3.339	0.746	1	0.901	-3.065	0.473	0.407
Ecuador	OCM_20	Epoxiconazole	-1.342	-3.384	0.700	1	0.901	-3.111	0.427	0.394
Ecuador	OCM_20	Propiconazole	-0.181	-2.223	1.862	1	0.901	-1.949	1.588	0.882
Ecuador	OCM_26	Difenoconazole	-1.820	-3.862	0.222	1	0.901	-3.589	-0.051	0.283
Ecuador	OCM_26	Epoxiconazole	-1.489	-3.532	0.553	1	0.901	-3.258	0.280	0.356
Ecuador	OCM_26	Propiconazole	-0.367	-2.409	1.675	1	0.901	-2.136	1.402	0.775
Ecuador	OCM_6	Difenoconazole	-1.373	-3.415	0.670	3	0.520	-2.394	-0.351	0.386
Ecuador	OCM_6	Epoxiconazole	-2.894	-4.936	-0.852	3	0.520	-3.915	-1.873	0.135
Ecuador	OCM_6	Propiconazole	-1.489	-3.531	0.554	3	0.520	-2.510	-0.467	0.356
Ecuador	ONM_20	Difenoconazole	0.602	-1.440	2.645	1	0.901	-1.166	2.371	1.518
Ecuador	ONM_20	Epoxiconazole	-0.829	-2.872	1.213	1	0.901	-2.598	0.939	0.563
Ecuador	ONM_20	Propiconazole	-0.665	-2.708	1.377	1	0.901	-2.434	1.104	0.631
Ecuador	ONM_9	Difenoconazole	-0.660	-2.702	1.383	1	0.901	-2.428	1.109	0.633
Ecuador	ONM_9	Epoxiconazole	-0.052	-2.095	1.990	1	0.901	-1.821	1.716	0.964
Ecuador	ONM_9	Propiconazole	0.029	-2.013	2.072	1	0.901	-1.740	1.798	1.020
Ecuador	ONP_2	Difenoconazole	-1.741	-3.783	0.301	1	0.901	-3.510	0.028	0.299
Ecuador	ONP_2	Epoxiconazole	-1.959	-4.002	0.083	1	0.901	-3.728	-0.191	0.257
Ecuador	ONP_2	Propiconazole	-0.361	-2.404	1.681	1	0.901	-2.130	1.408	0.779
Ecuador	ONS_34	Difenoconazole	-2.449	-4.491	-0.407	1	0.901	-4.218	-0.680	0.183
Ecuador	ONS_34	Epoxiconazole	-2.419	-4.461	-0.376	1	0.901	-4.187	-0.650	0.187
Ecuador	ONS_34	Propiconazole	-1.886	-3.929	0.156	1	0.901	-3.655	-0.117	0.271
Ecuador	ONS_51	Difenoconazole	-1.737	-3.779	0.306	1	0.901	-3.505	0.032	0.300
Ecuador	ONS_51	Epoxiconazole	-1.367	-3.410	0.675	1	0.901	-3.136	0.402	0.388

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Ecuador	ONS_51	Propiconazole	0.437	-1.606	2.479	1	0.901	-1.332	2.205	1.353
Ecuador	ONS_8	Difenoconazole	0.848	-1.195	2.890	1	0.901	-0.921	2.616	1.799
Ecuador	ONS_8	Epoxiconazole	-0.467	-2.509	1.576	1	0.901	-2.236	1.302	0.724
Ecuador	ONS_8	Propiconazole	1.164	-0.879	3.206	1	0.901	-0.605	2.932	2.240
Ecuador	Osa_19	Difenoconazole	0.901	-1.142	2.943	1	0.901	-0.868	2.669	1.867
Ecuador	Osa_19	Epoxiconazole	-0.898	-2.940	1.144	1	0.901	-2.667	0.871	0.537
Ecuador	Osa_19	Propiconazole	0.925	-1.118	2.967	1	0.901	-0.844	2.694	1.898
Ecuador	Osa_20	Difenoconazole	-1.155	-3.198	0.887	1	0.901	-2.924	0.613	0.449
Ecuador	Osa_20	Epoxiconazole	-1.111	-3.153	0.931	1	0.901	-2.880	0.658	0.463
Ecuador	Osa_20	Propiconazole	0.770	-1.272	2.813	1	0.901	-0.998	2.539	1.706
Ecuador	Osa_22	Difenoconazole	-1.973	-4.015	0.070	1	0.901	-3.742	-0.204	0.255
Ecuador	Osa_22	Epoxiconazole	-1.708	-3.750	0.335	1	0.901	-3.477	0.061	0.306
Ecuador	Osa_22	Propiconazole	0.798	-1.244	2.841	1	0.901	-0.970	2.567	1.739
Ecuador	Osa_23	Difenoconazole	-1.606	-3.648	0.437	1	0.901	-3.375	0.163	0.329
Ecuador	Osa_23	Epoxiconazole	-1.896	-3.938	0.147	1	0.901	-3.664	-0.127	0.269
Ecuador	Osa_23	Propiconazole	-0.314	-2.356	1.729	1	0.901	-2.082	1.455	0.805
Ecuador	Osa_25	Difenoconazole	-1.347	-3.390	0.695	1	0.901	-3.116	0.421	0.393
Ecuador	Osa_25	Epoxiconazole	-1.002	-3.045	1.040	1	0.901	-2.771	0.766	0.499
Ecuador	Osa_25	Propiconazole	0.051	-1.991	2.094	1	0.901	-1.718	1.820	1.036
Ecuador	Osa_31	Difenoconazole	-1.931	-3.973	0.111	1	0.901	-3.700	-0.162	0.262
Ecuador	Osa_31	Epoxiconazole	-2.716	-4.758	-0.673	1	0.901	-4.484	-0.947	0.152
Ecuador	Osa_31	Propiconazole	-0.836	-2.879	1.206	1	0.901	-2.605	0.933	0.560
Ecuador	Osa_32	Difenoconazole	-1.047	-3.089	0.996	1	0.901	-2.815	0.722	0.484
Ecuador	Osa_32	Epoxiconazole	-1.326	-3.369	0.716	1	0.901	-3.095	0.442	0.399
Ecuador	Osa_32	Propiconazole	-1.402	-3.445	0.640	1	0.901	-3.171	0.367	0.378
Ecuador	OSSR_13	Difenoconazole	-2.526	-4.568	-0.483	1	0.901	-4.295	-0.757	0.174
Ecuador	OSSR_13	Epoxiconazole	-1.745	-3.787	0.297	1	0.901	-3.514	0.024	0.298
Ecuador	OSSR_13	Propiconazole	-0.509	-2.552	1.533	1	0.901	-2.278	1.260	0.703
Ecuador	OSSR_35	Difenoconazole	-2.000	-4.042	0.043	1	0.901	-3.769	-0.231	0.250
Ecuador	OSSR_35	Epoxiconazole	-1.106	-3.148	0.937	1	0.901	-2.874	0.663	0.465
Ecuador	OSSR_35	Propiconazole	-0.103	-2.145	1.940	1	0.901	-1.871	1.666	0.931
Ecuador	OSSR_36	Difenoconazole	-0.897	-2.939	1.145	3	0.520	-1.918	0.124	0.537
Ecuador	OSSR_36	Epoxiconazole	-1.838	-3.881	0.204	3	0.520	-2.859	-0.817	0.280
Ecuador	OSSR_36	Propiconazole	-1.118	-3.160	0.925	3	0.520	-2.139	-0.097	0.461
Ecuador	OSSR_51	Difenoconazole	-1.632	-3.675	0.410	1	0.901	-3.401	0.136	0.323
Ecuador	OSSR_51	Epoxiconazole	-0.887	-2.929	1.156	1	0.901	-2.655	0.882	0.541
Ecuador	OSSR_51	Propiconazole	-0.082	-2.124	1.960	1	0.901	-1.851	1.687	0.945
Ecuador	OSSR_87	Difenoconazole	-1.882	-3.924	0.160	1	0.901	-3.651	-0.113	0.271

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC50
Ecuador	OSSR_87	Epoxiconazole	-1.197	-3.240	0.845	1	0.901	-2.966	0.571	0.436
Ecuador	OSSR_87	Propiconazole	0.213	-1.829	2.256	1	0.901	-1.555	1.982	1.159
Ecuador	OSSR_96	Difenoconazole	0.637	-1.406	2.679	1	0.901	-1.132	2.406	1.555
Ecuador	OSSR_96	Epoxiconazole	-0.992	-3.035	1.050	1	0.901	-2.761	0.776	0.503
Ecuador	OSSR_96	Propiconazole	-1.204	-3.246	0.839	1	0.901	-2.973	0.565	0.434
Cameroon	P0S_14	Difenoconazole	0.761	-1.281	2.803	3	0.520	-0.260	1.782	1.695
Cameroon	P0S_14	Epoxiconazole	0.068	-1.975	2.110	3	0.520	-0.954	1.089	1.048
Cameroon	P0S_14	Propiconazole	0.844	-1.199	2.886	3	0.520	-0.177	1.865	1.795
Cameroon	P0S_16	Difenoconazole	-6.640	-8.682	-4.598	3	0.520	-7.661	-5.619	0.010
Cameroon	P0S_16	Epoxiconazole	-6.086	-8.128	-4.043	3	0.520	-7.107	-5.065	0.015
Cameroon	P0S_16	Propiconazole	-4.583	-6.626	-2.541	3	0.520	-5.604	-3.562	0.042
Cameroon	P0S_18b	Difenoconazole	-0.483	-2.525	1.559	3	0.520	-1.504	0.538	0.715
Cameroon	P0S_18b	Epoxiconazole	-0.596	-2.639	1.446	3	0.520	-1.617	0.425	0.661
Cameroon	P0S_18b	Propiconazole	0.486	-1.556	2.529	3	0.520	-0.535	1.508	1.401
Cameroon	P0S_22a	Difenoconazole				0				<0.004
Cameroon	P0S_22a	Epoxiconazole	-7.805	-9.847	-5.762	2	0.637	-9.056	-6.554	0.004
Cameroon	P0S_22a	Propiconazole	-7.305	-9.347	-5.262	2	0.637	-8.556	-6.054	0.006
Cameroon	P0S_22b	Difenoconazole	-7.699	-9.741	-5.657	2	0.637	-8.950	-6.448	0.005
Cameroon	P0S_22b	Epoxiconazole	-7.233	-9.275	-5.191	3	0.520	-8.254	-6.212	0.007
Cameroon	P0S_22b	Propiconazole	-6.458	-8.501	-4.416	3	0.520	-7.479	-5.437	0.011
Cameroon	P0S_29	Difenoconazole	0.969	-1.073	3.012	3	0.520	-0.052	1.990	1.958
Cameroon	P0S_29	Epoxiconazole	-0.456	-2.498	1.587	3	0.520	-1.477	0.565	0.729
Cameroon	P0S_29	Propiconazole	0.988	-1.055	3.030	3	0.520	-0.033	2.009	1.983
Cameroon	P0S_38	Difenoconazole	-1.112	-3.154	0.930	3	0.520	-2.133	-0.091	0.463
Cameroon	P0S_38	Epoxiconazole	-1.373	-3.415	0.670	3	0.520	-2.394	-0.351	0.386
Cameroon	P0S_38	Propiconazole	-0.425	-2.468	1.617	3	0.520	-1.447	0.596	0.745
Cameroon	P0S_53	Difenoconazole	-3.381	-5.423	-1.338	1	0.901	-5.150	-1.612	0.096
Cameroon	P0S_53	Epoxiconazole	-3.211	-5.253	-1.169	1	0.901	-4.980	-1.442	0.108
Cameroon	P0S_53	Propiconazole	-1.276	-3.318	0.767	1	0.901	-3.045	0.493	0.413
Cameroon	P0S_54	Difenoconazole	-0.684	-2.726	1.358	3	0.520	-1.705	0.337	0.622
Cameroon	P0S_54	Epoxiconazole	-1.226	-3.269	0.816	3	0.520	-2.248	-0.205	0.427
Cameroon	P0S_54	Propiconazole	-0.081	-2.123	1.962	3	0.520	-1.102	0.940	0.946
Cameroon	P0S_58b	Difenoconazole	-2.398	-4.440	-0.355	2	0.637	-3.648	-1.147	0.190
Cameroon	P0S_58b	Epoxiconazole	-3.748	-5.791	-1.706	2	0.637	-4.999	-2.498	0.074
Cameroon	P0S_58b	Propiconazole	-1.363	-3.406	0.679	2	0.637	-2.614	-0.112	0.389
Cameroon	P0S_59a	Difenoconazole	-0.864	-2.906	1.179	3	0.520	-1.885	0.158	0.550
Cameroon	P0S_59a	Epoxiconazole	-2.936	-4.978	-0.894	3	0.520	-3.957	-1.915	0.131
Cameroon	P0S_59a	Propiconazole	-0.429	-2.471	1.613	3	0.520	-1.450	0.592	0.743

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Cameroon	P0S_59b	Difenoconazole	-4.828	-6.871	-2.786	3	0.520	-5.850	-3.807	0.035
Cameroon	P0S_59b	Epoxiconazole	-4.622	-6.664	-2.579	3	0.520	-5.643	-3.600	0.041
Cameroon	P0S_59b	Propiconazole	-2.174	-4.216	-0.131	3	0.520	-3.195	-1.152	0.222
Cameroon	P0S_7a	Difenoconazole	-2.327	-4.369	-0.284	3	0.520	-3.348	-1.306	0.199
Cameroon	P0S_7a	Epoxiconazole	-2.747	-4.789	-0.705	3	0.520	-3.768	-1.726	0.149
Cameroon	P0S_7a	Propiconazole	-1.344	-3.387	0.698	3	0.520	-2.365	-0.323	0.394
Cameroon	P0S_72	Difenoconazole	0.939	-1.103	2.981	3	0.520	-0.082	1.960	1.917
Cameroon	P0S_72	Epoxiconazole	0.207	-1.835	2.250	3	0.520	-0.814	1.229	1.155
Cameroon	P0S_72	Propiconazole	0.387	-1.655	2.430	3	0.520	-0.634	1.408	1.308
Cameroon	P0S_76a	Difenoconazole	-2.352	-4.394	-0.309	3	0.520	-3.373	-1.330	0.196
Cameroon	P0S_76a	Epoxiconazole	-2.448	-4.490	-0.405	3	0.520	-3.469	-1.427	0.183
Cameroon	P0S_76a	Propiconazole	-1.095	-3.137	0.947	3	0.520	-2.116	-0.074	0.468
Cameroon	P0S_84a	Difenoconazole	-6.566	-8.608	-4.523	3	0.520	-7.587	-5.545	0.011
Cameroon	P0S_84a	Epoxiconazole	-5.884	-7.926	-3.841	3	0.520	-6.905	-4.863	0.017
Cameroon	P0S_84a	Propiconazole	-5.681	-7.724	-3.639	3	0.520	-6.703	-4.660	0.019
Cameroon	P0S_84b	Difenoconazole	-1.435	-3.477	0.607	3	0.520	-2.456	-0.414	0.370
Cameroon	P0S_84b	Epoxiconazole	-1.574	-3.617	0.468	3	0.520	-2.596	-0.553	0.336
Cameroon	P0S_84b	Propiconazole	-0.694	-2.737	1.348	3	0.520	-1.715	0.327	0.618
Cameroon	P0S_9	Difenoconazole	-3.224	-5.266	-1.181	3	0.520	-4.245	-2.202	0.107
Cameroon	P0S_9	Epoxiconazole	-3.225	-5.268	-1.183	3	0.520	-4.246	-2.204	0.107
Cameroon	P0S_9	Propiconazole	-1.565	-3.608	0.477	3	0.520	-2.586	-0.544	0.338
Cameroon	P0S_91	Difenoconazole	-4.178	-6.221	-2.136	3	0.520	-5.200	-3.157	0.055
Cameroon	P0S_91	Epoxiconazole	-4.097	-6.140	-2.055	3	0.520	-5.118	-3.076	0.058
Cameroon	P0S_91	Propiconazole	-2.414	-4.456	-0.372	3	0.520	-3.435	-1.393	0.188
Cameroon	P2S_14	Difenoconazole	0.436	-1.606	2.478	2	0.637	-0.815	1.687	1.353
Cameroon	P2S_14	Epoxiconazole	0.037	-2.005	2.080	3	0.520	-0.984	1.059	1.026
Cameroon	P2S_14	Propiconazole	1.231	-0.812	3.273	3	0.520	0.210	2.252	2.347
Cameroon	P2S_16	Difenoconazole	-0.989	-3.031	1.054	3	0.520	-2.010	0.033	0.504
Cameroon	P2S_16	Epoxiconazole	-1.566	-3.609	0.476	3	0.520	-2.587	-0.545	0.338
Cameroon	P2S_16	Propiconazole	-0.487	-2.530	1.555	3	0.520	-1.509	0.534	0.713
Cameroon	P2S_19	Difenoconazole	-0.577	-2.619	1.466	3	0.520	-1.598	0.444	0.670
Cameroon	P2S_19	Epoxiconazole	-1.118	-3.160	0.924	3	0.520	-2.139	-0.097	0.461
Cameroon	P2S_19	Propiconazole	0.408	-1.634	2.451	3	0.520	-0.613	1.430	1.327
Cameroon	P2S_20	Difenoconazole	-0.542	-2.584	1.501	3	0.520	-1.563	0.479	0.687
Cameroon	P2S_20	Epoxiconazole	-0.119	-2.161	1.924	3	0.520	-1.140	0.903	0.921
Cameroon	P2S_20	Propiconazole	0.316	-1.727	2.358	3	0.520	-0.705	1.337	1.245
Cameroon	P2S_24	Difenoconazole	-0.368	-2.411	1.674	3	0.520	-1.390	0.653	0.775
Cameroon	P2S_24	Epoxiconazole	-1.718	-3.761	0.324	3	0.520	-2.740	-0.697	0.304

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC50
,	Doc. 11		0.555				0.500			4 500
Cameroon	P2\$_24	Propiconazole	0.593	-1.449	2.636	3	0.520	-0.428	1.614	1.509
Cameroon	P2S_25	Difenoconazole	-1.657	-3.699	0.386	3	0.520	-2.678	-0.636	0.317
Cameroon	P2S_25	Epoxiconazole	-1.708	-3.751	0.334	3	0.520	-2.730	-0.687	0.306
Cameroon	P2S_25	Propiconazole	-0.372	-2.415	1.670	3	0.520	-1.394	0.649	0.772
Cameroon	P2S_31	Difenoconazole	-0.650	-2.693	1.392	3	0.520	-1.672	0.371	0.637
Cameroon	P2S_31	Epoxiconazole	-1.261	-3.304	0.781	3	0.520	-2.282	-0.240	0.417
Cameroon	P2S_31	Propiconazole	0.207	-1.836	2.249	3	0.520	-0.815	1.228	1.154
Cameroon	P2S_37	Difenoconazole	-0.856	-2.898	1.187	3	0.520	-1.877	0.166	0.553
Cameroon	P2S_37	Epoxiconazole	-1.794	-3.837	0.248	3	0.520	-2.816	-0.773	0.288
Cameroon	P2S_37	Propiconazole	-0.020	-2.063	2.022	3	0.520	-1.041	1.001	0.986
Cameroon	P2S_40	Difenoconazole	-0.484	-2.527	1.558	3	0.520	-1.506	0.537	0.715
Cameroon	P2S_40	Epoxiconazole	-1.025	-3.067	1.018	3	0.520	-2.046	-0.004	0.491
Cameroon	P2S_40	Propiconazole	0.056	-1.987	2.098	3	0.520	-0.966	1.077	1.039
Cameroon	P2S_41	Difenoconazole	0.163	-1.879	2.206	3	0.520	-0.858	1.185	1.120
Cameroon	P2S_41	Epoxiconazole	-0.738	-2.781	1.304	3	0.520	-1.760	0.283	0.599
Cameroon	P2S_41	Propiconazole	0.725	-1.318	2.767	3	0.520	-0.296	1.746	1.653
Cameroon	P2S_42	Difenoconazole	-0.896	-2.939	1.146	3	0.520	-1.917	0.125	0.537
Cameroon	P2S_42	Epoxiconazole	-0.764	-2.806	1.279	3	0.520	-1.785	0.257	0.589
Cameroon	P2S_42	Propiconazole	0.267	-1.775	2.310	3	0.520	-0.754	1.289	1.204
Cameroon	P2S_44	Difenoconazole	-1.025	-3.068	1.017	3	0.520	-2.047	-0.004	0.491
Cameroon	P2S_44	Epoxiconazole	-1.571	-3.613	0.472	3	0.520	-2.592	-0.549	0.337
Cameroon	P2S_44	Propiconazole	-0.541	-2.583	1.502	3	0.520	-1.562	0.480	0.687
Cameroon	P2S_47	Difenoconazole	0.603	-1.439	2.646	3	0.520	-0.418	1.624	1.519
Cameroon	P2S_47	Epoxiconazole	0.244	-1.799	2.286	3	0.520	-0.778	1.265	1.184
Cameroon	P2S_47	Propiconazole	0.467	-1.575	2.509	3	0.520	-0.554	1.488	1.382
Cameroon	P2S_62	Difenoconazole	-0.733	-2.775	1.310	3	0.520	-1.754	0.288	0.602
Cameroon	P2S_62	Epoxiconazole	-1.742	-3.785	0.300	3	0.520	-2.763	-0.721	0.299
Cameroon	P2S_62	Propiconazole	-0.474	-2.517	1.568	3	0.520	-1.496	0.547	0.720
Cameroon	P2S_64	Difenoconazole	-1.384	-3.427	0.658	3	0.520	-2.405	-0.363	0.383
Cameroon	P2S_64	Epoxiconazole	0.437	-1.605	2.480	3	0.520	-0.584	1.459	1.354
Cameroon	P2S_64	Propiconazole	0.994	-1.048	3.037	3	0.520	-0.027	2.016	1.992
Cameroon	P2S_68	Difenoconazole	-2.009	-4.051	0.033	3	0.520	-3.030	-0.988	0.248
Cameroon	P2S_68	Epoxiconazole	-2.366	-4.409	-0.324	3	0.520	-3.388	-1.345	0.194
Cameroon	P2S_68	Propiconazole	-0.606	-2.649	1.436	3	0.520	-1.627	0.415	0.657
Cameroon	P2S_7	Difenoconazole	-0.704	-2.746	1.339	3	0.520	-1.725	0.318	0.614
Cameroon	P2S_7	Epoxiconazole	-0.882	-2.925	1.160	3	0.520	-1.903	0.139	0.543
Cameroon	P2S_7	Propiconazole	-0.167	-2.209	1.876	3	0.520	-1.188	0.854	0.891
Cameroon	P2S_78	Difenoconazole	0.130	-1.913	2.172	3	0.520	-0.891	1.151	1.094

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Cameroon	P2S_78	Epoxiconazole	-0.429	-2.472	1.613	3	0.520	-1.450	0.592	0.743
Cameroon	P2S_78	Propiconazole	0.219	-1.824	2.261	3	0.520	-0.803	1.240	1.164
Cameroon	P2S_79	Difenoconazole	-0.327	-2.369	1.715	3	0.520	-1.348	0.694	0.797
Cameroon	P2S_79	Epoxiconazole	-0.672	-2.715	1.370	3	0.520	-1.694	0.349	0.627
Cameroon	P2S_79	Propiconazole	0.926	-1.117	2.968	3	0.520	-0.095	1.947	1.900
Cameroon	P2S_81	Difenoconazole	-1.620	-3.663	0.422	3	0.520	-2.642	-0.599	0.325
Cameroon	P2S_81	Epoxiconazole	-1.752	-3.794	0.291	3	0.520	-2.773	-0.730	0.297
Cameroon	P2S_81	Propiconazole	-0.909	-2.952	1.133	3	0.520	-1.931	0.112	0.532
Cameroon	P2S_X	Difenoconazole	-0.819	-2.862	1.223	3	0.520	-1.841	0.202	0.567
Cameroon	P2S_X	Epoxiconazole	-1.568	-3.611	0.474	3	0.520	-2.590	-0.547	0.337
Cameroon	P2S_X	Propiconazole	-0.342	-2.385	1.700	3	0.520	-1.363	0.679	0.789
Cameroon	P4S_1	Difenoconazole	1.029	-1.013	3.071	3	0.520	0.008	2.050	2.041
Cameroon	P4S_1	Epoxiconazole	0.699	-1.344	2.741	3	0.520	-0.323	1.720	1.623
Cameroon	P4S_1	Propiconazole	1.134	-0.909	3.176	3	0.520	0.113	2.155	2.194
Cameroon	P4S_13	Difenoconazole	0.190	-1.852	2.233	3	0.520	-0.831	1.212	1.141
Cameroon	P4S_13	Epoxiconazole	-0.036	-2.079	2.006	3	0.520	-1.058	0.985	0.975
Cameroon	P4S_13	Propiconazole	-0.305	-2.348	1.737	3	0.520	-1.326	0.716	0.809
Cameroon	P4S_16	Difenoconazole	-0.100	-2.143	1.942	3	0.520	-1.121	0.921	0.933
Cameroon	P4S_16	Epoxiconazole	-0.247	-2.289	1.795	3	0.520	-1.268	0.774	0.843
Cameroon	P4S_16	Propiconazole	0.194	-1.848	2.237	3	0.520	-0.827	1.215	1.144
Cameroon	P4S_19	Difenoconazole	-0.775	-2.818	1.267	3	0.520	-1.796	0.246	0.584
Cameroon	P4S_19	Epoxiconazole	-1.059	-3.101	0.984	3	0.520	-2.080	-0.037	0.480
Cameroon	P4S_19	Propiconazole	0.465	-1.578	2.507	3	0.520	-0.557	1.486	1.380
Cameroon	P4S_22	Difenoconazole	0.491	-1.551	2.533	3	0.520	-0.530	1.512	1.405
Cameroon	P4S_22	Epoxiconazole	0.137	-1.905	2.180	3	0.520	-0.884	1.159	1.100
Cameroon	P4S_22	Propiconazole	0.819	-1.224	2.861	3	0.520	-0.202	1.840	1.764
Cameroon	P4S_24	Difenoconazole	-0.884	-2.926	1.159	3	0.520	-1.905	0.137	0.542
Cameroon	P4S_24	Epoxiconazole	-0.913	-2.956	1.129	3	0.520	-1.934	0.108	0.531
Cameroon	P4S_24	Propiconazole	0.586	-1.456	2.628	3	0.520	-0.435	1.607	1.501
Cameroon	P4S_28	Difenoconazole	-1.059	-3.101	0.983	3	0.520	-2.080	-0.038	0.480
Cameroon	P4S_28	Epoxiconazole	-1.226	-3.269	0.816	3	0.520	-2.248	-0.205	0.427
Cameroon	P4S_28	Propiconazole	0.066	-1.977	2.108	3	0.520	-0.955	1.087	1.047
Cameroon	P4S_33	Difenoconazole	-0.028	-2.071	2.014	3	0.520	-1.049	0.993	0.981
Cameroon	P4S_33	Epoxiconazole	-0.217	-2.259	1.826	3	0.520	-1.238	0.804	0.860
Cameroon	P4S_33	Propiconazole	0.363	-1.680	2.405	3	0.520	-0.659	1.384	1.286
Cameroon	P4S_38	Difenoconazole	-1.139	-3.181	0.904	3	0.520	-2.160	-0.118	0.454
Cameroon	P4S_38	Epoxiconazole	-1.534	-3.577	0.508	3	0.520	-2.556	-0.513	0.345
Cameroon	P4S_38	Propiconazole	-0.884	-2.926	1.159	3	0.520	-1.905	0.137	0.542

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Cameroon	P4S_42	Difenoconazole	-0.864	-2.906	1.179	3	0.520	-1.885	0.157	0.549
Cameroon	P4S_42	Epoxiconazole	-1.112	-3.154	0.930	3	0.520	-2.133	-0.091	0.463
Cameroon	P4S_42	Propiconazole	0.431	-1.611	2.473	3	0.520	-0.590	1.452	1.348
Cameroon	P4S_47	Difenoconazole	-2.116	-4.159	-0.074	3	0.520	-3.138	-1.095	0.231
Cameroon	P4S_47	Epoxiconazole	-3.368	-5.411	-1.326	3	0.520	-4.389	-2.347	0.097
Cameroon	P4S_47	Propiconazole	-1.386	-3.429	0.656	3	0.520	-2.408	-0.365	0.382
Cameroon	P4S_5	Difenoconazole	0.016	-2.026	2.059	3	0.520	-1.005	1.037	1.011
Cameroon	P4S_5	Epoxiconazole	0.290	-1.752	2.332	3	0.520	-0.731	1.311	1.223
Cameroon	P4S_5	Propiconazole	0.796	-1.246	2.839	3	0.520	-0.225	1.818	1.737
Cameroon	P4S_51	Difenoconazole	-1.419	-3.461	0.623	3	0.520	-2.440	-0.398	0.374
Cameroon	P4S_51	Epoxiconazole	-1.591	-3.634	0.451	3	0.520	-2.612	-0.570	0.332
Cameroon	P4S_51	Propiconazole	0.152	-1.891	2.194	3	0.520	-0.870	1.173	1.111
Cameroon	P4S_53	Difenoconazole	-1.521	-3.564	0.521	3	0.520	-2.542	-0.500	0.348
Cameroon	P4S_53	Epoxiconazole	-1.313	-3.355	0.730	3	0.520	-2.334	-0.291	0.403
Cameroon	P4S_53	Propiconazole	-0.607	-2.650	1.435	3	0.520	-1.628	0.414	0.656
Cameroon	P4S_58	Difenoconazole	-0.795	-2.837	1.248	3	0.520	-1.816	0.226	0.576
Cameroon	P4S_58	Epoxiconazole	-0.899	-2.941	1.144	3	0.520	-1.920	0.122	0.536
Cameroon	P4S_58	Propiconazole	0.179	-1.864	2.221	3	0.520	-0.842	1.200	1.132
Cameroon	P4S_60a	Difenoconazole	-1.033	-3.075	1.010	2	0.637	-2.284	0.218	0.489
Cameroon	P4S_60a	Epoxiconazole	-1.050	-3.092	0.993	2	0.637	-2.300	0.201	0.483
Cameroon	P4S_60a	Propiconazole	0.129	-1.913	2.172	2	0.637	-1.121	1.380	1.094
Cameroon	P4S_60b	Difenoconazole	-0.833	-2.875	1.210	3	0.520	-1.854	0.189	0.562
Cameroon	P4S_60b	Epoxiconazole	-0.731	-2.773	1.311	3	0.520	-1.752	0.290	0.603
Cameroon	P4S_60b	Propiconazole	0.112	-1.930	2.154	3	0.520	-0.909	1.133	1.081
Cameroon	P4S_64	Difenoconazole	2.736	0.694	4.778	3	0.520	1.715	3.757	6.663
Cameroon	P4S_64	Epoxiconazole	1.965	-0.078	4.007	3	0.520	0.944	2.986	3.904
Cameroon	P4S_64	Propiconazole	2.966	0.924	5.009	2	0.637	1.716	4.217	7.816
Cameroon	P4S_65	Difenoconazole	0.322	-1.720	2.364	3	0.520	-0.699	1.343	1.250
Cameroon	P4S_65	Epoxiconazole	0.375	-1.667	2.418	3	0.520	-0.646	1.397	1.297
Cameroon	P4S_65	Propiconazole	0.439	-1.603	2.482	3	0.520	-0.582	1.460	1.356
Cameroon	P4S_7a	Difenoconazole	0.251	-1.792	2.293	3	0.520	-0.771	1.272	1.190
Cameroon	P4S_7a	Epoxiconazole	-0.705	-2.747	1.338	3	0.520	-1.726	0.316	0.614
Cameroon	P4S_7a	Propiconazole	0.675	-1.368	2.717	3	0.520	-0.347	1.696	1.596
Cameroon	P4S_7b	Difenoconazole	0.247	-1.795	2.290	3	0.520	-0.774	1.269	1.187
Cameroon	P4S_7b	Epoxiconazole	0.077	-1.965	2.120	3	0.520	-0.944	1.098	1.055
Cameroon	P4S_7b	Propiconazole	0.859	-1.184	2.901	3	0.520	-0.162	1.880	1.814
Cameroon	P4S_72	Difenoconazole	-0.574	-2.617	1.468	3	0.520	-1.595	0.447	0.672
Cameroon	P4S_72	Epoxiconazole	-0.942	-2.985	1.100	3	0.520	-1.964	0.079	0.520

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Cameroon	P4S_72	Propiconazole	0.441	-1.601	2.484	3	0.520	-0.580	1.462	1.358
Cameroon	P4S_78	Difenoconazole	0.932	-1.110	2.975	2	0.637	-0.318	2.183	1.908
Cameroon	P4S_78	Epoxiconazole	-1.108	-3.150	0.935	1	0.901	-2.877	0.661	0.464
Cameroon	P4S_78	Propiconazole	0.794	-1.248	2.836	2	0.637	-0.457	2.045	1.734
Cameroon	P4S_81	Difenoconazole	-1.347	-3.390	0.695	1	0.901	-3.116	0.421	1.264
Cameroon	P4S_81	Epoxiconazole	-1.831	-3.874	0.211	1	0.901	-3.600	-0.063	0.706
Cameroon	P4S_81	Propiconazole	-0.086	-2.129	1.956	1	0.901	-1.855	1.683	1.778
Colombia	Paraguay_1	Difenoconazole	2.741	0.699	4.784	1	0.901	0.972	4.510	6.686
Colombia	Paraguay_1	Epoxiconazole	-1.272	-3.314	0.771	1	0.901	-3.040	0.497	0.414
Colombia	Paraguay_1	Propiconazole	0.200	-1.843	2.242	1	0.901	-1.569	1.968	1.148
Colombia	Pinos_1	Difenoconazole	0.385	-1.658	2.427	1	0.901	-1.384	2.154	1.306
Colombia	Pinos_1	Epoxiconazole	-1.303	-3.345	0.740	1	0.901	-3.071	0.466	0.405
Colombia	Pinos_1	Propiconazole	-0.245	-2.287	1.798	1	0.901	-2.014	1.524	0.844
Colombia	Raices_1	Difenoconazole	1.518	-0.524	3.560	2	0.637	0.267	2.769	2.864
Colombia	Raices_1	Epoxiconazole	1.164	-0.879	3.206	2	0.637	-0.087	2.414	2.240
Colombia	Raices_1	Propiconazole	1.994	-0.049	4.036	3	0.520	0.972	3.015	3.983
Colombia	Raices_2	Difenoconazole				0				>10.24
Colombia	Raices_2	Epoxiconazole	2.510	0.467	4.552	1	0.901	0.741	4.279	5.696
Colombia	Raices_2	Propiconazole	3.286	1.244	5.329	1	0.901	1.518	5.055	9.757
Colombia	Raices_4	Difenoconazole	2.701	0.658	4.743	1	0.901	0.932	4.469	6.501
Colombia	Raices_4	Epoxiconazole	1.576	-0.467	3.618	1	0.901	-0.193	3.344	2.981
Colombia	Raices_4	Propiconazole	1.931	-0.111	3.974	1	0.901	0.162	3.700	3.814
Colombia	Raices_5	Difenoconazole	3.091	1.048	5.133	1	0.901	1.322	4.860	8.520
Colombia	Raices_5	Epoxiconazole	0.990	-1.052	3.033	1	0.901	-0.778	2.759	1.987
Colombia	Raices_5	Propiconazole	2.734	0.692	4.777	1	0.901	0.966	4.503	6.655
Colombia	Raices_6	Difenoconazole	2.602	0.559	4.644	1	0.901	0.833	4.371	6.071
Colombia	Raices_6	Epoxiconazole	1.509	-0.533	3.551	1	0.901	-0.260	3.278	2.846
Colombia	Raices_6	Propiconazole				0				>10.24
Ecuador	RCM_14	Difenoconazole	-0.769	-2.811	1.273	1	0.901	-2.538	1.000	0.587
Ecuador	RCM_14	Epoxiconazole	0.750	-1.292	2.793	1	0.901	-1.018	2.519	1.682
Ecuador	RCM_14	Propiconazole	0.644	-1.398	2.686	1	0.901	-1.125	2.413	1.563
Ecuador	RCM_15	Difenoconazole	-2.268	-4.310	-0.225	2	0.637	-3.518	-1.017	0.208
Ecuador	RCM_15	Epoxiconazole	-2.270	-4.312	-0.228	2	0.637	-3.521	-1.019	0.207
Ecuador	RCM_15	Propiconazole	-1.865	-3.907	0.178	2	0.637	-3.115	-0.614	0.275
Ecuador	RCM_16	Difenoconazole	-2.408	-4.450	-0.365	2	0.637	-3.658	-1.157	0.188
Ecuador	RCM_16	Epoxiconazole	-4.044	-6.086	-2.001	2	0.637	-5.294	-2.793	0.061
Ecuador	RCM_16	Propiconazole	-2.232	-4.275	-0.190	2	0.637	-3.483	-0.981	0.213
Ecuador	RCQS_16	Difenoconazole	1.216	-0.826	3.259	3	0.520	0.195	2.238	2.324

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Ecuador	RCQS_16	Epoxiconazole	-0.086	-2.128	1.957	3	0.520	-1.107	0.936	0.942
Ecuador	RCQS_16	Propiconazole	1.465	-0.577	3.508	3	0.520	0.444	2.486	2.761
Ecuador	RCQS_19	Difenoconazole	2.365	0.323	4.408	1	0.901	0.596	4.134	5.152
Ecuador	RCQS_19	Epoxiconazole	2.169	0.127	4.212	1	0.901	0.401	3.938	4.498
Ecuador	RCQS_19	Propiconazole	-0.860	-2.903	1.182	1	0.901	-2.629	0.908	0.551
Ecuador	RCQS_3	Difenoconazole	0.380	-1.663	2.422	5	0.403	-0.411	1.171	1.301
Ecuador	RCQS_3	Epoxiconazole	-0.119	-2.161	1.924	5	0.403	-0.910	0.672	0.921
Ecuador	RCQS_3	Propiconazole	1.557	-0.486	3.599	5	0.403	0.766	2.348	2.942
Colombia	Rena_1	Difenoconazole	-0.350	-2.392	1.693	1	0.901	-2.118	1.419	0.785
Colombia	Rena_1	Epoxiconazole	0.679	-1.364	2.721	1	0.901	-1.090	2.447	1.601
Colombia	Rena_1	Propiconazole	0.813	-1.229	2.856	1	0.901	-0.956	2.582	1.757
Ecuador	RNB_13	Difenoconazole	-0.082	-2.125	1.960	1	0.901	-1.851	1.687	0.945
Ecuador	RNB_13	Epoxiconazole	2.493	0.451	4.536	1	0.901	0.724	4.262	5.630
Ecuador	RNB_13	Propiconazole	0.366	-1.677	2.408	1	0.901	-1.403	2.135	1.289
Ecuador	RNB_18	Difenoconazole	0.569	-1.474	2.611	1	0.901	-1.200	2.337	1.483
Ecuador	RNB_18	Epoxiconazole	0.302	-1.740	2.345	1	0.901	-1.466	2.071	1.233
Ecuador	RNB_18	Propiconazole	-0.193	-2.235	1.850	1	0.901	-1.962	1.576	0.875
Ecuador	RNB_19	Difenoconazole	-1.735	-3.778	0.307	1	0.901	-3.504	0.034	0.300
Ecuador	RNB_19	Epoxiconazole	-2.605	-4.647	-0.563	1	0.901	-4.374	-0.836	0.164
Ecuador	RNB_19	Propiconazole	-1.289	-3.331	0.753	1	0.901	-3.058	0.480	0.409
Ecuador	RNVE_10	Difenoconazole	0.680	-1.362	2.723	1	0.901	-1.089	2.449	1.602
Ecuador	RNVE_10	Epoxiconazole	1.358	-0.684	3.400	1	0.901	-0.411	3.127	2.563
Ecuador	RNVE_10	Propiconazole	2.094	0.052	4.136	1	0.901	0.325	3.863	4.269
Ecuador	RNVP_4	Difenoconazole	-0.709	-2.751	1.333	1	0.901	-2.478	1.060	0.612
Ecuador	RNVP_4	Epoxiconazole	1.189	-0.853	3.232	1	0.901	-0.579	2.958	2.280
Ecuador	RNVP_4	Propiconazole	0.336	-1.707	2.378	1	0.901	-1.433	2.104	1.262
Ecuador	RNVP_8	Difenoconazole	1.045	-0.998	3.087	1	0.901	-0.724	2.814	2.063
Ecuador	RNVP_8	Epoxiconazole	-0.187	-2.229	1.855	1	0.901	-1.956	1.582	0.878
Ecuador	RNVP_8	Propiconazole	-0.016	-2.059	2.026	1	0.901	-1.785	1.753	0.989
Ecuador	RSaB_14	Difenoconazole	-7.446	-9.488	-5.403	1	0.901	-9.214	-5.677	0.006
Ecuador	RSaB_14	Epoxiconazole				0				<0.004
Ecuador	RSaB_14	Propiconazole	-7.835	-9.878	-5.793	1	0.901	-9.604	-6.067	0.004
Ecuador	RSaB_36	Difenoconazole	-1.903	-3.945	0.139	1	0.901	-3.672	-0.134	0.267
Ecuador	RSaB_36	Epoxiconazole	-2.078	-4.120	-0.035	1	0.901	-3.846	-0.309	0.237
Ecuador	RSaB_36	Propiconazole	-2.001	-4.044	0.041	1	0.901	-3.770	-0.232	0.250
Ecuador	RSaB_37	Difenoconazole	-1.856	-3.899	0.186	1	0.901	-3.625	-0.088	0.276
Ecuador	RSaB_37	Epoxiconazole	-2.226	-4.268	-0.184	1	0.901	-3.995	-0.457	0.214
Ecuador	RSaB_37	Propiconazole	-1.026	-3.068	1.017	1	0.901	-2.794	0.743	0.491

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Ecuador	RSaB_6	Difenoconazole	-4.783	-6.825	-2.740	1	0.901	-6.551	-3.014	0.036
Ecuador	RSaB_6	Epoxiconazole	-5.627	-7.670	-3.585	1	0.901	-7.396	-3.859	0.020
Ecuador	RSaB_6	Propiconazole	-3.542	-5.584	-1.499	1	0.901	-5.311	-1.773	0.086
Ecuador	RSaV_6	Difenoconazole	-6.074	-8.117	-4.032	1	0.901	-7.843	-4.306	0.015
Ecuador	RSaV_6	Epoxiconazole	-4.036	-6.078	-1.993	1	0.901	-5.804	-2.267	0.061
Ecuador	RSaV_6	Propiconazole	-4.243	-6.286	-2.201	1	0.901	-6.012	-2.475	0.053
Ecuador	RSaV_7	Difenoconazole	-2.583	-4.625	-0.540	1	0.901	-4.351	-0.814	0.167
Ecuador	RSaV_7	Epoxiconazole	-1.842	-3.884	0.200	1	0.901	-3.611	-0.073	0.279
Ecuador	RSaV_7	Propiconazole	-0.489	-2.531	1.553	1	0.901	-2.258	1.280	0.712
Ecuador	RSaV_8	Difenoconazole	-7.000	-9.042	-4.957	3	0.520	-8.021	-5.979	0.008
Ecuador	RSaV_8	Epoxiconazole	-5.919	-7.961	-3.877	3	0.520	-6.940	-4.898	0.017
Ecuador	RSaV_8	Propiconazole	-5.581	-7.623	-3.538	3	0.520	-6.602	-4.559	0.021
Ecuador	RSP_1	Difenoconazole	-2.791	-4.833	-0.748	1	0.901	-4.560	-1.022	0.145
Ecuador	RSP_1	Epoxiconazole	-3.746	-5.789	-1.704	1	0.901	-5.515	-1.978	0.075
Ecuador	RSP_1	Propiconazole	-2.329	-4.371	-0.286	1	0.901	-4.097	-0.560	0.199
Ecuador	RSP_11	Difenoconazole	-2.221	-4.263	-0.179	1	0.901	-3.990	-0.452	0.214
Ecuador	RSP_11	Epoxiconazole	-3.497	-5.539	-1.454	1	0.901	-5.265	-1.728	0.089
Ecuador	RSP_11	Propiconazole	-1.711	-3.754	0.331	1	0.901	-3.480	0.058	0.305
Ecuador	RSP_2	Difenoconazole	-2.571	-4.614	-0.529	3	0.520	-3.592	-1.550	0.168
Ecuador	RSP_2	Epoxiconazole	-2.872	-4.915	-0.830	3	0.520	-3.893	-1.851	0.137
Ecuador	RSP_2	Propiconazole	-1.668	-3.711	0.374	3	0.520	-2.689	-0.647	0.315
Ecuador	RSP_3	Difenoconazole	0.387	-1.655	2.429	1	0.901	-1.382	2.156	1.308
Ecuador	RSP_3	Epoxiconazole	0.573	-1.469	2.616	1	0.901	-1.196	2.342	1.488
Ecuador	RSP_3	Propiconazole	0.914	-1.129	2.956	1	0.901	-0.855	2.682	1.884
Ecuador	RSSB_16	Difenoconazole	-1.414	-3.457	0.628	1	0.901	-3.183	0.355	0.375
Ecuador	RSSB_16	Epoxiconazole	-0.676	-2.718	1.367	1	0.901	-2.444	1.093	0.626
Ecuador	RSSB_16	Propiconazole	0.051	-1.991	2.094	1	0.901	-1.717	1.820	1.036
Ecuador	RSSB_22	Difenoconazole	-1.947	-3.989	0.095	3	0.520	-2.968	-0.926	0.259
Ecuador	RSSB_22	Epoxiconazole	-2.827	-4.869	-0.785	3	0.520	-3.848	-1.806	0.141
Ecuador	RSSB_22	Propiconazole	-0.923	-2.965	1.119	3	0.520	-1.944	0.098	0.527
Ecuador	RSSM_6	Difenoconazole	-1.898	-3.940	0.145	3	0.520	-2.919	-0.877	0.268
Ecuador	RSSM_6	Epoxiconazole	-2.650	-4.693	-0.608	3	0.520	-3.671	-1.629	0.159
Ecuador	RSSM_6	Propiconazole	-0.923	-2.966	1.119	3	0.520	-1.945	0.098	0.527
Colombia	Salvis_1	Difenoconazole	0.272	-1.770	2.314	1	0.901	-1.497	2.041	1.208
Colombia	Salvis_1	Epoxiconazole	-1.625	-3.667	0.417	1	0.901	-3.394	0.144	0.324
Colombia	Salvis_1	Propiconazole	-1.560	-3.603	0.482	1	0.901	-3.329	0.208	0.339
Colombia	Santillana_1	Difenoconazole	0.413	-1.629	2.456	1	0.901	-1.355	2.182	1.332
Colombia	Santillana_1	Epoxiconazole	-0.297	-2.339	1.746	1	0.901	-2.066	1.472	0.814

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Colombia	Santillana_1	Propiconazole	-0.083	-2.125	1.960	1	0.901	-1.851	1.686	0.944
Colombia	Santillana_12	Difenoconazole	2.706	0.664	4.749	1	0.901	0.937	4.475	6.526
Colombia	Santillana_12	Epoxiconazole	0.718	-1.324	2.761	1	0.901	-1.050	2.487	1.645
Colombia	Santillana_12	Propiconazole	0.920	-1.123	2.962	1	0.901	-0.849	2.688	1.892
Colombia	Santillana_13	Difenoconazole	3.149	1.106	5.191	3	0.520	2.127	4.170	8.868
Colombia	Santillana_13	Epoxiconazole	0.992	-1.050	3.034	3	0.520	-0.029	2.013	1.989
Colombia	Santillana_13	Propiconazole	2.429	0.386	4.471	3	0.520	1.408	3.450	5.384
Colombia	Santillana_2	Difenoconazole	1.756	-0.286	3.799	3	0.520	0.735	2.777	3.378
Colombia	Santillana_2	Epoxiconazole	0.158	-1.885	2.200	3	0.520	-0.863	1.179	1.116
Colombia	Santillana_2	Propiconazole	1.001	-1.041	3.044	3	0.520	-0.020	2.023	2.002
Colombia	Santillana_3	Difenoconazole	0.725	-1.317	2.767	1	0.901	-1.044	2.494	1.653
Colombia	Santillana_3	Epoxiconazole	-1.607	-3.649	0.436	1	0.901	-3.376	0.162	0.328
Colombia	Santillana_3	Propiconazole	0.852	-1.190	2.895	1	0.901	-0.916	2.621	1.805
Colombia	Santillana_4	Difenoconazole	2.200	0.158	4.243	2	0.637	0.950	3.451	4.596
Colombia	Santillana_4	Epoxiconazole	-0.080	-2.122	1.963	2	0.637	-1.330	1.171	0.946
Colombia	Santillana_4	Propiconazole	0.541	-1.501	2.584	2	0.637	-0.709	1.792	1.455
Colombia	Santillana_5	Difenoconazole				0				>10.24
Colombia	Santillana_5	Epoxiconazole	2.999	0.957	5.042	1	0.901	1.231	4.768	7.996
Colombia	Santillana_5	Propiconazole				0				>10.24
Colombia	Santillana_6	Difenoconazole				0				>10.24
Colombia	Santillana_6	Epoxiconazole	2.729	0.687	4.772	1	0.901	0.960	4.498	6.631
Colombia	Santillana_6	Propiconazole	2.135	0.093	4.178	1	0.901	0.367	3.904	4.393
Colombia	Sierra_1	Difenoconazole	0.945	-1.098	2.987	1	0.901	-0.824	2.713	1.925
Colombia	Sierra_1	Epoxiconazole	0.717	-1.325	2.760	1	0.901	-1.052	2.486	1.644
Colombia	Sierra_1	Propiconazole	1.078	-0.965	3.120	1	0.901	-0.691	2.847	2.111
Costa Rica	SPM2_1	Difenoconazole	1.410	-0.632	3.453	4	0.451	0.526	2.295	2.658
Costa Rica	SPM2_1	Epoxiconazole	0.724	-1.319	2.766	4	0.451	-0.161	1.608	1.651
Costa Rica	SPM2_1	Propiconazole	1.486	-0.556	3.529	4	0.451	0.602	2.371	2.801
Costa Rica	SPM2_11	Difenoconazole	1.746	-0.296	3.789	2	0.637	0.495	2.997	3.355
Costa Rica	SPM2_11	Epoxiconazole	0.597	-1.445	2.640	2	0.637	-0.654	1.848	1.513
Costa Rica	SPM2_11	Propiconazole	1.575	-0.468	3.617	2	0.637	0.324	2.826	2.979
Costa Rica	SPM2_2	Difenoconazole	0.677	-1.366	2.719	4	0.451	-0.208	1.561	1.599
Costa Rica	SPM2_2	Epoxiconazole	0.072	-1.970	2.115	4	0.451	-0.812	0.957	1.051
Costa Rica	SPM2_2	Propiconazole	0.404	-1.639	2.446	4	0.451	-0.481	1.288	1.323
Costa Rica	SPM2_3	Difenoconazole	1.514	-0.529	3.556	4	0.451	0.629	2.398	2.855
Costa Rica	SPM2_3	Epoxiconazole	0.587	-1.455	2.630	4	0.451	-0.297	1.472	1.502
Costa Rica	SPM2_3	Propiconazole	0.811	-1.231	2.853	4	0.451	-0.073	1.695	1.755
Costa Rica	SPM2_4	Difenoconazole	1.834	-0.208	3.877	4	0.451	0.950	2.719	3.566

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Costa Rica	SPM2_4	Epoxiconazole	0.524	-1.519	2.566	4	0.451	-0.361	1.408	1.438
Costa Rica	SPM2_4	Propiconazole	1.796	-0.246	3.838	4	0.451	0.912	2.680	3.472
Costa Rica	SPM2_5	Difenoconazole	2.240	0.197	4.282	2	0.637	0.989	3.490	4.722
Costa Rica	SPM2_5	Epoxiconazole	1.938	-0.105	3.980	2	0.637	0.687	3.188	3.831
Costa Rica	SPM2_5	Propiconazole	2.229	0.187	4.271	2	0.637	0.978	3.480	4.688
Costa Rica	SPM2_6	Difenoconazole	1.506	-0.536	3.548	2	0.637	0.255	2.757	2.840
Costa Rica	SPM2_6	Epoxiconazole	1.149	-0.893	3.192	2	0.637	-0.101	2.400	2.218
Costa Rica	SPM2_6	Propiconazole	1.402	-0.640	3.444	2	0.637	0.151	2.653	2.643
Costa Rica	SPM2_7	Difenoconazole	1.578	-0.464	3.621	2	0.637	0.328	2.829	2.986
Costa Rica	SPM2_7	Epoxiconazole	1.332	-0.711	3.374	2	0.637	0.081	2.582	2.517
Costa Rica	SPM2_7	Propiconazole	1.091	-0.951	3.133	2	0.637	-0.160	2.342	2.130
Costa Rica	SPM2_8	Difenoconazole	1.214	-0.828	3.257	2	0.637	-0.037	2.465	2.320
Costa Rica	SPM2_8	Epoxiconazole	-0.011	-2.053	2.032	2	0.637	-1.261	1.240	0.993
Costa Rica	SPM2_8	Propiconazole	0.229	-1.814	2.271	2	0.637	-1.022	1.479	1.172
Costa Rica	SPM2_9	Difenoconazole	2.267	0.225	4.310	2	0.637	1.016	3.518	4.814
Costa Rica	SPM2_9	Epoxiconazole	1.800	-0.242	3.842	2	0.637	0.549	3.051	3.482
Costa Rica	SPM2_9	Propiconazole	2.200	0.158	4.243	2	0.637	0.949	3.451	4.595
Costa Rica	SPM3_1	Difenoconazole				0				>10.24
Costa Rica	SPM3_1	Epoxiconazole	3.013	0.970	5.055	1	0.901	1.244	4.781	8.071
Costa Rica	SPM3_1	Propiconazole	2.945	0.903	4.988	1	0.901	1.176	4.714	7.702
Costa Rica	SPM3_2	Difenoconazole	2.892	0.849	4.934	1	0.901	1.123	4.660	7.420
Costa Rica	SPM3_2	Epoxiconazole	1.508	-0.535	3.550	1	0.901	-0.261	3.277	2.844
Costa Rica	SPM3_2	Propiconazole	1.428	-0.614	3.471	1	0.901	-0.340	3.197	2.691
Costa Rica	SPM4_1	Difenoconazole	3.331	1.289	5.374	1	0.901	1.563	5.100	10.066
Costa Rica	SPM4_1	Epoxiconazole				0				>10.24
Costa Rica	SPM4_1	Propiconazole				0				>10.24
Costa Rica	SPM4_10	Difenoconazole				0				>10.24
Costa Rica	SPM4_10	Epoxiconazole	2.855	0.813	4.898	1	0.901	1.087	4.624	7.236
Costa Rica	SPM4_10	Propiconazole				0				>10.24
Costa Rica	SPM4_11	Difenoconazole	2.834	0.791	4.876	1	0.901	1.065	4.602	7.128
Costa Rica	SPM4_11	Epoxiconazole	2.459	0.416	4.501	1	0.901	0.690	4.228	5.498
Costa Rica	SPM4_11	Propiconazole	2.450	0.408	4.493	1	0.901	0.682	4.219	5.466
Costa Rica	SPM4_12	Difenoconazole	3.202	1.160	5.244	1	0.901	1.433	4.971	9.203
Costa Rica	SPM4_12	Epoxiconazole	2.369	0.326	4.411	1	0.901	0.600	4.137	5.164
Costa Rica	SPM4_12	Propiconazole	3.098	1.056	5.141	1	0.901	1.330	4.867	8.565
Costa Rica	SPM4_13	Difenoconazole	1.182	-0.860	3.224	1	0.901	-0.587	2.951	2.269
Costa Rica	SPM4_13	Epoxiconazole	0.475	-1.567	2.518	1	0.901	-1.293	2.244	1.390
Costa Rica	SPM4_13	Propiconazole	2.217	0.175	4.260	1	0.901	0.449	3.986	4.651

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Costa Rica	SPM4_14	Difenoconazole	0.855	-1.187	2.898	1	0.901	-0.913	2.624	1.809
Costa Rica	SPM4_14	Epoxiconazole	0.475	-1.567	2.518	1	0.901	-1.293	2.244	1.390
Costa Rica	SPM4_14	Propiconazole	2.402	0.360	4.445	1	0.901	0.633	4.171	5.286
Costa Rica	SPM4_15	Difenoconazole				0				>10.24
Costa Rica	SPM4_15	Epoxiconazole	2.885	0.842	4.927	1	0.901	1.116	4.653	7.385
Costa Rica	SPM4_15	Propiconazole				0				>10.24
Costa Rica	SPM4_2	Difenoconazole	3.064	1.021	5.106	1	0.901	1.295	4.832	8.361
Costa Rica	SPM4_2	Epoxiconazole	2.411	0.368	4.453	1	0.901	0.642	4.179	5.317
Costa Rica	SPM4_2	Propiconazole	3.045	1.003	5.088	1	0.901	1.277	4.814	8.255
Costa Rica	SPM4_3	Difenoconazole				0				>10.24
Costa Rica	SPM4_3	Epoxiconazole	2.739	0.696	4.781	1	0.901	0.970	4.507	6.674
Costa Rica	SPM4_3	Propiconazole				0				>10.24
Costa Rica	SPM4_4	Difenoconazole	2.742	0.700	4.785	1	0.901	0.974	4.511	6.692
Costa Rica	SPM4_4	Epoxiconazole	2.574	0.531	4.616	1	0.901	0.805	4.342	5.953
Costa Rica	SPM4_4	Propiconazole	2.849	0.807	4.892	1	0.901	1.080	4.618	7.206
Costa Rica	SPM4_5	Difenoconazole	1.808	-0.235	3.850	1	0.901	0.039	3.576	3.501
Costa Rica	SPM4_5	Epoxiconazole	1.150	-0.893	3.192	1	0.901	-0.619	2.918	2.218
Costa Rica	SPM4_5	Propiconazole	1.226	-0.816	3.269	1	0.901	-0.543	2.995	2.339
Costa Rica	SPM4_6	Difenoconazole	2.743	0.700	4.785	1	0.901	0.974	4.511	6.693
Costa Rica	SPM4_6	Epoxiconazole	2.419	0.377	4.462	1	0.901	0.651	4.188	5.349
Costa Rica	SPM4_6	Propiconazole	3.065	1.022	5.107	1	0.901	1.296	4.833	8.367
Costa Rica	SPM4_7	Difenoconazole	3.077	1.035	5.120	1	0.901	1.308	4.846	8.440
Costa Rica	SPM4_7	Epoxiconazole				0				>10.24
Costa Rica	SPM4_7	Propiconazole	2.329	0.286	4.371	1	0.901	0.560	4.097	5.023
Costa Rica	SPM4_8	Difenoconazole	3.245	1.203	5.288	1	0.901	1.477	5.014	9.482
Costa Rica	SPM4_8	Epoxiconazole	1.289	-0.754	3.331	1	0.901	-0.480	3.057	2.443
Costa Rica	SPM4_8	Propiconazole	2.457	0.415	4.500	1	0.901	0.689	4.226	5.492
Costa Rica	SPM4_9	Difenoconazole	1.193	-0.850	3.235	1	0.901	-0.576	2.962	2.286
Costa Rica	SPM4_9	Epoxiconazole	0.724	-1.318	2.766	1	0.901	-1.045	2.493	1.652
Costa Rica	SPM4_9	Propiconazole	0.908	-1.135	2.950	1	0.901	-0.861	2.676	1.876
Costa Rica	SPM5_1	Difenoconazole	-0.161	-2.203	1.881	3	0.520	-1.182	0.860	0.894
Costa Rica	SPM5_1	Epoxiconazole	-0.742	-2.784	1.301	3	0.520	-1.763	0.280	0.598
Costa Rica	SPM5_1	Propiconazole	1.087	-0.956	3.129	3	0.520	0.065	2.108	2.124
Costa Rica	SPM5_2	Difenoconazole	2.635	0.593	4.678	1	0.901	0.866	4.404	6.212
Costa Rica	SPM5_2	Epoxiconazole	1.166	-0.877	3.208	1	0.901	-0.603	2.935	2.244
Costa Rica	SPM5_2	Propiconazole	1.239	-0.804	3.281	1	0.901	-0.530	3.008	2.360
Costa Rica	SPM5_3	Difenoconazole				0				>10.24
Costa Rica	SPM5_3	Epoxiconazole	1.849	-0.194	3.891	1	0.901	0.080	3.617	3.601

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Costa Rica	SPM5_3	Propiconazole				0				>10.24
Costa Rica	SPM6_1	Difenoconazole	2.984	0.941	5.026	3	0.520	1.962	4.005	7.910
Costa Rica	SPM6_1	Epoxiconazole	2.153	0.111	4.196	3	0.520	1.132	3.174	4.448
Costa Rica	SPM6_1	Propiconazole	2.482	0.440	4.525	3	0.520	1.461	3.504	5.588
Costa Rica	SPM6_10	Difenoconazole				0				>10.24
Costa Rica	SPM6_10	Epoxiconazole	2.537	0.495	4.580	1	0.901	0.768	4.306	5.804
Costa Rica	SPM6_10	Propiconazole				0				>10.24
Costa Rica	SPM6_11	Difenoconazole				0				>10.24
Costa Rica	SPM6_11	Epoxiconazole	1.024	-1.018	3.066	1	0.901	-0.745	2.793	2.034
Costa Rica	SPM6_11	Propiconazole	2.740	0.698	4.782	1	0.901	0.971	4.509	6.681
Costa Rica	SPM6_12	Difenoconazole				0				>10.24
Costa Rica	SPM6_12	Epoxiconazole	3.252	1.209	5.294	1	0.901	1.483	5.020	9.525
Costa Rica	SPM6_12	Propiconazole				0				>10.24
Costa Rica	SPM6_13	Difenoconazole	2.970	0.928	5.013	1	0.901	1.202	4.739	7.837
Costa Rica	SPM6_13	Epoxiconazole	2.664	0.622	4.707	1	0.901	0.895	4.433	6.339
Costa Rica	SPM6_13	Propiconazole	0.953	-1.090	2.995	1	0.901	-0.816	2.722	1.936
Costa Rica	SPM6_14	Difenoconazole				0				>10.24
Costa Rica	SPM6_14	Epoxiconazole	2.745	0.702	4.787	1	0.901	0.976	4.513	6.702
Costa Rica	SPM6_14	Propiconazole	2.796	0.753	4.838	1	0.901	1.027	4.564	6.943
Costa Rica	SPM6_15	Difenoconazole				0				>10.24
Costa Rica	SPM6_15	Epoxiconazole	2.474	0.431	4.516	1	0.901	0.705	4.242	5.554
Costa Rica	SPM6_15	Propiconazole	2.809	0.766	4.851	1	0.901	1.040	4.577	7.006
Costa Rica	SPM6_2	Difenoconazole	2.634	0.591	4.676	1	0.901	0.865	4.402	6.206
Costa Rica	SPM6_2	Epoxiconazole	1.011	-1.032	3.053	1	0.901	-0.758	2.779	2.015
Costa Rica	SPM6_2	Propiconazole	2.675	0.632	4.717	1	0.901	0.906	4.443	6.385
Costa Rica	SPM6_3	Difenoconazole				0				>10.24
Costa Rica	SPM6_3	Epoxiconazole				0				>10.24
Costa Rica	SPM6_3	Propiconazole				0				>10.24
Costa Rica	SPM6_4	Difenoconazole				0				>10.24
Costa Rica	SPM6_4	Epoxiconazole	2.998	0.956	5.041	1	0.901	1.229	4.767	7.990
Costa Rica	SPM6_4	Propiconazole				0				>10.24
Costa Rica	SPM6_5	Difenoconazole	2.811	0.769	4.854	1	0.901	1.043	4.580	7.019
Costa Rica	SPM6_5	Epoxiconazole	1.149	-0.894	3.191	1	0.901	-0.620	2.917	2.217
Costa Rica	SPM6_5	Propiconazole	2.733	0.691	4.776	1	0.901	0.965	4.502	6.650
Costa Rica	SPM6_6	Difenoconazole	1.703	-0.339	3.745	1	0.901	-0.066	3.472	3.256
Costa Rica	SPM6_6	Epoxiconazole	0.454	-1.588	2.497	1	0.901	-1.314	2.223	1.370
Costa Rica	SPM6_6	Propiconazole	0.785	-1.257	2.828	1	0.901	-0.984	2.554	1.723
Costa Rica	SPM6_7	Difenoconazole				0				>10.24

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Costa Rica	SPM6 7	Epoxiconazole	1.651	-0.391	3.693	1	0,901	-0,118	3,420	3.141
Costa Rica	SPM6 7	Propiconazole	2 870	0.837	4 921	1	0 901	1 110	4 648	7,356
Costa Nica	05M0_7	Propiconazole	2.075	0.007	4.321	1	0.301	1.110	4.040	10.00
Costa Rica	5PM6_8	Difenoconazole				0				>10.24
Costa Rica	SPM6_8	Epoxiconazole	3.188	1.146	5.231	1	0.901	1.420	4.957	9.117
Costa Rica	SPM6_8	Propiconazole				0				>10.24
Costa Rica	SPM6_9	Difenoconazole				0				>10.24
Costa Rica	SPM6_9	Epoxiconazole	2.170	0.127	4.212	1	0.901	0.401	3.938	4.499
Costa Rica	SPM6_9	Propiconazole	2.764	0.722	4.806	1	0.901	0.995	4.533	6.793
Costa Rica	SPM7_1	Difenoconazole	2.066	0.024	4.108	2	0.637	0.815	3.317	4.187
Costa Rica	SPM7_1	Epoxiconazole	0.686	-1.356	2.729	3	0.520	-0.335	1.707	1.609
Costa Rica	SPM7_1	Propiconazole	2.366	0.324	4.409	3	0.520	1.345	3.387	5.156
Costa Rica	SPM7_2	Difenoconazole	2.624	0.582	4.666	1	0.901	0.855	4.393	6.164
Costa Rica	SPM7_2	Epoxiconazole	1.273	-0.770	3.315	1	0.901	-0.496	3.041	2.416
Costa Rica	SPM7_2	Propiconazole	1.583	-0.460	3.625	1	0.901	-0.186	3.352	2.996
Costa Rica	SPM7_3	Difenoconazole	1.389	-0.654	3.431	1	0.901	-0.380	3.158	2.619
Costa Rica	SPM7_3	Epoxiconazole	1.182	-0.860	3.225	1	0.901	-0.587	2.951	2.269
Costa Rica	SPM7_3	Propiconazole	1.217	-0.825	3.260	1	0.901	-0.551	2.986	2.325
Costa Rica	SPM7_4	Difenoconazole	2.670	0.627	4.712	1	0.901	0.901	4.439	6.363
Costa Rica	SPM7_4	Epoxiconazole	1.092	-0.951	3.134	1	0.901	-0.677	2.861	2.132
Costa Rica	SPM7_4	Propiconazole	2.634	0.592	4.676	1	0.901	0.865	4.403	6.207
Colombia	Stal_4	Difenoconazole	2.830	0.788	4.873	1	0.901	1.062	4.599	7.113
Colombia	Stal_4	Epoxiconazole	0.794	-1.249	2.836	1	0.901	-0.975	2.562	1.734
Colombia	Stal_4	Propiconazole	2.886	0.844	4.928	1	0.901	1.117	4.655	7.392
Philippines	T52_1	Difenoconazole	2.467	0.424	4.509	2	0.637	1.216	3.717	5.528
Philippines	T52_1	Epoxiconazole	0.887	-1.156	2.929	3	0.520	-0.135	1.908	1.849
Philippines	T52_1	Propiconazole	1.179	-0.864	3.221	2	0.637	-0.072	2.430	2.264
Philippines	T52_10	Difenoconazole	2.407	0.364	4.449	3	0.520	1.385	3.428	5.302
Philippines	T52_10	Epoxiconazole	1.890	-0.152	3.933	4	0.451	1.006	2.775	3.707
Philippines	T52_10	Propiconazole	2.225	0.183	4.268	4	0.451	1.341	3.110	4.676
Philippines	T52 12	Difenoconazole	3.094	1.052	5.137	1	0.901	1.326	4.863	8.541
Philippines	T52 12	Epoxiconazole				0				>10.24
Philippines		Propiconazole	2,720	0.678	4,763	1	0.901	0.951	4.489	6.590
Philippines	T52_13	Difenoconazole	2 154	0.112	4 197	3	0.520	1 133	3 176	4 452
Dhilippines	TEO 40	Enoviocanalia	2.104	0.005	4 4 9 0	2	0.520	1 1 4 7	2.170	4.404
Philippines	152_13	Epoxiconazole	2.138	0.095	4.180	3	0.520	1.11/	3.159	4.401
Philippines	T52_13	Propiconazole	2.946	0.903	4.988	3	0.520	1.925	3.967	7.705
Philippines	T52_14	Difenoconazole				0				>10.24
Philippines	T52_14	Epoxiconazole				0				>10.24
Philippines	T52_14	Propiconazole				0				>10.24
Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
-------------	---------	----------------	---------------------	--------	-------	-----	-------	--------	-------	------------------
Philippines	T52_15	Difenoconazole	2.590	0.548	4.632	3	0.520	1.569	3.611	6.021
Philippines	T52_15	Epoxiconazole	2.857	0.815	4.899	2	0.637	1.606	4.108	7.245
Philippines	T52_15	Propiconazole	2.329	0.287	4.372	4	0.451	1.445	3.214	5.025
Philippines	T52_16	Difenoconazole	3.185	1.143	5.227	1	0.901	1.416	4.954	9.095
Philippines	T52_16	Epoxiconazole	2.786	0.744	4.828	1	0.901	1.017	4.555	6.897
Philippines	T52_16	Propiconazole	2.805	0.763	4.847	1	0.901	1.036	4.574	6.989
Philippines	T52_17	Difenoconazole				0				>10.24
Philippines	T52_17	Epoxiconazole				0				>10.24
Philippines	T52_17	Propiconazole				0				>10.24
Philippines	T52_18	Difenoconazole				0				>10.24
Philippines	T52_18	Epoxiconazole	3.095	1.053	5.137	1	0.901	1.326	4.864	8.544
Philippines	T52_18	Propiconazole	2.538	0.495	4.580	1	0.901	0.769	4.306	5.807
Philippines	T52_19	Difenoconazole	2.869	0.827	4.912	1	0.901	1.101	4.638	7.307
Philippines	T52_19	Epoxiconazole	3.016	0.974	5.058	1	0.901	1.247	4.785	8.089
Philippines	T52_19	Propiconazole	1.668	-0.374	3.710	1	0.901	-0.101	3.437	3.178
Philippines	T52_2	Difenoconazole	3.327	1.285	5.369	1	0.901	1.558	5.096	10.035
Philippines	T52_2	Epoxiconazole	1.285	-0.758	3.327	2	0.637	0.034	2.535	2.436
Philippines	T52_2	Propiconazole	3.136	1.094	5.178	2	0.637	1.885	4.387	8.791
Philippines	T52_20	Difenoconazole	2.609	0.567	4.652	1	0.901	0.840	4.378	6.101
Philippines	T52_20	Epoxiconazole	2.298	0.255	4.340	1	0.901	0.529	4.066	4.917
Philippines	T52_20	Propiconazole	2.566	0.524	4.608	1	0.901	0.797	4.335	5.922
Philippines	T52_21	Difenoconazole	2.904	0.862	4.946	1	0.901	1.135	4.673	7.485
Philippines	T52_21	Epoxiconazole				0				>10.24
Philippines	T52_21	Propiconazole	2.912	0.869	4.954	1	0.901	1.143	4.681	7.525
Philippines	T52_22	Difenoconazole	2.815	0.772	4.857	4	0.451	1.930	3.699	7.035
Philippines	T52_22	Epoxiconazole	1.735	-0.308	3.777	6	0.368	1.012	2.457	3.328
Philippines	T52_22	Propiconazole	3.067	1.024	5.109	5	0.403	2.276	3.858	8.379
Philippines	T52_23	Difenoconazole	-0.064	-2.107	1.978	3	0.520	-1.085	0.957	0.956
Philippines	T52_23	Epoxiconazole	0.115	-1.928	2.157	3	0.520	-0.907	1.136	1.083
Philippines	T52_23	Propiconazole	-0.558	-2.600	1.484	2	0.637	-1.809	0.693	0.679
Philippines	T52_3	Difenoconazole	3.255	1.212	5.297	1	0.901	1.486	5.023	9.544
Philippines	T52_3	Epoxiconazole	2.678	0.636	4.721	1	0.901	0.910	4.447	6.402
Philippines	T52_3	Propiconazole	0.693	-1.350	2.735	1	0.901	-1.076	2.462	1.616
Philippines	T52_36	Difenoconazole	1.438	-0.605	3.480	1	0.901	-0.331	3.207	2.709
Philippines	T52_36	Epoxiconazole	1.295	-0.748	3.337	1	0.901	-0.474	3.063	2.453
Philippines	T52_36	Propiconazole	0.218	-1.825	2.260	1	0.901	-1.551	1.987	1.163
Philippines	T52_4	Difenoconazole				0				>10.24
Philippines	T52_4	Epoxiconazole				0				>10.24

			24 ()				-			= 0
Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Philippines	T52_4	Propiconazole				0				>10.24
Philippines	T52_5	Difenoconazole	3.353	1.311	5.396	1	0.901	1.585	5.122	10.220
Philippines	T52_5	Epoxiconazole	3.085	1.042	5.127	2	0.637	1.834	4.335	8.484
Philippines	T52_5	Propiconazole	2.694	0.651	4.736	3	0.520	1.673	3.715	6.470
Philippines	T52_6	Difenoconazole				0				>10.24
Philippines	T52_6	Epoxiconazole	2.874	0.832	4.916	1	0.901	1.105	4.643	7.331
Philippines	T52_6	Propiconazole				0				>10.24
Philippines	T52_7	Difenoconazole	2.539	0.496	4.581	1	0.901	0.770	4.307	5.810
Philippines	T52_7	Epoxiconazole	2.689	0.646	4.731	1	0.901	0.920	4.458	6.448
Philippines	T52_7	Propiconazole				0				>10.24
Philippines	T52_8	Difenoconazole	2.920	0.877	4.962	3	0.520	1.898	3.941	7.567
Philippines	T52_8	Epoxiconazole	1.343	-0.699	3.386	3	0.520	0.322	2.365	2.538
Philippines	T52_8	Propiconazole	1.974	-0.068	4.016	3	0.520	0.953	2.995	3.929
Philippines	T52_9	Difenoconazole				0				>10.24
Philippines	T52_9	Epoxiconazole				0				>10.24
Philippines	T52_9	Propiconazole				0				>10.24
Colombia	Tamaca_1	Difenoconazole	0.165	-1.877	2.208	1	0.901	-1.603	1.934	1.121
Colombia	Tamaca_1	Epoxiconazole	-1.102	-3.145	0.940	1	0.901	-2.871	0.666	0.466
Colombia	Tamaca_1	Propiconazole	0.387	-1.655	2.430	1	0.901	-1.381	2.156	1.308
Colombia	Teresa_1	Difenoconazole	2.790	0.748	4.832	1	0.901	1.021	4.559	6.916
Colombia	Teresa_1	Epoxiconazole	-3.510	-5.553	-1.468	1	0.901	-5.279	-1.742	0.088
Colombia	Teresa_1	Propiconazole	0.634	-1.408	2.676	1	0.901	-1.135	2.403	1.552
Colombia	Teresa_2	Difenoconazole	-0.313	-2.356	1.729	1	0.901	-2.082	1.455	0.805
Colombia	Teresa_2	Epoxiconazole	-0.914	-2.956	1.129	1	0.901	-2.683	0.855	0.531
Colombia	Teresa_2	Propiconazole	0.130	-1.913	2.172	1	0.901	-1.639	1.898	1.094
Colombia	Teresa_3	Difenoconazole	-0.534	-2.576	1.508	3	0.520	-1.555	0.487	0.691
Colombia	Teresa_3	Epoxiconazole	0.333	-1.710	2.375	3	0.520	-0.688	1.354	1.259
Colombia	Teresa_3	Propiconazole	1.954	-0.089	3.996	3	0.520	0.933	2.975	3.874
Colombia	Toscana_12	Difenoconazole	2.554	0.511	4.596	1	0.901	0.785	4.322	5.871
Colombia	Toscana_12	Epoxiconazole	0.910	-1.132	2.952	1	0.901	-0.859	2.679	1.879
Colombia	Toscana_12	Propiconazole	2.562	0.520	4.604	1	0.901	0.793	4.331	5.906
Colombia	Toscana_2	Difenoconazole	1.833	-0.209	3.876	1	0.901	0.065	3.602	3.564
Colombia	Toscana_2	Epoxiconazole	1.905	-0.138	3.947	1	0.901	0.136	3.673	3.744
Colombia	Toscana_2	Propiconazole	2.684	0.642	4.727	1	0.901	0.915	4.453	6.427
Colombia	Toscana_3	Difenoconazole	1.113	-0.929	3.156	1	0.901	-0.656	2.882	2.163
Colombia	Toscana_3	Epoxiconazole	-0.004	-2.047	2.038	1	0.901	-1.773	1.765	0.997
Colombia	Toscana_3	Propiconazole	0.938	-1.104	2.981	1	0.901	-0.830	2.707	1.916
Colombia	Toscana_4	Difenoconazole	-1.668	-3.710	0.375	1	0.901	-3.436	0.101	0.315

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Colombia	Toscana_4	Epoxiconazole	-3.667	-5.709	-1.625	1	0.901	-5.436	-1.898	0.079
Colombia	Toscana_4	Propiconazole	-0.678	-2.721	1.364	1	0.901	-2.447	1.090	0.625
Colombia	Toscana_5	Difenoconazole	1.264	-0.778	3.306	1	0.901	-0.505	3.033	2.402
Colombia	Toscana_5	Epoxiconazole	0.231	-1.811	2.273	1	0.901	-1.538	2.000	1.174
Colombia	Toscana_5	Propiconazole	2.777	0.735	4.820	1	0.901	1.009	4.546	6.856
Colombia	Toscana_6	Difenoconazole	2.207	0.165	4.249	1	0.901	0.438	3.976	4.617
Colombia	Toscana_6	Epoxiconazole	0.001	-2.041	2.044	1	0.901	-1.767	1.770	1.001
Colombia	Toscana_6	Propiconazole	0.911	-1.131	2.954	1	0.901	-0.858	2.680	1.881
Colombia	Toscana_7	Difenoconazole	1.125	-0.918	3.167	1	0.901	-0.644	2.893	2.181
Colombia	Toscana_7	Epoxiconazole	-0.654	-2.696	1.388	1	0.901	-2.423	1.115	0.636
Colombia	Toscana_7	Propiconazole	1.021	-1.022	3.063	1	0.901	-0.748	2.789	2.029
Colombia	Toscana_8	Difenoconazole	1.950	-0.092	3.993	4	0.451	1.066	2.835	3.864
Colombia	Toscana_8	Epoxiconazole	1.081	-0.961	3.124	4	0.451	0.197	1.966	2.116
Colombia	Toscana_8	Propiconazole	2.356	0.314	4.399	4	0.451	1.472	3.241	5.120
Philippines	U22_1	Difenoconazole	0.385	-1.657	2.428	2	0.637	-0.865	1.636	1.306
Philippines	U22_1	Epoxiconazole	0.449	-1.593	2.491	2	0.637	-0.802	1.700	1.365
Philippines	U22_1	Propiconazole	0.772	-1.270	2.814	2	0.637	-0.479	2.023	1.708
Philippines	U22_10	Difenoconazole	0.935	-1.107	2.978	1	0.901	-0.834	2.704	1.912
Philippines	U22_10	Epoxiconazole	0.603	-1.440	2.645	1	0.901	-1.166	2.371	1.518
Philippines	U22_10	Propiconazole	0.586	-1.457	2.628	1	0.901	-1.183	2.354	1.501
Philippines	U22_11	Difenoconazole	2.389	0.347	4.432	1	0.901	0.620	4.158	5.239
Philippines	U22_11	Epoxiconazole	0.350	-1.692	2.392	1	0.901	-1.419	2.119	1.274
Philippines	U22_11	Propiconazole	1.315	-0.727	3.357	1	0.901	-0.454	3.084	2.488
Philippines	U22_12	Difenoconazole	1.485	-0.558	3.527	1	0.901	-0.284	3.254	2.799
Philippines	U22_12	Epoxiconazole	1.371	-0.671	3.413	1	0.901	-0.398	3.140	2.586
Philippines	U22_12	Propiconazole	1.428	-0.614	3.470	1	0.901	-0.341	3.197	2.691
Philippines	U22_13	Difenoconazole	2.650	0.608	4.692	1	0.901	0.881	4.419	6.277
Philippines	U22_13	Epoxiconazole	2.443	0.401	4.486	1	0.901	0.675	4.212	5.439
Philippines	U22_13	Propiconazole	0.539	-1.503	2.582	1	0.901	-1.230	2.308	1.453
Philippines	U22_14	Difenoconazole	-1.134	-3.176	0.909	1	0.901	-2.902	0.635	0.456
Philippines	U22_14	Epoxiconazole	-1.709	-3.751	0.334	1	0.901	-3.477	0.060	0.306
Philippines	U22_14	Propiconazole	-0.812	-2.854	1.230	1	0.901	-2.581	0.957	0.570
Philippines	U22_15	Difenoconazole	0.370	-1.673	2.412	1	0.901	-1.399	2.138	1.292
Philippines	U22_15	Epoxiconazole	-0.493	-2.535	1.549	1	0.901	-2.262	1.276	0.711
Philippines	U22_15	Propiconazole	0.938	-1.104	2.980	1	0.901	-0.831	2.707	1.916
Philippines	U22_16	Difenoconazole	2.790	0.748	4.832	1	0.901	1.021	4.559	6.916
Philippines	U22_16	Epoxiconazole	2.168	0.125	4.210	1	0.901	0.399	3.936	4.493
Philippines	U22_16	Propiconazole	1.417	-0.625	3.460	1	0.901	-0.352	3.186	2.671

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Philippines	U22_17	Difenoconazole	-0.501	-2.544	1.541	1	0.901	-2.270	1.267	0.706
Philippines	U22_17	Epoxiconazole	-0.875	-2.917	1.168	1	0.901	-2.644	0.894	0.545
Philippines	U22_17	Propiconazole	0.364	-1.678	2.407	1	0.901	-1.405	2.133	1.287
Philippines	U22_18	Difenoconazole	1.764	-0.278	3.806	1	0.901	-0.005	3.533	3.397
Philippines	U22_18	Epoxiconazole	1.250	-0.792	3.292	1	0.901	-0.519	3.019	2.379
Philippines	U22_18	Propiconazole	0.715	-1.328	2.757	1	0.901	-1.054	2.483	1.641
Philippines	U22_19	Difenoconazole	-1.072	-3.114	0.971	1	0.901	-2.840	0.697	0.476
Philippines	U22_19	Epoxiconazole	-1.731	-3.773	0.311	1	0.901	-3.500	0.038	0.301
Philippines	U22_19	Propiconazole	-1.186	-3.229	0.856	1	0.901	-2.955	0.582	0.439
Philippines	U22_2	Difenoconazole	1.067	-0.976	3.109	3	0.520	0.046	2.088	2.095
Philippines	U22_2	Epoxiconazole	0.663	-1.380	2.705	3	0.520	-0.359	1.684	1.583
Philippines	U22_2	Propiconazole	1.377	-0.665	3.420	3	0.520	0.356	2.399	2.598
Philippines	U22_20	Difenoconazole	2.201	0.158	4.243	1	0.901	0.432	3.970	4.598
Philippines	U22_20	Epoxiconazole	1.826	-0.216	3.869	1	0.901	0.058	3.595	3.546
Philippines	U22_20	Propiconazole	0.624	-1.419	2.666	1	0.901	-1.145	2.393	1.541
Philippines	U22_21	Difenoconazole	1.357	-0.685	3.400	1	0.901	-0.411	3.126	2.562
Philippines	U22_21	Epoxiconazole	1.426	-0.616	3.469	1	0.901	-0.343	3.195	2.687
Philippines	U22_21	Propiconazole	0.853	-1.189	2.895	1	0.901	-0.916	2.622	1.806
Philippines	U22_22	Difenoconazole	0.607	-1.435	2.649	1	0.901	-1.162	2.376	1.523
Philippines	U22_22	Epoxiconazole	0.633	-1.409	2.676	1	0.901	-1.136	2.402	1.551
Philippines	U22_22	Propiconazole	0.693	-1.350	2.735	1	0.901	-1.076	2.462	1.616
Philippines	U22_3	Difenoconazole	-0.356	-2.398	1.686	3	0.520	-1.377	0.665	0.781
Philippines	U22_3	Epoxiconazole	-1.241	-3.284	0.801	3	0.520	-2.262	-0.220	0.423
Philippines	U22_3	Propiconazole	-0.888	-2.930	1.154	3	0.520	-1.909	0.133	0.540
Philippines	U22_4	Difenoconazole	-1.549	-3.592	0.493	3	0.520	-2.570	-0.528	0.342
Philippines	U22_4	Epoxiconazole	-1.701	-3.743	0.341	3	0.520	-2.722	-0.680	0.308
Philippines	U22_4	Propiconazole	-0.418	-2.460	1.625	3	0.520	-1.439	0.604	0.749
Philippines	U22_5	Difenoconazole	-1.508	-3.550	0.534	3	0.520	-2.529	-0.487	0.352
Philippines	U22_5	Epoxiconazole	-1.690	-3.732	0.353	3	0.520	-2.711	-0.668	0.310
Philippines	U22_5	Propiconazole	-0.849	-2.892	1.193	3	0.520	-1.871	0.172	0.555
Philippines	U22_6	Difenoconazole	-1.012	-3.054	1.031	3	0.520	-2.033	0.009	0.496
Philippines	U22_6	Epoxiconazole	-1.462	-3.504	0.581	3	0.520	-2.483	-0.441	0.363
Philippines	U22_6	Propiconazole	-0.257	-2.299	1.786	3	0.520	-1.278	0.764	0.837
Philippines	U22_7	Difenoconazole	0.199	-1.843	2.242	1	0.901	-1.570	1.968	1.148
Philippines	U22_7	Epoxiconazole	-0.334	-2.376	1.708	1	0.901	-2.103	1.435	0.793
Philippines	U22_7	Propiconazole	0.454	-1.589	2.496	1	0.901	-1.315	2.222	1.369
Philippines	U22_8	Difenoconazole	2.816	0.773	4.858	1	0.901	1.047	4.584	7.040
Philippines	U22_8	Epoxiconazole	2.738	0.696	4.781	1	0.901	0.970	4.507	6.674

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Philippines	U22_8	Propiconazole	2.517	0.474	4.559	1	0.901	0.748	4.285	5.722
Philippines	U22_9	Difenoconazole	-0.638	-2.681	1.404	1	0.901	-2.407	1.131	0.643
Philippines	U22_9	Epoxiconazole	-1.394	-3.437	0.648	1	0.901	-3.163	0.374	0.380
Philippines	U22_9	Propiconazole	0.233	-1.810	2.275	1	0.901	-1.536	2.001	1.175
Colombia	Universalia_1	Difenoconazole	-3.646	-5.688	-1.603	1	0.901	-5.414	-1.877	0.080
Colombia	Universalia_1	Epoxiconazole	-5.279	-7.321	-3.236	1	0.901	-7.047	-3.510	0.026
Colombia	Universalia_1	Propiconazole	-2.090	-4.133	-0.048	1	0.901	-3.859	-0.321	0.235
Colombia	Universalia_2	Difenoconazole	-5.315	-7.357	-3.273	1	0.901	-7.084	-3.546	0.025
Colombia	Universalia_2	Epoxiconazole	-1.665	-3.708	0.377	1	0.901	-3.434	0.104	0.315
Colombia	Universalia_2	Propiconazole	1.311	-0.731	3.353	1	0.901	-0.458	3.080	2.481
Colombia	Universalia_3	Difenoconazole	2.804	0.762	4.847	2	0.637	1.554	4.055	6.985
Colombia	Universalia_3	Epoxiconazole	1.479	-0.564	3.521	3	0.520	0.458	2.500	2.787
Colombia	Universalia_3	Propiconazole	0.995	-1.047	3.037	2	0.637	-0.256	2.246	1.993
Colombia	Vega_1	Difenoconazole	1.015	-1.027	3.058	1	0.901	-0.754	2.784	2.021
Colombia	Vega_1	Epoxiconazole	0.716	-1.326	2.759	1	0.901	-1.052	2.485	1.643
Colombia	Vega_1	Propiconazole	2.497	0.454	4.539	1	0.901	0.728	4.266	5.644
Colombia	Victoria	Difenoconazole	2.199	0.157	4.242	1	0.901	0.431	3.968	4.593
Colombia	Victoria	Epoxiconazole	1.846	-0.197	3.888	1	0.901	0.077	3.614	3.594
Colombia	Victoria	Propiconazole	-0.437	-2.480	1.605	1	0.901	-2.206	1.332	0.739
Cameroon	X02_4	Difenoconazole	-7.663	-9.706	-5.621	3	0.520	-8.685	-6.642	0.005
Cameroon	X02_4	Epoxiconazole	-6.968	-9.010	-4.925	3	0.520	-7.989	-5.946	0.008
Cameroon	X02_4	Propiconazole	-6.547	-8.589	-4.504	3	0.520	-7.568	-5.525	0.011
Cameroon	X03_2	Difenoconazole	-7.644	-9.686	-5.601	2	0.637	-8.895	-6.393	0.005
Cameroon	X03_2	Epoxiconazole	-7.437	-9.480	-5.395	3	0.520	-8.459	-6.416	0.006
Cameroon	X03_2	Propiconazole	-6.835	-8.877	-4.793	3	0.520	-7.856	-5.814	0.009
Cameroon	X04_2	Difenoconazole	-7.966	-10.008	-5.923	3	0.520	-8.987	-6.945	0.004
Cameroon	X04_2	Epoxiconazole	-7.199	-9.242	-5.157	3	0.520	-8.221	-6.178	0.007
Cameroon	X04_2	Propiconazole	-6.418	-8.460	-4.375	3	0.520	-7.439	-5.397	0.012
Cameroon	X04_5	Difenoconazole	-7.562	-9.604	-5.520	2	0.637	-8.813	-6.311	0.005
Cameroon	X04_5	Epoxiconazole	-6.609	-8.651	-4.566	2	0.637	-7.859	-5.358	0.010
Cameroon	X04_5	Propiconazole	-6.119	-8.161	-4.077	2	0.637	-7.370	-4.868	0.014
Cameroon	X05_3	Difenoconazole	-7.163	-9.205	-5.120	3	0.520	-8.184	-6.141	0.007
Cameroon	X05_3	Epoxiconazole	-6.844	-8.886	-4.801	3	0.520	-7.865	-5.822	0.009
Cameroon	X05_3	Propiconazole	-6.264	-8.306	-4.221	3	0.520	-7.285	-5.242	0.013
Cameroon	X05_5	Difenoconazole	-7.506	-9.548	-5.463	4	0.451	-8.390	-6.621	0.006
Cameroon	X05_5	Epoxiconazole	-7.065	-9.107	-5.022	4	0.451	-7.949	-6.180	0.007
Cameroon	X05_5	Propiconazole	-6.011	-8.053	-3.968	4	0.451	-6.895	-5.126	0.016
Cameroon	X07_2	Difenoconazole	-7.270	-9.312	-5.227	2	0.637	-8.520	-6.019	0.006

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Cameroon	X07_2	Epoxiconazole	-6.550	-8.592	-4.507	3	0.520	-7.571	-5.529	0.011
Cameroon	X07_2	Propiconazole	-6.004	-8.047	-3.962	3	0.520	-7.026	-4.983	0.016
Cameroon	X08_1	Difenoconazole	-7.644	-9.686	-5.601	2	0.637	-8.895	-6.393	0.005
Cameroon	X08_1	Epoxiconazole	-6.060	-8.103	-4.018	3	0.520	-7.081	-5.039	0.015
Cameroon	X08_1	Propiconazole	-6.015	-8.058	-3.973	3	0.520	-7.036	-4.994	0.015
Cameroon	X08_2	Difenoconazole	-7.644	-9.686	-5.601	2	0.637	-8.895	-6.393	0.005
Cameroon	X08_2	Epoxiconazole	-6.835	-8.877	-4.793	3	0.520	-7.856	-5.814	0.009
Cameroon	X08_2	Propiconazole	-6.117	-8.159	-4.074	3	0.520	-7.138	-5.096	0.014
Cameroon	X13_3	Difenoconazole	-7.576	-9.618	-5.533	3	0.520	-8.597	-6.555	0.005
Cameroon	X13_3	Epoxiconazole	-6.676	-8.719	-4.634	3	0.520	-7.697	-5.655	0.010
Cameroon	X13_3	Propiconazole	-6.428	-8.470	-4.385	3	0.520	-7.449	-5.406	0.012
Cameroon	X14_3	Difenoconazole	-7.512	-9.555	-5.470	2	0.637	-8.763	-6.262	0.005
Cameroon	X14_3	Epoxiconazole	-6.815	-8.858	-4.773	3	0.520	-7.837	-5.794	0.009
Cameroon	X14_3	Propiconazole	-5.968	-8.010	-3.925	3	0.520	-6.989	-4.946	0.016
Cameroon	X14_4	Difenoconazole	-7.663	-9.706	-5.621	3	0.520	-8.685	-6.642	0.005
Cameroon	X14_4	Epoxiconazole	-6.745	-8.788	-4.703	3	0.520	-7.766	-5.724	0.009
Cameroon	X14_4	Propiconazole	-6.366	-8.408	-4.324	3	0.520	-7.387	-5.345	0.012
Cameroon	X14_5	Difenoconazole	-7.104	-9.146	-5.062	3	0.520	-8.125	-6.083	0.007
Cameroon	X14_5	Epoxiconazole	-5.340	-7.382	-3.297	3	0.520	-6.361	-4.319	0.025
Cameroon	X14_5	Propiconazole	-5.152	-7.194	-3.109	3	0.520	-6.173	-4.131	0.028
Cameroon	X16_1	Difenoconazole	-7.413	-9.455	-5.371	3	0.520	-8.434	-6.392	0.006
Cameroon	X16_1	Epoxiconazole	-6.260	-8.302	-4.218	3	0.520	-7.281	-5.239	0.013
Cameroon	X16_1	Propiconazole	-5.858	-7.901	-3.816	3	0.520	-6.880	-4.837	0.017
Cameroon	X16_3	Difenoconazole	-6.629	-8.671	-4.586	3	0.520	-7.650	-5.607	0.010
Cameroon	X16_3	Epoxiconazole	-4.915	-6.958	-2.873	3	0.520	-5.936	-3.894	0.033
Cameroon	X16_3	Propiconazole	-4.269	-6.311	-2.227	3	0.520	-5.290	-3.248	0.052
Cameroon	X18_10	Difenoconazole	-7.792	-9.834	-5.749	2	0.637	-9.042	-6.541	0.005
Cameroon	X18_10	Epoxiconazole	-6.945	-8.988	-4.903	2	0.637	-8.196	-5.694	0.008
Cameroon	X18_10	Propiconazole	-6.592	-8.634	-4.549	3	0.520	-7.613	-5.571	0.010
Cameroon	X18_5	Difenoconazole	-7.170	-9.212	-5.127	3	0.520	-8.191	-6.149	0.007
Cameroon	X18_5	Epoxiconazole	-5.869	-7.912	-3.827	3	0.520	-6.890	-4.848	0.017
Cameroon	X18_5	Propiconazole	-5.652	-7.694	-3.609	3	0.520	-6.673	-4.630	0.020
Cameroon	X18_7	Difenoconazole	-7.134	-9.176	-5.091	2	0.637	-8.385	-5.883	0.007
Cameroon	X18_7	Epoxiconazole	-6.606	-8.649	-4.564	3	0.520	-7.627	-5.585	0.010
Cameroon	X18_7	Propiconazole	-5.607	-7.650	-3.565	3	0.520	-6.629	-4.586	0.021
Cameroon	X18_8	Difenoconazole	-7.341	-9.383	-5.299	3	0.520	-8.362	-6.320	0.006
Cameroon	X18_8	Epoxiconazole	-6.613	-8.655	-4.571	3	0.520	-7.634	-5.592	0.010
Cameroon	X18_8	Propiconazole	-5.849	-7.892	-3.807	3	0.520	-6.870	-4.828	0.017

Country	Isolate	Fungicide	² Log(m)	Lsed	Used	(n)	Sem	LMCI	UMCI	EC ₅₀
Cameroon	X19_1	Difenoconazole	-7.291	-9.333	-5.248	3	0.520	-8.312	-6.270	0.006
Cameroon	X19_1	Epoxiconazole	-6.446	-8.488	-4.403	3	0.520	-7.467	-5.425	0.011
Cameroon	X19_1	Propiconazole	-5.961	-8.003	-3.918	3	0.520	-6.982	-4.940	0.016
Cameroon	X19_3	Difenoconazole	-7.644	-9.686	-5.601	1	0.901	-9.413	-5.875	0.005
Cameroon	X19_3	Epoxiconazole	-7.663	-9.706	-5.621	3	0.520	-8.685	-6.642	0.005
Cameroon	X19_3	Propiconazole	-7.556	-9.599	-5.514	3	0.520	-8.577	-6.535	0.005
Cameroon	X23_2	Difenoconazole	-7.519	-9.561	-5.476	2	0.637	-8.769	-6.268	0.005
Cameroon	X23_2	Epoxiconazole	-7.242	-9.284	-5.199	3	0.520	-8.263	-6.221	0.007
Cameroon	X23_2	Propiconazole	-6.237	-8.279	-4.195	3	0.520	-7.258	-5.216	0.013
Cameroon	X23_3	Difenoconazole	-7.151	-9.193	-5.109	3	0.520	-8.172	-6.130	0.007
Cameroon	X23_3	Epoxiconazole	-5.791	-7.833	-3.749	3	0.520	-6.812	-4.770	0.018
Cameroon	X23_3	Propiconazole	-5.415	-7.458	-3.373	3	0.520	-6.436	-4.394	0.023
Cameroon	X24_2	Difenoconazole	-7.412	-9.454	-5.369	3	0.520	-8.433	-6.391	0.006
Cameroon	X24_2	Epoxiconazole	-6.628	-8.671	-4.586	3	0.520	-7.649	-5.607	0.010
Cameroon	X24_2	Propiconazole	-6.120	-8.162	-4.077	3	0.520	-7.141	-5.099	0.014
Cameroon	X26_7	Difenoconazole	-7.184	-9.227	-5.142	3	0.520	-8.206	-6.163	0.007
Cameroon	X26_7	Epoxiconazole	-6.487	-8.529	-4.444	3	0.520	-7.508	-5.466	0.011
Cameroon	X26_7	Propiconazole	-5.858	-7.900	-3.815	3	0.520	-6.879	-4.836	0.017
Costa Rica	ZentM1_1	Difenoconazole	0.767	-1.275	2.809	3	0.520	-0.254	1.788	1.702
Costa Rica	ZentM1_1	Epoxiconazole	0.278	-1.764	2.321	3	0.520	-0.743	1.299	1.213
Costa Rica	ZentM1_1	Propiconazole	1.575	-0.468	3.617	3	0.520	0.554	2.596	2.979
Costa Rica	ZentM1_2	Difenoconazole	-0.848	-2.891	1.194	3	0.520	-1.870	0.173	0.555
Costa Rica	ZentM1_2	Epoxiconazole	-1.206	-3.249	0.836	3	0.520	-2.227	-0.185	0.433
Costa Rica	ZentM1_2	Propiconazole	-1.561	-3.603	0.482	3	0.520	-2.582	-0.540	0.339
Costa Rica	ZentM2_2	Difenoconazole	0.577	-1.466	2.619	3	0.520	-0.445	1.598	1.491
Costa Rica	ZentM2_2	Epoxiconazole	0.078	-1.964	2.120	3	0.520	-0.943	1.099	1.055
Costa Rica	ZentM2_2	Propiconazole	0.321	-1.721	2.364	3	0.520	-0.700	1.343	1.250
Colombia	Zurrambay_1	Difenoconazole	-4.212	-6.254	-2.169	1	0.901	-5.981	-2.443	0.054
Colombia	Zurrambay_1	Epoxiconazole	-4.818	-6.860	-2.775	1	0.901	-6.586	-3.049	0.035
Colombia	Zurrambay_1	Propiconazole	-3.603	-5.645	-1.561	1	0.901	-5.372	-1.834	0.082
Colombia	Zurrambay_2	Difenoconazole	-5.990	-8.033	-3.948	1	0.901	-7.759	-4.222	0.016
Colombia	Zurrambay_2	Epoxiconazole	-4.760	-6.803	-2.718	1	0.901	-6.529	-2.991	0.037
Colombia	Zurrambay_2	Propiconazole	-4.597	-6.640	-2.555	1	0.901	-6.366	-2.829	0.041
Colombia	Zurrambay_3	Difenoconazole	-5.651	-7.694	-3.609	1	0.901	-7.420	-3.883	0.020
Colombia	Zurrambay_3	Epoxiconazole	-4.652	-6.694	-2.609	1	0.901	-6.421	-2.883	0.040
Colombia	Zurrambay_3	Propiconazole	-4.010	-6.052	-1.968	1	0.901	-5.779	-2.241	0.062
l	1	1	L	1	1		1	1	L	

Chapter 3

Table S2. Description of the *Pseudocercospora fijiensis* population EC_{50} values. Minimum, maximum, average and standard deviation per country and the percentage of the sensitivity trait are indicated. The sensitivity trait was characterized by arbitrary thresholds. Average EC_{50} values higher than 1 mg.L⁻¹were labelled "resistant", 0.1 to 0.99 mg.L⁻¹ "tolerant" and lower than 0.1 mg.L⁻¹ as "sensitive".

Fung	icide		Difen	oconazole			Epo	kiconazole			Prop	iconazole	
Country (Cycles DMI/total)	Resistance Categories*	Mini. Value	Max. Value	Average (SD)	Percentage	Mini. Value	Max. Value	Average (SD)	Percentage	Mini. Value	Max. Value	Average (SD)	Percentage
	S	0	0	0	0%	0	0	0	0%	0	0	0	0%
Costa Rica	т	0.526	0.894	0.725 (0.170)	1.87%	0.403	0.993	0.675 (0.235)	2.80%	0.339	0.339	0.339 (0)	0.94%
//56	R	1.491	20.925	6.172 (3.214)	98.13%	1.016	10.054	4.129 (2.186)	97.20%	1.172	18.414	5.814 (3.462)	99.07%
	s	0.005	0.080	0.02 (0.002)	15.31%	0.014	0.088	0.03 (0.022)	16.33%	0.016	0.082	0.038 (0.021)	13.27%
Colombia 7/32	т	0.123	0.940	0.538 (0.276)	13.27%	0.118	0.997	0.555 (0.240)	34.69%	0.235	0.983	0.670 (0.246)	17.35%
	R	1.121	10.418	4.571 (2.415)	71.43%	1.001	8.411	2.913 (1.926)	48.98%	1.079	13.653	3.806 (2.209)	69.39%
	s	0.004	0.096	0.011 (0.018)	36.96%	0.004	0.097	0.018 (0.02)	38.04%	0.005	0.052	0.017 (0.009)	33.70%
Cameroon 7/45	т	0.107	0.981	0.512 (0.196)	44.57%	0.107	0.975	0.460 (0.21)	50.00%	0.188	0.986	0.622 (0.222)	27.17%
	R	1.011	6.663	1.748 (1.272)	18.48%	1.026	3.904	1.452 (0.792)	11.96%	1.039	7.816	1.658 (1.094)	39.13%
Dominican	s	0.007	0.087	0.056 (0.03)	16%	0.012	0.09	0.045 (0.028)	20%	0.016	0.016	0.016 (0)	4%
Republic	т	0.16	0.541	0.452 (0.259)	40%	0.155	0.59	0.598 (0.295)	52%	0.179	0.994	0.507 (0.297)	44%
	R	1.048	2.863	1.691 (0.510)	44%	1.165	1.819	1.402 (0.218)	28%	1.037	3.321	1.720 (0.704)	52%
	s	0.004	0.084	0.026 (0.025)	29.7%	0.003	0.095	0.039 (0.029)	38.61%	0.004	0.086	0.027 (0.019)	24.75%
Ecuador 13/30	т	0.105	0.945	0.337 (0.196)	53.47%	0.106	0.964	0.367 (0.232)	52.48%	0.103	0.328	0.433 (241)	53.47%
	R	1.079	5.152	1.848 (0.917)	16.83%	1.132	5.63	2.455 (1.484)	8.91%	1.006	5.351	1.928 (1.088)	21.78%
Guadalupe 6/10	S	0.004	0.061	0.017 (0.013)	100%	0.005	0.083	0.020 (0.016)	100%	0.004	0.058	0.022 (0.015)	100%
(Low time	T	0	0	0	0%	0	0	0	0%	0	0	0	0%
exposure)	R	0	0	0	0%	0	0	0	0%	0	0	0	0%
Martinique 9/11	s	0.004	0.086	0.022 (0.02)	100%	0.004	0.099	0.03 (0.022)	100%	0.005	0.086	0.022 (0.016)	100%
(Low time		0	0	0	0%	0	0	0	0%	0	0	0	0%
exposure)	к	U	0	0.066	0%	U	0	0 011	U%	U	0	0.058	0%
	S	0.006	0.099	(0.043)	3.06%	0.011	0.011	(0)	1.02%	0.017	0.099	(0.041)	2.04%
Philippines 12/54	т	0.168	0.956	0.510 (0.214)	38.78%	0.11	0.986	0.435 (0.238)	44.90%	0.166	0.954	0.683 (0.178)	25.51%
	R	1.029	10.22	4.351 (2.702)	58.16%	1.083	8.544	3.823 (2.295)	54.08%	1.029	12.518	3.079 (2.114)	72.45%

*Resistance categories: S=Sensitive, T=Tolerant, R=Resistant

Table S3. Different genotypes based on the CYP51 protein sequences of *Pseudocercospora fijiensis* isolates. The genotypes numbers are ordered based on the number of mutations. Average DMI EC50 values higher than 1 mg.L-1 are indicated in red, from 0.1 to 0.99 mg.L-1 in yellow and lower than 0.1 mg.L-1 in green. Predicted resistant mutations and the different promoter insertion are mark with different colours.

	(u)	(II)	1	32	19	2	1	1	1	1	1	1	1	45	4	1	2	2	3	1	1
	g.L ⁻¹	Propiconazole	0.010	0.048	0.045	0.011	0.079	0.055	0.027	0.179	0.016	0.017	0.034	1.188	1.277	0.188	0.338	0.563	0.704	1.132	1.653
	EC ₅₀ value in mg	Epoxiconazole	0.007	0.024	0.016	600.0	*	*	0.035	0.053	0.012	0.011	*	0.62	0.666	0.058	0.107	0.114	0.318	0.536	0.599
	Average	Difenoconazole	0.004	0.022	0.014	0.007	¥	ĸ	0.072	0.087	0.007	0.006	*	0.798	0.637	0.055	0.107	0.391	0.547	0.576	1.12
		M7																			
		M6																			
	the PfCYP51	M5																			
	ons found in	M4																			
	Substituti	M3				V106D	V106D	V116L	1264T	A381G	R418G	A446S	A446S	D460V	D460V	G462D	G462D	Y463D	Y463D	Y463D	Y463N
		M2			V106D	A19E	Y58F	V106D	V106D	V106D	V106D	V106D	K171R	A313G							
		M1		V106D	T18I	T 18I	T 18I	T 18I	T 18I	T18I	T18I	T18I	V106D								
Demotor	alamant	TCGTACGA	1	1	1	1	1	1	1	1	1	1	1	3	4	1	2	1	3	4	3
	Conchine	aelinibe	G1^ (model C86)	G2	G3	G4	G5	G6	G7	G8	69	G10 (model Bo_1)	G11	G12	G13	G14	G15	G16	G17	G18	G19

	(u)	3	-	2	19	4	1	2	1	1	2	1	4	16	12	2	19	3	3	1	1	2
1g.L ⁻¹	Propiconazole	1.553	0.138	0.192	2.529	3.777	7.816	0.611	0.147	2.823	1.049	1.708	1.96	1.949	0.452	0.983	0.624	2.236	0.207	1.344	1.764	8.201
e EC ₅₀ value in m	Epoxiconazole	0.459	÷	*	1.337	2.32	3.904	0.172	*	1.132	*	1.365	1.401	1.423	0.19	0.589	0.24	0.759	¥	0.786	1.1	3.695
Averag	Difenoconazole	0.983	ŧ	*	3.466	5.744	6.663	0.304	*	1.376	*	1.306	2.371	2.02	0.289	0.94	0.252	1.478	¥	1.411	1.405	6.053
	M7																					
	MG																					
the PfCYP51	M5																					Y461D
ons found in	M4		G462A	Y463D	Y463D	Y463D	G462D	Y461N	Y461D	Y461D	Y463D	Y463D	Y463D	Y463D	Y463H	Y463H	Y463N	Y463N	Y463S	Y463S	Y463N	A313G
Substituti	M3	Y463N	A381G	Y136F	Y136F	Y136F	A313G	D460V	Y136F													
	M2	A313G	V106D	V106D	V106D	V106D	Y136F	V106D	A313G	V106D												
	M1	V106D	T18I	T18I	T18I	T18I	V106D	T18I	V106D	T18I												
Promoter	element TCGTACGA	4	1	3	4	9	4	1	1	8	1	4	5	9	1	3	1	8	1	9	3	4
	Genotype	G20	G21 (model Z4_16)	G22	G23	G24	G25	G26	G27	G28	G29	G30	G31	G32	G33	G34	G35	G36	G37	G38	G39	G40

	(L)	-	1	4	5	Ļ	2	1	1	1		.	2	1	ç	71	1	2	2	1	1	2	c	7
.L-1	Propiconazole	3.16	5.156	8.585	8.734	5.588	*	¥	2.783	3.874		6.299	4.644	2.804	1 15	0.01	5.069	4.828	0.605	2.804	1.228	3.309	7 7 7 T	1.714
je EC ₅₀ value in mg	Epoxiconazole	0.27	1.609	2.882	4.859	4.448	*	*	1.016	1.259		10.054	3.883	0.439	0.670	0.372	4.41	4.449	0.38	0.439	0.127	3.197	000 0	N.338
Averaç	Difenoconazole	*	4.187	8.535	13.181	7.91	*	*	3.202	0.691		7.787	3.129	0.51	174	0.74	6.042	9.219	0.652	0.51	0.22	5.508	0.045	C+0.0
	M7																						A MACAN	(1.0+1)ك
	M6																Y461D	Y463D	Y461D	Y461S	Y461N	Y461N	JUPPY	C0++A
the PfCYP51	M5	Y461D	Y463D	Y463D	Y463D	Y463S	Y463N	Y463N	Y463D	Y463H		Y463D	Y463N	Y461S	VAPAN	140 I N	A381G	A313G	A446S	A446S	D460E	D460E	O C F C F	D010H
ions found ir	M4	A381G	A313G	A313G	A313G	A313G	A381G	A381G	A381G	A381G		A381G	A381G	A446S	LIEDE		A313G	V260L	A313G	A313G	A446S	A446S	00011	
Substitut	M3	Y136F	Y136F	Y136F	Y136F	Y136F	Y136F	Y136F	Y136F	A313G		H380N	H380N	A313G	VAACO	C0++H	Y136F	Y136F	K171R	K171R	A313G	A313G	174L	טי וב
	M2	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D		V106D	V106D	V106D	00100	DCI CH	V106D	V106D	V106D	V106D	K171R	V106D	PAOL	I/ UM
	M1	T 181	T18I	T18I	T18I	T18I	T 18I	T 18I	T18I	T 18I		T18I	T 18I	T 18I	U100D		T 18I	T18I	T 18I	T 18I	V106D	T18I	T 401	1 101
Promoter	element TCGTACGA	9	3	4	6	5	3	5	9	1		g	9	1	Ţ	_	6	6	1	1	1	4		_
	Genotype	G41	G42	G43	G44 (model CaM10_6)	G45	G46	G47	G48	G49	G50	(model CaM10_21)	G51	G52	G53	(model M52_10)	G54	G55	G56	G57	G58	G59	G60	(model M52_10)

Substitution	Reference sequence	Position from start codon	Alternative m	utations found
T18I	ACA	53 bp	ATA	non
A19E	GCG	56 bp	G <mark>A</mark> G	non
Y58F	TAC	174 bp	TTC	non
170M	ATC	210 bp	ATG	non
D71E	GAC	213 bp	GA <mark>A</mark>	non
V106D	GTC	318 bp	G <mark>A</mark> C	non
V116L	GTC	348 bp	CTC	non
Y136F	TAC	408 bp	TTC	TTT
K171R	AAA	513 bp	AGA	non
V260L	GTC	780 bp	CTC	non
I264T	ATC	792 bp	A <mark>C</mark> C	non
A313G	GCT	939 bp	G <mark>G</mark> T	non
H380N	CAT	1140 bp	AAT	non
A381G	GCT	1143 bp	G <mark>G</mark> T	non
R418G	CGA	1254 bp	<mark>G</mark> GA	non
A446S	GCA	1338 bp	TCA	non
D460E	GAT	1380 bp	GA <mark>A</mark>	non
D460V	GAT	1380 bp	GTT	non
Y461D	TAC	1383 bp	GAC	non
Y461N	TAC	1383 bp	AAC	non
Y461S	TAC	1383 bp	T <mark>C</mark> C	non
Δ(Y461)	TAC	1383 bp		non
G462A	GGC	1386 bp	G <mark>C</mark> C	non
G462D	GGC	1386 bp	G <mark>A</mark> C	non
Y463D	TAT	1389 bp	GAT	non
Y463H	TAT	1389 bp	CAT	non
Y463N	TAT	1389 bp	AAT	non
Y463S	TAT	1389 bp	T <mark>C</mark> T	non

Table S4. Substitutions in the *Pseudocercospora fijiensis* CYP51 protein. The position of the reference codon, the reference sequence and the mutations in the *Pfcyp51* gene are indicated.

Position	Variant	Amino acid	Group	Charac	cteristic	Hydropho	bic Index*
FUSILION	valialit	Amino aciu	Group	pH2	pH7	pH2	pH7
T18	Wild type	Threonine	Neutral – polar side chain	Neutral	Neutral	13	13
118	Mutant	Isoleucine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	100	99
A19	Wild type	Alanine	Hydrophobic aliphatic	Hydrophobic	Hydrophobic	47	41
E19	Mutant	Glutamic acid	Acidic	Neutral	Hydrophilic	8	-31
Y58	Wild type	Tyrosine	Hydrophobic aromatic	Hydrophobic	Hydrophobic	49	63
F58	Mutant	Phenylalanine	Hydrophobic aromatic	Very Hydrophobic	Very Hydrophobic	92	100
170	Wild type	Isoleucine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	100	99
M70	Mutant	Methionine	Neutral – polar side chain	Very Hydrophobic	Very Hydrophobic	74	74
D71	Wild type	Aspartic Acid	Acidic	Neutral	Hydrophilic	-18	-55
E71	Mutant	Glutamic acid	Acidic	Neutral	Hydrophilic	8	-31
V106	Wild type	Valine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	79	76
D106	Mutant	Aspartic Acid	Acidic	Neutral	Hydrophilic	-18	-55
V116	Wild type	Valine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	79	76
L116	Mutant	Leucine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	100	97
Y136	Wild type	Tyrosine	Hydrophobic aromatic	Hydrophobic	Hydrophobic	49	63
F136	Mutant	Phenylalanine	Hydrophobic aromatic	Very Hydrophobic	Very Hydrophobic	92	100
K171	Wild type	Lysine	Basic	Hydrophilic	Hydrophilic	-37	-23
R171	Mutant	Arginine	Basic	Hydrophilic	Hydrophilic	-26	-14
V260	Wild type	Valine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	79	76
L260	Mutant	Leucine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	100	97
1264	Wild type	Isoleucine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	100	99
T264	Mutant	Threonine	Neutral – polar side chain	Neutral	Neutral	13	13
A313	Wild type	Alanine	Hydrophobic aliphatic	Hydrophobic	Hydrophobic	47	41
G313	Mutant	Glycine	Unique	Neutral	Neutral	0	0
H380	Wild type	Histidine	Basic	Hydrophobic	Neutral	-42	8
N380	Mutant	Asparagine	Neutral – polar side chain	Hydrophilic	Hydrophilic	-41	-28
A381	Wild type	Alanine	Hydrophobic aliphatic	Hydrophobic	Hydrophobic	47	41
G381	Mutant	Glycine	Unique	Neutral	Neutral	0	0
R418	Wild type	Arginine	Basic	Hydrophilic	Hydrophilic	-26	-14
G418	Mutant	Glycine	Unique	Neutral	Neutral	0	0
A446	Wild type	Alanine	Hydrophobic aliphatic	Hydrophobic	Hydrophobic	47	41
S446	Mutant	Serine	Neutral – polar side chain	Neutral	Neutral	-7	-5
D460	Wild type	Aspartic Acid	Acidic	Neutral	Hydrophilic	-18	-55
E460	Mutant	Glutamic acid	Acidic	Neutral	Hydrophilic	8	-31
V460	Mutant	Valine	Hydrophobic aliphatic	Very Hydrophobic	Very Hydrophobic	79	76
Y461	Wild type	Tyrosine	Hydrophobic aromatic	Hydrophobic	Hydrophobic	49	63
D461	Mutant	Aspartic Acid	Acidic	Neutral	Hydrophilic	-18	-55
N461	Mutant	Asparagine	Neutral – polar side chain	Hydrophilic	Hydrophilic	-41	-28
S461	Mutant	Serine	Neutral – polar side chain	Neutral	Neutral	-7	-5
Δ461	Mutant	non	non	non	non	non	Non
Y463	Wild type	Tyrosine	Hydrophobic aromatic	Hydrophobic	Hydrophobic	49	63
D463	Mutant	Aspartic Acid	Acidic	Neutral	Hydrophilic	-18	-55
N463	Mutant	Asparagine	Neutral – polar side chain	Hydrophilic	Hydrophilic	-41	-28
S463	Mutant	Serine	Neutral – polar side chain	Neutral	Neutral	-7	-5

Table S5. Characteristics of the amino acid changes in the enzyme 14α demethylase sequences of *Pseudocercospora fijiensis* isolates.

*pH2 values normalized from Sereda et al 1994 (Sereda *et al.* 1994), pH7 values from Monera et al 1995 (Monera *et al.* 1995).

Table S6. YASARA CYP51 hybrid models quality Z-scores. The score includes floppy terminal tails. Values close to +1 are consider optimal (in green), negative values close to 0 are consider good (in Blue) and values close to -1 are consider satisfactory (in yellow).

			ŀ	Hybrid moo	dels									
	C86	Bo_1	CaM10_21	Z14_16	M52_10	M52_22	CaM10_6							
Check type		Hybrid models Bo_1 CaM10_21 Z14_16 M52_10 M52_22 CaM Quality Z-score 0.305 0.429 0.129 0.156 0.268 0.4 5 0.116 -0.279 0.163 0.04 0.117 -0.4												
Dihedrals	0.427	0.305	0.429	0.129	0.156	0.268	0.416							
Packing 1D	-0.286	0.116	-0.279	0.163	0.04	0.117	-0.412							
Packing 3D	-1.087	-1.083	-1.268	-1.132	-1.21	-1.057	-1.287							
Overall	-0.555	-0.414	-0.636	-0.444	-0.524	-0.407	-0.699							

models. Distance in angstrom (Å) of the amino acid positions that are present closer than 7Å to the nearest propiconazole atom. Amino acid substitutions in this area are mark in orange. All resistant models have substitutions around positions 461 to 463 (outside the Table S7. Comparison of distances of propiconazole docking simulated experiments in different *Pseudocercospora fijiensis* CYP51 substrate binding site). The specific substitutions are indicated below the model name in parentheses.

Global	Distance Test with reference		100%		85.61%		83.41%		82.02%		81.80%		80.42%		76.95%
	526	S	4.05	S	4.40	S	4.24	S	3.81	R	8.13	S	4.24	S	3.79
	525	Ч	4.91	Ł	4.90	F	5.06	F	4.92	S	5.23	F	7.86	F	4.25
	524	٢	5.87	٢	8.21	٢	7.05	Γ	9.08	F	6.80	٢	8.41	٢	5.03
	523	٦	>7Å	٢	>7Å	٢	<i>>7</i> Å	٦	>7Å	L	4.92	L	<i>></i> 7Å	٢	<i>></i> 7Å
in 7Å)	387	-	5.74	٢	6.38	L	6.09	-	6.19	L	6.58	L	5.53	٦	6.23
ls with	386	-	7.04	-	7.27	-	7.03	-	7.40	-	7.63	-	7.25	-	5.63
no acid	385	s	4.85	S	5.18	S	5.26	S	5.11	S	5.39	S	4.94	S	4.69
(amir	384	т	3.85	н	4.50	т	4.15	т	4.16	н	4.23	т	4.10	т	3.82
ligand	383	-	1.85	-	1.33	-	1.40	-	1.70	-	1.90	-	1.69	-	1.83
azole	382	٩	2.48	Ч	3.03	٩	2.31	٩	2.72	Р	3.24	٩	2.41	٩	2.21
opicon	381	A	5.03	A	5.30	b	3.89	b	4.03	A	5.01	A	5.52	A	6.24
ith pr	380	т	4.80	Н	5.45	N	5.56	н	4.90	н	4.90	н	4.83	н	4.88
ons v	377	٢	3.13	٢	3.08	٢	3.51	٢	3.20	L	2.85	٢	3.76	٢	3.64
positi	321	Т	3.37	T	3.37	Т	3.32	Т	2.93	Т	2.68	Т	2.77	Т	3.08
CYP51	317	S	1.27	S	2.70	S	3.03	S	1.27	S	1.50	S	3.01	S	1.27
ocking	313	A	2.91	А	2.35	А	2.55	b	2.30	g	2.13	B	2.54	b	2.35
cted do	312	Σ	5.43	Σ	5.21	Σ	4.95	Σ	5.40	Σ	4.87	Σ	5.83	Σ	5.50
Predic	237	ч	6.65	F	15.0 3	F	7.64	F	13.5 5	F	9.31	F	8.53	F	5.32
	136	٢	6.28	Y	5.81	٢	5.95	٢	5.58	٢	5.90	٢	5.82	Ч	6.53
	130	F	6.27	Ł	5.34	F	5.64	F	5.46	F	5.48	F	6.12	F	6.35
	125	L	4.73	Γ	8.19	Γ	8.29	L	7.36	L	5.44	L	8.05	Γ	5.54
	122	۲	5.40	Y	6.53	٢	6.24	٢	6.11	Υ	5.33	٢	4.57	٢	4.10
	Model/Po sition	Amino acid	C86 reference	Amino acid	Bo_1	Amino acid	CaM10_21 (Y463D)	Amino acid	Z4_16 (G462A)	Amino acid	M52_10 (ΔY461)	Amino acid	M52_22 (Y461N)	Amino acid	CaM10_6 (Y463D)

Table S8. Table with the information of the Pseudocercospora fijiensis CYP51 substitutions and Pfcyp51 promoter sequences, including
he number of palindromic sequences present, per isolates, DMI fungicides (difenoconazole, epoxiconazole and propiconazole) and country
vith their respective EC ₃₀ mean values. The online file will include the aligned sequence of the Pfcyp51 gene and promoter of each
equenced isolate. (Excel file).

ropi.		2.993	0.831	0.755	0.016	0.027	0.021	0.051	0.034	0.032	0.288	5.839	1.145	3.181	0.442	1,227	2.095	3.263	10.26	1.079	2.227
xi. P		78 2	37 (69	15 (15 (15 (18 (16 (25 (49 (60	90	2	18 (8 4	48 2	91 8	48 >	18	35
Epé		11	0.6	0.4	0:0	0.0	0.0	0.0	0:0	0.0	0.1	5.4	17	2	0.1	2]	2.1	4.1	5.2	1.0	0.6
Difen		5.936	0.887	0.332	600.0	0.011	0.006	0.015	0.013	0.014	0.235	7.468	3.038	5.694	0.123	6.407	3.139	5.031	>10.24	2.602	2.769
Y463		Y463D	Y463D	Y463D								Y463D	Y463D	Y463D	Y463H	Y463D	Y463D		Y463D	Y463D	Y463D
G462																					
Y461											Y461N							Y461D			
D460																					
A446																					
R418G																					
A381																					
H380																					
A313											A313G	A313G	A313G		A313G			A313G			
1264																					
V260																					
K171																					
Y136		Y136F	Y136F	Y136F										Y136F		Y136F	Y136F	Y136F	Y136F	Y136F	Y136F
V116																					
V106		V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D
D71																					
0/1																					
Y58																					
A19					A19E																
T18		T18I	T18I	T18I	T181	T181	T181	T181	T181	T181	T181	T18I	T181	T181	T18I	T18I	T18I	T181	T181	T18I	T18I
TCGTACGA		4	4	4	-	-	-	-	-	-	-	9	6	4	t	4	4	4	4	4	4
Isolate		Almendros_2	Almendros_3	Almendros_4	Bejuquillo_1	Bejuquillo_2	Bejuquillo_4	Bejuquillo_5	Bejuquillo_6	Bejuquillo_7	Bonita_2	Caribe_1	Caribe_2	Caribe_3	C080910	Esmeral1	Esmeral_3	Espe4	Estadero_1	Estadero_2	Estadero_3
c	OMBIA	-	2	3	4	5	9	7		6	10	11	12	13	14	15	16	17	18	19	20
z	COL	-	2	3	4	2	9	7	~	6	10	1	12	13	14	15	16	17	18	19	20

		0.01	0.776	2.287
Epoxi, 0589 0589 0801 1111 1111 0589 059 059 059 050 050 052 052 1259 0534 0534 0534 0535 0535 0536 0536 0535 0536 0535 0536 0536	0.266	0.011	0.177	0.435
Difen. 094 449 2745 2745 1578 1578 1578 4405 4005 4005 1563 4005 1563 4566 0163 1466 1466 1466 1466 1466 1466 1466 1	0364	90010	0.328	050
Y4630 Y4630 Y4630 Y4630 Y4630 Y4630 Y4630 Y4630 Y4630 Y4630				
IBAY NIBAY NIBAY NIBAY NIBAY NIBAY	Y461N		Y481N	Δ(Y481)
D460 D460	D460E		D460E	
AM65 AM85 AM85 AM85 AM85 AM85 AM85 AM85 AM8	A446S	A446S	A446S	A446S
K4180				
4381 Yashi Y				
A3136 A3136 A3136 A3136 A3136 A3136 A3136 A3136 A3136 A3136 A3136	A313G		A313G	A313G
<u>3</u>				
3617 3627 3627 <td></td> <td></td> <td></td> <td></td>				
M06 00000 <td>V106D</td> <td>V106D</td> <td>V106D</td> <td>V106D</td>	V106D	V106D	V106D	V106D
				D71E
	+			MOTI
	+			\vdash
113 1	+	T181		T181
000 100 m m m m m m m m m m m m m m m m		-	-	-
	1 8		-	
International in	B1(1	80.	M52_	M52_
	2 D	6	9 15	6

Propi.	0.614	1.029	0.863	0.67	1.14	3.905	0.612	1.345	2.804	1.228	0.595	2.264	8.791	>10.24	8.379	>10.24	1.708	0.54		0.011	0.015	0.011	0.03	0.013	0.01	2823
Epoxi.	0.149	0.194	2.393	0.336	0.242	0.841	0.69	0.807	0.439	0.127	0.125	1.849	2436	>10.24	3.328	>10.24	1.365	0.423		0.008	0.008	0000	0.04	0.008	0.006	1.132
Difen.	0.237	0.168	2.804	0.523	0.386	0.521	0.764	1.806	0.51	0.22	0.093	5.528	10.035	>10.24	7.035	>10.24	1.305	0.781		0.005	0.005	0.007	<0.004	0.006	<0.004	1.376
Y463			Y463D										Y463D	Y463D	Y463D	Y463D	Y463D									
G462																										
Y461	Y461S	Y461N		Y461D	Δ(Y481)	Y461N	Y461N	Y461N	Y461S	Y461N	Y461N	Y461N						Y461D								Y461D
D460		D460E				D460E	D460E	D460E		D460E	D460E	D460E														
A446	A446S	A446S		A446S	A465	A446S	A465	A446S	A465	A446S	A446S	A446S						A446S								
R418G																										
A381																										
H380																										
A313	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A313G								A313G
1264																										
V260																										
K171				K171R					K171R	K171R								K171R								
Y136													Y138F	Y138F	Y138F	Y130F										
V116																										
V106	V106D	V106D	U106D	0901A	V106D	V106D	V106D	V106D	V106D	V106D	U106D	V106D	V106D	V106D	0901A	V106D	V106D	V106D		V106D	V106D	0901A	V106D	V106D	V106D	V106D
D71					D71E																					
0/1					W0/JI																					
Y58																										
A19																						A19E				
T18	T18I		T18I	1181	T18I				T18I			T18I	T18I	T18I	1181	T18I	T18I	T18I		T18I	T181	T181	T18I	T181	T18I	T181
TCGTACGA	÷	ł	4	-	-	-	t	t	÷	t	t	4	4	4	4	-	4	ţ		t	÷	ţ	t	÷	t	3
Isolate	M52_4	M52_6	M52_7	e_SM	M52_10	M52_12	M52_14	N52_22	N52_23	M52_24	N52_25	152_1	T52_2	T52_4	T52_22	6,22T	U22_1	U22_3		E.22	EC_1	EC.5	ENB_1	ENB_52	6_V/9	GND_18
c	17	18	19	20	21	22	23	24	25	26	27	28	62	30	31	32	8	34	DOR	+	2	3	4	5	9	7
Z	51	52	8	3	8	85	25	8	8	99	61	62	8	64	66	99	29	89	ECUA	8	54	99	99	29	89	69

Global anal	ysis of	the	sensitivity	to	azoles
-------------	---------	-----	-------------	----	--------

Propi.	5,351	ć	0.103	0.161	0.271	0.485	0.458	020	0.261	1.006	0.192	0.353	0.69	0.356	0.278	1.374	1.02	199	0.32	3.16	2.08	0.945	2.942	2.761	0.271
Epoxi.	1.589	ć	0.07	0.069	0.119	ć	ć	0.111	0.144	0.413	0.05	0.193	ć	0.135	780'0	0.286	0.964	ć	¢.	ć	¢.	0.541	0.921	0.942	¢.
Difen.	2.709	ć	0.062	0.114	0.179	ć	ć	0.205	0.232	0.808	0.05	0.387	ć	0.386	0.194	0.85	0.633	ć	¢.	ć	ć	0.323	1.301	2.324	ć
Y463	Y463H	Y463H	Y463N	Y463H	Y463H	Y463N	Y463N	Y463N	Y463N	Y463N	Y463N	Y463N	Y463N	Y463N	Y463H	Y463H	Y463N	Y463D	Y463N	Y463N	Y463N	Y463H	Y463N	Y463N	Y463H
G462																									
Y461																									
D460																									
A446																									
R418G																									
A381																									
H380																									
A313	A313G	A313G	A313G	A3136	A3136	A313G	A313G	A313G	A3136	A3136	A313G	A3136	A313G	A313G	A3136	A313G	A3136	A3136	A313G	A313G	A313G	A3136	A313G	A313G	A313G
1264																									
V260																									
K171																									
Y136																									
V116																									
V106	V106D	V106D	V106D	0901A	V106D	V106D	V106D	V106D	0901-A	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D
D71																									
0/1																									
Y58																									
A19																									
T18	1181	1811	1181	1181	1181	1811	1181	1181	1811	1181	1811	1181	1811	1181	1811	1181	1181	1481	1181	1811	1181	1811	1181	1181	181
TCGTACGA	3	÷	t	ţ	-	-	t	-	ţ	e	-	-	-	-	-	ţ	-	-	-	-	-	-	3	3	÷
Isolate	GNP_3	6C8_17	GCMA_4	6CMS_7	6CS8_13	63_4	GS_10	Gsa_13	638_5	C88_7	638_11	GSN_1	OCNL5	0CNL6	0CNL11	OCNL12	6 TWNO	ONP_20	ONS_1	CNS_5	0SSR_24	0SSR_51	RCOS_3	RCQS_16	RN.3
c	~	6	10	Ŧ	12	13	14	15	16	17	8	6	20	21	22	23	54	25	58	27	23	53	90	31	32
z	70	11	72	73	74	75	9/	11	78	6/	8	8	82	8	25	8	8	28	8	8	8	5	92	8	2

Propi.	0.404	0.103	0.086	1.036	0.527	0.527	0.147	0.251		5,668	3.464	4,644	6.191	1931	4.063	4.13	8.328	2.783	2.164	5.069	****	5,609	6299	2.801	1.323
Epoxi.	ć	ć	0.02	0.626	0.141	0.159	ć	ć		2.859	3.722	3.883	5.176	4.44	4.205	5.094	3.84	1.016	4.871	441	6.298	2321		1.651	1.051
Difen.	ć	ć	0.036	0.375	0.259	0.268	¢.	ė		4.088	5.384	3.129	13.054	2.788	8.082	4.977	18.741	3.202	7.126	6.042	20.925	6.014	7.787	2.658	1.599
Y463	Y483H	Y463N		Y483N	Y463N	Y463N		Y463N		Y483D	Y463D	Y463N	Y463D	Y463N	Y483D	Y463D	Y483D	Y483D			Y463D	Y463D	Y463D	Y463D	Y483D
G462																									
Y461							Y481D												Y481D	Y461D					
D460																									
A446																									
R418G																									
A381												A381G		A381G				A381G	A381G	A381G			A381G		
H380												H380N		H380N									H380N		
A313	A313G	A313G		A313G	A313G	A313G	A313G	A313G		A313G	A313G		A313G		A313G	A313G	A313G			A313G	A313G			A313G	A313G
1264																									
V260											V260L		V260L												
K171																									
Y136										Y138F	Y138F		Y138F		Y138F	Y138F	Y138F	Y138F	Y138F	Y138F	Y138F	Y138F			
V116																									
V106	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D		V106D	V106D	V106D	V106D	V106D	V106D	V106D									
D71																									
0/1																									
Y58																									
A19																									
T18	T18I	1181	T18I	1181	1181	T18I	T18I	1181		1181	1181	1181	1181	T18I	1181	1181	1181	T18I	T18I	T18I	T18I	1181	1181	T18I	1181
TCGTACGA	÷	-	-	-	-	-	-	-		9	9	9	9	9	9	9	9	9	9	9	9	9	9	5	5
Isolate	RN_5	RS_13	RSaB_6	RSS8_16	RISSB_22	9 TNSSH	SaR.2	SaRJS		CaM1_2	CaM1_3	CaM1_4	CaM1_5	CaM1_8	CaN2_2	CaM2_3	CaMB_1	CaMB_3	CaMF_10	CaM7_19	CaM10_6	CaM10_16	CaM10_21	SPN2_1	SPN2_2
c	8	34	35	8	37	38	30	40	TA RICA	-	2	3	4	5	9	7		6	10	11	12	13	14	15	16
z	35	8	26	8	8	100	101	102	COS	103	104	105	106	107	108	109	110	111	112	113	114	115	116	111	118

poxi. Propi.	1.502 1.755	4.448 5.588	1609 5.156		0.433 0.539	0.433 0.399 0.27 3.16	0433 0399 027 316 1255 2776	0433 0339 027 316 1255 2776 ? 275	0433 0439 027 316 1255 2776 7 275 3388 3571	0433 0439 027 346 1255 2776 7 275 3856 3571 3856 3571	0480 0280 027 028 1258 0278 338 357 3385 357 7 0241	043 026 027 216 125 276 7 223 136 351 7 024 7 024	043 0286 027 246 1258 2276 7 253 1581 7 0241 7 0241 7 071 7 071	0430 0336 227 316 1436 2376 338 3471 7 0.341 7 0.341 7 0.341 7 0.325	043 026 027 216 128 2.76 7 2.75 3.61 7 0.61 7 0.61 7 0.68 7 0.68	043 0336 027 346 123 2.776 134 2.776 134 2.776 134 2.776 134 2.776 134 2.776 134 2.776 134 2.776 134 2.776 134 2.776 134 2.776 134 2.776 134 2.776 135 2.776 135 0.014 135 0.014 135 0.014 135 0.014	0450 0256 027 316 128 2.776 128 3.61 129 2.776 129 2.61 7 0.61 7 0.61 7 0.61 7 0.61 7 0.61 7 0.61 7 0.61 7 0.61 7 0.61 7 0.61 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62 7 0.62	0403 0304 027 3.49 123 2.776 234 2.776 234 2.776 234 2.776 234 2.776 234 2.776 234 2.776 234 2.776 23 0.614 27 0.022 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 29 0.026 20 0.046	045 0306 027 346 123 2.776 134 3.571 135 3.571 135 3.571 135 3.571 135 3.571 135 3.571 135 3.571 135 3.571 135 0.641 135 0.641 135 0.641 135 0.641 135 0.642 135 0.642 135 0.643 14 0.644 15 0.644	043 0336 027 316 1235 2736 235 2531 235 2531 235 2531 235 2531 235 2341 235 2341 235 2341 235 2341 235 0341 23 0341 23 0341 23 0341 23 0341 24 0345 25 0345 26 0345 27 0345 28 0346 29 0345 29 0345 29 0345 29 0345 29 0345 29 0345 29 0345 29 0345 29 0345 29 0345	047 028 027 236 128 237 238 237 238 237 238 231 238 231 239 231 239 231 230 231 231 232 231 232 231 234 232 234 233 234 23 234 23 044 23 046 23 046 24 046 25 046 26 046 27 056 28 046	047 020 027 2176 128 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1385 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395 2176 1395	645 0396 027 316 123 3171 318 3171	040 0306 027 0346 128 2776 128 2576 238 3511 238 3511 239 0511 29 0511 29 0511 29 0512 29 0516 29 0516 29 0516 29 0516 29 0516 29 0516 29 0516 29 0516 29 0516 29 0516 29 0516 29 0516 29 0516 20 0516 20 0516 20 0516 20 0516 20 0516 20 0516 20 0516 20 0511	0450 0206 027 2376 1285 2376 2385 2371 2385 2576 239 0111 27 0264 29 0114 29 0114 21 0106 21 0106 21 0114 21 0114 21 0114 21 0114 22 0205 23 0114 23 0114 24 0114 25 0114 26 0114 27 0217 28 0114 29 0214 2005 0214 2005 0214 2005 0214 2005 0214 2005 0214 2005 0214 2005 0214 2005 0214 2005 0214
2855	i	7.91	4,187	0.555	ć	5.613	ć	5.604	ć	ć	ć	ć	ć	ć	ć	ć	ć		0.16	0.24	0.087	0.007	2117	0.291	1.837
	r483D	Y483S	r483D	r483D	r483D	r483D	r483D	<u>483D</u>	14835	r483H	1483D		483D	14835	1483D	r4835			Y483N	K483H			<u> 1483D</u>	r483H	r483D
												G482A													
140																									
U400																									
A446																									
R418G																						R418G			
A381					A381G							A381G									A381G				
H380																									
A313	A313G	A313G	A3136	A3136					A3136	A313G	A313G			A313G		A313G			A3136	A313G			A313G	A313G	A3136
1264																									
V260																									
K171																									
Y136		Y136F	Y136F		Y136F	Y136F	Y136F	Y136F					Y136F		Y136F										
V116																									
V106	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D		V106D	V106D	V106D	V106D	V106D	V106D	V106D
D71																									
021																									
Y58																									
A19																									
T18	T18I	1181	1181	1181	1181	T18I	1181	1181	T18I	1181	T18I	1181	1181	1181	1181	1181	T18I		T18I	1181	T18I	T18I	T18I	T18I	1181
TCGTACGA	s	s	3	s	3	8	Ŷ	9	-	-	-	-	3	-	3	-	-		-	-	-	-	9	-	9
Isolate	SPA12_3	1_BMB_1	\$PM7_1	Zent1_2	Cal_S	Ca5_16	Ca6_11	Ca10_13	Z4_7	24_11	24_14	Z4_16	28_12	28_17	28_18	ZTSC_77	ZTSC_79	REPUBLIC	A7	84	A10	A12	A13	A14	A15
-	12	18	19	20	21	22	23	24	25	92	27	28	23	30	31	32	8	INICAN	+	2	3	4	5	9	7
z	119	120	121	122	123	124	125	126	127	128	129	130	131	132	133	134	135	DOM	136	137	138	139	140	141	142

Propi.	0.197	0,886	1.322	1037	1475	1.133	ذ	ć	ė	ć	ė	3.004	1.344	3.321	1,626	08.0		0.015	0.02	0.027	0.008	0.013		0.027	0.026	0.012
Epoxi.	0.028	0.983	0.841	0,653	1211	0.687	ć	ć	ć	ć	ć		0.786	1.288		0.567		0.025	0.029	0.035	0.008	0.005		0.011	0.012	0.018
Difen.	0.079	1.048	1050	0.518	1201	0.893	ć	ć	ė	ć	ė	2.863	1171	1,617	2.181	0.578		0.043	0.029	0.072	0.005	0.005		0.005	0.012	0.02
Y463	Y4835	Y483D	Y483N	Y483N	Y483D	Y4835	Y483D	Y463D	Y483D																	
G462																										
Y461																										
D460																										
A446																										
R418G																										
A381										A381G	A381G															
H380																										
A313	A313G			A313G	A3136	A313G	A313G	A313G																		
1264																				1264T						
V260																										
K171																										
Y136										Y136F	Y136F															
V116																										
V106	V106D	V106D	V106D	V106D	0901A	V106D		V106D	V106D	V106D	V106D	V106D		V106D	V106D	V106D										
D71																										
021																										
9 Y56																										
T18 A ⁻	1181	1181	1181	1811	1181	1181	T18I	1181	1181	T18I	1811	1181	T18I	1181	1181	1181		1811	1181	1181	T18I	1181		1811	1181	T18I
ACGA	-	-	8	\$	5	5	5	-	5	5		5	5		-	6					-	~				Ŧ
TCGI	-								_	-*			_*			_										
Isolate	Dom 001	Dom 002	Dom 003	Dom 006	Dom 007	Dom 009	Dom 014	Dom 016	Dom 029	Dom 036	Dom 037	10	03	8	3	8		Ma_26_2	Ma_26_16	Ma_26_18	Ma_26_30	Ma_26_32		GW_33	GW_35	GW_36
-		6	10	÷	12	13	41	15	16	17	18	19	20	21	22	23	TINIQUE	1	2	3	4	5	DALUPE	-	2	3
z	143	14	145	146	147	148	149	150	151	152	153	5	155	156	157	158	MAR	159	160	161	162	163	GUA	164	165	166

Propi.		¢.	0.338	1.795	1091	0.011	1,983	ė	0.41	945'0	0.413	ć	1.308	0.468	ć	0.019	0.394	0.042	1061	90010	0.743	0.618	0.188	0.891	2.347	0.713	1.327
Epoxi.		ċ	0.107	1.048	0.661	000	0.729	ć	0.108	0.427	0.108	ė	1.155	0.183	ć	0.017	0.149	0.015	0.661	0.004	0.131	0.336	0.058	0.543	1.026	0.338	0.461
Difen.		¢.	0.107	1.695	0.715	0.005	1958	ć	96010	0.622	0.096	e.	11917	0.196	¢	0.011	0.199	0.01	0.715	40.004	0.55	0.37	0.055	0.614	1.353	0.504	0.67
Y463		Y463D						Y463N													Y463D						
G462			G462D																				G462D				
Y461																											
D460				D460V	D460V		D460V		D460V	D460V	D460V		D460V	D460V	D460V		D460V		D460V			D460V		D460V	D460V	D460V	D460V
A446																											
R418G																											
A381																											
H380																											
A313		A313G	A313G	A313G	A313G		A313G	A313G	A313G	A313G	A313G		A313G	A313G	A313G		A313G		A313G		A313G	A313G	A313G	A313G	A313G	A313G	A313G
1264																											
V260																											
K171																											
Y136																											
V116																											
V106		V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	0901A	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D
D71																											
0/1																											
Y58																											
18 A19																											
DGA T)																											
TCGTAC		6	2		4	-		7		8		~			"	-		-	3	-	*	3	-	~	3	8	3
Isolate		POS_7	6_209	POS_14	POS_18b	P05_22b	POS_29	P05_45	POS_53	POS_54	POS_58b	POS_63	POS_72	POS_76a	POS_76b	POS_84b	POS_7(a)	P05_16	P05_18	P05_22a	POS_59a	POS_84a	POS_91	P25_7	P2S_14	P25_16	P25_19
-	ROON	-	2		4	5	9	7		6	ę	÷	12	13	4	15	16	11	18	19	20	21	22	23	24	25	92
z	CAME	167	<u>8</u>	169	5	5	172	173	174	175	176	Ê	178	179	<u>8</u>	181	182	ŝ	184	ŝî	<u>8</u>	187	\$	189	6	191	192

Propi.	1.245	1.509	0.772	1.154	0.986	1.039	1.653	1.204	0.687	1.382	ć	0.72	1.992	0.657	1.164	19	0.532	0.789	2.194	1.737	1.596	1.814	0.809	1.144	138	1,764	1.501
Epoxi.	0.921	0.304	0.306	0.417	0.288	0.491	0.599	0.589	0.337	1.184	ć	0.299	1.354	0.194	0.743	0.627	0.297	0.337		1.223	0.614	1.055	0.975	0.843	0.48		0.531
Difen.	0.687	0.775	0.317	0.637	0.553	0.715	1.12	0.537	0.491	1.519	ć	0.602	0.383	0.248	1.094	767.0	0.325	0.567	2.041	1.011	1.19	1.187	1.141	0.933	0.584	1.405	0.542
Y463		Y483N					Y463N		Y483D			Y483D									Y483N					Y483N	
G462																											
Y461																											
D460	D460V		D460V	D460V	D460V	D460V		D460V		D460V	D460V		D460V	D460V	D460V	D460V	D460V	D460V	D460V	D460V		D460V	D460V	D460V	D460V	D460V	D460V
A446																											
R418G																											
A381																											
H380																											
A313	A313G	A313G	A313G	A313G	A313G	A313G	A313G	A3136	A313G	A313G	A313G																
1264																											
V260																											
K171																											
Y136																											
V116																											
V106	V106D	0106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D														
D71																											
021																											
Y58																											
A19																											
T18																											
TCGTACGA	-	-	3	3		3	3	3	3	3	3	3	3	3	3	3	3	3	3	3	-	3	3	3	7	3	3
Isolate	P25_20	P25_24	P25_25	P25_31	P25_37	P25_40	P25_41	P25_42	P2S_44	P25_47	P25_58	P25_62	P25_64	P25_68	P25_78	67_259	P25_81	X_229	P45_1	P45_5	P45_7a	92 ⁻ 249	P45_13	P45_16	P45_19	P45_22	P45_24
c	27	28	52	30	31	32	33	35	35	8	37	8	30	40	41	42	43	44	45	46	47	48	49	50	51	52	53
z	193	194	195	196	197	198	199	200	201	202	203	204	205	206	207	208	209	210	211	212	213	214	215	216	217	218	219

Global anal	ysis of	the	sensitivity	to	azoles
-------------	---------	-----	-------------	----	--------

Propi.	1.047	ċ	1.286	0.542	1.348	0.382	1111	0.656	1.132	¥60'1	1001	7,816	1,356	1.358	1,734	\$77.1	0.011	60010	0.012	0.014	0.013	0.016	0.016	0.015	0.014	0.012	0.016
Epoxi.	0.427	ć	0.86	0.345	0.463	26010	0.332	0.403	0.536	0.483	0,603	3.904	1297	0.52	0,464	0.706	0.008	900/0	0.007	0.01	60010	0.007	0.011	0.015	60010	1010	60010
Difen.	0.48	ć	0.981	0.454	0.549	0.231	0.374	0.348	0.576	0.489	0.562	6.663	1.25	0.672	1908	1.264	0.005	0.005	0.004	0.005	0.007	0.006	0.006	0.005	0.005	0.005	0.005
Y463						Y463D			Y483D																		
G462		G462D										G462D															
Y461																											
D460	D460V		D460V	D460V	D460V		D460V	D460V		D460V	D460V		D460V	D460V	D460V	D460V											
A446																											
R418G																											
A381																											
H380																											
A313	A313G	A313G	A313G	A313G	A313G	A313G	A313G																				
1264																											
V260																											
K171																											
Y136												Y138F															
V116																											
V106	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D									
D71																											
0/1																											
Y58																											
A19																											
T18																											
TCGTACGA	3	2	3	3	8	-	3	3	7	3	4	4	8	3	3	3	-	-	-	-	-	÷	-	-	-	-	-
Isolate	P45_28	62_284	542_33	P45_38	P45_42	P45_47	P45_51	P45_53	P45_58	P45_60a	P45_60b	P4S_64	P45_65	P45_72	P45_78	P45_81	X02_04	X03_02	X04_02	X04_05	X05_03	X05_05	X07_02	10_01X	X08_02	X13_03	X14_03
c	35	8	8	57	8	\$	8	61	62	83	z	8	8	29	89	69	70	14	72	73	74	75	76	11	78	62	8
z	220	224	222	223	224	225	226	227	228	229	230	231	232	233	234	235	236	237	238	239	240	241	242	243	244	245	246

Propi.	0.012	0.028	0.017	0.052	0.02	0.021	0.017	0.01	0.016	0.005	0.013	0.023	0.014	0.017		0.079	0.055	0.034	0.053	0.06	0.01
Epoxi.	0.009	0.025	0.013	0.033	0.017	0.01	0.01	0.008	0.011	0.005	0.007	0.018	0.01	0.011		ė	ė	ė	ć	ė	0.007
Difen.	0.005	0.007	0.006	0.01	0.007	0.007	0.006	0.005	0.006	0.005	0.005	0.007	0.006	0.007		ć	ć	ć	ć	ć	0.004
Y463																					
G462																					
Y461																					
D460																					
A446																		A446S			
R418G																					
A381																					
H380																					
A313																					
1264																					
V260																					
K171																		K171R			
Y136																					
V116																	V116L				
V106	V106D		V106D	V106D	V106D	V106D	V106D														
D71																					
021																					
Y58																Y58F					
A19																					
T18																T181	T181				
TCGTACGA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	SOLATES	-	-	-	-	-	-
Isolate	X14_04	X14_05	X16_01	X16_03	X18_05	X18_07	X18_08	X18_10	X19_01	X19_03	X23_02	X23_03	X24_02	X26_07	SENSITIVE I	X845 (Indonesia)	X846 (Philippines)	X847 (Taiwan)	(849 (Burundi)	(851 (Gabon)	C_86*
-	81	82	83	8	85	98	87	88	8	06	91	92	93	55	IDUAL	-	2	3	4 >	5	9
N	247	248	249	250	251	252	253	254	255	256	257	258	259	260	NON	261	262	263	264	265	266

*Reference Isolate CIRAD86, Isolates in blue were used for PfCYP51 in silico modelling



Figure S1. A. Banana plant infected with *Pseudocercospora. fijiensis* in a greenhouse experiment. The plant shows the typical symptom of the disease, elliptical necrotic lesions with water-soaked border and a chlorotic yellow halo. B. Symptoms of naturally infected banana plants in the field.



Figure S2. Plots of the Finlay-Wilkinson model (FW) describing the interaction between the three fungicides (model: $y_{ijk} =$ Fungicide_i + b_j x Isolate_j + ε_{ijk} or $y_{ijk} =$ Isolate_i + b_j x Fungicide_j + ε_{ijk} .) in 592 isolates of *Pseudocercospora fijiensis*. A) Individual strains ²Log EC₅₀ raw data (3 repeats) of the three DMI. B) Fitted ²Log EC₅₀ mean data. Sensitive and resistant threshold are show in blue and red dashes lines, respectively. Indicated in black dots are the isolates of which the *Pfcyp51* gene is sequenced. General difference between fungicides exist where isolates reacts proportionally by the EC₅₀. Nonetheless the main effects of isolate still describe nearly 92% of the variation in EC₅₀ found.



Figure S3. Plot of the ²Log mean EC_{50} values distribution of the frequency of all *Pseudocercospora fijiensis* isolates and their interaction with each DMI fungicide: A) difenoconazole, B) epoxiconazole and C) propiconazole. The thresholds grouping criteria is coloured green for sensitivity, yellow for tolerance and red for resistance.



Figure S4. Calculated EC_{50} means of the tested *Pseudocercospora fijiensis* isolates with fungicide concentration up to 40.96 mg.L⁻¹. The dashed line represents the threshold value (1 mg.L⁻¹) for DMI resistant isolates.



Figure S5. Predicted interaction of propiconazole in the binding site of *Pseudocercospora fijiensis* CYP51. Amino acid residues in the active site are shown in green. The heme group's carbon atoms are depicted in magenta and the propiconazole carbon atoms are shown in cyan. Hydrogen atoms are coloured in light grey, oxygen in red and nitrogen in blue. The iron atom is also depicted in magenta in the heme group. Interaction forces are shown in blue (cation- π), pink or red ($\pi - \pi$) lines.







Chapter 4

A new resistance mechanism to DMI fungicides in the fungal banana black Sigatoka pathogen *Pseudocercospora fijiensis* is driven by increased expression of *Pfcyp51* through multiple promoter repeats

Caucasella Diaz-Trujillo[†], Pablo Chong[†], Viviane Cordovez, Mauricio Guzmán, Pierre J.G.M. De Wit Ioannis Stergiopoulos, Harold J. G. Meijer, Rafael E. Arango Isaza, Gabriel Scalliet, Helge Sierotzki, Esther Lilia Peralta and Gerrit H. J. Kema.

Summary

Black Sigatoka is one of the most important disease in bananas and plantains and the most relevant economically. Black Sigatoka is caused by the dothideomycete fungus Pseudocercospora fijiensis, previously known as Mycosphaerella fijiensis. Disease control is mainly obtained through the application of fungicides, including the lanosterol demethylationinhibitors (DMIs). The continued use of DMI has triggered the appearance of novel genotypes, displaying reduced sensitivity to this class of fungicides. So far the phenotype of these isolates was found to be linked to the presence of non-synonymous point mutations in the target gene encoding the lanosterol 14 α -demethylase enzyme (*Pfcyp51*). In this study, we identify a 19 base pairs (bp) repeat element in the promoter region (103 bp upstream the coding region) of the *Pfcyp51* gene, whose copy number correlates positively with increased resistance to DMIs. A PCR-based assay was developed to characterize four field populations of P. fijiensis in Costa Rica for the presence and copy numbers of repeated elements within the *Pfcyp51* promoter. Additionally, functional analyses - including promoter swapping - showed that the presence of the repeat element proportionally upregulates *Pfcyp51* expression which consequently decreases sensitivity to the DMIs in vivo. This study provides important information on the genetic mechanisms that confer reduced sensitivity to azole fungicides and might offer a tool for optimizing the use of azoles in disease management of black Sigatoka.

Introduction

Black Sigatoka, caused by the ascomycete *Pseudocercospora fijiensis* (Morelet) Deighton (1976), (synonym, *Mycosphaerella fijiensis* Morelet (1969)), is one of the most devastating and economically significant diseases for export bananas and plantains. Disease management of black Sigatoka is mainly based on the application of fungicides, in which single-sites plays an important role. However, the high level of sexual reproduction of this fungus favours the generation and maintenance of highly diverse populations with a broad base-line sensitivity towards fungicides (Arango Isaza et al., 2016; Conde-Ferráez et al., 2007; Hayden and Carlier, 2003; Rivas et al., 2004; Romero and Sutton, 1997). As a result, fungicide resistance develops frequently and spreads rapidly, particularly when pathogen populations are under strong selection pressure (Arango *et al.* 2016; Ware *et al.* 2006). This situation has contributed to a dramatic increase in the number of fungicide applications, which can tally up to over 50 applications (12 azoles applications) per year in some banana export countries (Chong *et al.* 2016b; FRAC 2010; Lapeyre *et al.* 2010a; Martínez-Bolaños *et al.* 2012). This can dramatically increase production costs by as high as 30% (Marín et al., 2003) and additionally poses a threat to occupational health and the environment. It is thus imperative to understand the mechanisms by which resistance towards DMIs develops in order to enable adequate long-term disease management strategies with optimized chemical input.

Azoles fungicides have been used against black Sigatoka as early as 1987, but became widely used since 1991 when propiconazole, one of the currently prominent lanosterol 14 α demethylation inhibitors (DMIs), was introduce in the market (Chong *et al.* 2016a; Romero & Sutton 1997) (Chong et al., 2016a; Romero and Sutton, 1997). Currently, several DMI fungicides, such difenoconazole, bitertanol, and epoxiconazole are commonly used in spray programs (Chong et al., 2016a). DMI fungicides act as inhibitors of the CYP51 enzyme involved in the 14 α -demethylation of the ergosterol precursor eburicol (24-methylene-24, 25dihydrolanosterol). Ergosterol regulates cellular membranes fluidity and permeability, and is essential for cell viability (Lepesheva and Waterman, 2011). Resistance or reduced sensitivity for most single-site fungicides developed rapidly in *P. fijiensis* after introduction of strobilurins, benzimidazoles, and DMI for disease control in banana production (Arango et al., 2016; Amil et al., 2007; Cañas-Gutiérrez et al., 2009, 2006; Romero and Sutton, 1997).
Previous studies on *P. fijiensis* revealed the correlation between resistance to propiconazole and point mutations in the Pfcyp51 gene, which caused amino acid (aa) substitutions surrounding the Substrate Recognition Site (SRS) at positions Y136, A313, Y461 and Y463 (Cañas-Gutiérrez et al., 2009; Chong et al., 2016b). Prior to this work, as substitutions were the only described mechanisms for shifting sensitivity to azoles in P. fijiensis. Here, we report the presence and analysis of a repetitive element in the promoter region of *Pfcyp51* gene from *P. fijiensis* field strains that are resistant to propiconazole. Specifically, we have studied the presence and copy number of these elements in 239 field isolates that were collected in Costa Rican banana plantations with and without fungicide applications, and compared them with control isolates originating from Ecuador, Asia and Africa. This comparison enabled us to establish positive correlation between the presence and copy number of the elements in the *Pfcyp51* promoter, on one hand, and its overexpression and reduced fungicide sensitivity, on the other. The influence of promoter inserts, on increased target expression and reduced azole sensitivity was experimentally corroborated by using promoter swaps between propiconazole, difenoconazole and epoxiconazole sensitive and resistant P. fijiensis strains. These promoter inserts upstream of the Pfcyp51 gene represent an additional resistance mechanism in P. fijiensis.

Materials and methods

Pseudocercospora fijiensis strains

A set of 25 monoascosporic *P. fijiensis* strains from Africa, Asia and Latin America, was used for fungicide sensitivity assays. Eight of the Latin-American strains were collected in Ecuador and 11 strains in Costa Rica. The larger set of Costa Rican strains was from four different banana plantations: Cartagena (Ca), Zent (Z), San Pablo (SP) and San Carlos (ZTSC) (Arango et al., 2016). The former three are frequently sprayed with fungicides, whereas the San Carlos is a plantain growing area with low *P. fijiensis* incidence, hence fungicides are not required for disease control. We consider the *P. fijiensis* population from this area as a wt population. Strains were obtained from CORBANA (Costa Rica), CIBE-ESPOL (Ecuador) and CBS-KNAW Fungal Biodiversity Centre (Africa and Asia).

Determination of *in vitro* sensitivity to azole fungicides

The fungicides propiconazole and difenoconazole were provided by Syngenta Crop Protection AG, Basel, Switzerland. Epoxiconazole was obtained from Sigma (Sigma Aldrich, Missouri, USA). All compounds were technical grade quality and were kept in 100x stock solutions, either in methanol or DMSO. When applied to the culture medium the final concentration of the solvents was <1% (v/v). For the initial *in vitro* sensitivity assays the final concentrations tested for propiconazole were 10, 5.62, 3.16, 1.78, 1.0, 0.56, and 0.31 mg·L⁻¹. Subsequently, to evaluate sensitive strains more accurately, lower concentrations of fungicides were included in the assays (10.24, 2.56, 0.64, 0.16, 0.04, 0.016, 0.004, 0 mg·L⁻¹) and exploited to evaluate the performance of *P. fijiensis* transformants in the presence of propiconazole, difenoconazole and epoxiconazole.

Fungicide sensitivity of each strain was determined by calculating the 50% inhibitory concentration (EC₅₀). Quantitative analysis of fungal growth, was determined by the 96 -well microtiter plate dilution assay (Peláez *et al.* 2006) with some modifications. Fifty microliters of a 1×10^5 mycelial parts/mL solution from each strain were inoculated in 200 µl potato dextrose broth medium per well of a 96-well polystyrene, flat bottom, transparent, plate (Corning, USA; cat. # 3370). Plates were incubated at 25 °C in an incubator (Elbanton, Kerkdriel, Netherlands) for seven days before mycelial growth was measured. Each

concentration was tested in duplicate per strain, and per plate four blank controls were present. Individual plates were considered as one biological replicate, and tests were performed in triplicate. Absorbance was initially measured at 620 nm in a TECAN A5082 plate reader (Männedorf, Switzerland), but due to the variation of mycelial colours over the strains as well as the different colony morphologies, we eventually monitored growth at an absorbance of 690 nm in an Infinite® M200 PRO reader (TECAN, Männedorf, Switzerland), which enabled measuring higher sensitivities. The read design per well was settled at room temperature, leaving a border of 1,000 μ m, a bandwidth of 9 μ m, circle-filled reads of 25 read points (5x5), and each read point was measured 5 times. Read averages were plotted against dpi and compared with the other strains and controls. The fungicide sensitivity of transformants and control strains was determined by the aforementioned 96-well polystyrene plates. Sealed plates were maintained at 27 °C in an incubator (Elbanton, Kerkdriel, Netherlands) in darkness and fungal growth was evaluated 10 days post inoculation (dpi). Plates were evaluated at 690 nm, while covered to reduce contamination.

Pfcyp51 gene and promoter amplification and sequencing

To amplify the *Pfcyp51* gene and the promoter region, specific primers located at the first repeat element and 22 bp upstream of the open reading frame (ORF) were used: *CYP51_Pfijien_F1* (5'-AAGGTCATATCGCAGG-3') and *CYP51_Pfijien_R1* (5'-GAATGTTATCGTGTGACA-3'). A basic PCR mix was prepared and the PCR program consisted of 5 min. of denaturation at 94 °C followed by 34 cycles of 30 sec. at 94 °C, 30 sec. of annealing at 55 °C and 90 sec. of extension at 68 °C. An additional extension step of 7 min. at 72 °C was performed at the end. DNA sequencing of the gene was performed at Macrogen (Seoul, Korea) and by the Genomics facility of Wageningen University and Research Centre (WUR), directly using the PCR products. In order to obtain the entire sequence of the gene and the promoter region four primers were used in the sequencing reactions: *CYP51_Pfijien_F2* (5'-ACAGAAACATCACCTCC-3'), *CYP51_Pfijien_F3* (5'-ATTGCTTCACTTTCATCC-3'), *CYP51_Pfijien_F4* (5'-CTCTACCACGATCTCGAC-3') and *CYP51_Pfijien_R2* (5'-GATATGGATATAGTTGTC-3'). The obtained sequences were assembled in contigs per strain using CLC DNA Workbench software (CLC bio, Aarhus, Denmark) and the ORF was translated to aa and the protein sequences were aligned using the ClustalW plug in. The sequence alignments allowed the identification of mutations.

Pfcyp51 gene expression analysis

Extraction of total RNA was carried out with mycelia of P. fijiensis isolates grown for 10 days in liquid PDB using the Qiagen RNA extraction plus mini kit (QIAGEN Inc., Valencia, USA). The integrity of the RNA was checked using agarose gel electrophoresis and the concentration was determined by measuring absorbance at 260 nm in a nanodrop spectrophotometer (Thermo scientific, Wilmington, USA). Expression analysis was performed by quantitative real time -PCR (qRT-PCR) using primers ORTCYP-forward: (5'-CGCCAGTATTCGGCACAGATGTCG-3') ORTCYP-reverse: (5'and TAACGTAGGACTGGAGGGCGGA-3'), which amplify a fragment of 89 bp of the *Pfcyp51* gene and primers ORTACT-forward: (5'-TCCGTCCTTGGTCTCGAATCTGGT-3') and QRTACT-reverse: (5'-TGCATACGGTCGGAGATACCTGGA-3'), which amplify a fragment 146 bp of the P. fijiensis actin gene that was used to normalize the expression. Quantitative RT-PCR reactions were performed using 20 ng of total RNA per strain in an Applied Biosystems ABI 7500 thermocycler (Waltham, USA) using the Applied Biosystems Power SYBR® Green RNA-to-CTTM 1-Step Kit, according to the manufactures instructions. The delta-delta Ct method was used - with the actin gene as the endogenous control - to determine the level of *Pfcyp51* gene expression (Livak & Schmittgen 2001).

Analysis of promoter repeats of *Pfcyp51* gene in four Costa Rican *P. fijiensis* populations

Genomic DNA (gDNA) of 225 P. fijiensis isolates from the four Costa Rican populations was analysed; 82 from the Cartagena population, 43 from the San Pablo population, 84 from the Zent population, and 16 from the San Carlos wt population. PCR fragments were amplified from gDNA using the specific primer pair, P. *fijiensis*_repeats_F (5'-TCTCGTACGATAGCACCTGCCCA-3') and P. fijiensis repeats R (5'-TGTTGGTGTAGGGGGTTAGGCCA-3') that was designed to amplify the promoter region of Pfcyp51. PCR conditions comprised 2 min. at 95 °C, 30 cycles of 30 sec. denaturation at 95 °C, 30 sec. of annealing at 68 °C, and 2 min. of extension at 72 °C with an additional extension step of 10 min. at 72 °C at the end of the reaction. PCR products were visualized and evaluated on a 1% agarose gels and eleven isolates were selected for sequencing and subsequent analysis of promoter and coding sequences. Different repeated elements were aligned and a weblogo consensus sequence was generated (Crooks et al. 2004) to graph nucleotide conservation within the elements.

Promoter swapping

 fluorescent protein (*gfp*) gene, followed by the upstream region of 1,737 bp obtained with primers 3-CYP-Prom Fwd (5^{-,} GGGGACAGCTTTCTTGTACAAAGTGGGAATGAGCATTTGAGAGC-3⁻) and Rev (5^{-,}GGGGACAACTTTGTATAATAAAGTTAATACTAGCGGAGGTTCG-3⁻), containing the promoter region of strain Ca5_16, which has six promoter repeats. Transformations were performed by *Agrobacterium tumefaciens* mediated transformation (Díaz-Trujillo *et al.* 2016b) using the sensitive *P. fijiensis* strain E22, with a single repeat element and no mutations in the coding region. The promoter length of 250 GFP labelled transformants was compared with the promoter length of the resistant donor Ca5_16 and the sensitive recipient E22 strains. Transformants with a Ca5_16 sized promoter are considered to be homologous recombinants, hence promoter swapped transformants, which were subsequently analysed for the integration site using PCR of a 2,629 bp amplicon using primers PROM-HR-3⁻ Fwd (5⁻-TGAGCATTTGAGAGC-3⁻) and Rev (5⁻-TTATGATCGCCTCCAAGC-3⁻) located in the cassette and the *Pfcyp51* ORF, respectively.

Results

In vitro sensitivity to propiconazole

The *P. fijiensis* isolates that were tested for sensitivity to the azole fungicides were classified in three groups; strains with (1) EC_{50} values of ≤ 0.10 mg.L⁻¹ were marked sensitive; (2) EC_{50} values between 0.10 to 0.90 mg.L⁻¹ were consider tolerant and (3) those with EC_{50} values ≥ 1.0 mg.L⁻¹ were consider resistant (Figure 1 and Table 1). Among the 25 isolates tested for sensitivity to propiconazole, 7 were sensitive, 14 moderately resistant and four were resistant. Clear cross-resistance was observed, since all isolates showed similar EC_{50} values (data not shown). In general, strains coming from banana plantations in Costa Rica and Ecuador displayed higher EC_{50} values compared to strains coming from Africa or Asia. Also strains originating from frequently (>50/year) sprayed plantations (Chong et al., 2016a; De Lapeyre De Bellaire et al., 2010), such as Cartagena, showed significantly reduced sensitivities to the fungicides, contrary to strains coming from regions not subjected to fungicide applications (Figure 1, Table 1).



Figure 1. Sensitivity of *Pseudocercospora fijiensis* strains to propiconazole. The sensitivity thresholds are marked with dotted lines. Sensitive strains from different origin are inhibited at very low concentrations (green bars). The other strains were obtained from various banana plantations in Ecuador (E, RS, SaR, RN and GS) and Costa Rica (Ca and Z) where black Sigatoka disease is controlled through frequent fungicide applications. Tolerant *Pseudocercospora fijiensis* isolates are shown in orange. The "Ca" strains originate from the Costa Rican Cartagena banana plantation, which is frequently sprayed with fungicides, and they display the lowest level of sensitivity (blue bars).

Ð																					Γ				
Propiconazol EC ₅₀ (mg.L-1)	0.010	0.011	0.034	0.053	0.055	0.060	0.079	0.103	0.108	0.114	0.138	0.147	0.162	0.171	0.222	0.241	0.251	0.271	0.404	0.458	0.485	2.75	2.776	3.16	3.971
								Y463N	Y463D	Y463S			Y463D	Y463H	Y463D	Y463S	Y463N	Y463H	Y463H	Y463N	Y463N	Y463D	Y463D	Y463D	Y463D
											G462A														
												Y461D													
			A446S																						
											A381G													A381G	
modulations								A313G	A313G	A313G		A313G		A313G		A313G	A313G	A313G	A313G	A313G	A313G				
CYP51			K171R																						
													Y136F		Y136F							Y136F	Y136F	Y136F	Y136F
					V116L																				
		V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D
							Y58F																		
		T18I			T18I		T18I	T181	T181	T181	T18I	T181	T18I	T181	T18I	T181	T181	T181	T181	T181	T181	T18I	T18I	T18I	T18I
Element present	+	-	-	-	÷	-	-	-	-	-	-	-	e	-	3	-	-	-	-	-	-	9	9	3	9
Promoter insertions	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	WT	CTCGTACGATAGCACAAATGTTAAA TCTCGTACGATAGC	WT	CTCGTACGATAGCACAAATGTTAAA TCTCGTACGATAGC	WT	WT	WT	WT	WT	WT	AATCTCGTACGATAGGATAGATGT CGTACGATAGCATAAAATCTCGTAC GATGTTAAATCTCGTACGATAGGATA AATCTCGTACGATAGCACTGCC AATCTCGTACGATAGCACCTGCC	AATCTCGTACGATAGGATAGAATCT CGTACGATAGCATAAAATCTCGTAC GATGTTAAATCTCGTACGATAGGATAG	CTCGTACGATAGCACAAATGTTAAA TCTCGTACGATAGC	AAATCTCGTACGATAGCATAAAATCT CGTACGATAGCATAAAATCTCGTAC
Isolate	C_86*	E_22	X847	X849	X846	X851	X845	RS_13	Z4_14	Z8_17	Z4_16	SaR_2	Z8_18	Z4_11	Z8_12	Z4_7	SaR_5	RN_3	RN_5	GS_10	GS_4	Ca6_11	Ca5_16	Ca1_5	Ca10_13
Origin	Cameroon	Ecuador	Taiwan	Burundi	Philippines	Gabon	Indonesia	Ecuador	Costa Rica	Costa Rica	Costa Rica	Ecuador	Costa Rica	Costa Rica	Costa Rica	Costa Rica	Ecuador	Ecuador	Ecuador	Ecuador	Ecuador	Costa Rica	Costa Rica	Costa Rica	Costa Rica

Table 1. Origin and characteristics of the *Pfcyp51* gene and its promoter in 25 *Pseudocercospora fijiensis* strains used in this study, including their condition to monitoring the promotion of the providence of the provid

Resistant *Pseudocercospora fijiensis* strains always contain repetitive elements in the *Pfcyp51* promoter

Closer examination of the promoter of the *Pfcyp51* gene revealed that sensitive isolates contain a 19 bp promoter element "TAAATCTCGTACGATAGCA" (Figure 2). This element is present as a single element in the CIRAD86 reference and originally located a few nucleotides downstream in the promoter MYCFIscaffold_7:2121794 – 2121813, (-122 bp upstream of the *Pfcyp51* start codon).

A detailed analysis of the promoter of the resistant strains identify a region of high variation, with insertions starting at position at 2,121,774 of scaffold 7 in the genome sequence of the reference strain (Pseudocercospora fijiensis v2.0, JGI), ~103 bp upstream of the start codon of *Pfcyp51* (antisense direction). Some isolates contain a partial construction of the element in their insertions, while others have a modified element due to a few additional nucleotides. Additional to the 19 bp element of a partial construction element of 16 bp 20 (TAAAATCTCGTACGAT) and а modify element of bp (TAAAATCTCGTACGATAGCA), were also present. For example, in highly resistant strains Ca1_5, Ca5_16, Ca6_11, and Ca10_13 (Figure 2) this element is repeated up to six times (four fully conserved and one partial, mostly in tandem insertion) and three tandem times in the tolerant P. fijiensis strains Z8 12 and Z8 18. DNA sequence analysis of the most resistant strains from Costa Rica (Ca5_16, Ca6_11 and Ca10_13), revealed that these contain identical mutations in the coding region of the *Pfcyp51* gene, and that the length of the insertion in the promoter reach 100 bp (Table 1).



Figure 2. Sequence logo of the *Pfcyp51* promoter repeat element. Sequences of all repeat elements were aligned and used to generate a sequence logo using the WebLogo website (http://weblogo.berkeley.edu/logo.cgi). The logo displays the frequency of the nucleotides within the three different repeated elements with 16, 19 or 20 bp that we observed in the promoter. Nucleotide frequency is scaled relative to the information content (measure of conservation) at each position. The positions 3-16 are most characteristic for the repeat element.

Repetitive elements in the promoter of *Pfcyp51* upregulate its expression

In order to test whether *Pfcyp51* gene expression is affected by the presence of repetitive element, we performed quantitative real time RT-PCR on total RNA from mycelia, normalized to the expression of the actin gene, *Pfact. Pseudocercospora fijiensis* strains Ca5_16, Ca6_11 and Ca10_13, which have six repetitive units in their promoter, have a five-fold increase in *Pfcyp51* gene expression as compared to strains E22 and CIRAD86, that have only one (Figure 3). In contrast, no significant difference was found between the control strains and *P. fijiensis* strain Z8_12, with three units. The up-regulation of *Pfcyp51* was constitutive and independent of addition of propiconazole in the culture medium (data not shown).

High frequency of the repetitive element in reduce sensitive strains from Costa Rican banana plantations

To identify the copy number of the repetitive element present in the promoter of *Pfcyp51*, we performed PCR analysis on 225 isolates originating from four banana plantations in Costa Rica that were previously studied (Arango et al., 2016): three plantations (Cartagena, Zent and San Pablo) with intensive fungicide applications and one plantation (wild type; wt)

(ZTSC) that has not received any fungicide applications. Examination of the amplicon sizes by gel electrophoresis revealed banding patterns that correspond to two, three and six promoter repeats (Figure 4A).



Figure 3. Relative expression of the *Pfcyp51* gene in six *Pseudocercospora fijiensis* strains carrying different numbers of the promoter element. Relative expression was normalized with the *P. fijiensis* actin gene. Numbers on top of each bar stand for the number of promoter element present. Reference isolate CIRAD86 (C86) is shown in green. Data represent averages of three biological repetitions with each at least three technical replicates (error bars indicate standard variations).

Amongst *P. fijiensis* populations collected from fungicide treated plantation, the Cartagena population was dominated by isolates containing six *Pfcyp51* copies of the element, (50 out of 82) followed by isolates with two copies (29 out of 82), isolates carrying the unique element were the least represented (3 out of 82). In contrast, Zent population was dominated by strains carrying the unique element (59 out of 84) but isolates containing two and six promoter repeats were also found (11 and 14 out of 84 respectively). San Pablo population was dominated by isolates carrying three promoter repeats (23 out of 43), this genotype was not observed in the Cartagena and Zent populations, followed by isolates with six (10 out of 23), one (8 out of 23) and two (2 out of 23) promoter repeats. In contrast, the population from

untreated plantations exclusively contained strains with just one 19 bp element in the *Pfcyp51* promoter (Figure 4B).



Figure 4. Screening for the *Pfcyp51* promoter repeats in *Pseudocercospora fijiensis* strains from four Costa Rican populations. A) Example of PCR amplification of *Pfcyp51* promoter in isolates from different populations. Isolate CIRAD86 (C86) was used as indicative control for the presence of one promoter element, Z8.12 as control with three element repeats and Ca5_16 as control of six element repeats. The number of elements repeated in each control sample is showed above the corresponding band. The other strains originate from banana plantations under fungicide disease management and represent various promoter length variants as controls. B) Distribution of the number of *Pfcyp51* promoter inserts within Costa Rican populations of *Pseudocercospora fijiensis*, based on 225 PCR amplifications.

Subsequent sequence analysis revealed that the promoter insertions were 100 (six elements), 59 (three elements) or 42 bp (two elements) in length. Most repetitive elements are inserted at 103 bp upstream of the start codon of the *Pfcyp51* gene. As mention before some isolates contain a partial construction of the element in their insertions, while others have a modified element due to a few additional nucleotides comprising three different alternatives (element of 20 bp, 19 bp, or 16 bp). Elements of 20 bp and 19 bp only differ in one nucleotide

an extra adenine, whereas the 16 bp element represents a shorter version of the 19 bp insert (Figure 5). The 19 bp element was found alone in isolates with one, two and three copies, whereas in isolates with six copies of the repetitive element, the 19 bp element was accompanied by the 20 bp and 16 bp variants present as single units. Hence, the 19 bp element is the commonest insertion across all isolates analysed (Figure 2).



Figure 5. Alignment of the promoter region of the *Pfcyp51* gene of *Pseudocercospora fijiensis* strains from the Zent (Z), Cartagena (Ca), San Pablo (SP) and the wt San Carlos (ZTSC) banana plantations in Costa Rica. Isolate CIRAD86 (C86) is the reference wt isolate. The normal element present in all isolate at position -122 bp is shown in green arrows. The different repeated insertions found in some *P. fijiensis* isolates are shown in red.

Analysis of the *Pfcyp51* coding sequence

As expected, sequence analyses of different isolates revealed the presence of nonsynonymous mutations in the coding region of *Pfcyp51*. These resulted in the amino acid (aa) changes Y136F, A313G, Y463D/H/N that were previously reported and linked to sensitivity loss for propiconazole (Cañas-Gutiérrez et al., 2009). In addition, nine not previously described aa changes (T18I, Y58F, V106D, V116L, K171R, A381G, A446S, G462A, and Y463S) were detected (Table 1). In all isolates T18I and V106D were identified. Excluding these, the most frequent aa changes were A313G and Y463N/D/S/H, present in 44% and 66% of the analysed isolates, respectively. These were often found in combination with Y136F and A381G. The most frequent haplotype amongst the 25 isolates was T18I, V106D, Y136F, A313G, Y463D/N/S, which was found present in combination with two, three or six copies of the repetitive element and accounts for 30% of the isolates. In addition, several other combinations of aa substitutions were observed in the analysed cohort of *P. fijiensis* strains, including A313G - Y463S/H/D/N, G381A - G462A, Y136F - Y463D, Y136F - A381G - Y463D, and K171R - A446S.

Functional analysis of the Pfcyp51 promoter insertions

We discovered a range of promoter insertions exclusively in P. fijiensis populations from treated banana plantations. The promoter insertions, in particular the six repeats insertion was shown to confer enhanced expression of *Pfcyp51*. The strains carrying the insertions display reduced sensitivity to DMI fungicides but, also carry *Pfcyp51* mutations in the coding sequence which is the most common mechanism for conferring shifted sensitivities to these fungicides. To disentangle the relation between both mutations in the coding sequence and the promoter insertions, we introduced the *Pfcyp51* promoter from the resistant *P. fijiensis* strain Ca5_16, (Costa Rica, Table 1) which has six repetitive elements into the sensitive wt E22 strain from Ecuador (Table 1). Transformation of P. fijiensis strain E22 resulted in 250 green fluorescent protein (GFP) and hygromycine (HGH) positive transformants (Figure 6A). The transformants were PCR characterized to identify strains with the six repeat elements promoter region inserted at the correct integration site from ectopic transformants (Figure 6B). Two independent transformants, Swap26 and Swap121 (Figure 6C), showing the Ca5_16 promoter amplicon (Figure 6B) and positive for the correct integration site (Figure 6C) were selected for further analyses. Subsequently, we performed qRT-PCR analyses on Swap26 and Swap121 along with the P. fijiensis control strains comprising the recipient wt strain E22 and the wt resistant strains Ca5_16 and Ca10_13 and an ectopic transformant.



Figure 6. Transformation design for Pfcyp51 promoter swap strains of *Pseudocercospora fijiensis.* A) Strain Ca5_16 is the Pfcyp51 promoter donor (slashed area) in the 3'recombination fragment together with 5'fragment (crossed out area) was amplified with CYP-Prom primers and ligated to a cassette with the HGH and GFP markers into construct pPROM_CYP51_Ca5_16. This construct was inserted into the *P. fijiensis* recipient E22 sensitive strain, containing a single promoter element (dotted area). After *Agrobacterium*-mediated transformation and selection for *gfp* tagged strains, homologous recombination sites were amplified with PROM-HR-3'primers to detect and characterize promoter swapped transformants. **B**) The promoter lengths of positive GFP tagged transformants was amplified and compared with the donor and the wt recipient strain. Transformant Swap 26 is shown as an example of a true promoter replacement transformant, which show a similar amplicon as the donor strain. Ectopic transformants possess the promoter fragment of both the donor and the recipient strain, respectively, whereas untransformed strains only show the wt-sized amplicon. C) Verification of swapping by amplification of the 2,629 bp cassette between the homologous recombination sites and the *Pfcyp51* coding region using primers PROM-HR-3'.

Consistent with previous results, the resistant strains Ca5_16 and Ca10_13 express Pfcyp51 at a higher level than the E22 recipient strain. Moreover, the expression of Pfcyp51 was significantly increased in both Swap26 and Swap121 compared to E22 and the ectopic strain. The expression phenotype of both Swap26 and Swap121 was not significantly different from that of the resistant donor strain Ca5_16 (Figure 8A). Hence, these results prove that replacing the Pfcyp51 promoter from a resistant strain to a sensitive strain results in over expression of Pfcyp51.

To determine whether the observed effect was independent of azole fungicides we challenged the transformants with difenoconazole, epoxiconazole and propiconazole, and calculated the EC_{50} . A consistent pattern of growth was observed on the plates. The resistant Ca10 13 strain up to concentration of 2.56 mg \cdot L⁻¹ of difenoconazole or epoxiconazole, and 10 mg·L⁻¹ of propiconazole. The sensitive strain E22 and the ectopic transformant only grew up to concentration of 0.016 mg·L⁻¹ of difenoconazole and 0.04 mg·L⁻¹ of epoxiconazole or propiconazole. The Swap26 and Swap121 transformants grew at least on fourfold higher concentrations as compared to the sensitive wt strain E22. The ectopic transformant, displayed similar sensitivity to E22 regardless of the fungicide used (Figure 8B and 8C; Table 2). For difenoconazole, transformants Sawp26 and Sawp121 displayed a twofold and over fourfold (4,25) increment of EC₅₀ compared to the sensitive E22 strain, whereas the resistant strain Ca10 13 was 703-fold more resistant. For epoxiconazole, Swap26 displayed a 4.48-fold reduction in sensitivity, while Swap121 displayed a slightly higher shift of 8.36-fold. By contrast the resistant strain Ca10_13 was 185.84-fold less sensitive to epoxiconazole than wt strain E22. The EC₅₀ value for propiconazole of this strain was 4.65- and 5.23-fold higher compared to Swap26 and Swap121, respectively. The resistant strain Ca10 13 was 217.42fold less sensitive in comparison with wt E22 (the resistant strain Ca5_16 was not analysed at this point due to contamination). Overall this data confirms the contribution of promoter modifications in the overall sensitivity shift to the azoles in *P. fijiensis*.

Table 2. Means of EC_{50} values¹ (mg.L⁻¹) of the *Pseudocercospora fijiensis* promoter swapped transformants Swap26 and Swap121 and various control strains to three azole fungicides.

Difenoconazole Sample Epoxiconazole Propiconazole 5,653 ± 0,1905 Ca10 13 (Resistant) 5,629 ± 0,1789 4,646 ± 0,1818 E22 (Sensitive) $0,008 \pm 0,0009$ 0.025 ± 0.0014 $0,026 \pm 0,0012$ Swap 26 $0,016 \pm 0,0062$ $0,112 \pm 0,0205$ $0,121 \pm 0,0228$ Swap 121 $0,034 \pm 0,0010$ 0,209 ± 0,0450 0,136 ± 0,0370 Ectopic $0,003 \pm 0,0001$ 0.023 ± 0.0011 $0,014 \pm 0,0016$

¹Data represent at least three independent biological replicates with each two technical repeats.



Figure 7. Configuration of the *Pfcyp51* promoter of the *Pseudocercospora fijiensis* strains used for transformation and the recombinant individuals. The promoter region is represented at the left as a blue line with different coloured boxes. Green boxes represent the 19 bp promoter repeat element. Blue and orange boxes represent alteration of 20 bp and 16 bp element respectively. Rectangular boxes at the right represent the coding region. The sensitive wt configuration is depicted in green and the resistant donor (resistant wt) configuration is shown in blue. Vertical lines –with aa substitutions - in these blue and green rectangular boxes represent mutations in the coding region.





Pseudocercospora fijiensis strains



Figure 8. *In vitro* sensitivity of the promoter swapped *Pseudocercospora fijiensis* transformants Swap26 and Swap121 vs. various control strains. (A) The relative expression (normalized with the expression in wt sensitive donor strain E_22) of *Pfcyp51* in Swap26 and Swap121, the wt E22 and the resistant strain (Ca10_13) with identical promoter and coding region as donor strain (Ca5_16) as well as the ectopic control strain (Ectopic 34). Data represent the averages of three replications. (B) Fungicide sensitivity assays of Swap26 and Swap121 and the ectopic, wt resistant (Ca10_13) and recipient (E_22) controls to 0 – 10.24 ppm of difenoconazole, epoxiconazole and propiconazole at 10 days post inoculation (pictures are representative for three independent repetitions). (C) Graphical interpretation of the fungicide sensitivity assays shown in (B).

Discussion

Management of crop diseases is commonly based on an integrated approach making use of combined breeding for host resistance, agronomic measurements and crop protection agents whenever necessary (Matthews *et al.* 2014). Due to the overall *P. fijiensis* susceptibility and ubiquity of "Cavendish" clones, which represent over 90% of the global banana trade, disease control in banana is almost entirely relying on crop protection agents and prophylaxis measures. Despite the use, under particular conditions, of forecast and disease monitoring as decision support systems, accompanied with prophylaxis measures as leaf surgery and removal of infected material to reduce the inoculum potential, the cornerstone for *P. fijiensis* control remains chemical crop protection (Chong et al., 2016a). Consequently, the selection pressure on the pathogen has been enormous, which resulted in the appearance of fungicide resistant populations. This urges for a better understanding of the nature and development of resistance.

Known mechanisms of resistance against azole fungicides include non-synonymous point mutations in the cyp51 coding region, overexpression of the gene and the overexpression of membrane efflux pumps (Ma et al., 2006; Stergiopoulos et al., 2002). A number of mutations in the cyp51 gene that are linked to DMI resistance are shared across diverse species and some are linked to a specific azole (reviewed by Becher and Wirsel, 2012). In the case of *P. fijiensis*, the presence of mutations in the *Pfcyp51* gene was related to propiconazole resistance (Cañas-Gutiérrez et al., 2009). In the present work we have focused on the promoter region as an important determinant for *Pfcyp51* gene expression, and describe the identification of a 19 bp repetitive element, whose presence upregulates *Pfcyp51* expression and leads to reduced DMI sensitivity. Our data represent the first report of targeted genetic manipulation in *P. fijiensis*, and the first description of a modified promoter resulting in the

over expression of *Pfcyp51* and contributing to reduced DMI sensitivity, thereby constituting a new mechanism of DMI resistance in this organism.

We observed a broad sensitivity range among the different *P. fijiensis* strains to the tested DMI fungicides with a clear connection between geographical origin of the strains and reduced sensitivity to these compounds. This is in agreement with previous work showing that the majority of resistant strains was isolated from countries where the banana production is economically very important, such as Costa Rica and Ecuador, and where fungicide application frequencies are very high (Aguilar-Barragan *et al.* 2014; Amil *et al.* 2007; Arango *et al.* 2016; Chong *et al.* 2016b; Marín *et al.* 2003).

The majority of *P. fijiensis* isolates from the Zent population were tolerant, whereas the strains from the Cartagena population were amongst the most resistant encountered in this study. Interestingly, sensitive strains were still found in these heavily treated plantations and, more surprisingly, some strains from the non-treated ZTSC population showed tolerance or resistance (Chong et al., 2016a). Despite this pattern was observed in very small portion of these populations, it raises questions about the underlying mechanisms. We tentatively propose that this could be due to a low frequency gene flow according to the stratified dispersal combination with the relatively narrow spatial scale of ascospore distribution (Rieux et al., 2014, 2013) for the approximately 100km distance between ZTSC and the other locations (Arango et al., 2016).

Pseudocercospora fijiensis populations in banana plantations in Costa Rica that are frequently sprayed with fungicides comprise a plethora of genotypes with diverse mutations in the coding region of the *Pfcyp51* gene (Chong et al., 2016b). Some of these mutations were previously reported in Colombian *P. fijiensis* populations and were related with resistance to propiconazole (Cañas-Gutiérrez et al., 2009) as well as to other azoles in *Zymoseptoria tritici, Candida albicans,* and *Aspergillus fumigatus* (Akins and Sobel, 2009; Cools et al., 2013; Mellado et al., 2007). These aa changes are all located at the SRS (Alvarez-Rueda *et al.* 2011; Becher & Wirsel 2012; Morio *et al.* 2010; Mullins *et al.* 2011).

One of the most frequent aa substitutions found in our work, Y136F, was previously reported for *Blumeria graminis* (Wyand & Brown 2005), and for *C. albicans* (Morio *et al.* 2010). Changes in the Ca5_16 and Ca10_13 strains are equivalent to Y137F, A379G and Y461 in *Z. tritici*, which are related to different and highly resistant azole phenotypes (Leroux & Walker 2011; Stammler *et al.* 2009). The substitution Y137F is close to the azole docking site, A379 forms part of the secondary structure adjacent to the cavity, and Y461 is located at the heme end(Mullins et al., 2011). For many of the isolates we eventually had only DNA available, as *P. fijiensis* isolates are hard to maintain, hence there was no possibility to examine for the DMI sensitivity phenotypes in all the haplotypes. However, this will be addressed in a wider study in the future (Chong et al., 2016b).

Unexpectedly, we found that in addition to the *Pfcyp51* coding region mutations, the majority of the *P. fijiensis* strains from the Costa Rican Cartagena population contain a 100 bp insertion in the promoter region. These insertions are composed of six copies of a repetitive element, whereas a single copy of this element is present in all sensitive strains. Strains with reduced sensitivity have usually two, three or more copies of this element. Changes in the promoter region of the *cyp51* gene have been described in other fungi, such as truncated derivatives of a LINE-like retrotransposon in *Blumeriella jaappi* (Ma et al., 2006), a MITE-like transposon named PdMLE1 in *Penicillium digitatum* (Sun *et al.* 2013), a larger transposon of 1.8 kb in *A. fumigatus* (Albarrag et al., 2011; Verweij et al., 2013) and transcription factors binding site in *V. inaequalis* (Villani et al., 2016). More detailed studies would be required in *P. fijiensis* to decipher whether the insertions we observed corresponds to the movements of a transposon sequence or whether the *Pfcyp51* expression might also be regulated by transposons. However, unlike previous reports of promoter insertions with a 199 bp to 5.6 kb-

sequence transposon, the promoter insertion in *Pfcyp51* is a repeated merely 19 bp fragment, reaching only 100 bp in length, even shorter than insertions in *Venturia inaequalis* (Schnabel and Jones, 2001; Villani et al., 2016) and *Z. tritici* (Cools et al., 2012), where transposons were not reported. In other organisms e.g. *E. coli*, overexpression of a desired gene was achieved by tandem repeats of core promoter sequences called "MCP*tacs*" (Li et al., 2012).

Repeated elements in the *ERG11* promoter sequence from *Z. tritici*, were suggested to have appeared after the initial mutations in the coding region. In this way, a larger accumulation of mutations could be avoided, that would compromise the activity of the enzyme (Cools *et al.* 2012; Leroux & Walker 2011), but however, contribute further to sensitivity reduction. Possibly, this also applies to *P. fijiensis*, for which we did not find tolerant or resistant isolates with insertions in the promoter and no mutations within the coding region. Isolates from wild populations lacked promoter insertions, but - occasionally - possessed mutations within the coding region. Thus far, we do not have any indication for promoter insertions being driven by sexual recombination (Chong et al., 2016c).

We studied the regulatory nature of the inserted sequences in *P. fijiensis in silico* and show that the 19 bp (TAAATCTCGTACGATAGCA) repetitive element is the most common feature. Using a targeted reverse genetics approach in *P. fijiensis* we for the first time could validate that the presence of six copies of this element in the *Pfcyp51* promoter increases the expression of *Pfcyp51* at least five-fold, compared to wt strains and those with one or three elements of tolerant phenotypes. Previously, Cañas-Gutiérrez et al. (2009) were unable to show such expression in experiments with *P. fijiensis* in response to propiconazole and considered it either a non-existent or unimportant mechanism in this fungus. However, this can be explained by a smaller data set and the fact that those strains had a much higher sensitivity than the strains in our study. Hence, we now propose that promoter repeats constitute a genetic adaptation mechanism to the high selective pressure imposed on *P. fijiensis*

by the repeated use of different DMI fungicides, particularly since this same phenomenon has been observed in various geographically discontinuous populations, including the Philippines, Cameroon, Colombia and Costa Rica (Chong et al., 2016b).

Within population, we identified a clear genetic diversity in the number of promoter repeats. The frequency of strains with more repeats was higher in banana plantations with up to 8 DMI cycles sprayed, such as Cartagena, Zent and San Pablo. Strikingly, all isolates from the untreated San Carlos plantation contained the single 19 bp element present in sensitive wild isolate around the world. These data provide additional evidence that the promoter insertions constitute an adaptation mechanism to fungicide applications in banana plantations.

Even though *P. fijiensis* is a difficult fungus to transform (Díaz-Trujillo *et al.* 2016b), and despite site specific recombinations levels seem to be very low, promoter swapping was successfully applied in our study. The introduction of the promoter from a resistant *P. fijiensis* strain into a sensitive isolate by site specific recombination resulted in a transformant with increased expression of *Pfcyp51*, and consequently reduced sensitivity to three azole fungicides, as a result of the promoter replacement. The Swap26 and Swap121 transformants were at least four times less sensitive than the recipient wt strain E22, but not as resistant as the resistant strains Ca10_13 or the donor strain Ca5_16 which were both carrying similar (Y136F and Y463D) mutations in the coding region. From our results it is expected that the reverse experiment, swapping the promoter from the resistant strain for a wild type promoter should lead to reduced resistance. Finally swapping the wt *Pfcyp51* gene into a resistant strain but keeping the insertions might reveal differential genetic backgrounds between sensitive and resistant strains that might contributed to the sensitivity. The combination of both mechanisms: 1) overexpression conferred by promoter insertions and 2) target mutation likely explain most of the shift towards DMIs. DMIs are and will likely remain a cornerstone for global black Sigatoka disease management. However, the risks of bad practices and too frequent applications are considerable since they exert a significant selection pressure on *P. fijiensis* populations, turning these increasingly more resistant. Hence, DMI applications are, may lose their competitive advantage compared to other less environmentally friendly compounds. The practical spin-off of this study is that we now can use a simple PCR assay to monitor, evaluate and predict reduced DMI sensitivity in *P. fijiensis* field populations.

Evidently, DMIs are under pressure due to resistance and therefore increasingly being studied in various fungal pathogens, including *P. fijiensis*. This fosters efforts into the research and development for novel chemistry for efficient black Sigatoka control, although alternative products, such as the strobilurins and Succinate Dehydrogenase Inhibitors (SDHIs), are also prone to resistance development (Arango *et al.* 2016; Scalliet *et al.* 2012). Therefore, disease management should embark on the availability of resistant banana germplasms. Nonetheless, disregarding of which banana cultivars dominate the export trade, fungicide resistance monitoring and the strict adoption of use recommendations of the products is an absolute necessity.

Acknowledgements

Caucasella Díaz thanks the National Council of Science and Technology (CONACyT) from Mexico. Pablo Chong is thankful to the Escuela Superior Politécnica del Litoral (ESPOL) and the National Secretary of Higher Education, Science and Technology from Ecuador (SENESCYT) and Syngenta. Rafael Arango is grateful to the Universidad Nacional de Colombia, Medellín. Amir Mirzadi is gratefully acknowledged for technical advice on *P. fijiensis* genetic transformation. This research was partially enabled through a grant of the Dutch Dioraphte Foundation.

Chapter 5

Genetic mapping of resistance to 14a-demethylase inhibitor fungicides in the banana black Sigatoka pathogen *Pseudocercospora fijiensis* reveals *Pfcyp51* as a single explanatory factor

Pablo Chong, Aikaterini Vichou, Henk Schouten, Harold J. G. Meijer, Rafael Arango and Gert H. J. Kema

Abstract

The haploid fungus *Pseudocercospora fijiensis* causes black Sigatoka in banana and is chiefly controlled by extensive fungicide applications, threatening occupational health and the environment. The 14 α -Demethylase Inhibitors (DMIs) are important disease control agents, but they lose sensitivity in a rather gradual fashion, suggesting an underlying polygenic genetic mechanism. Evidence found thus far suggests that P. fijiensis cyp51 gene is the single responsible factor for sensitivity loss in the field. In this study we performed molecular analysis, including the construction of genetic maps, to better understand the mechanisms involved in DMI resistance in P. fijiensis. Two different DMI resistant P. fijiensis strains were crossed with a sensitive strain. Analysis of the inheritance of DMI resistance in the two F_1 populations revealed a strong bimodal distribution, indicative of a single major responsible gene. Based on the bimodal distribution, the causal factor was genetically mapped as a single factor, using DArTseq markers and DMI-sensitivity scorings of both F1 populations. This results in the generation a genetic linkage maps for each population. Both maps indicated a similar genetic region on the resistant parents harbouring the responsible factor for DMI resistance. Full agreement was found for genetic markers in either population, underlining the robustness of the approach. The two maps indicated a similar genetic region where the *Pfcyp51* gene is found. Sequence analyses of the P_{fcyp51} gene of the F_1 populations also revealed a matching bimodal distribution with the DMI resistant. Amino acid substitutions in P. fijiensis CYP51 enzyme of the resistant progeny were previously correlated with the loss of DMI sensitivity. In addition, the resistant progeny inherited a *Pfcyp51* gene promoter insertion, composed of a repeat element with a palindromic core, also previously correlated with increased gene expression. This genetic approach confirms that *Pfcyp51* is the single explanatory gene for reduced sensitivity to DMI fungicides in the analysed P. fijiensis isolates.

Introduction

The dothideomycete fungus Pseudocercospora fijiensis (previously Mycosphaerella *fijiensis*) is the causal agent of black Sigatoka, a major global threat to banana crops that is responsible for serious economic losses in banana production and provokes major negative environmental impacts due to the current control strategies (Chong et al. 2016a). Contemporary disease control is mainly achieved by the application of systemic fungicides of which the most commonly used fungicides belong to the 14 α -Demethylase Inhibitors (DMIs) group. DMI are single target fungicides, hence, sensitive to resistance development. Fungicide application frequencies for black Sigatoka management are extensive and DMIs are important constituents of the spray schedules, which have not only serious negative environmental and social impacts, but also contribute to the development of resistance in the pathogen populations (Beaglehole et al. 2003; Guzmán et al. 2013; Marín et al. 2003). In general, most microorganisms adapt to fungicides by the selection of individuals with modulated genetic information. Commonly observed genetic mechanisms resulting in reduced DMI sensitivity in *P. fijiensis* are point mutations in and overexpression of 14α -demethylase that is encoded by the *Pfcyp51* gene (Bolton *et al.* 2016; Cañas *et al.* 2009; Chong *et al.* 2010; Chong *et al.* 2016b; Churchill 2011a; Díaz-Trujillo et al. 2016a; Lepesheva & Waterman 2004).

Abrupt loss of fungicide efficacy in the field is usually considered to be monogenic, resulting from mutations in a single major gene. As a result, the pathogen subpopulation carrying the mutation(s) becomes dominant and higher fungicide concentrations do not enable improved disease management, also indicated as qualitative resistance. The resistance to strobilurins in various plant pathogenic fungi, including *P. fijiensis*, illustrates this observation (Arango *et al.* 2016). In contrast, quantitative and hence, gradually shifting reduced sensitivities are enabled by the interaction of a number of different genes (Dyer *et al.* 2000). DMI resistance mechanisms in fungi have a quantitative polygenic nature. In *Candida* 207

albicans, Aspergillus fumigatus and Zymoseptoria tritici DMI resistance involves modification of sterol biosynthesis and increased expression of membrane transporters, e.g. ATP-binding cassette transporters and major facilitators, resulting in modified fungicide efflux that leads to reduced efficacy (Cools *et al.* 2013; Cowen 2008). All current evidence in *P. fijiensis* points to *Pfcyp51* as a major factor responsible for reduced sensitivity to DMIs. However, the loss of sensitivity to DMIs in the field has been gradual in nature (Cañas *et al.* 2009; Marín *et al.* 2003) and a recent study revealed extraordinary high EC₅₀ values in some strains, questioning whether changes in the *Pfcyp51* gene are the only underlying genetic mechanism (Chong *et al.* 2016b). Hence, additional quantitative genetic components may exist that directly or indirectly modulate resistance.

P. fijiensis has a bipolar heterothallic mating system (Conde-Ferraez *et al.* 2007), which facilitates genetic studies by crossing strains with opposite mating types (Arango *et al.* 2016; Kema 2009). Recently, a genetic linkage map for *P. fijiensis* was generated to support genome assembly, but specific mapping studies on fungal characteristics have not been accomplished (Arango et al., 2016). The aim of the present study was to unravel the genetic basis for reduced sensitivity towards DMI's fungicides in *P. fijiensis* by objective genetic mapping using Diversity Array Technology (DArTs) markers that also were used to generate a new genome assembly. Contrary to our expectations, progeny analyses provided strong evidence that DMI resistance in *P. fijiensis* is solely based on *Pfcyp51* modulation and not on other previously reported mechanisms such as increased efflux (Becher & Wirsel 2012; Cools *et al.* 2013; Leroux & Walker 2011). Despite increasing and accumulating data on fungicide resistance in fugal human and plant pathogens (Chowdhary *et al.* 2013; Cools & Fraaije 2013; Cools *et al.* 2013; Villani *et al.* 2016), our study is the first genetic analysis to map the underlying genetic factors for reduced DMI efficacy.

Materials and methods

Fungal isolation

Banana leaves with black Sigatoka symptoms were collected from untreated field plots on the island of Bohol, Philippines, and from the commercial Cartagena plantation in Costa Rica that is weekly sprayed with fungicides (Chong *et al.* 2016b). Infected leaf pieces (~2x3 cm) with mature necrotic lesions were retrieved and stapled to a circular 90 mm diameter filter paper (Whatman 113, Little Chalfont, UK). Filter papers containing four or five leaf pieces were incubated for 48 hours in humid chambers (sealed plastic container with humid cotton) and subsequently soaked in water for five minutes. The excess of water was blotted with paper towel and the filter papers were placed on the lid of inverted petri dishes filled with 1% water agar. The drop in relative humidity facilitates the discharge of ascospores and single spore isolates were recovered with a needle after one-night incubation at 4°C in a refrigerator and transferred to Petri dishes with potato dextrose agar (PDA) medium that were incubated at 27°C in the dark for three weeks.

Inoculum preparation

To prepare inoculum, a piece of mycelium (~ 0.5 cm^2) from a mono-ascosporic *P*. *fijiensis* colony (three to four weeks old) grown on PDA was blended for 20 seconds at 6,000 rpm in an Ultra Turrax Tube Drive machine using a sterile DT-20 tube (Tube with rotor stator element, IKA, Staufen, Germany) in 15 ml of distilled water (Peláez *et al.* 2006). The mycelial fragments were filtered through a Steriflip Vacuum-driven Filtration System (100 μ m, Millipore, Billerica, USA) and counted with a Kova glasstic slide 10 with a grids coverslip microscope slide (Kova, California, USA) and the suspensions were diluted to a final concentration of approximately 5x10⁵ mycelial fragments.ml⁻¹.

Microtiter experiments and analyses

From the abovementioned mycelium solution, a 50 μ l aliquot was transferred to each well of a 96-well microtiter plate (Corning 96-well Flat Bottom Transparent Polystyrene uncoated, Corning, USA) that were filled with 200 μ l potato dextrose broth (PDB) medium with antifungal compounds. Seven compound concentrations were tested with two technical repetitions per strain. All experiments were repeated three times. The samples were incubated in the dark at 27°C for 10 days to allow the mycelium to grow. Subsequently, the microtiter plates were analysed in the Infinite® 200 PRO machine branch (TEKAN, Switzerland) at room temperature (~20°C), without cover, at a wavelength of 690 nm with multiple reads per well in a 5x5 circle-filled form to determine mycelium proliferation by optical density. The bandwidth was 9 μ m with five flashes per read that started 1 mm from the well wall to prevent border effects.

Fungicide compounds

The fungicides propiconazole, difenoconazole and epoxiconazole were provided by Syngenta Crop Protection AG (Basel, Switzerland), were of technical grade quality and maintained as stock solution in DMSO (propiconazole and difenoconazole at 50,000x and epoxiconazole at 20,000x). The final testing concentrations for all compounds were 0; 0,004; 0,016; 0,04; 0,16; 0,64; 2,56 and 10,24 mg.L⁻¹ with 1% DMSO. The sensitivity ranges for the compounds were established by calculating the 50% effective concentration (EC₅₀) by plotting the growth profiles based on OD readings. Monotone regression spline functions (Ramsay 1988) were applied to fit the curve profiles using GenStat 18th Edition software (VSN International, Hemel Hempstead, UK). The EC₅₀ thresholds for categorizing *P. fijiensis* isolates as either DMI resistant or sensitive were arbitrary chosen based on the cluster analysis of the Least Standard error of the Differences (LSD) of the ²log EC₅₀ individual means in each population. The selected EC_{50} thresholds were: resistant isolates >1 mg.L⁻¹ and sensitive isolates ≤ 0.2 mg.L⁻¹

Crosses between sensitive and resistant P. fijiensis strains

Five DMI resistant mono-ascosporic P. fijiensis field isolates from Costa Rica (CaM10_16, CaM10_6, CaM7_19, CaM7_10 and CaM10_21), maintained in the Plant Research International collection were selected for crosses with the mono-ascosporic wild type strain Bo 1 (Bohol, Philippines, Table 1). The isolates were crossed shortly after the first sensitivity assay to avoid loss of sexual fitness as experienced in numerous other tries for developing P. *fijiensis* mapping populations (no more than two sub-cultivation steps). The mating type locus configuration was determined using the mat1-1 primers Mat1F (5'-(mat) CATGAGCACGCTGCAGCAAG-3') and Mat1R (5'-GTAGCAGTGGTTGACCAGGTCAT-3') *mat1-2* primers Mat2F (5'and the GGCGCTCCGGCAAATCTTC-3') and Mat2R (5'-CTTCTCGGATGGCTTGCGTG-3') (Arzanlou et al. 2010). The PCR reaction was performed using Roche Taq DNA polymerase with a standard mix containing 10 ng of gDNA according to the following protocol: 94°C for 4 min., then 30 cycles 30 sec. at 94°C, 40 sec. at 62°C and 40 sec. at 72°C, followed by a final extension step for 7 min. at 72°C. As Mat determinations by PCR were not conclusive, we eventually decided to use the Bo 1 isolate as common parent in five pairings, which we expected to be no less than 40% successful due to the bipolar heterothallic mating system of P. fijiensis (Conde-Ferraez et al. 2007). We, therefore prepared 15 ml of mycelium solution as described above - of each parental strain and then mixed the sensitive P. fijiensis strain Bo 1 in a 1:1 ratio with each of the other aforementioned Costa Rican strains, hence in total five mixtures, which were incubated overnight at 27°C to recover from blending. The next day the inoculum mixtures were atomized on individual "Cavendish" banana plants, variety Grand Nain, using a spray device (#0267-6, Preval®, Chicago, USA) at both sides of the leaves until run-off. Each plant was six months old to ensure large leaves with more surface area for disease development. After inoculation, plants were maintained in the greenhouse for 14 weeks with the following growth regime: light (>300 μ mol m⁻² s⁻¹) period of ~12 hours; day/night temperatures of 28°C/25°C with a relative humidity >90%. First necrosis and mature spots appeared around 65 days after inoculation (dai) and starting from that day, leaf pieces with the mature reproductive lesions were taken for ascospore discharge as described above. The first set of spores was observed and collected 73 days after inoculation from two crosses (Table 1) and 100 ascospores were isolated from each cross for further analyses.

Table 1. Crossing *Pseudocercospora fijiensis*. The DMI sensitive strain (Bo_1), mating type *mat1-1*, was crossed to five *mat1-2* DMIs resistant strains (CaM10_16, CaM10_6, CaM7_19, CaM10_21) and one *mat1-1* resistant strain (CaM7_10). Crosses were performed directly after the preliminary sensitive assay to avoid possible loss of sexual fitness due to sub-cultivation.

Cross	DMI sensitive parent 1	Propiconazole EC50 average score (mg.L ⁻¹)	DMI resistant parent 2	Propiconazole EC50 average score (mg.L ⁻¹)	Progeny	
N1			CaM10_16	5.730	No progeny	
N2			CaM10_6	11.750	Successful cross	
N3	Bo_1	0.020	CaM7_19	5.125	No progeny	
N4			CaM7_10	2.205	Incompatible cross*	
N5			CaM10_21	6.349	Successful cross	

* The mat gene configuration was unknown in the moment of the cross experiment.

DArTseq marker generation

A set of 98 isolates from each population was genotyped using DArTseq technology (www.diversityarrays.com). DNA samples were processed as described previously with few modifications (Kilian *et al.* 2012). The technology was optimized for *P. fijiensis* by using two restriction enzymes, i.e. *PstI* and *MseI*, rather than *PstI* only. The Restriction Enzyme (RE) overhangs differed from one another, allowing ligation of RE-site specific adaptors. The *Pst*I-212 compatible adapter was designed to include Illumina flow cell attachment sequence, the sequencing primer sequence and a "staggered", varying length barcode region, similar to the sequence reported by Elshire (Elshire et al. 2011). The reverse adapter contained the flow cell attachment region and a MseI-compatible overhang sequence. Only "mixed fragments" (PstI-*MseI*) were effectively amplified by PCR. Equimolar amounts of amplification products from each sample of the 96-well microtiter plate were bulked and applied to c-Bot (Illumina) bridge PCR followed by sequencing on an Illumina Hiseq2000. Each generated marker had a sequence length of 68 bp. Sequences generated from each lane were processed using proprietary DArT analytical pipelines (Kilian et al. 2012). In the primary pipeline the fastq files were processed to filter away poor quality sequences, applying more stringent selection criteria to the barcode region compared to the rest of the sequence. In that way the assignments of the sequences to specific samples carried in the "barcode split" steps were very reliable. Approximately 2,000,000 sequences per barcode/sample were identified and used in marker calling. Identical sequences were collapsed into "fastqcoll files" and a second pipeline was followed for further quality selection criteria as described (Kilian et al. 2012). Finally, the scored markers (presence/absence of restriction fragments) were represented in a 0/1 binary matrix to be used in the calculation of the genetic similarity.

Genetic linkage maps

Approximately 5,400 DArTseq markers were generated for the segregating F_1 populations N2 and N5 (Table 1). As the DMI sensitivity trait showed a clear bimodal distribution (sensitive versus resistant), this trait was integrated as phenotypic marker in both genetic maps. The markers were filtered based on their co-segregation with the sensitivity trait and those with close linkage (<10cM) to the trait were selected for the construction of a linkage group to identify the genetic region of the responsible gene. The linkage group markers were

sorted with the genetic mapping software JoinMap 4.1 (Stam 1993) and, according to the positions of the recombination events, the strains were sorted to identify the chromosomal region harboring the sensitivity gene. Subsequently, the genetic map was linked to the physical map by aligning the DNA sequences of the DArTseq markers to the *P. fijiensis* CIRAD 86 reference genome version 2.0 (http://fungi.ensembl.org/Pseudocercospora_fijiensis_cirad86/Info/Index).

Pfcyp51 sequencing

The *Pfcvp51* genes of a total of 193 isolates from both populations (98 strains from N2 and 95 strains from N5) were sequenced. To amplify the Pfcyp51 gene, specific primers were used: CYP51_Pfijien_F1 (5'-AAGGTCATATCGCAGG-3') and CYP51_Pfijien_R1 (5'-GAATGTTATCGTGTGACA-3'). A standard PCR mix was used in the following program; initiation with a 5 min. denaturation at 94°C followed by 35 cycles of 30 sec. denaturation at 94°C, 30 sec. annealing at 55°C and 90 sec. extension at 68°C with a final round of seven min. extension at 72°C. The DNA sequencing of the *Pfcyp51* amplicons was directly performed on the PCR products (Macrogen Europe, Amsterdam, The Netherlands). Full sequence coverage was obtained by using four primers: CYP51_Mfijien_F2 (5'-ACAGAAACATCACCTCC-3', CYP51_Mfijien_F3 (5'-ATTGCTTCACTTTCATCC-3'), CYP51 Mfijien F4 (5'-CTCTACCACGATCTCGAC-3') and CYP51 Mfijien R2 (5'-GATATGGATATAGTTGTC-3'). The obtained *Pfcyp51* sequences were assembled per strain in contigs (SeqMan application software Lasergene v8, DNASTAR[®], Madison, USA) and aligned to gene model MYCFIDRAFT 30715 of the reference genome (P. fijiensis CIRAD 86, genome version 2.0, (Arango et al. 2016)), using the CLC Genomic Workbench software (version 7.5.2, CLC Bio-Qiagen, Aarhus, Denmark).

Results

Progeny generation and DMI segregation

Successful crosses were accomplished after two experimental failures where we empirically determined the critical number of sub-cultivations of the parental strains, which should not be more than two in order to maintain sexual fitness. Among the five evaluated crosses, four combinations produced mature lesions at 65 dai, but ascospores were only discharged from N2 and N5 at 73 dai (Table 1). Other crosses failed, apparently due to identical *mat* genotypes. A total of 200 progeny isolates was characterized for DMI sensitivity using epoxiconazole, propiconazole and difenoconazole (Table 2).

The segregation ratios for sensitivity versus resistance of the N2 and N5 progenies were 47:53 and 44:56, respectively, according to an expected 1:1 ratio for a single gene inheritance. Hence, examination of the sensitivity response in both F_1 populations revealed a clear bimodal distribution (Figure 1, Figures S1 and S2). Despite these bimodal distributions, four strains (N2_21, N2_89, N5_1, and N5_57) had an intermediate response to the tested DMIs (Figure 1). These four strains were included in the mapping generation. Based on the sequence analyses, only N5_1 was regarded as resistant, whereas the others were considered sensitive. The average EC₅₀ scores for each strain are shown in the Table S2.

Genetic linkage maps

We used the DArTseq markers to construct two linkage maps. From population N2, 53 markers were selected with 17 markers in coupling phase to resistance and 36 markers in coupling phase to sensitivity to DMIs (Figure S4a and Table S1). The markers were clustered in seven groups based on their segregation patterns. Thirty-three of the markers were placed onto scaffold 7 of the physical map of *P. fijiensis* (Table S1). The recombination events for the seven groups in the N2 population are shown in the right panel of Figure 2. From 53

markers, 21 fully co-segregated with sensitivity to the DMIs. Markers 12410413 and

12405280 were identified as the flanking markers of the sensitivity trait with physical positions

scaffold_7:1,779,092 bp and scaffold_7:2,130,447 bp, respectively, and a physical distance of 351,355 bp.

Table 2. Summary of the EC_{50} data for DMIs for the two *Pseudocercospora fijiensis* mapping populations N2 and N5. Indicated are the highest (Max) and lowest (Min) values that were obtained in the discretely segregating sensitive or resistant groups as well as their average values, the percentage of strains in each category and the average resistance factor (RF) of the resistant segregants.

			Dif	enoconaz	ole			Epo	xiconazo	le		Propiconazole				
Pop	Trait ¹	Max	Min	Av (SD)	%	RF	Max	Min	Av (SD)	%	RF	Max	Min	Av (SD)	%	RF
N2	s	0.213 ²	0.009	0.05 (0.04)	47	-	0.19	0.015	0.04 (0.04)	47	-	0.21 ²	0.027	0.07 (0.03)	47	-
	R	>10.24	5.669	8.82 (1.268)	53	187.57	>10.24	1.351	4.78 (2.08)	53	108.65	>10.24	3.732	7.91 (2.1)	53	106.90
	s	0.108	0.005	0.04 (0.03)	44	-	0.315 ²	0.011	0.05 (0.05)	44	-	0.273 ²	0.015	0.07 (0.04)	44	-
N5	R	7.664	0.597 ²	4.30 (2.21)	56	107.43	9.459	0.748 ²	5.30 (2.22)	56	98.47	7.233	0.683 ²		56	94.22

¹Sensitivity trait: S = sensitive, R = resistant.

²Four strains showed intermediate phenotypes.


Figure 1. Segregation of DMI sensitivity in the *Pseudocercospora fijiensis* mapping population N2 and N5. Histograms of the ²log average EC_{50} data per fungicide are shown for each population. Resistant and sensitive strains show the same sensitivity response to all three DMI fungicides respectively. A minority of the progeny isolates showed intermediate phenotypes in some fungicides (EC_{50} thresholds between resistant >1 mg.L⁻¹, Intermediates from 0.2 - 1 mg.L⁻¹ and sensitive ≤ 0.2 .mg.L⁻¹). The Bin range was based on the lower and upper intervals of the standard error of the difference of the ²Log means. The EC_{50} positions of the parental strains are marked with triangles. Least Significant Difference (LSD) values are shown above the histograms.

From population N5, 41 markers were selected with eight markers in coupling phase with resistance and 33 markers in coupling phase with sensitivity to the tested DMIs (Figure S4b and Table S1). The markers were clustered in three groups by their genetic distance, of which 27 placed on scaffold 7. All recombination events for the N5 population are shown in the left panel of Figure 2. From the 41 markers, 32 fully co-segregate with sensitivity to the tested DMIs. Markers 12397726 and 12399875 were identified as the flanking markers with positions scaffold_7:1,879,787 bp and scaffold_7:2,175,183 bp, respectively, and a physical distance of 295,396 bp.

The order of the genetic markers in both the N2 and N5 populations was in full agreement (Figure 2). The N2 and N5 populations share 38 markers and 17 markers from both maps show inconsistencies or low coverage scores, which were therefore omitted from place them in the reference physical map. Markers with inconsistences between the physical and the genetic maps are markers 12412057 on scaffold_7 - but in a displace position - 12,412,405 on scaffold_27, marker 12397704 on scaffold_6 and marker 12410210 on scaffold_5. Since they co-segregated with the groups of markers close to or in the area carrying the sensitivity locus, we assume there are either differences between the sequences of the CIRAD86 reference genome and the parental/progeny isolates or there are a few errors in their positioning on the physical map. The positions of all markers are indicated in Figure 2 and a summary of the information is compiled in Table S1 and Figure S4. Based on the flanking markers, there is an overlapping region for the N2 and N5 populations of 250,660 bp between scaffold_7:1,879,787 (marker 12397726) and scaffold_7:2,130,447 (marker 12405280). This genetic window harbours 53 putative genes among which is *Pfcyp51*, located at scaffold_7:2,119,919-2,121,685 (Figure 2, Figure S5, Table S3).



Figure 2. Integration of the *Pseudocercospora fijiensis* N2 (left) and N5 (right) genetic linkage maps with the physical map (Partial Scaffold_7) of the genomic reference *P. fijiensis* CIRAD86 (middle; *Mycosphaerella fijiensis* version 2.0). The genetic map was generated using DArTseq markers. The sensitive trait is taken as phenotypic marker in the genetic map (marker in yellow). The number of recombinations between the markers is indicated between the linkage groups. Markers perfectly co-segregating with the sensitivity trait are indicated in blue, with the direct flanking markers depicted in red for both populations. The area of the co-segregating markers for each population is presented as a light blue line and the overlapping region is depicted in yellow on the physical map. The genetic and the physical map are linked for each marker by arrows. The flanking markers are indicated in red while the remaining markers are printed in black. Genetically linked markers without a position in the physical region are indicated with a question mark (?) and unpositioned markers are placed with a light blue dashed line. The position of *Pfcyp51* is marked in bold letters with a yellow triangle and is represented by a yellow box.

Molecular analyses of the Pfcyp51 configuration in the N2 and N5 progenies

Analysis of the *Pfcyp51* gene, including the promoter, revealed that all *P. fijiensis* progeny strains only had parental genotypes. Resistant strains carried the *Pfcyp51* gene encoding protein modifications T18I and V106D, which have no DMI phenotypic consequences, and three other substitutions related to DMI resistant describe in Figure 3, whereas all sensitive isolates were identical to the wild type genotype of the parental strain Bo_1, lacking any insertion in the promoter region and a *Pfcyp51* sequence encoding the non-phenotypical T18I, V106D and A446S amino acid (aa) modifications compared with the reference sequence of P. fijiensis CIRAD86 (Table S2). However, all resistant progenies from either population contained a 103 bp promoter insertion located 94 bp upstream of the reference *Pfcyp51* start codon. The insertion is accompanied with an 18 bp substitution "GGACCACTCGAACATCAC". (reference position MYCFIscaffold 7:2121783, Mycosphaerella fijiensis v2.0, JGI) and is composed of repeated elements interspersed with non-repeated sequences. The repeated element is described in Chong et al. (2016) (Chong et al. 2016b) and possesses a palindromic core. In total, three exact copies and a single modified copy of this element - from here identified as element A - are present in the insertion. The modified copy (A^*) carries an additional one bp substitution, resulting in the sequence "TAAAATCTCGTACGATAGCA. All sensitive isolates have only one A element in their promoter (Chong et al., 2016; Figure 2). So, when taking into account this single A element in wt Bo_1, resistant progeny isolates contained five A copies (Figure 3 and Figure S3).



Figure 3. Schematic visualization of the *Pfcyp51* gene configuration derived from the *Pseudocercospora fijiensis* crossing partners and segregating progenies, based on the expressed phenotypes towards three DMI fungicides. All progeny isolates exclusively showed parental genotypes. Resistant isolates have promoter insertions while sensitive isolates have no insertions. Mutations in the coding domain are marked with colored lines and the resulting aa substitutions.

All resistant progeny isolates from the N2 population share Pfcyp51 substitutions resulting in the aa modifications Y136F, A313G and Y463D originating from their resistant parent CaM10_6 (Figure 2 and Table S2). The resistant progeny from the N5 population have substitutions resulting in the aa changes H380N, A381G and Y463D, originating from the parental resistant strain CaM10_21 (Figure 3 and Table S2). All *Pfcyp51* sequences from parents and progenies of both the N2 and N5 populations showed a perfect match with the segregating phenotypes (sensitive: resistant = 1:1, Table S2). From the aforementioned four strains with intermediate behaviour, strains N2_21, N2_89 and N5_57 contained the *Pfcyp51* sequence of the sensitive parent and isolate N5_1 had the configuration of the resistant parent. Hence, their phenotypes were either scoring errors or caused by other genomic modifications.

Discussion

Disease management in agricultural crops largely depends of two crucial factors: host resistance and crop protection agents. As Cavendish bananas are highly susceptible to P. *fijiensis* and represent 85% of the global trade, there is essentially one option left for disease control, i.e. fungicides. This has huge implications for overall management. One important implication is for the disease, with an imminent risk for the selection of increasingly resistant P. fijiensis populations. Another important implication is on the occupational health of thousands of workers in banana plantations and the environmental issues due to the precarious tropical landscapes where bananas are usually produced (Risède et al. 2010). The latter issue results in significant water contaminations (van Wendel de Joode et al. 2016) as well as the risk of non-target hits, which for instance is considered to be the reasons of increasing fungicide resistance in Aspergillus fumigatus to medical azoles (Chowdhary et al. 2013). On top of that, the increasing loss of DMI efficacy resulted in higher frequency of contact fungicide that are more hazardous to the environment (Chong et al. 2016a; Guzmán et al. 2013; Pereira et al. 2014; van Wendel de Joode et al. 2016). Hence, a thorough analysis of DMI resistance in P. *fijiensis* is both necessary and urgent to raise awareness of spending more efforts to develop new banana germplasm with resistance to black Sigatoka (Chong et al. 2016a; Guzmán et al. 2013; Risède et al. 2010; Stergiopoulos et al. 2014; Stergiopoulos et al. 2010). However, this will take considerable time and hence altered strategies for the use of fungicides are required and necessitate scrutinizing the current disease control practice and its consequences. Without doubt, black Sigatoka disease is the most costly disease of global banana production with an estimated cost of at least US \$1000.ha⁻¹ in most environments (Arias et al. 2003). After describing the global landscape of DMI resistance in P. fijiensis (Chong et al. 2016b) as well as the mechanistic proof of its mechanism (Díaz-Trujillo et al. 2016a), we decided to perform an unbiased genetic analysis to identify any other underlying factors for the resistance to DMIs

in *P. fijiensis*. Therefore, we generated two new high marker density genetic linkage maps after crossing sensitive and resistant *P. fijiensis* isolates. These crosses were not at all routine, required a pragmatic approach compared to previous reports (Manzo-Sanchez *et al.* 2008), and eventually resulted in two mapping populations. This classic genetic approach in combination with state of the art DArTseq molecular markers technology provided novel and key information to understand the development of DMI resistance and, hence, is the basis for optimizing their use for disease management.

Pseudocercospora fijiensis mating

One of the most challenging tasks in the present study was to perform the *P. fijiensis* crosses. First we were not able to unequivocally determine the mating type of each isolate, which previously also appeared difficult (Arzanlou et al. 2010), despite the fact that we earlier cloned the *P. fijiensis mat* genes (Conde-Ferraez et al. 2007). Our pragmatic approach is similar to the protocol being used for the related dothideomycete wheat pathogen Zymoseptoria tritici (Goodwin et al. 2011; Kema et al. 1996; Wittenberg et al. 2009). Recent genome data show that sub-culturing fungal isolates frequently results in chromosome loss (Johnson et al. 2001; Rodríguez et al. 2006), and hence it is conceivable that our failures to successfully cross P. *fijiensis* is related to the number of sub-cultivations of each candidate parent (Saleh *et al.* 2012). The moment we reduced these to maximally two - and essentially determined the DMI phenotype of the parents in retrospect – crosses proved to be successful, resulting in viable and sufficient progeny strains for formal genetic analyses. Hence, we conclude that subsequent subcultivation steps affect sexual fitness, although we do not know whether this has to do with the loss of essential chromosomes. Alteration of fungal properties by sub-cultivation not only affects mating but also for instance pathogenicity observed by Krokene and Solheim in the bluestain fungus Ceratocystis polonica (Krokene & Solheim 2001) and by Kashino et al. in

Paracoccidioides brasiliensis (Kashino *et al.* 1990). Krokene and Solheim also observed alterations in the ability to grow under oxygen-deficient and reduction in growth rate in *C. polonica* (Krokene & Solheim 2001).

Sensitivity tests results

Despite the bimodal distribution into sensitive and resistant progeny, the wide range of EC_{50} values' in each group was substantial and awaits further explanation as various strains exceeded the thresholds that were recently established for sensitivity based on global population analyses (Chong *et al.* 2016b). We, therefore, adopted another threshold in this experiment as it is conceivable that the chosen fungicide doses limited the precise determination of EC_{50} concentrations, especially at low concentrations. Potentially, other individual factors such as minor fungicide resistance genes, or genes related to stress responses or growth rates are involved. Nonetheless, the DMI response difference between sensitive and resistant isolates was clear and separates them into two major and discrete groups with an approximate differential resistance factor of approximately 100 (Table 2), resulting in a 1:1 segregation, indicating a single causal gene for DMI sensitivity in *P. fijiensis*.

Genetic linkage maps

By using the DMI phenotypes and progeny genotypes in a mapping approach we show that azole sensitivity in the two segregating *P. fijiensis* populations is due to a single major gene, *Pfcyp51*. Since no evidence was observed for the presence of any other sensitive genetic region in either progeny, this strongly supports the presence of the *Pfcyp51* gene as the single explanatory factor for DMI sensitivity. The progeny was no different when compared to the parents, despite the quantitative expression of DMI sensitivity (Cañas *et al.* 2009; Chong *et al.* 2016b; Dyer *et al.* 2000). In only four progeny isolates an alternative explanation seems appropriate, but was not apparent from the generated data set and might equally be due to experimental error due to e.g. age or density of *P. fijiensis* cultures.

The genetic window explaining DMI sensitivity contained 53 genes, of which the majority lack any functional clue. Predicted gene Id96804 encodes a putative transcription factor, which might regulate expression of (minor) genes that contribute to DMI resistance and predicted gene Id86816 encodes a putative transporter that might facilitate increased efflux (Stergiopoulos *et al.* 2002; Zwiers 2002) (Table S3). However, the overruling factor seems to be *Pfcyp51* that also maps to this exact region (Figure 2 and S4) and which accords with its importance in other – related – fungi (Cools *et al.* 2013) as well as with the accumulating evidence that recently became available (Cañas *et al.* 2009; Chong *et al.* 2010; Chong *et al.* 2016b; Díaz-Trujillo *et al.* 2016a). Therefore, despite the presence of other genes in the mapped genomic region, we propose that modifications of the *Pfcyp51* gene and its promoter are the driving molecular force for DMI fungicide resistance.

Molecular analysis of the Pfcyp51 configuration in F1 progenies

Common mechanisms described for the loss of sensitivity to DMIs are increased efflux of the fungicides from the cells (Cools *et al.* 2013; Leroux *et al.* 2010), adaptation and overexpression of the fungicide target gene (Bolton *et al.* 2016; Chong *et al.* 2016b; Cools *et al.* 2012; Díaz-Trujillo *et al.* 2016a; Villani *et al.* 2016) and cellular alterations that reduce the toxicity of the fungicides, such as modulation of the targeted biosynthesis pathway (Cowen 2008). Recently, we showed that modulation of the promoter and coding domain of *Pfcyp51* explains reduced DMI sensitivity (Chong *et al.* 2016b; Díaz-Trujillo *et al.* 2016a). Other fungal species, such as *Candida albicans* and *Aspergillus graminearum*, accommodate more than one of these mechanisms (Akins & Sobel 2009; Becher & Wirsel 2012; Cowen 2008). Our data suggests that in *P. fijiensis* modification and consistent alteration in the promoter region of the Pfcyp51 are the most plausible causes of the reduced sensitivity to DMIs. The current study underscores these observation as our unbiased linkage approach did not map any additional contributing factor to DMI sensitivity; none of the sensitive strains contained substitutions Y136F, A313G, H380N, A381G or Y463D or insertions in the promoter region of Pfcyp51, which were previously correlated with reduced efficacy in DMIs (Cañas *et al.* 2009; Chong *et al.* 2016b; Díaz-Trujillo *et al.* 2016a). Since there were no recombination events close to the Pfcyp51 gene, we also conclude that sexual reproduction apparently does not contribute to the important Pfcyp51 promoter modulations, which therefore awaits further mechanistic explanations.

Interestingly, the overall sensitivity loss in population N2 was higher than in N5. Based on the similarity of the promoter configuration we assume that the expression of the gene is comparable (Table 2). Therefore, the sensitivity difference might be explained by the non-synonymous mutations present in the *Pfcyp51* gene (Figure 2). Resistant progeny from N2 harbour aa substitutions Y136F, A313G and Y463D, while those in N5 comprise H380N, A381G and Y463D. The differentiating substitutions at positions 136 and 313 are particularly important since these are located in the substrate binding site (Cañas *et al.* 2009; Chong *et al.* 2016b).

Unlike other single site fungicide interactions, CYP51 substitutions often affect individual, or a subset of DMIs compounds, with generally incomplete cross-resistance across the whole class (Cools et al., 2013). This particular mode of interaction of the CYP51 protein can explain the unusual behaviour and the steep increase of DMI resistance in the banana plantations. It is likely that the quantitative resistance response – as observed for DMI resistance in the field - is due to an accumulation of different *Pfcyp51* non-synonymous mutations in response to the apparent selection pressure, which also and alternatively can be due to a

dramatic synergistic and epistatic effect explained by *Pfcyp51* overexpression under high selection pressure (Díaz-Trujillo *et al.* 2016a).

In comparison with the DMI resistance mechanisms present in other fungi (Becher & Wirsel 2012; Cools *et al.* 2013) it is at least remarkable that we have exclusively identified a role for *Pfcyp51* in DMI sensitivity. The lack of alternative quantitative mechanisms might indicate that we are just at the beginning of *P. fijiensis* DMI resistance development, illustrative for the recent development in DMI resistance in Latin America. Common DMI resistance mechanisms in other fungi include increased fungicide efflux or alternative ergosterol synthesis pathways (Cools *et al.* 2013; Cowen 2008) may therefore become more common in the future if the fitness penalty for these mechanisms is sufficiently low (Cools *et al.* 2013; Cowen 2008). However, this largely depends on future application of DMI fungicides. The current situation on reduced DMI efficacy has already resulted in a fall-back strategy avoiding DMIs and increased use of protectants and mineral oil (Chong *et al.* 2016a).

Our data have not shown any modulating effect of sexual reproduction on Pfcyp51, but the versatility of the fungus through an almost continuous production of offspring throughout the year is undeniable. Current spraying practices likely significantly contributed to the accumulation and actually fixation of strobilurin resistance, as was recently explained in *Zymoseptoria tritici* (Aouini 2016). This should - evidently - be a huge concern for the banana industry since the maximum number of fungicide applications seems to have plateaued and thus the efficacy of the treatments could be on the verge of breaking. In other species there are few indications that a temporal suspension of DMI applications results in a subsequent decrease of resistant isolates due to fitness penalty and stability restrains in the Pfcyp51 gene (Chowdhary *et al.* 2013; Lendenmann *et al.* 2015; Verweij *et al.* 2013), although in a limited number of cases this strategy was shown to be functional (Latin, 2011, Cowen, 2008). As stated above, resistance breeding, but also the introduction of biological control measures and the development of alternative non-DMI fungicides are considered as the most promising options for a more balanced and hence sustainable black Sigatoka management.

Acknowledgements

This work was supported by the Ecuadorian government through the "Secretaría de Educación Superior, Ciencia, Tecnología e Innovación", SENESCYT, The Ecuadorian University, "Escuela Superior Politécnica del Litoral" (ESPOL), the "Centro de Investigaciones Biotecnológicas del Ecuador" (CIBE) that belongs to ESPOL university and Syngenta AG. We also acknowledge the support of Mauricio Guzman, Corbana, Costa Rica; the advice of Marie-Francoise Zapater and Jean Carlier, Cirad, France, on the *P. fijiensis* crossing protocol. A special thanks to Esther Lilia Peralta for her support to the overall DMI project and to Pieter Vereijken for his support in data analyses. We thank Mrs. Lolit Bacus from Unifrutti Philippines, Inc. for making available the infected banana leaves from Bohol, Philippines.



Supporting information

Figure S1. Plots of the calculated EC_{50} values and residuals of the interaction of the *Pseudocercospora fijiensis* segregating N2 population with the three DMI fungicides. A) difenoconazole, B) epoxiconazole and C) propiconazole.



Figure S2. Plots of the calculated EC_{50} values and residuals of the interaction of the *Pseudocercospora fijiensis* segregating N5 population with the three DMI fungicides. A) difenoconazole, B) epoxiconazole and C) propiconazole

C86	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
Bo_1	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-		0.1710011711		C UT I C C
CaM10_6	TTAAATCICG	TACGATAGCA	COTGOCOATA	AATGTCGTAC	GATAGCATAA	AATOTOGTAC	GATAGC
N2.6-BC	TTAAATCTCG	TACGATAGCA	COTGCCCATA	AATCTCGTAC	GATAGCATAA	AATOTOGTAC	GATAGO
N2.95	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.91-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.87-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.96	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.76-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.45-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N5_23	TTAAATCICG	TACGATAGCA	COTGCCCATA	AATCICGTAC	GATAGCATAA	AATCICGTAC	GATAGC
N2.49-RC	TTAAATCICG	TACGATAGCA	COTGCCCATA	AATOTOGTAC	GATAGCATAA	AATOTCGTAC	GATAGC
N2.94-RC	TTAAATCTCC	TACGATAGCA	COTOCCATA	AATOTOGTAC	CATACCATAA	AATOTOGTAC	GATAGO
N2 97	TTAAATCTCC	TACGATAGCA	CCTGCCCATA	AATCICCTAC	GATAGCATAA	AATOTOGTAC	GATAGO
N5.1	TTAAATCTCC	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGO
N5.22	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N5.12	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.82	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.53-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.81-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N5_32	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N2.73-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
N5.6	TTAAATCICG	TACGATAGCA	CCTGCCCATA	AATCICGTAC	GATAGCATAA	AATCICGTAC	GATAGC
N5.44	TTAAATCICG	TACGATAGCA	COTGCCCATA	AATGTCGTAC	GATAGCATAA	AATOTOGTAC	GATAGO
N5.70	TTAAATCTCC	TACCATACCA	COTOCOCATA	AATOTOGTAC	CATACCATAA	AATOTOGTAC	CATAGO
N2.89-RC	TTAAATCTCC	TACGATAGCA	CCTGCCCAT-	AT GIOGIAC		ALC I COLAC	3/1/00
N5 27	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
N5_24	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
N5.34	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
N5.37	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
N2.42-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCAT -				
N5.18	TTAAATCTCG	TACGATAGCA	CCTGCCCAT -				
N2.57-RC	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
N5_26	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
N5.71	TTAAATCICG	TACGATAGCA	COTGCCCAT-				
N2.8-RC	TTAAATCTCC	TACGATAGCA	COTGCCCAT-				
N5 54	TTAAATCTCC	TACGATAGCA	COTGCCCAT-				
N5.51	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
N5 60	TTAAATCTCG	TACGATAGCA	CCTGCCCAT -				
N2.44	TTAAATCTCG	TACGATAGCA	CCTGCCCAT-				
Consensus	TTAAATCTCG	TACGATAGCA	CCTGCCCATA	AATCTCGTAC	GATAGCATAA	AATCTCGTAC	GATAGC
Conconvotion							
Conservation							
0%							
0%		80		100		120	
0% C86		80		100	GG		CATCAC -9
∞ C86 Bo_1		80		100	GG	120 ACCACTCGAA ACCACTCGAA	CATCAC -9 CCACAC -9
∝ C86 Bo_1 CaM10_6	ATAAAATQTC	80 TACGATGT	AAATQTCGTA		GG AATQTCGTAC	120 ACCACTCGAA ACCACTCGAA GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17
∝ C86 Bo_1 CaM10_6 CaM10_21	ATAAAATOTC ATAAAATOTC	80 1 GTACGATGTT GTACGATGTT	AAATGTCGTA AAATGTCGTA	100 I CGATAGCATA CGATAGCATA	AATCTCGTAC	120 I ACCACTCGAA ACCACTCGAA GATAGCACCT GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17
C86 Bo_1 CaM10_6 CaM10_21 N2.6-RC	ATAAAATOTC ATAAAATOTC ATAAAATOTC	BO T GTACGATGTT GTACGATGTT GTACGATGTT	AAATGTCGTA AAATGTCGTA AAATGTCGTA	100 CGATAGCATA CGATAGCATA CGATAGCATA	AATCTCGTAC AATCTCGTAC AATCTCGTAC	120 ACCACTCGAA ACCACTCGAA GATAGCACCT GATAGCACCT GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17 GCCCAT -17
C86 Bo_1 CaM10_6 CaM10_21 N2.6-RC N2.95 N2.01 PC	ATAAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC	GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA		AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC	120 ACCACTCGAA ACCACTCGAA GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17
C86 Bo_1 CaM10_6 CaM10_21 N2.6-RC N2.95 N2.91-RC N2.97-RC	ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC	GTACGATGT GTACGATGT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA	100 I CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	AATQTCGTAC AATQTCGTAC AATQTCGTAC AATQTCGTAC AATQTCGTAC AATQTCGTAC	120 I ACCACTCGAA ACCACTCGAA GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17
C86 Bo_1 CaM10_6 CaM10_21 N2.6-RC N2.95 N2.91-RC N2.87-RC N2.87-RC N2.92 96	ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC	GTACGATGT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA	CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC	120 ACCACTCGAA ACCACTCGAA GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17
C86 Bo_1 CaM10_6 CaM10_21 N2.6-RC N2.91-RC N2.91-RC N2.87-RC N2.96-RC	ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC	CT ACGATGTT GT ACGATGTT GT ACGATGTT GT ACGATGTT GT ACGATGTT GT ACGATGTT GT ACGATGTTT GT ACGATGTT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA	CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC	120 I ACCACTCGAA GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17
C86 Bo_1 CaM10_6 CaM10_21 N2.6-RC N2.91-RC N2.91-RC N2.96 N2.76-RC N2.45-RC	ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC ATAAAATGTC	BO TACGATGT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA	100 CG AT AGC AT A CG AT AGC AT A	AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC	120 ACCACTCGAA ACCACTCGAA GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17 GCCCAT -17
C86 B0_1 CaM10_6 CaM10_21 N2.6-RC N2.91-RC N2.91-RC N2.91-RC N2.96-RC N2.76-RC N2.45-RC N2.45-RC N2.45-RC	AT AAAATGTC AT AAAATGTC	BO T GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGCGTA	100 CCATAGCATA CCATAGCATA CCATAGCATA CCATAGCATA CCATAGCATA CCATAGCATA CCATAGCATA CCATAGCATA CCATAGCATA	AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC AATGTCGTAC	120 1 ACCACTCGAA GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT GATAGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17
C86 Bo_1 CaM10_6 CaM10_26 N2.95 N2.91-RC N2.95 N2.91-RC N2.7-RC N2.7-RC N2.7-RC N2.45-RC N5_23 N2.49-RC	AT AAAAT GTC AT AAAAT GTC	en GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA	100 1 CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	AAT GTCGTAC AAT GTCGTAC	120 ACCACTCGAA GAT AGCACCT GAT AGCACCT	CATCAC -9 CCACAC -9 GCCCAT -17 GCCCAT -17
C86 B0_1 C3M10_6 C3M10_21 N2.6-RC N2.91-RC N2.95-RC N2.96-RC N2.45-RC N2.45-RC N5.23 N2.49-RC N2.49-RC	AT AAAAT GTC AT AAAAT GTC	GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA	100 CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	AAT GT CGT AC AAT GT CGT AC	120 120 1 ACCACTCGAA ACCACTCGAA GAT AGCACCT GAT AGCACCT	CATCAC 9 CCACAC 9 GCCCAT 17 GCCCAT 17
C86 B0_1 CaM10_6 CaM10_6 CAM10_6 R2.95 N2.91-RC N2.95-RC N2.96-RC N2.76-RC N2.76-RC N2.76-RC N2.45-RC N2.45-RC N2.49-RC N2.49-RC N2.94-RC N2.94-RC N.5.62	AT AAAATGTC AT AAAATGTC	60 T GTACGATGGT GTACGATGGT GTACGATGGT GTACGATGGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT	AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA AAATGTCGTA	100 1 CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	ATT GTCGTAC AATT GTCGTAC		CATCAC 9 CCACAC 9 GCCCAT 17 GCCCAT 17
C86 Bo_1 CaM10_6 CaM10_26 N2.95 N2.91-RC N2.95 N2.91-RC N2.96-RC N2.45-RC N2.45-RC N2.45-RC N2.94-RC N2.95-RC N2.97-RC N2.96-RC N2.97-RC N2.96-RC N2.96-RC N2.96-RC N2.97-RC N2.96-RC N2.97-RC N2.96-RC N2.96-RC N2.97-R	AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT	AAAT GT CGTA AAAT GT CGTA	100 CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA CCG4TAGCATA		120 ACCACTCGAA ACCACTCGAA ACCACTCGAA ACCACCTGAA ACCACCTGAA CATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT	CATCAC 9 CCACAC 9 CCACAC 9 CCCAT 17 GCCCAT 17
C86 Bo_1 CaM10_6 CaM10_6 CaM10_6 N2.95 N2.91-RC N2.87-RC N2.96-RC N2.76-RC N2.96-RC N2.94-RC N2.94-RC N2.94-RC N2.97 N5.61 N5.52 N5.52	AT AAAAAT GTC AT AAAAT GTC	60 T T G T ACGAT G IT G T ACGAT G IT			ATTCTCGTAC AATTCTCGTAC AATTCTCGTAC AATTCTCGTAC AATTCTCGTAC AATTCTCGTAC AATTCTCGTAC AATTCTCGTAC AATCTCCGTAC AATCTCCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC AATCTCGTAC	120 ACCACTCGAA ACCACTCGAA ACCACTCGAA GAT AGCACCT GAT AGCACCT	CATCAC 9 CCACAC 9 CCCCAT 17 GCCCAT 17
C86 B0_1 CaM10_21 N2.95-RC N2.95 N2.91-RC N2.96-RC N2.91-RC N2.45-RC N2.45-RC N2.45-RC N2.49-RC N2.94-RC N2.95-RC N2.	AT AAAAAT GTC AT AAAAT GTC	GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA	100 CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA		120 ACCACTCGAA ACCACTCGAA ACCACTCGAA ACCACTCGAA ACCACCTGAA CATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT GATACCACCT	CATCAC 9 CCACAC 9 CCACAC 9 CCCCAT 17 GCCCAT 17
C86 B0_1 CaM10_26 CaM10_21 N2.6 RC N2.95 N2.91-RC N2.95-RC N2.95-RC N2.45-RC N2.45-RC N2.45-RC N2.49-RC N5.62 N5.23 N5.22 N5.12 N5.22 N	AT AAAAAT GTC AT AAAAT GTC	GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAAA GTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAT CTCGTA AAAT CTCGTA AAAT CTCGTA AAAT CTCGTA AAAT CTCGTA AAAT CTCGTA AAAT CTCGTA	100 1 CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	ATT GTGTAC AAT GTGGTAC AAT GTGGTAC	120 ACCACTCGAA ACCACTCGAA ACCACTCGAA GAT AGCACCT GAT AGCACCT	CATCAC 9 CCACAC 9 CCACAC 9 CCACAC 9 CCCCAT 17 CCCCAT 17 CCCCCAT 17 CCCCCAT 17 CCCCCAT 17 CCCCCAT 17 CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
C86 B0_1 CaM10_21 N2.6 RC N2.91 RC N2.91 RC N2.91 RC N2.91 RC N2.94 RC N2.94 RC N2.94 RC N2.94 RC N5.62 N2.94 RC N5.62 N5.12 N5.12 N2.51 2 N2.53 RC	AT AAAAATGTC AT AAAATGTC AT AAAATGTC	CTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA		AAT GTCGTAC AAT GTCGTAC		CATCAC 9 CCACAC 9 GCCCAT 17 GCCCAT 17
C86 B0_1 CaM10_26 CaM10_21 N2.6 RC N2.95 N2.91-RC N2.91-RC N2.95-RC N2.76-RC N2.45-RC N2.49-RC N5.62 N2.49-RC N5.23 N5.12 N5.12 N5.12 N5.22 N5.12 N5.22 N5.12 N5.22 N5.12 N5.22 N5.12 N5.22 N5.12 N5.22 N5.12 N5.23 N	AT AAAAT GTC AT AAAAT GTC	BO T T GTACGAT G GTT GTACGAT G GTT		100 1 CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	ATT GTGTAC AATT GTGTAC	120 ACCACTCGAA ACCACTCGAA ACCACTCGAA GAT AGCACCT GAT AGCACCT	CATCAC 9 CCACAC 9 CCACAC 9 CCACAC 9 CCACAC 9 CCCCAT 11 CCCCAT 11 CCCCCAT 11 CCCCCAT 11 CCCCCAT 11 CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
C86 B0_1 CaM10_21 N2.6 RC N2.91 - RC N2.91 - RC N2.91 - RC N2.91 - RC N2.94 - RC N2.94 - RC N2.94 - RC N2.94 - RC N5.62 N5.	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	CTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA	100 1 CGATAGCATA	ATT GTCGTAC AATT GTCGTAC		CATCAC 9 CCACACA 9 GCCCAT 17 GCCCAT 17
C86 B0_1 CaM10_26 CAM10_21 N2.6 RC N2.95 N2.91-RC N2.95 N2.76-RC N2.94-R	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	60 1 CTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGTT GTAGGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAAT CI CGTA AAAT CI CGTA	100 1 CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA	ATT CGTAC AATT CGTAC		CATCAC 9 GCACAC 9 GCACAC 9 GCCCAT 11 GCCCAT 11
C86 B0_1 CaM10_21 N2.6RC N2.95 N2.91-RC N2.95 N2.76-RC N2.94-RC N2.94-RC N2.94-RC N2.94-RC N5.62 N5.65 N5.62 N5.65 N5	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	CTACGATGTT GTACGATGTT	AAAT GTCGTA AAAT GTCGTA		ATT GTCGTAC AATT GTCGTAC		CATCAC 9 CCACACAC 9 GCCACAT 17 GCCCAT 17
• C86 B0_1 CaM10_26 CaM10_21 CaM10_21 CaM295 N2.91-RC N2.95-RC N2.95-RC N2.76-RC N2.45-RC N2.45-RC N2.94-RC N2.94-RC N2.97 N5.12 N2.97 N5.12 N2.93 RC N2.93 RC N2.93 RC N2.93 RC N2.94 RC N2.91 N5.12 N5.14 N5.41 N5.44	AT AAAAAT GTC AT AAAAAT GTC AT AAAAT GTC	GTACGATGTT GTACGATGTT	AAAT CITCGTA AAAT CITCGTA	100 1 CG AT AGC AT A CG AT	ATT CGTAC AATT CGTAC	120 ACCACTCGAA ACCACTCGAA ACCACTCGAA GAT AGCACCT GAT AGCACCT	CATCAC 9 GCACAC 9 GCACAC 9 GCCCAT 11 GCCCAT 11
C86 B0_1 CaM10_21 N2.6 RC N2.91 - RC N2.91 - RC N2.91 - RC N2.91 - RC N2.94 - RC N2.94 - RC N2.94 - RC N2.94 - RC N2.94 - RC N2.94 - RC N5.62 N5.64 N5.65 N5.64 N5.64 N5.65 N5.64 N5.65 N5.65 N5.65 N5.65 N5.65 N5.65 N5.65 N5.65 N5.65 N5.65 N5.65 N5.65	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	CTACGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT GTACGGATGTT	AAAT GTCGTA AAAT GTCGTA		ATTCTCGTAC AATTCTCGTAC	120 121 ACCACTOGAA ACCACTOGAA ACCACTOGAA GAT AGCACCT GAT AGCACCT	CATCAC 9 CCACACAC 9 GCCACAT 17 GCCCAT 17 GCCCA
C86 B0_1 CaM10_21 N2.6-RC N2.95 N2.91-RC N2.95-RC N2.95-RC N2.76-RC N2.45-RC N2.45-RC N2.45-RC N2.94-RC N2.94-RC N2.94-RC N2.94-RC N5.22 N2.97 N5.12 N2.82 N2.53-RC N2.94-RC N2.93 N5.44 N5.4	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA	100 1 CGATAGCATA	ATT CGTAC AATT CGTAC		CATCAC 9 GCACAC 9 GCACAC 9 GCCCAT 11 GCCCAT 11
C86 B0_1 CaM10_21 N2.6 RC N2.91 -RC N2.91 -RC N2.91 -RC N2.94 -RC N2.94 -RC N2.94 -RC N2.94 -RC N2.94 -RC N2.94 -RC N2.94 -RC N2.94 -RC N5.62 N5.62 N5.62 N5.62 N5.62 N5.62 N5.73 N5.74 N5.75	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	BO T CTACGATG CT CTACGATG CT C			ATT CGTAC AATT CGTAC		CATCAC 9 CCACACAC 9 GCCCAT 11 GCCCAT
C86 B0_1 CaM10_21 N2.67CC N2.95 N2.91-RC N2.95 N2.76-RC N2.96-RC N2.45-RC N2.94-RC N5.62 N2.97 N5.29 N5.29 N5.29 N5.29 N5.23 N2.73-RC N5.44 N5.53 N2.73-RC N5.44 N5.73 N5.53 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.74 N5.72 N5.74 N5.7	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA				CATCAC 9 GCACAC 9 GCACAC 9 GCCCAT 11 GCCCAT 11
C86 B0_1 CaM10_21 N2.6 RC N2.91 -RC N2.91 -RC N2.91 -RC N2.94 -RC N5.94 -	AT AAAAATGTC AT AAAATGTC AT AAAATGTC	60 1 CTACGATCGTT GTACGATCGTT		100 1 CGAT AGC ATA CGAT AGC	ATT CGTAC AATT CGTAC		CATCAC 9 CCACACAC 9 CCACACAC 9 CCACACAC 9 CCACACAC 9 CCACACACACACACACACACACACACACACACACACAC
C86 B0_1 CaM10_26 CAM10_21 N2.67C N2.95 N2.91-RC N2.95 N2.91-RC N2.94-RC N2.94-RC N2.94-RC N2.94-RC N2.94-RC N2.94-RC N2.94-RC N2.92 N2.92 N2.92 N2.92 N2.92 N2.92 N2.92 N2.93-RC N5.44 N5.44 N5.44 N5.44 N5.44 N5.44 N5.52 N2.73-RC N5.44 N5.44 N5.52 N2.73-RC N5.44 N5.52 N2.73-RC N5.54 N5.52 N5.52 N5.52 N5.52 N5.52 N5.52 N5.53 N5	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GTCGTA AAAT GTCGTA	100 CGAT AGC ATA CGAT AGC AT			CATCAC 9 GCACACAC 9 GCACACAC 9 GCCCAT 11 GCCCAT 11 GCCCA
C86 B0_1 CaM10_21 N2.6 RC N2.95 N2.91 RC N2.91 RC N2.94 RC N2.9	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAA GTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAAT CTCGTA AAAT CTCGTA	100 1 CGATAGCATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATA	ATT CGTAC AATT CGTAC A		CATCAC 9 CCACACAC 9 CCACACAC 9 CCACACAC 9 CCACACAC 9 CCCCAT 11 CCCCAT 11 CCCCCAT 11 CCCCCAT 11 CCCCCAT 11 CCCCCAT 11 CCCCCAT 11 CCCCCAT 11 CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC
5% C86 B0_1 CaM10_21 N2.95 N2.91-RC N2.95 N2.91-RC N2.95 N2.76-RC N2.45-RC N5.62 N5.62 N5.62 N5.62 N5.62 N5.42 N5.32 N2.73-RC N5.44 N5.45 N5.44 N5.45 N5.41 N5.42 N5.42 N5.42 N5.42 N5.42 N5.44 N5.44 N5.44 N5.44 N5.44 N5.44 N5.44 N5.45 N5.45 N5.47 N5.42 N5.47 N5.42 N5.42 N5.41 N5.43 N5.43 N5.44 N5.44 N5.44 N5.44 N5.44 N5.45 N5.44 N5.47 N5.42 N5.47 N5.42 N5.47 N5.41 N5.42 N5.41 N5.44 N5.	AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GTCGTA AAAT GTCGTA	100 CCGATAGCATA			CATCAC 9 GCACACAC 9 GCACACAC 9 GCCCAT 11 GCCCAT 11 GCCCA
C86 B0_1 CaM10_21 N2.6 RC N2.95 N2.91 RC N2.91 RC N2.94 RC N5.12 N5.12 N5.14 N5.74 N5.74 N5.74 RC N5.74 RC N	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTAGGATGT GTAGGATGT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTAGGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT GTACGATGTT	AAAT CICGTA AAAT CICGTA	100 1 CGATAGCATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATAGCATA CGATA	ATT CGTAC AATT CGTAC A		CATCAC 9 GCACACAC 9 GCCACAT 17 GCCCAT 17 GCCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCC
C86 B0_1 C3M10_21 N2.05RC N2.95 N2.91-RC N2.95 N2.91-RC N2.95 N2.75-RC N2.45-RC N2.45-RC N2.45-RC N2.94-RC N5.23 N2.49-RC N5.24 N5.22 N5.12 N5.12 N5.12 N5.32 N2.73-RC N5.44 N5.32 N2.73-RC N5.45 N5.44 N5.47 N5.47 N5.42 N5.41 N5.47 N5.41 N5.24 N5.37 N5.41 N5.41 N5.41 N5.24 N5.37 N5.41 N	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GTCGTA AAAT GTCGTA	100 CCGAT AGC ATA CCGAT AGC AT			CATCAC 9 GCACACAC 9 GCCCAT 17 GCCCAT 17 GCCCCAT 17 GCCCAT 17 GCCCCAT 17 GCCCAT 17 GCCCCAT 17 GCCCAT 17 GCCCCAT 17 GCCCCAT 17 GCCCCAT 17
C86 B0_1 CaM10_21 N2.67RC N2.95 N2.91-RC N2.87-RC N2.91-RC N2.94-RC N2.9	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGGTT GTAGGATGTT GTACGATGTT	AAAAT GT CGTA AAAAT GT CGTA AAAAT GT CGTA AAAAT GT CGTA AAAAT GT CGTA AAAAT GT CGTA AAAT GT CGTA	100 CGAT AGCATA CGAT AGCATA	ATT CGTAC AATT CGTAC A		CATCAC 9 GCACACAC 9 GCACACAC 9 GCCCAT 11 GCCCAT 11 GCCCA
C86 B0_1 C3M10_21 N2.6RC N2.95 N2.91-RC N2.95 N2.91-RC N2.95 N2.76-RC N2.95 N2.43-RC N5.22 N5.22 N5.27 N5.42 N5.22 N5.12 N5.22 N5.12 N5.22 N5.12 N5.32 N2.73-RC N5.44 N5.73 N5.73 N5.74 N5.75 N5.74 N5.74 N5.74 N5.75 N5.74 N5.74 N5.74 N5.74 N5.75 N5.74 N5.74 N5.74 N5.74 N5.75 N5.74 N5.75 N5.74 N5.74 N5.75 N5.74 N5.74 N5.74 N5.75 N5.75 N5.74 N5.74 N5.75 N5.75 N5.75 N5.74 N5.74 N5.74 N5.75 N5.75 N5.75 N5.74 N5.75 N5.74 N5.75 N5.74 N5.74 N5.74 N5.74 N5.75 N5.74	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA	100 CCGATAGCATA	AAT GT CGT AC AAT GT CGT AC AC AC GT AC AC GT AC AC GT AC AC GT AC AC AC GT AC AC AC AC AC A		CATCAC 9 GCACACAC 9 GCCCAT 17 GCCCAT 17 GCCCCAT 17 GCCCAT 17 GCCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCAT 17 GCCCACAC 9 GCCACAC 17 GCCACAC 17 GCCCACAC 17 GCCCAT 17 GCCCAT 17
C86 C86 B0_1 CaM10_21 CAM10_2 CAM10_2 CAM10_21 CAM10_2	AT AAAAAT GTC AT AAAAAT GTC AT AAAAT GTC	GTACGATGTT GTACGATGTT	AAAT CI CGTA AAAT CI CGTA	100 CGATAGCATA C	ATT CGTAC AATT CGTAC A		CATCAC 9 GCACACAC 9 GCACACAC 9 GCCCAT 11 GCCCAT 11 GCCCA
C86 B0_1 C3M10_21 N2.6RC N2.95 N2.91-RC N2.95 N2.91-RC N2.95 N2.76-RC N2.95 N2.76-RC N2.95 N2.75-RC N2.95 N2.73-RC N5.12 N5.22 N5.12 N2.92 N5.12 N2.93-RC N5.44 N5.73 N5.73 N5.74	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA	100 CCG4TAGCATA			CATCAC 9 GCACACAC 9 GCCACAT 17 GCCCAT 17 GCCCA
• • • • • • • • • • • • • • • • • • •	AT AAAAAT GTC AT AAAAAT GTC AT AAAAT GTC	GTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA	100 CGATAGCATA C	ATT CGTAC AATT CGTAC A		CATCAC 9 GCACACAC 9 GCACACAC 9 GCCCAT 11 GCCCAT 11 GCCCA
C86 B0_1 CaM10_21 N2.6RC N2.95 N2.91-RC N2.95 N2.91-RC N2.45-R2 N2.92 N2.74-RC N2.45-R2 N2.92 N5.12 N5.22 N5.12 N2.81-RC N5.12 N2.81-RC N5.73-RC N5.73-RC N5.73-RC N5.73-RC N5.74	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GT CGTA AAAT GT CGTA	100 CCG4TAGCATA CCATAGCATA			CATCAC 9 GCACACA 9 GCCACAT 17 GCCCAT 17 GCCAAC 9 GCCACAC 9 CCACAC 9 CC
5% C86 B0_1 C80 C80 C80 Call 10_21 Call 20, 295 N2.91-RC N2.95 N2.91-RC N2.95 N2.76-RC N2.94-RC N5.62 N2.97 N5.22 N5.23 N2.73-RC N2.93-RC N5.44 N5.74 N5.74 N5.77 N5.242 N5.242 N5.273 RC N5.273 N5.66 N5.73 N5.74 N5.74 N5.24 N5.71 N2.89-RC N5.54 Consensus Consensus	AT AAAAATGTC AT AAAAATGTC AT AAAATGTC AT AAAATGTC	GTACGATGTT GTACGATGTT	AAAT GTCGTA AAAT GTCGTA		ATT CGTAC ATT CG		CATCAC 9 GCACAC 9 GCACAC 9 GCCCAT 17 GCCCAT 17
C86 B0_1 CaM10_21 N2.6RC N2.97 N2.91-RC N2.91-RC N2.91-RC N2.94-RC N5.12 N5.12 N5.12 N5.12 N5.12 N5.24 N5.27 N5.24 N5.25 N5.24 N5.25 N5.24 N5.24 N5.25 N5.24 N5.24 N5.25 N5.24 N5.24 N5.24 N5.24 N5.24 N5.24 N5.24 N5.24 N5.24 N5.25 N5.24 N5.24 N5.24 N5.24 N5.26 N5.26 N5.26 N5.26 N5.24 N5.26 N5.24 N5.26 N5	AT AAAATGTC AT AAAATGTC			100 CCATTAGCATA CCATTAGCATA CCATAGCATA	AAT GT CGT AC AAT GT CGT AC AT G		CATCAC 9 CCACAC 9 GCCCAT 17 GCCCAT 1

Figure S3. Analysis of the insertions in the promoter region of Pfcyp51 gene in *Pseudocercospora fijiensis* progeny strains in both the N2 and N5 mapping populations. The promoter modifications start at -94 bp upstream of the *Pfcyp51* start codon of the reference sequence. Element "A" is shown in blue boxes together with the arrangement of the palindromic sequence TCGTACGA shown in green boxes. Element "A*" is shown in red as a partial construction of element "A" in purple. Negative values in the right bottom represent the positions from the beginning of the insertion related to the start codon of the gene.



Figure S4. *Pseudocercospora fijiensis* strains sorted according to the positions of the recombination events in the chromosomal region harbouring the *Pfcyp51* sensitivity gene. A) Mapping population N2 and B) Mapping population N5. The markers descending from the highly sensitive parent are coded "a" and shown in light red boxes, whereas the chromosomal segments inherited from the resistant parent genotype are coded "b" and shown in light green boxes. The unknown values are represented by dashes in grey boxes (-). The DArTseq markers fully co-segregating with sensitivity are shown in light blue with the sensitivity trait shown in yellow. The flanking markers are shown in red.



and N5 mapping populations that contains the sensitivity region. The cyp51 gene is highlighted in green. The figure was taken from the Figure S5. Scheme of the position of the 53 putative genes found in the overlapping genetic window of the *Pseudocercospora fijiensis* N2 Ensemble fungi portal website, http://fungi.ensembl.org/Pseudocercospora_fijiensis_cirad86/Location/View?r=MYCFIscaffold_7:1879787-2130447;site=ensemblthis;db=core.

Other Bills Coverage Scription Score Scription Score Marce Sequence Score Marce Score Marce Score Marce Score Marce Score Marce Score			_			-		_	_	_		_				_	_	
more towardscoverage sentimcartred sentimMaterial 								0.078	0.080		0.078	090.0	0.961	0.021	090.0	0.021	0.020	0.979
Other Biology B								0.947	0.919		0.925	0.947	0.000	1.000	1.000	1.000	1.000	0.000
More serves Coverage % Saffind Marken Sequence Marken Sequence 610 86.00 96.55 7 1600340 End Sequence Sequence 610 86.00 96.55 7 1600340 EG04402 TGCAGATTTATGATTGAGATTGAGAGGGAGAGATTTATGATGA	0.960	0.960	0.960	0.959	0.040	0.043	0.022	0.022	0.021	0.021	0.021	0.020	1.000	0.021	0.021	0.021	0.000	1.000
Nome before b	0.091	0.070	0.091	0.070	0.927	0.929	1.000	1.000	1.000	1.000	1.000	1.000	0.000	1.000	1.000	0.976	1.000	000.0
Mome letence score Coverage % bestifit Scarfoid Beginning Reference conner Position 100 68.00 98.55 7 1600334 1600402 100 68.00 98.55 7 1620537 162045 100 68.00 98.55 7 1726456 1726491 100 65.00 94.20 27(7) 6204 6569 100 65.00 94.20 27(7) 6204 6569 100 65.00 94.20 7 1772634 1772631 100 65.00 98.55 7 1772634 1772631 100 65.00 98.11 7 1772634 1772631 100 65.00 98.11 7 1772634 1772631 100 65.00 98.11 7 1772634 1772631 100 65.00 98.11 7 1772634 1772631 100 65.00 98.11 7 1772634 1772631 <	TGCAGCAGGCAATGCTTATACCTAGGCTGCTAC TTAGGGACGTAGTGCTTATACCTAGGCTGCTAC TTAGGGACGTAGTCGTAGTCTAGGTTGT	A DECAGORANCE AND AN AND AND	TGCAGCAGGCAAATGCTTATCCTAGGCTGCTAC TTAGGGACGTAGTCGTAGTCTAGGTTCTAGGTTGT	TGCAGGACGCGTGCCAGGCAGAGTGGGGCCTGC TTGACTTTGAGCAGCGCAGAGCGCAAAGGA	TGCAGGACGCGTGCCCAAGCCAGGCGTGGGGCCTGC TTGACTTCGACTTTGAGGAGCTCTGGCCAAACGAT	TGCAGCGTTCTCAACAGGGTCCTGATGGCAGGAGG AACGAGGGGGGGGGTTATTACAGATCGGAAGAGCG	TGCAGTATCITTCTAACTAGACAAGACCTACATT ACTTATACTGTTCCAGAAGAGAGGGGTTCAG	TGCAGCTGCTAGAAAGATAATAGCAGGATGAT AATAACGAGTGTAAATCAGATCGGAAGG	TGCAGTAGTAGTAGTAGCGCAGTTAGAAGTTAGA TATTGTATTAGAGGTAAGGGTTTACAGATCGGAAGA	TGCAGTAACAATAAGGTGTTATATAGCTATGTAAA TTACAGATCGGAAGAGGGGGTTCAGCAGGAATGCC	TGCAGAGGTAGAATTCTTCCATTGCCTTCTCGCAA TGCAAGGATATGCGCAAATGTAACATACATACAT	TGCAGGAGTATTACTTCGCGAAGCACCGGGGTAGC TTCGATGAGGTTGCTAGGCCGTCTAGAACCCGCGT	TGCAGGTTTTCTTTTAGTTCCTAGGTGTTTTCTAA ATATAGGTATCCTTTCTATTTGATAAGGTATTTC	TGCAGTTTGAAATATTCTACAATGCCATAGTTCTC ATCGGCCATGCAATTACAGATCGGAAGAGCGGGTT	TGCAGGAGAATCTTCCAGGCCATCAGGGTAGGGT CTTCGCCGTTGATTGGTGGAGGGGGGGGGG	TGCAGCTCCCTCGACCGTAGTTATCTGTA CAGAGCGGAGAATCTCTCGAGTCAGCGGTCGCCA	TGCAGCAGTTTTCCTGAACCGGGGCTTCCGATGTGC AGGCTTTCATGGAGCTCGGGAGCTAATGCTTCTGG	TGCAGTTTTCCTGAACDGGGCTTCCGATATGCAGG CTTTCATGGAGCTCGGGGCTAATGCTTCTGGGCCG
nome erence score coverage % coverage best hit best hit ReferenceGe 100 68.00 98.55 7 160034 100 68.00 98.55 7 160034 100 68.00 98.55 7 1620637 100 68.00 98.55 7 1526456 100 65.00 94.20 27(7) 6204 100 65.00 94.20 17 172634 100 65.00 94.20 1 371382 100 65.00 94.20 1 371382 100 65.00 94.20 1 371382 100 65.00 94.20 7 1779032 100 65.00 94.20 7 1779032 100 65.00 94.20 7 1779032 100 53.00 76.81 7 1779032 101 53.00 7 7 1779032 101 53.00 7	371447	6269 371447	371447	1772702	1772681	1779145	ć	ć	ć	ć	1879380	1879852	1561649	ė	1959758	2021793	2021996	2021999
nome coverage Scarford Scarford <th< td=""><td>371382</td><td>6204 371382</td><td>371382</td><td>1772634</td><td>1772634</td><td>1779092</td><td>ć</td><td>ć</td><td>ć</td><td>ć</td><td>1879315</td><td>1879787</td><td>1561581</td><td>ċ</td><td>1959690</td><td>2021725</td><td>2021928</td><td>2021932</td></th<>	371382	6204 371382	371382	1772634	1772634	1779092	ć	ć	ć	ć	1879315	1879787	1561581	ċ	1959690	2021725	2021928	2021932
nome coverage Coverage erence \$5.00 98.55 100 68.00 98.55 100 68.00 98.55 100 68.00 98.55 100 68.00 98.55 100 65.00 94.20 100 65.00 94.20 100 65.00 94.20 100 65.00 94.20 100 65.00 94.20 100 65.00 94.20 100 65.00 94.20 100 65.00 94.20 101 53.00 7 7 101 53.00 7 7 101 53.00 7 7 101 53.00 7 7 101 53.00 7 7 101 50.00 94.20 7 101 65.00 94.20 7 100 65.00 94.20 7	-	27(?) 1	-	7	7	7	9 & 17(?)	ć	ć	ć	7	7	7(?)	ċ	7	7	7	7
Monue coverage (ID 68.00 100 68.00 100 68.00 100 68.00 100 68.00 100 68.00 100 65.00 100 65.00 100 65.00 100 65.00 100 65.00 100 65.00 100 65.00 100 65.00 100 65.00 101 65.00 101 65.00 101 65.00 100 65.00 100 65.00 100 65.00	94.20	94.20 94.20	94.20	98.55	68.11	76.81	59.42	2	ć	ć	94.20	94.20	98.55	ė	98.55	98.55	98.55	97.10
mome etendos (si D 100 100 100 100 100 100 100 100 100 10	65.00	65.00 65.00	65.00	68.00	47.00	53.00	41	2	6	Low	65.00	65.00	68.00	Low	68.00	68.00	68.00	67.00
Generation of the second secon	100	100	100	100	100	100	two hits	many hits	many hits	many hits	100	100	100	many hits	100	100	100	100
N5 D code 								12410844	12389607		12389384	12397726	12412057	12411328	12389492	12408335	12404162	12407731
N2 Marker1 12409914 124099189 12409189 12410366 124103600 124096800 124096800 124096800 124103616 12410816 12410816 123894907 123894607 123898607 123898607 12389384 123895855 123895855 123895855 123895855 123895855 12389555 12385555 1238555555555555555555555555555555555555	12409680	12412405 12409680	12409680	12403800	12389490	12410413	12410616	12410844	12389607	12406367	12389384	12397726	12412057	12411328	12389492	12408335	12404162	12407731

Table S1. Sequence information of the DArTseq markers used to generate the Pseudocercospora finiensis N2 and N5 population linkage maps. The markers were selected based on their co-segregation with the sensitivity trait.

gregation	Recictant	0.039	0.960	0.020	0.021	0.000	0.038	0.020	0.956	0.020	0:060	0.020	0.022	0.058	0.039	0.021	0.021	0.058	0.059	0.020		0.955	0.929
N5 sensitivity se score	Sensitive	1.000	0.000	1.000	1.000	1.000	1.000	1.000	0.000	1.000	0.974	1.000	1.000	1.000	1.000	1.000	1.000	0.974	1.000	1.000		0.000	0.000
segregation	Recictant	0.020	1.000	0.021	0.021	0.020	0.020	0.020	1.000	0.000	0.065	0.061	0.063	0.061	0.064	0.061	0.061	0.061	0.061	0.060	0.086		0.956
N2 sensitivity s	Sencitive	1.000	0000	1.000	1.000	1.000	0.976	1.000	0.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	1.000	0.974	1.000		0.000
Markar Continued		TGCAGGATGTGGCAGTTTGGGCTTAGAATGCA AGAAGAATTG1GTTTTGAGTDCGGCCAATGTGTC	TIGCAGAGCTGTCATCTCCTACCBACGGAATGTGTCT GGGAAAGGGGGTCAATGCTGGTGCATATGGCCAT	TGCAGCGCTGTCATCTCCTACCAACGGATGTGTCT GGGAAAGGCGGTCAATGCTGGTGGTATGGCCAT	TGCAGAGGGGCTCGCACTCAGGGGGCAGGCAT GAGCAGATACGCAAGTGCATGGGCAAGATCTCGAA	TGCAGCGCAGGCATTTGGCAT TCTGGCTTCGCATC CAAGCGCAAGAGCCCAGCAGCAAGCTTGCACAGCT	TECAETCATEGCBACCATEGCTEATTEGATTTEA GTAAGGTTAGEGAAAACTCGGTCCBACCGTCCAACGTE	TGCAGTTTGAGGGGAAGGATTGGTTGCTTGCCCA GTCGATGAATTCAACACTGGGTACAGCATCTGGG	TGCAGACTCCGACCAAGGCTAGAGTTATCACATAG TAAACTAAATGGATCGGCGGAATGGCTGCAAGT	TGCAGCGCCTACCCACGCAGCCACAGGCATCACC TTTGTCTC3GGTTCAGATCGGAGGAGGAGCGGGTTCAGC	TGCAGCTCGGTTGGGCTTCGTGGACGCACTTGAGATG TTATGCTGCGGTTGAGTGAGAAGATTCAGAAGC	TGCAGCTAAGAGCCTACCGCCCGAAGAACAAT ACACTAGCTGCACCTAGGTAGCTACTAGCAATAA	TGCAGTCAAGCAAGTGCAGACTTGGTCCATGGAAA GAGCGGGTCTTACAGATCGGAAGAGCGGTTCAGC	TGCAGTAGTAGTAGCATTCAATTCAATATCTACTA TATTACAGATCGGAAGAGCGGGTTCAGCAGGAATG	TGCAGGAATAC9CACTCTCTAGAC9TC3GTAG CTATTCCTAAAATTGCACTTAGGACAGCTCTTATA	TGCAGTAGTGOCTGTTGCGACGGGTATAGGOSTCT TAGTCGTATTATTCTTACAGATCGGAAGAGGGGGT	TGCAGACCGGCCCGCTAGCGGCGCTATTACAGATC GGAAGAGCGGGTTCAGCAGGAAGGCGAGACCGAT	TGCAGTACTITATAACAACGAAACAGAACGAACGAACGAACGAACGAAC CGGAAGAGCGGTTCAGCAGGAATGCCGAAGACCGA	TGCAGTAAACCOGCCTACTTTACAGATOSGAAGA GCGGTTCAGCAGGAATGCOSAGACOSATOTOCTA	TGCAGGTAGTAGTAGTAGTAGTATTCCGTCCTT TAGTAGGTAGTAGTAGTAGTAGTAAGTAAGTAAGTAA	TGCAGCCGGGAACGCGTACGGGGGGGGCACCGTAC TTGTTTGTAGACGACGGCGAGGGTAGGGCTAGG	TGCAGAACTGTTAGTAGATAATCAAAAATTTCAA AACCGAATAAAAAGAAATAACTAGTATAGGAAT	TGCAGAACACTCCTGGGAACTCACATCTCAGCAT CGTTGTTTTGCTGCGTAGGAAACATGGGGATGCGC
nome Position	End	2053937	2060467	2060467	2086806	2093479	2093544	2096405	2116259	2119816	2130515	4164554	2135321	ė	ė	ć	ė	ė	ė	ć	513826	ć	2145537
ReferenceGe	Rectioning	2053869	2060399	2060399	2086738	2093411	2093476	2096337	2116191	2119772	2130447	4164497	2135277	ė	ė	ċ	ċ	ė	ė	ċ	513760	5	2145469
Scaffold	best hit	7	7	7	7	7	7	7	7	7	7	(j) g	7	ė	ė	ċ	ė	ė	1(?)	ė	2 (2)	2	7
Coverage	%	98.55	98.55	98.55	98.55	98.55	98.55	98.55	98.55	63.76	98.55	82.60	65.21	ė	ė	ė	ė	ė	ė	ė	95.65	2	98.55
coverage	score	68.00	68.00	68.00	68.00	68.00	68.00	68.00	68.00	44.00	68.00	57.00	45.00	ė	ė	ė	Low score	Low score	Low score	Low score	66.00	?	68.00
Genome		100	100	100	100	100	100	100	100	100	100	100	100	No hit	many hits	many hits	many hits	many hits	two hits	many hits	100	many hits	100
ςΝ) rode	12389489	12406518	12406517	12411995	12400645	12400691	12389586	12409026	12401391	12405280	12397704	12408748	12406369	12410930	12408983	12408494	12403131	12406338	12389524		12412318	12388740
N2	Marker IC	12389489	12406518	12406517	12411995	12400645	12400691	12389586	12409026	12401391	12405280	12397704	12408748	12406369	12410930	12408983	12408494	12403131	12406338	12389524	12410210		12388740

N2	N5	Genome Reference	coverage	Coverage	Scaffold	ReferenceGe	nomePosition	Narker Sentence	N2 sensitivi so	ty segregation core	N5 sensitivity s score	segregation e
Marker IC) code	dl%	score	8	besthit	Beginning	End		Sensitive	Resistant	Sensitive	Resistant
12403524	12403524	100	68.00	98.55	7	2160240	2160308	Techeagtcaatcattattectceceageaaagcacac Gaggetagatgatgattattectctectctec	1.000	090.0	0.967	0.057
12396542	12396542	100	68.00	98.55	7	2163974	2164042	TecaeAaACTCAGAGTCATGGTTTTGeGeOGSTCG CCCTGGTTTTCATCAAGAGAGAGAACATTATACAATC	0.000	0.951	0.000	0.957
12396543	12396543	100	68.00	98.55	7	2163974	2164042	TECAEAGECTCAGEGTCATEGTTTTGESCOSTOS CCCTGGTTTTCATCAAGAGAGAACATTATATATC	1.000	090:0	1.000	0.038
12405725	12405725	100	68.00	98.55	7	2164326	2164394	TECAEATCGAGACTICTTTECTTGACTCTACTTC CTCAEBCGAGACAECCETCEGTGECAAGCAAA	0.000	0.959	0.000	0.957
12405724	12405724	100	68.00	98.55	7	2164326	2164394	TECAEATICGAGACTICTITECTTGACTCGACTIC CTCAGGCAGACGGCCGTGTTCGTGGCAGGCAAG	1.000	0.065	1.000	0.020
12399874		100	68.00	98.55	7	2175183	2175251	TGCAGCCC4ACSCTCC3CCAGGAGCAGGTTC3A GCTCGGCAGGAGCAGGATCGGCAGGGTGAGCAGG	0.068	0.957		
12399875	12399875	100	00.89	98.55	7	2175183	2175251	TGCAGCCCAACGTCCCCCCAGATCAGGTTCGA GCTCGGCAGGAGCAGGATCGGCAGCGTGAGCAGG	0.925	090.0	0.947	0.096
12406320		many hits	Low score	i	ė	ė	ė	TGCAGCAATTICATCCTACITACITAGAGGTCCTT TAGATATACAGATCGGAAGAGGGGGTICAGCA	0.070	0.956		
12389553	12389653	many hits	Low score	i	i	ė	ė	TGCAGTCAGCGCAGATGGCCATCGATAATTGATG AGCGATAGGGCGGGCCGAGAAGCAGCTTATGAGA	0:930	0.063	0:950	0.078
	12406151	26	29.00	42.02	7	2177024	2177056	TGCAGCTCTGT03GT0CTTG03GTGG6GCT003AGA CCGACGCTGTCT00GGAAGGAGCQTGGGGTC			0:950	0.082
	12399094	93.9	25.00	36.23	7	2177225	2177257	TGCAGCCTGGCGTGGCATCTCCTTCGGCCTTAC AGATCGGAAGAGCGGTTCAGCAGGAATGCCGAAGA			0.950	0.080
12397650	12397650	many hits	Low score	i	i	ė	ė	TGCABAGCTCGCABAAGAGCGGGGGGGGGTGTACCAT CTTGCTCTGC3CGAGATGGCGGATGAGAATCTTGC	0:930	0.064	0.950	0.082
12403967		100	68.00	98.55	7	2207215	2207283	TGCAGTCCTGTATGGAGCCAGCAGATGGCTATTA CACCAATGGTGAGGCGCTATCTGAGTCGGGAGA	0.140	0.909		

Table S2. Sequence information of the *Pfcyp51* gene of the *Pseudocercospora fijiensis* parental isolates and the N2 and N5 progenies and their as sensitive and isolates with scores >1.00 mg.L⁻¹ were classified as resistant. Isolates with intermediate response are marked in orange. Isolates green background and resistant isolates with a red background based on their EC₃₀ scores where isolates with scores <0.2 mg.L⁻¹ were classified average EC₅₀ scores against the three DMI fungicides difenoconazole, epoxiconazole and propiconazole. Sensitive isolates are marked with

	cores	Propiconazole	0.018	11.750	>10.24	5.521	6.082	0.052	6.392	5.958	0.102	0.034	0.069	>10.24	>10.24	5.385	6.199	0/00
	ngicide EC ₅₀ average so	Epoxiconazole	0.013	7.496	5.036	6.886	4.059	0.026	3.693	5.966	0.089	0.016	0.036	4.855	5.553	2.690	2.320	0.064
	DMI fu	Difenoconazole	9:006	17,194	>10.24	9:086	2.900	0.017	9.420	8.313	660'0	0.014	0.028	8.749	>10.24	6.528	7,994	0.037
		A446	A446S	WT	WT	WT	TW	A446S	WT	TW	A446S	A446S	A446S	TW	WT	WT	د	A446S
		Y463	WT	Y463D	Y463D	Y463D	Y463D	WT	Y463D	Y463D	WT	TW	WT	Y463D	Y463D	Y463D	~	WT
	ions	A381	WT	WT	WT	WT	WT	WT	ΜT	WT	WT	M	WT	TW	WT	WT	6	M
	51 substitut	H380	MT	WT	WT	WT	ΜŢ	MT	WT	TW	MT	TW	MT	TW	WT	WT	6	TW
	ino acid CYF	A313	WT	A313G	A313G	A313G	A313G	WT	A313G	A313G	WT	MT	WT	A313G	A313G	A313G	6	
	Am	Y136	WT	Y136F	Y136F	Y136F	Y136F	MT	Y136F	Y136F	WT	TW	WT	Y136F	Y136F	Y136F	6	WT
		V106	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	V106D	6	V106D
		T18	T181	T18I	1181	T18I	T18I	T181	T18I	T18I	T181	T181	T18I	T18I	T18I	T18I	ć	T181
urks (?) remained undetermined.	Insertions in the promoter of the cyp51 gene	Promoter	WT	AAATCTGGT AGGATAGGAT AAATCTGGT AGGATAGGAT	AMATCTOST AGGATAGCAT AMATCTOST AGGATAGATAMATCTOST AGGATGTTAMATCTOSTAGGATAMA TCTOSTAGGA TAGCACCTGC CCAT	AARTCFGGT AGGRIAGCAT AAARTCFGGT AGGRIAGCAT AAARTCFGGT AGGRIGTTAAATCFGGTAGGATAGGATAAA TCFGGTAGGA TAGGAGCFGG CCAT	AARTCFGGF ACSAFFACAT AAARTCFGGF ACSAFFACAT AAARTCFGGF ACGATGFTAAATCFGGFACS ATAGCATAAA TCFGGFACGA TAGCACGFGC CCAT	WT	AMATCTOGT ACGATAGOAT AMATCTOGT ACGATAGOAT AMATCTOGT ACGATGTTAMATCTOGTACGATAGOATAGOATAGOACCTGC COAT	AARTCFGGT AGGRIAGCAT AAARTCFGGT AGGRIAGCAT AAARTCFGGT AGGRIGTTAA ATCFGGTAGG ATAGCATAAA TCFGGTAGGA TAGCAGCFGG CCAT	WT	M	WT	AMATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAA ATCTCGSTACGA ATAGCATAAA TCTCGSTACGA TAGCACCTGC CCAT	AAATCTGGT AGGATAGGAT AAATCTGGT AGGATAGGAT	AMECTOST ACGATAGCAT AMATCTOST ACGATAGCAT AMATCTOST ACGATGTTAAATCTOSTACGATAGCATAAA TCTOSTACGA TAGCACCTGC CCAT	6	M
estion ma		Isolate	Bo_1	CaM10_6	N2_1	N2_2	N2_3	N2_4	N2_5	N2_6	N2_7	N2_8	N2_9	N2_10	N2_11	N2_12	N2_13	N2_14
with que		number	Ref_1	Ref_2	1	2	3	4	5	Q	7	∞	6	10	£	12	13	14

		Insertions in the promoter of the cyp51 gene			Ami	no acid CYP5	1 substitutio	su			DMI fui	igicide EC ₅₀ average sc	Ser
number	Isolate	Promoter	T18	V106	Y136	A313	H380	A381	Y463	A446	Difenoconazole	Epoxiconazole	Propiconazole
15	N2_15	WT	T18I	V106D	WT	M	WT	WT	MT	A446S	0.034	0.052	0.056
16	N2_16	IM	T181	V106D	WT	WT	WT	WT	WT	A446S	0.017	0.025	0.057
17	N2_17	WT	T18I	V106D	M	M	MT	MT	WT	A446S	0.059	0.069	0.073
18	N2_18	AMICICGT AGAITAGCAT AMALCICGT AGAITAGCATAMATCICGT ACGATGTTAMATCICGTAGGATAGCATAMATCICGGTGCCATGCCCGCCCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	8.474	1.995	8.059
19	N2_19	AMICICGT ACGATAGCAT AMATCICGT ACGATAGCATAMATCICGT ACGATGTTAAATCICGTACG ATAGCATAMA TCICGTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	>10.24	4.332	>10.24
20	N2_20	AMATCICGT ACANTACOAT AMATCICGT ACAATAGCAT AMATCICGT ACGATGATAMATCICGTACG ATAGCATAMA TCICGGTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	7.132	1.894	8.337
21	N2_21	IW	T18I	V106D	WT	WT	WT	WT	WT	A446S	0.213	0.111	0.120
22	N2_22	WT	T181	V106D	WT	M	WT	WT	WT	A446S	0.022	0.021	0.063
23	N2_23	AMATCICGT ACGATAGCAT AMATCICGT ACGATAGCATAMATCICGT ACGATGTTAMATCICGTACG ATAGCATAMA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	8.459	3.239	6.902
24	N2_24	LM	T18I	V106D	M	MT	MT	WT	WT	A446S	0.010	0.015	0.027
25	N2_25	LM	T18I	V106D	W		WT	WT	WT	A446S	0.094	0.086	0.081
26	N2_26	MT	T18I	V106D	M	M	M	WT	WT	A446S	0.091	0.036	0.090
27	N2_27	AMICICGT AGAITAGCAT AMATCICGT AGAITAGCAT AMATCICGT AGGATGTTAMATCICGTAGGATAGCATAMATCICGGTGCGATGCGCCGCGCCCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	9.589	7.057	8.697
28	N2_28	LM	T18I	V106D	MT	WT	M	WT	WT	A446S	0.061	0.036	0.074
29	N2_29	AMICICGT AGAITAGCAT AMATCICGT AGAITAGCAT AMATCICGT ACGATGTTAMATCICGTAGCATAMATCICGTAGCA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	8.274	4.781	6.005
30	N2_30	AMATCICGT ACGATAGCAT AMATCICGT ACGATAGCATAMATCICGT ACGATGTTAMATCICGTACG ATAGCATAMA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	8.064	3.219	7.893
31	N2_31	IW	T18I	V106D	WT	M	WT	WT	WT	A446S	0.032	0.024	0.080
32	N2_32	LM	T18I	V106D	M	M	M	WT	MT	A446S	0.042	0.031	0.077
33	N2_33	LM	T18I	V106D	MT	M	MT	MT	MT	A446S	0.082	0.073	0.088
34	N2_34	LM	T18I	V106D	M	M	MT	WT	MT	A446S	0.017	0.018	0.065
35	N2_35	LM	T18I	V106D	M	M	WT	WT	M	A446S	0.099	0.190	0.135
36	N2_36	WT	T181	V106D	WT	WT	MT	WT	WT	A446S	0.019	0.020	0.055
37	N2_37	AMATCICGT AGBATAGCAT AMATCICGT AGBATAGCAT AMATCICGT ACGATGTTA ATCTCGTACG ATAGCATAMA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	6.654	2.838	6.327
38	N2_38	AMATCICGT ACGATAGCAT AMATCICGT ACGATAGCATAMATCICGT ACGATGTTAMATCICGTACG ATAGCATAMA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	>10.24	>10.24	>10.24

		Insertions in the promoter of the cyp51 gene			Am	ino acid CYP	51 substitutio	S			DMIfu	ngicide EC ₃₆ average sc	ores
number	Isolate	Promoter	T18	V106	Y136	A313	H380	A381	Y463	A446	Difenoconazole	Epoxiconazole	Propiconazole
39	N2_39	AMATOFOST ACGATAGGAT AMATOFOST AGGATAGGAT AMATOFOST ACGATGTTAA ATOFOSTAGGATAGAT COTOGTAGGA TAGGACOTGC COAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	9.127	4,996	4,463
40	N2_40	AATCTOST ADGATAGOAT AMATCTOST AOANAGOAT AMATCTOST AOSATGTTAA ATCTOSTAGGATAGOATAAA TCTOSTAGGA TAGOAOCTGS COAT	T18I	V106D	Y136F	A313G	MT	WT	Y463D	MT	9.310	3.568	9.174
41	N2_41	M	T181	V106D	MT	WT	M	MT	WT	A446S	0.009	0.018	0.048
42	N2_42	WT	T18I	V106D	WT	WT	WT	WT	WT	A446S	0.013	0.018	0.036
43	N2_43	WT	T18I	V106D	WT	WT	WT	WT	WT	A446S	0.013	0.018	0.028
44	N2_44	TW.	T18I	V106D	TW	WT	MT	WT	WT	A446S	0.068	0.061	0.073
45	N2_45	AATCTOST ADSATAGCAT AMATCTOST ADSATAGCAT AMATCTOST AOSATGTTAA ATCTOSTAGG ATAGCATAAA TCTOSTAGGA TAGCACCTGC COAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	10.072	5.651	>10.24
46	N2_46	AATCTOST ACGATAGCAT AAMTCTOST ACGATAGCAT AAATCTOST AOSATGTTAA ATCTOSTAGG ATAGCATAAA TCTOSTAGGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	>10.24	5.014	>10.24
47	N2_47	WT	T18I	V106D	MT	WT	WT	WT	WT	A446S	0.031	0.021	0.057
48	N2_48	AATCTOST ACBATAGCAT AAMTCTOST ACBATAGCAT AAATCTOST AOSATGTTAA ATCTOSTAGG ATAGCATAAA TCTOSTAGGA TAGCACCTGC COAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	8.675	2.173	9.186
49	N2_49	AATCTOST ACGATAGCAT AAATCTOST ACGATAGCAT AAATCTOST ACGATGTTAA ATCTOSTACG ATAGCATAAA TCTOSTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	8.196	5.808	>10.24
50	N2_50	AATCTOGT ACGATAGCAT AAATCTOGT ACGATAGCAT AAATCTOGT ACGATGTTAA ATCTOGTACGATAGCATAAA TCTOGTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	10.142	2.202	10.051
51	N2_51	WT	T18I	V106D	WT	WT	WT	WT	WT	A446S	0.030	0.018	0.059
52	N2_52	ANTCTOST ACATAGCAT ANMICTOST ACANTAGCAT ANAUCTOST ACANTGTTAM ATCTOSTACG ATAGCATAMA TCTOSTACGA TAGCACCTGC COAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	>10.24	6.359	>10.24
53	N2_53	AATCTOST ACGATAGCAT AAATCTOST ACGATAGCAT AAATCTOST ACGATGTTAA ATCTOSTACGATAGCATAAA TCTOSTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	MT	MT	Y463D	WT	7.049	5.746	6.272
54	N2_54	M	T181	V106D	MT	WT	M	WT	MT	A46S	0.068	0.056	0.082
55	N2_55	WT	T181	V106D	WT	WT	WT	WT	WT	A446S	0.045	0.058	0.076
56	N2_56	AATCTOST ACATAGCAT AAMTCTOST ACATAGCAT AAATCTOST ACATGTTAA ATCTOSTACG ATAGCATAAA TCTOSTACGA TAGCACCTGC CCAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	WT	>10.24	8.699	9.446
57	N2_57	WT	T18I	V106D	WT	WT	WT	WT	WT	A446S	0.091	0.066	0.101
58	N2_58	IM	T18I	V106D	MT	WT	MT	WT	MT	A446S	0.087	0.058	0.102
59	N2_59	WT	T181	V106D	TW	TW	M	WT	M	A446S	0.078	0.073	0.077
09	N2_60	ANTCTOST ACATAGOAT AMMICTOST ACATAGOAT AMATCTOST ACATGITAA ATCTOSTAGG ATAGOATAAA TCTOSTAGGA TASCACCTGC COAT	T18I	V106D	Y136F	A313G	WT	WT	Y463D	MT	>10.24	3.645	>10.24

Insertions in the promo	insertions in the promo	ter of the cyp51 gene			A	nino acid CY	51 substituti	suo			DMIfu	ngicide EC ₃₆ average s	:ores
Promoter	Promoter	-	T18	V106	Y136	A313	H380	A381	Y463	A446	Difenoconazole	Epoxiconazole	Propiconazole
N2_61 AMICTOST ACEATAGCAT AWATCTOST ACEATAGCATAWATCTOST ACEATGTTAAATCTOSTACGATAGCATAMATCTOSTACCATAGCACCTSC CCAT	AMICTOST ACSATAGCAT AWATCTOST ACSATAGCATAWATCTOST ACSATISTTAAATCTOSTACSATAGCATAWATCTOSTACCATAGCACCTSC CCAT		T181	V106D	Y136F	A313G	MT	WT	Y463D	WT	8.646	6.709	1.779
N2.82 AAMTOTOST AGATAGOAT AAMTOTOST AGATAGOATAGOAT AAMTOTOST AOGATGTTAAATOTOSTAGOATAGOATAGOATAGOATAGO	AMATCICGET ACGATAGCAT AMATCICGET ACGATAGCAT AMATCICGET ACGATGTTAA ATCICGETACGATAAA TCICGETACGA TAGCACCTGC CCAT	Ĥ	181	V106D	Y136F	A313G	WT	WT	Y463D	WT	>10.24	3.105	>10.24
N2_63 AMICTOST ACATAGCAT AWATCTOST ACATAGCAT AWATCTOST ACCATGTTAMATCTOSTACCATAGCATAMA TCTOSTACCA TAGCACCTGC CCAT T18	AMICTOST ACATAGCAT AWATCTOST ACGATAGCAT AWATCTOST ACGATGTTAN ATCTOSTACGATAGCATAMA TCTOSTACCA TAGCACCTGC CCAT	T18	_	V106D	Y136F	A313G	MT	WT	Y463D	WT	9.886	2.980	7,598
N2_64 WT T181	WT T18	T181		V106D	WT	WT	MT	WT	WT	A446S	0,063	0.017	0.075
N2.657 ?	2 2	~		6	6	6	6	6	6	6	7.457	1.351	3.887
N2.06 AMTCTCGT ACGATAGCAT AMATCTCGT ACGATAGCATAMATCTCGT ACGATGTTAA ATCTCGTACGATAGCATAMA TCTCGTACGA TASCACCTGC CCAT 148	AMATCTCGT ACBATAGCAT AMATCTCGT ACBATAGCATAMATCTCGT ACBATGTCATAAATCTCGTAACBATAGCATAGCATAGCACCTGC CCAT ACBATGTTAAATCTCGTAGGATAGCATAGAATCGCGTACGATAGCACCTGC CCAT	T18I		V106D	Y136F	A313G	WT	WT	Y463D	WT	>10.24	7.392	8.710
N2_67 WT T161	MT T181	T181		V106D	MT	WT	WT	WT	WT	A446S	0.014	0.015	0.027
N2_68 AMTCTOGT ACGATAGCAT AMATCTOGT ACGATAGCAT AMATCTOGT ACGATGATAA ATCTOGTAGCATAGCATAMA TCTOGTACGAT AGCACTGC CCAT T181	AATCTOST ACEATAGCAT AWATCTOST ACEATAGCAT AWATCTOST ACEATEATAA ATCTOSTACSATAGCATAWA TCTOSTACSATCASCACCTOSC CCAT T181	T18		V106D	Y136F	A313G	WT	WT	Y463D	WT	7.430	4.047	5.682
N2_69 MT T181	MT T18I	T181		V106D	WT		WT	WT	WT	A446S	0.025	0.018	0.067
N2_70 AAATCTOST ACBATAGCAT AMATCTOST ACBATAGCAT AMATCTOST ACCATGTTAA ATCTOSTACS ATAGCATAMA TCTOSTACGAT ACACCTGC CCAT T181	AATCTOGT ACBATAGCAT AMATCTOGT ACBATAGCAT AMATCTOGT AOGATGTTAA ATCTOGTACGATAMATCTOGTACGATACACCTGC CCAT T181	T18I		V106D	Y136F	A313G	WT	WT	Y463D	WT	8.125	6.326	6.596
N2_71 AANTGTOST ACBATAGGAT AMANTGTOST ACBATAGGAT AMANTGTOST ACGATGTTAA ATCTOSTACGATAGGATAMA TCTOSTACGA TAGCACCTGC CCAT T481	AAATCTOST ACOATAGCAT AMAATCTOST ACOATAGCAT AMAATCTOST ACCATISTTAA ATCTOSTACS ATAGCATAAA TCTOSTACGA TAGCACCTGC CCAT T181	T18I		V106D	Y136F	A313G	WT	WT	Y463D	WT	7.181	2.295	6.488
N2_72 NT T18	WT T181	T181		V106D	WT	WT	WT	WT	WT	A446S	0.025	0.020	0.068
N2.73 AMATCTCGT AOGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAAATCTCGTACGATAGCATAAA TCTCGTACGA TAGCACCTGC CCAT T18	AMATCTOGT ACGATAGCAT AMATCTOGT ACGATAGCAT AMATCTOGT ACGATGTTAA ATCTOGTACGATAMATCTOGTACGAT TAGCACCTGC CCAT T181	T181		V106D	Y136F	A313G	WT	WT	Y463D	WT	8.169	7.973	8.452
N2.74 AMATCTOGT ACGATAMCATCTOGT ACGATAMCATCTOGT ACGATGTTAMATCTOGTACGATAMCATCTOGTACGATAMATCTOGT ACGATGTTAMATCTOGTACGATAMCTCTOGTACGATAMCATCTOGCCCT	AAATCTOGT ACGATAACATCTOGT ACGATAACATCTOGT ACGATGTTAAATCTOGTACGATAACATCTOGTACGATAACATCTOGT ACGATGTTAAATCTOGTACGATAACATCTOGTACGATAACATCTOGT	T18I		V106D	Y136F	A313G	WT	WT	Y463D	WT	>10.24	7.302	8.374
N2.75 AAATCTOST ACBATAGCAT AMAATCTOST ACBATAMAATCTOST ACGATGTTAAATCTOSTACCATAGCATAMA TCTOSTACCATACCTGC CCAT T181	AAATCTOGT ACGATAACATTOGT ACGATAGCATAWATCTOGT ACGATGTTAAATCTOGTACGATAGCATAWATCTOGTACCATGCCTGC CCAT T181	T18I		V106D	Y136F	A313G	WT	WT	Y463D	WT	7.564	5.258	4.859
N2.76 AMATCFOST ADGATAGCAT AMATCFOST ACGATAGCAT AMATCFOST ACGATGFTAAATCFOSTAGCATAGATAGATAAA TCFOSTAGCATAGCACTGSC CCAT T181	AMATCTOGT ACCATACCAT AMATCTOGT ACCATACCATCAMATCTOGT ACCATGTTAA ATCTOGTACGATAGCATAMA TCTOGTACCA TAGCACCTGC CCAT	T18I		V106D	Y136F	A313G	WT	WT	Y463D	WT	5.669	1.612	4.982
N2_77 WT T181	MT T188	T181		V106D	WT	WT	WT	WT	WT	A446S	0.025	0.023	0.080
N2.78 AMATCTOST ADGATAGCAT AMATCTOST ADGATAGCAT AMANTCTOST ACGATGTTAMATCTOSTAGCATAMA TCTOSTAGCATAGCATGCCOST ACGATGTTAMATCTOSTAGCATAMA TCTOSTAGGA TAGCACCTGC COAT	AATCTOGT ACGATAGCAT AMATCTOGT ACGATAGCATAMATCTOGT ACGATGTTAA ATCTOGTACGATAMATCTOGTACGATAGCATAMATCTOGT ACGATGTTAA ATCTOGTACGATAMATCTOGTACGATAGCATAMATCTOGT	T18I		V106D	Y136F	A313G	WT	WT	Y463D	WT	9.560	6.697	112.1
N2_79 WT T181	MT T18	T18I	_	V106D	M	WT	MT	WT	WT	A446S	0.093	0.078	0.095
N2_30 V/T T181	WT T18	1181		V106D	WT		WT	WT	WT	A446S	0.032	0.020	0.080

		Insortions in the neomotor afthe auraft acres			Λmi	DV Dion on	Ed auhatiku	ficme			DMI function	vida En avarade	000100
number	Isolate	Insertions in the promoter of the cyport gene			Am	noacia u r	DI SUDSTRU	SUON			DMITUD	cide Eu ₅₀ average	scores
		Promoter	T18	V106	Y136	A313	H380	A381	Y463	A446	Difenoconazole	Epoxiconazole	Propiconazole
81	N2_81	AMATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAAATCTCGTACGATAGCATAAA TCTCGTACGATAGCACCTGCCCAT	T 181	V106D	Y136F	A313G	WT	WT	Y463D	WΤ	>10.24	2.780	>10.24
82	N2_82	AMATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAA ATCTCGTACGATAGCATAAA TCTCGTACGATAGCACCTGC CCAT	T 181	V106D	Y136F	A313G	WT	WT	Y463D	ΜŢ	7.223	4.711	6.111
83	N2_83	MT	T 181	V106D	ΜŢ	ΜT	WT	WT	MT	A446S	0.015	0.017	0.031
84	N2_84	TW	T 181	V106D	WT		WT	WT	WT	A446S	0.023	0.027	0.072
85	N2_85	AMATCTOGT ACGATAGCAT AMATCTCGTACGATAGCAT AMATCTCGT ACCATGTTAAATCTCGTACGATAGCATAAA TCTCGTACGATAGCACCTGCCCAT	T 181	V106D	Y136F	A313G	WT	WT	Y463D	WΤ	7.696	2.712	8.177
86	N2_86	WT	T 181	V106D	ΜŢ	ΜT	WT	WT	ΜT	A446S	0.025	0.020	0.068
87	N2_87	AMATCTGGT AGGATAGCAT AMATCTCGT AGGATAGGAT AMATCTGGT AGGATGTTAA ATCTGGTAGGATAGGATAAA TCTGGTAGGATAGGA	T 181	V106D	Y136F	A313G	WT	WT	Y463D	ΜT	7.786	3.531	6.172
88	N2 88	MT	T181	V106D	ΜT	ΜT	WT	WT	WT	A446S	0.026	0.018	0:080
68	N2_89	MT	T181	V106D	ΜT	ΜŢ	WT	WT	WT	A446S	0.112	0.154	0.210
06	N2_90	AMATCTGGT AGGATAGCAT AMATCTGGT AGGATAGGAT AMATCTGGT AGGATGTTAA ATCTGGTAGGATAGGATAAA TCTGGTAGGATAGGA	T 181	V106D	Y136F	A313G	WT	WT	Y463D	WΤ	7.799	5.684	3.958
91	N2_91	AMATCTCGTACGATAGCAT AMATCTCGTACGATAGCAT AMATCTCGT ACCATGTTAAATCTCGTACGATAGCATAAA TCTCGTACGATAGCACTGCCCAT	T 181	V106D	Y136F	A313G	WΤ	WT	Y463D	ΜŢ	>10.24	5.969	>10.24
92	N2_92	M	T181	V106D	ΜŢ	ΜT	MT	ΜŢ	ΜT	A446S	0.022	0.021	0.067
93	N2_93	WT	T 181	V106D	ΜŢ	ΜŢ	WT	WT	WT	A446S	0.011	0.019	0.046
94	N2_94	AMATCTOGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAAATCTCGTACGATAGCATAAA TCTCGTACGATAGCACCTGCCCAT	T 181	V106D	Y136F	A313G	WT	WT	Y463D	ΜT	>10.24	5.477	>10.24
95	N2_95	AMATCTGGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAAATCTCGTAGCATAGCATAAA TCTCGTACGATAGCACCTGCCCAT	T 181	V106D	Y136F	A313G	WT	WT	Y463D	ΜŢ	>10.24	9.276	>10.24
96	N2_96	AMATCTGGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAAATCTCGTACCATAGCATAAA TCTCGTACGA TAGCACCTGC CCAT	T 181	V106D	Y136F	A313G	WT	WT	Y463D	WΤ	>10.24	7.419	>10.24
26	N2_97	AMATCTOGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAA ATCTCGTACGATAGCATAAA TCTCGTACGATAGCACCTGC CCAT	T 181	V106D	Y136F	A313G	WT	WΤ	Y463D	ΜT	7.248	2.563	3.732
86	N2_98	WT	T 181	V106D	ΜŢ	WT	WT	WT	WT	A446S	0.015	0.022	0.068
66	N2_99	AMATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAAATCTCGTACGATAGCATAMA TCTCGTACGATAGCACCTGCCCAT	T18I	V106D	Y136F	A313G	WΤ	WT	Y463D	WΤ	8.764	5.704	>>10.24
100	N2_100	WT	T18I	V106D	WT	WT	WT	WΤ	WT	A446S	0.072	0.067	0.113

nimhor	le n leto	Insertions in the promoter of the cyp51 gene			Amir	to acid CYP	51 substitu	tions			DMI fungio	ide EC ₃₀ average	scores
	1901900	Promoter	T18	V106	Y136	A313	H380	A381	Y463	A446	Difenoconazole	Epoxiconazole	Propiconazole
102	N5_2	WT	T181	V106D	WT	WT	WT	ΜT	WT	A446S	0.079	0.142	0.157
103	N5_3	AMATOTOGTACGATAGCAT AMATOTOGTACGATAGCATAMATOTOGT ACCATGTTAA ATOTOGTACGATAGCATAAA TOTOGTACGA TAGCACOTOGOCCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	2.104	3.162	4.616
104	N5_4	WT	T181	V106D	MT		WT	WT	WT	A446S	0.020	0.035	0.069
105	N5_5	AMICTOGTACGATAGCAT AMATCTOGTACGATAGCATAMATCTOGT ACCATGTTAA ATCTOGATAGCATAAG TOTOGTACGA TAGCACCTGC COAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	2.589	5.128	2.931
106	N5_6	AMATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAA ATCTCGTAGCATAGCATAGA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	5.675	6.923	6.329
107	N5_7	WT	T181	V106D	WT	WT	WT	WT	WT	A446S	0.067	0.073	0.084
108	N5_8	MT TW	T181	V106D	WT	WT	WT	WT	WT	A446S	0.011	0.015	0.031
109	N5_9	AMICTOGTACGATAGCAT AAAITOTOGTACGATAAGCATAMATOTOGT AOCATGTTAAATOTOGTAOCATAGCATAAA TOTOGTACGATAGCATGCAGT	T181	V106D	WT	WT	H380N	A381G	Y463D	WT	5.140	6.041	5.197
110	N5_10	MT MT	T18I	V106D	WT	WT	WT	WT	WT	A446S	0.011	0.015	0.032
111	N5_11	AMATCTGGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAA ATCTCGTAGCATAGCATAMA TCTCGTAGCATAGCACCTGC CCAT	T181	V106D	WT	WT	H380N	A381G	Y463D	WT	7.527	7.976	7.058
112	N5_12	AMATCTCGTACGATAGCAT AMATCTCGTACGATAGCAT AMATCTCGT ACCATGTTAAATCTCGTACGATAGCATAAA TCTCGTACGA TAGCACCTGC CCAT	T181	V106D	WT	WT	H380N	A381G	Y463D	WT	6.973	8.439	7.132
113	N5_13	MT	T18I	V106D	MT	WT	WT	WT	WT	A446S	0.047	090:0	0.066
114	N5_14	AMATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAM ATCTCGTAGCATAGCATAGA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	1.556	1717	1.323
115	N5_15	MT	T181	V106D	ΜT	WT	WT	WT	WT	A446S	0.047	0.081	0.077
116	N5_16	AMATCTGGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAA ATCTCGTAGGATAGCATAMA TCTCGTAGGATAGCACCTGCCCAT	T181	V106D	WT	WT	H380N	A381G	Y463D	WT	6.259	8.082	3.523
117	N5_17	AMICTOGTACGATAGCAT AMATCTOGTACGATAGCATAMATCTOGT ACCATGTTAA ATCTOGTACCATAGCATAAA TCTOGTACGA TAGCACCTGC CCAT	T181	V106D	WT	WT	H380N	A381G	Y463D	WT	6.120	6.266	3.562
118	N5_18	MT	T 181	V106D	ΜT	WT	WT	WT	WT	A446S	0.010	0.011	0.032
119	N5_19	AMATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAM ATCTCGTAGCATAGCATAGA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	3.355	6.146	2.787
120	N5_20	WT	T 181	V106D	WT	WT	WT	WT	WT	A446S	0.012	0.016	0.052
121	N5_21	AMATCTGGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAA ATCTCGTAGCATAGCATAMA TCTCGTAGCATAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	1.278	2.714	1.135
122	N5_22	AMATCTOGTACGATAGCAT AMATCTCGTACGATAGCATAMATCTCGT ACGATGTTAMATCTCGTACGATAGCATAMA TCTCGTACGATAGCACCTGCCCAT	T18I	V106D	WΤ	WT	H380N	A381G	Y463D	WT	1.683	1.875	1.793

		Insertions in the promoter of the cvo51 aene			Amir	no acid CYP	51 substitu	tions			DMI funaio	ide EC average	scores
number	Isolate	Promoter	T18	V106	Y136	A313	H380	A381	Y463	A46	Difenoconazole	Epoxiconazole	Propiconazole
123	N5_23	AMICTOGTAGGATAGCATAMATCTOGTAGGATAGCATAMATCTOGT ACCATGTTAMATCTOGTAGGATAMA TCTOGTAGGATAGCACTGCOCTGCOCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	1.658	3.687	2.518
124	N5_24	MT	T181	V106D	WT	WT	WT	WT	WT	A46S	0.086	060:0	0.072
125	N5_25	AMTCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAMATCTCGTACGATAGCATAMA TCTCGTACGA TAGCACCTGCCCGT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	3.139	5.592	3.953
126	N5_26	WT	T181	V106D	WT	WT	WT	WT	WT	A46S	0.010	0.019	0.029
127	N5_27	WT	T181	V106D	WT	WT	WT	WT	WT	A446S	0.005	0.013	0.015
128	N5_28	AMICTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAA ATCTCGTACGATAGCATAMA TCTCGTACGA TAGCACTGCCCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	7.607	>10.24	6.899
129	N5_29	WT	T181	V106D	WT	WT	WT	WT	WT	A446S	0.026	0.046	0.065
130	N5_30	WT	T181	V106D	MT	WT	WT	WT	MT	A446S	0.018	0.023	0.061
131	N5_31	WT	T181	V106D	WT	WT	WT	WT	WT	A446S	0.034	0.036	0.061
132	N5_32	AMICTOGT ACGATAGCAT AMATCTOGTACGATAGCAT AMATCTOGT ACGATGTTAA ATCTOGTACGATAGCATAAA TCTOGTACGA TAGCACCTGCOCOAT	T 18I	V106D	WT	WT	H380N	A381G	Y463D	WT	5.918	8.960	6.037
133	N5_33	AMICTOGT ACGATAGCAT AMATOTOGT ACGATAGCAT AMATOTOGT ACGATGTTA ATOTOGTACGATAGCATAMA TOTOGTACGATAGCACTGCOCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	6.851	7.410	4.996
134	N5_34	WT	T181	V106D	WT	WT	WT	WT	WT	A446S	0.018	0.022	0.056
135	N5_35?	ć	~	~	~	~	~	~	~	~	6.799	>10.24	7,111
136	N5 362	~	~	~	~	~	~	~	~	~	7.664	>10.24	7.233
137	N5_37	WT	T181	V106D	WT	WT	WT	WT	WT	A446S	0.034	0.029	0.072
138	N5_38	AMICTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAA ATCTCGTACGATAGCATAAA TCTCGTACGA TAGCACTGCCCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	6.952	7.935	6.417
139	N5_39	AMICTOGTACGATAGCAT AMATCTCGTACGATAGCAT AMATCTCGT ACCATGTTAMATCTCGTACGATAGCATAMA TCTCGTACGATAGCACTGCCCGCCCAT	T 18I	V106D	WT	WT	H380N	A381G	Y463D	WT	6.038	6.297	5.778
140	N5_40	AMICTOSTACGATAGCATAMATCTOSTACGATAGCATAMATCTOST ACCATGTTAAATCTOSTACGATAGCATAMA TCTOSTACGATAGCACTGSOCCAT	T 18I	V106D	WT	WT	H380N	A381G	Y463D	WT	3.378	4,699	2.404
141	N5_41	AMICTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAA ATCTCGTACGATAGCATAMA TCTCGTACGA TAGCACTGCCCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	2.596	3.825	2.489
142	N5_42	AMICTOGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACCATGTTAA ATCTCGTAGCATAGCATAGA TCTCGTACGA TAGCACCTGC CCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	2.565	4.474	2.026
143	N5_43	AMATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAM ATCTCGTAGCATAGCATAGA TCTCGTAGCATAGCACCTGC CCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	1.810	3.084	1.288
144	N5_44	AMICTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTA ATCTCGTACGATAGCATAM TCTCGTACGA TAGCACCTGCCCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	7.370	>10.24	4.511

ar le	anlata	Insertions in the promoter of the cyp51 gene			Amir	10 acid CYP	51 substitu	tions			DMIfungi	cide EC ₅₀ average	scores
-	201810	Promoter	T18	V106	Y136	A313	H380	A381	Y463	A446	Difenoconazole	Epoxiconazole	Propiconazole
~	N5_45	AMICTOGT ACGATAGCAT AMATCTOGTACGATAGCAT AMATCTOGT ACGATGTTAA ATCTOGTACGATAGCATAAA TCTOGTACGA TAGCACCTGC CCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	6.778	8.602	3.462
2	N5_46	AMICTOGT ACGATAGCAT AMATCTOGTACGATAGCAT AMATCTOGT AOGATGTTAA ATCTOGTACGATAGCATAAA TCTOGTACGA TAGCACCTGC CCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	6.768	8.069	2.540
2	N5_47	AAATCTGGT AGGATAGGAT AAAATCTGGT AGGAT AGAATCTGGT AGGATGTTAA ATCTGGTAGGATAGGATAAA TCTGGTAGGA TAGCAGCTGC GCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	4.868	3.809	4.303
2	N5_48	WT	T181	V106D	ΜT	ΜT	ΜT	WT	ΜT	A446S	0.074	060.0	0.084
2	N5_49	WT	T181	V106D	MT	ΜŢ	WT	WT	ΜT	A446S	060'0	0.110	0.096
2	N5_50	WT	T181	V106D	WT	ΜT	WT	WT	ΜT	A446S	0.008	0.016	0.024
2	N5_51	WT	T181	V106D	ΜŢ	ΜŢ	WT	WT	ΜT	A446S	0.015	0.016	0.045
1	N5_52	WT	T181	V106D	WT	WT	WT	WT	ΜŢ	A446S	0.012	0.018	0.042
2	N5_53	AATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AAATCTCGT ACGAT GTTAA ATCTCGTACGATAGCATAAA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WΤ	2.270	5.514	1.574
2	N5_54	WT	T181	V106D	WT	ΜŢ	WT	ΜT	Μ	A446S	0.084	0.056	0.078
Z	N5_55?	ć	ć	ć	6	ć	ć	~	ć	ç	1.543	5.979	1.380
<	N5_56	WT	T18I	V106D	WT	ΜŢ	WT	WT	MT	A446S	0.015	0.015	0.043
É	N5_57	WT	T181	V106D	WT	ΜŢ	WT	WT	MT	A446S	0.108	0.315	0.273
~	N5_58	AMICTOGT ACGATAGCAT AMATOTOGTACGATAGCAT AMATOTOGT AOGATGTTAA ATOTOGTACGATAGCATAMA TOTOGTACGATOGTOGOCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	1.250	1.673	1.672
2	N5_59	MT	T18I	V106D	MT	ΜT	MT	MT	MT	A446S	0.039	0/020	0.064
N	N5_60?	6	2	ć	2	2	2	6	2	2	2.497	2.415	2.751
~	N5_61	AATCTGGT ACGATAGCAT AAATCTGGTACGATAGCAT AAATCTGGT AGGATGTTAA ATCTGGTAGGATAGCATAAA TCTGGTACGA TAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	1.277	2.034	1.657
~	N5_62	AMICTOGT ACGATAGCAT AMATCTOGTACGATAGCAT AMATCTOGT AOGATGTTAA ATCTOGTACGATAGCATAAA TCTOGTACGA TAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	0.759	0.870	1.091
~	N5_63	AMICTOGT ACGATAGCAT AMATOTOGTACGATAGCAT AMATOTOGT AOGATGTTAA ATOTOGTACGATAGCATAMA TOTOGTACGATACACOTOG COAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	3.711	4.724	1.836
~	N5_64	TW	T18I	V106D	MT	MT	MT	MT	LΜ	A446S	0.094	0.087	0.080
~	N5_65	LM	T18I	V106D	MT	MT	MT	MT	LΜ	A446S	0.074	0.069	0.094
2	N5_66	MT	T181	V106D	MT	MT	ΜT	MT	LΜ	A446S	0.087	0/0/0	0.076
~	N5_67	WT	T18I	V106D	WT	WT	WT	WT	WT	A446S	0.013	0.015	0.034
2	N5_68	AMICTOGTACGATAGCAT AMATCTOGTACGATAGCAT AMATCTOGT AOGATGTTAA ATCTOGTACGATAGCATAMA TCTOGTACGA TAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	1.340	2.321	1.718
~	N5_69	WT	T181	V106D	WT	WT	WΤ	WT	WT	A446S	0.018	0.021	0.047
2	N5_70	AATCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AAATCTCGT ACGATGTTAA ATCTCGTACGATAGCATAAA TCTCGTACGA TAGCACCTGC CCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	6.878	8:358	4.955
É	N5_71	WT	T181	V106D	WΤ	WT	WT	WT	ΜT	A446S	0.053	060.0	0.083

		Insertions in the promoter of the cyp51 gene			Ami	no acid CYP	51 substitu	tions			DMIfungi	cide EC ₅₀ average	scores
number	solate	Promoter	118	V106	Y136	A313	H380	A381	Y463	A446	Difenoconazole	Epoxiconazole	Propiconazole
172	N5_72	AMICTOGTACGATACATAMATCTOGTACGATACCATAMATCTOGT ACCATGTTAMATCTOGTACGATAGCATAMA TCTOGTACGATACACCTOCCOCT	T181	V106D	WT	WT	H380N	A381G	Y463D	WT	5.592	7.162	6.173
173	N5_73	AMTCTCGT ACGATAGCAT AAATCTCGT ACGATAAGCAT AMATCTCGT ACGATGTTAA ATCTCGTACGATAGCATAAA TCTCGTACGA TAGCACCTGC CCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	4.497	4.222	4.500
174	N5_74	WT	T181	V106D	WT	WT	WT	WT	WT	A446S	0.027	0.038	0.074
175	N5_75	AMICTOGTACGATAGCATAAATCTOGTACGATAGCATAMATCTOGT ACGATGTTAAATCTOGTACGATAGCATAAA TCTOGTACGATAGCACTGCOCAT	T18I	V106D	WΤ	WT	H380N	A381G	Y463D	ΜŢ	5.290	4.509	5.688
176	N5_76	AMICTOGTACGATAGCATAAATCTOGTACGATAGCATAMATCTOGT ACCATGTTAAATCTOGTACGATAGCATAAA TCTOGTACGATAGCACTGCOCAT	T 181	V106D	WΤ	WT	H380N	A381G	Y463D	WT	6.004	5.679	6.047
177	N5_77	AMICTOGTACGATAGCATAAATCTOGTACGATAGCATAMATCTOGT ACGATGTTAAATCTOGTACGATAGCATAAA TCTOGTACGATAGCACTGCOCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	5.330	5.347	5.224
178	N5_78	LM	T181	V106D	WT	WT	WT	WT	WT	A446S	0.005	0.015	0.021
179	N5_81	LM	T 181	V106D	LΜ	MT	ΜT	MT	MT	A446S	0.048	0.054	0.063
180	N5_82	LM	T 181	V106D	WT	MT	WT	WT	WT	A446S	0.016	0.017	0.041
181	N5_83	AMICTOGTACGATAGCATAMATCTCGTACGATAGCATAMATCTCGT ACGATGTTAAATCTCGTACGATAGCATAMA TCTCGTACGATAGCACTGCOCAT	T18I	V106D	ΜŢ	WT	H380N	A381G	Y463D	ΜŢ	2.634	6.064	3.011
182	N5_84	AMICTOGTACGATAGCATAAATCTOGTACGATAAGCATAMATCTOGT ACGATGTTAAATCTOGTACGATAGCATAAA TCTOGTACGATAGCACTGCOCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	4.754	5.864	3.780
183	N5_85	LM	T 181	V106D	MT	WT	WT	MT	WT	A446S	0:080	0.094	0.088
184	N5_86	AMICTOSTACGATAGCATAAATCTOSTACSATAGCATAMATCTOST ACGATGTTAAATCTOSTACGATAGCATAAA TCTOSTACGATAGCACTGS OCAT	T 181	V106D	WΤ	WT	H380N	A381G	Y463D	WΤ	5.153	5.370	2.111
185	N5_87	AMICTOGTACGATAGCATAAATCTOGTACGATAGCATAMATCTOGT ACCATGTTAAATCTOGTACGATAGCATAAA TCTOGTACGATAGCACTGCOCAT	T 181	V106D	WT	WT	H380N	A381G	Y463D	WT	6.803	8.057	6.775
186	N5_88	LM	T 181	V106D	MT	WT	WT	WT	WT	A446S	0.061	0.087	0.079
187	N5_89	AMICTOGTACGATAGCATAAATCTOGTACGATAGCATAMATCTOGT ACGATGTTAAATCTOGTACGATAGCATAAA TCTOGTACGATAGCACTGCOCAT	T181	V106D	WT	WT	H380N	A381G	Y463D	WT	2.449	4.478	2.317
188	N5_90	LM	T 181	V106D	WT	MT	WT	WT	WT	A446S	0.018	0.020	0.055
189	N5_91	AMICTOGTACGATAGCATAAATCTOGTACGATAGCATAMATCTOGT ACGATGTTAAATCTOGTACGATAGCATAAA TCTOGTACGATAGCACTGCOCAT	T 181	V106D	ΜT	WT	H380N	A381G	Y463D	WT	3.130	4.263	3.355
190	N5_92	LM	T181	V106D	WT	MT	WT	WT	WT	A446S	0.029	0.036	0.074
191	N5_93	AMICTOGTACGATAGCATAAATCTOGTACGATAGCATAMATCTOGT ACGATGTTAAATCTOGTACGATAGCATAAA TCTOGTACGATAGCACTGCOCAT	T18I	V106D	WT	WT	H380N	A381G	Y463D	WT	1.491	4.167	3.211
192	N5_94	TW	T 181	V106D	ΜT	ΜŢ	ΜT	ΜŢ	ΜT	A446S	0.018	0.024	0.062
193	N5_95	AMICTOGTACGATAGCATAMATCTCGTACGATAGCATAMATCTCGT ACGATGTTAAATCTCGFACGATAGCATAGCATAGCATAGC	T 181	V106D	WΤ	WT	H380N	A381G	Y463D	WT	2.557	3.482	2.635

Genetic mapping of resistance

ragescores	ole Propiconazole	5.895	0.107	7.229	2.938	5.381	3.281	0.069
icide EC ₅₀ ave	Epoxiconaz	7.430	0.077	9.459	6.688	4.959	3.863	0.028
DMI fung	Difenoconazole	6.681	0.065	7.336	5.599	5.702	2.803	0.030
	A446	ΤW	A446S	ΜT	ć	WT	WT	A446S
	Y463	Y463D	ΜT	Y463D	ė	Y463D	Y463D	LΜ
utions	A381	A381G	ΜT	A381G	ί	A381G	A381G	LΜ
P51 substitu	H380	H380N	MT	H380N	ė	H380N	H380N	LΜ
ino acid CY	A313	WT	MT	WT	i	WT	WT	LΜ
Ami	Y136	ΤW	ΜŢ	ΜŢ	i	WT	WT	LΜ
	V106	V106D	V106D	V106D	ć	V106D	V106D	V106D
	T18	T18I	T181	T18I	ė	T18I	T18I	T181
Insertions in the promoter of the cyp51 gene	Promoter	AATCTCGT ACGATAGCAT AAATCTCGT ACGATAGATAAATCTCGT ACGATGTTAA ATCTCGTAGCATAAA TCTCGTACGA TAGCACCTGC CCAT	WT	AMTCTCGT ACGATAGCAT AMATCTCGT ACGATAGCAT AMATCTCGT ACGATGTTAA ATCTCGTAGCATAMA TCTCGTACGA TAGCACCTGC CCAT	i	AATCTGGT ACGATAGGAT AMATCTGGT ACGATAGGAT AAATCTGGT ACGATGTTAA ATCTGGTAGGATAAA TCTGGTAGGA TAGGACGTGG CGAT	AATCTCGT ACGATAGCAT AAATCTCGT ACGATAGCAT AAATCTCGT ACGATGTTAA ATCTCGTAGCATAAA TCTCGTACGA TAGCACCTGC CCAT	LM
Isolate		N5_96	N5_97	N5_98	N5_997	N5_100	N5_101	N5_102
number		194	195	196	197	198	199	200

populations fijiensis (Pse	tnat contains the sensitivi eudocercospora fijiensis) v	y region. The information of the genes was collected from the Joint 2.0 portal. http://genome.jgi.doe.gov/Mycfi2/Mycfi2.home.html.	Genome Institute, <i>Mycosphaerella</i>
Transcript ID:	Location:	Gene ontology	Definition
177154	scaffold_7:1909687-1917514 (+)	Putative protein	No annotation yet
177158	scaffold_7:1938540-1939146 (-)	Putative protein	No annotation yet
31195	scaffold_7:1967582-1967875 (+)	Putative protein	No annotation yet
31837	scaffold_7:1920971-1921141(+)	Putative protein	No annotation yet
22691	scaffold_7:1949446-1950451 (-)	G0:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds. Catalysis of the hydrolysis of any O- glycosyl bond.	No annotation yet
189819	scaffold_7:1929097-1930398 (-)	GO:0003824 catalytic activities. Catalysis of a biochemical reaction at physiological temperatures.	No annotation yet
30851	scaffold_7:1959643-1961193 (-)	Putative protein	No annotation yet
101452	scaffold_7:1931010-1931678 (-)	Putative protein	No annotation yet
101452	scaffold_7:1931010-1931678 (-)	Putative protein	No annotation yet
211990	scaffold_7:1943313-1944619 (-)	GO:0000172 ribonuclease MRP complex. A ribonucleoprotein complex that contains an RNA molecule of the snoRNA family, and cleaves the rRNA precursor as part of rRNA transcript processing. It also has other roles: In S. cerevisiae it is involved in cell cycle-regulated degradation of daughter cell-specific mRNAs, while in mammalian cells it also enters the mitochondria and processes RNAs to create RNA primers for DNA replication.	No annotation yet
7504	scaffold_7:1939638-1940268 (+)	Putative protein	No annotation yet
77954	scaffold_7:1945205-1946623 (-)	G0:0004553 hydrolase activity, hydrolyzing O-glycosyl compounds. Catalysis of the hydrolysis of any O- glycosyl bond.	No annotation yet
31273	scaffold_7:1947348-1948031 (-)	GO:0004733 pyridoxamine-phosphate oxidase activity. Catalysis of the reaction: pyridoxamine 5'-phosphate + H2O + O2 = pyridoxal 5'-phosphate + NH3 + hydrogen peroxide.	No annotation yet
198484	scaffold_7:1951727-1952825 (-)	Putative protein	No annotation yet
77958	scaffold_7:1953723-1954161 (-)	Putative protein	No annotation yet
77959	scaffold_7:1954646-1955608 (+)	Putative protein	No annotation yet
198487	scaffold_7:1955999-1956492 (+)	Putative protein	No annotation yet
204493	scaffold_7:1957874-1958706 (+)	Putative protein	No annotation yet
77962	scaffold_7:2016030-2016929 (-)	Putative protein	No annotation yet

 Table S3. Information of the 53 putative genes found in the overlapping genetic window of the *Pseudocercospora fijiensis* N2 and N5 mapping

Transcript ID:	Location:	Gene ontology	Definition
177166	scaffold_7:2021508-2023032 (+)	Putative protein	No annotation yet
177167	scaffold_7:2026479-2029163 (+)	Putative protein	No annotation yet
177169	scaffold_7:2032413-2034139 (+)	Putative protein	No annotation yet
77963	scaffold_7:2035236-2035724 (+)	Putative protein	No annotation yet
77964	scaffold_7:2036475-2038341 (-)	Putative protein	No annotation yet
208509	scaffold_7:2038381-2039739 (+)	Putative protein	No annotation yet
155993	scaffold_7:2039032-2039971 (-)	GO:0003723 RNA binding. Interacting selectively and non-covalently with an RNA molecule or a portion thereof.	No annotation yet
49844	scaffold_7:2040187-2041265 (+)	GO:0004298 threonine-type endopeptidase activity. Catalysis of the hydrolysis of internal peptide bonds in a polypeptide chain by a mechanism in which the hydroxyl group of a threonine residue at the active centre acts as a nucleophile.	No annotation yet
96804	scaffold_6:4257330-4259091 (-)	G0:0003677 DNA binding. Any molecular function by which a gene product interacts selectively with DNA (deoxyribonucleic acid). G0:0003700 sequence-specific DNA binding transcription factor activity. Interacting selectively and non-covalently with a specific DNA sequence in order to modulate transcription. The transcription factor may or may not also interact selectively with a protein or macromolecular complex. G0:0006355 regulation of transcription, DNA-dependent. Any process that modulates the frequency, rate or extent of cellular DNA-dependent transcription.	No annotation yet
166575	scaffold_7:2042679-2044011 (+)	GO:0005515 protein binding, Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other non-protein molecules).	No annotation yet
77971	scaffold_7:2049509-2051776 (-)	Putative protein	No annotation yet
31107	scaffold_7:2054261-2055433 (+)	G0:0003824 catalytic activity. Catalysis of a biochemical reaction at physiological temperatures. In biologically catalysed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic.	No annotation yet
204500	scaffold_7:2056817-2057682 (+)	Putative protein	No annotation yet
156006	scaffold_7:2058401-2059893 (-)	GO:0000166 nucleotide binding. Interacting selectively and non-covalently with a nucleotide, any compound consisting of a nucleoside that is esterified with (ortho)phosphate or an oligophosphate at any hydroxyl group on the ribose or deoxyribose moiety.	No annotation yet

Transcript ID:	Location:	Gene ontology	Definition
49849	scaffold_7:2060248-2062273 (+)	GO:0000015 phosphopyruvate hydratase complex. A multimeric enzyme complex, usually a dimer or an octamer, that catalyses the conversion of 2-phospho-D-glycerate to phosphoenolpyruvate and water.	No annotation yet
208514	scaffold_7:2044371-2048954 (-)	GO:0008060 ARF GTPase activator activity. Increases the rate of GTP hydrolysis by the GTPase ARF.	No annotation yet
77972	scaffold_7:2052410-2053032 (-)	Putative protein	No annotation yet
31190	scaffold_7:2055461-2056561 (-)	GO:0003824 catalytic activity. Catalysis of a biochemical reaction at physiological temperatures. In biologically catalysed reactions, the reactants are known as substrates, and the catalysts are naturally occurring macromolecular substances known as enzymes. Enzymes possess specific binding sites for substrates, and are usually composed wholly or largely of protein, but RNA that has catalytic activity (ribozyme) is often also regarded as enzymatic.	No annotation yet
211997	scaffold_7:2062352-2063340 (-)	Putative protein	No annotation yet
198503	scaffold_7:2063728-2064756 (+)	Putative protein	No annotation yet
31199	scaffold_7:2082954-2084195 (-)	GO:0005508 proteolysis. The chemical reactions and pathways resulting in the breakdown of a protein by the destruction of the native, active configuration, with the hydrolysis of peptide bonds.	No annotation yet
156013	scaffold_7:2084798-2087077 (+)	GO:0004672 protein kinase activity. Catalysis of the phosphorylation of an amino acid residue in a protein, usually according to the reaction: a protein + ATP = a phosphoprotein + ADP.	No annotation yet
77984	scaffold_7:2088199-2089353 (-)	Putative protein	No annotation yet
211999	scaffold_7:2096114-2096935 (-)	Putative protein	No annotation yet
63438	scaffold_7:2122388-2122960 (+)	Putative protein	No annotation yet
104048	scaffold_7:2090006-2095772 (-)	GO:0005488 binding. The selective, non-covalent, often stoichiometric, interaction of a molecule with one or more specific sites on another molecule.	No annotation yet
156019	scaffold_7:2115877-2116567 (+)	Putative protein	No annotation yet
212000	scaffold_7:2117112-2119076 (+)	Putative protein	No annotation yet
204508	scaffold_7:2117112-2119587 (-)	Putative protein	No annotation yet
30715	scaffold_7:2119919-2121685 (-)	G0:0004497 monocwgenase activity. Catalysis of the incorporation of one atom from molecular oxygen into a compound and the reduction of the other atom of oxygen to water. G0:0005506 iron ion binding. Interacting selectively and non-covalently with iron (Fe) ions. G0:0006118 electron transport. OBSOLETE. The transport of electrons from an electron donor to an electron acceptor. G0:0020037 heme binding. Interacting selectively and non-covalently with heme, any compound of iron complexed in a porphyrin (tetrapyrrole) ring.	Lanosterol 14α-demethylase, catalyses the C-14 demethylation of lanosterol in the ergosterol biosynthesis pathway. Target for azole fungicides (Rafael Arango, 2008-11-10). Name: CYP51 (Rafael Arango, 2008-11-10)

Genetic mapping of resistance

Definition	No annotation yet	No annotation yet	No annotation yet	No annotation yet
Gene ontology	Putative protein	Putative protein	 GO:0005215 transporter activity. Enables the directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells. GO:0006810 transport. The directed movement of substances (such as macromolecules, small molecules, ions) into, out of or within a cell, or between cells, or within a multicellular organism by means of some agent such as a transporter or pore. GO:0016020 membrane. Double layer of lipid molecules that encloses all cells, and, in eukaryotes, many organelles; may be a single or double lipid bilayer; also includes associated proteins. 	Putative protein
Location:	scaffold_7:2122388-2122960 (+)	scaffold_7:2124095-2125034 (+)	scaffold_7:2125667-2128069 (+)	scaffold_7:2128129-2130717(-)
Transcript ID:	63438	212002	86816	77993

General discussion

General discussion

Fungicides are currently key tools for disease control. Among the fungicides, triazoles (azoles) belonging to the group of demethylation inhibitors (DMIs) are ubiquitous compounds for the control of human and plant diseases (Chowdhary et al. 2013; Cools et al. 2013; Ploetz et al. 2015; Verweij et al. 2013). Black Sigatoka control in banana, caused by *Pseudocercospora fijiensis*, relies on intensive application of triazoles in fungicide mixtures, next to cultural measures such as deleafing (Cañas et al. 2009; Marín et al. 2003; Pérez 2006). Although the disease is still manageable, the appearance and spread of resistant strains is alarming (Cañas et al. 2009; Churchill 2011b; Ploetz et al. 2015). The single target DMIs fungicides, targeting the 14α -demethylase enzyme, together with the sexual reproduction of P. fijiensis have greatly contributed to this phenomenon. The increasing problem of reduced efficacy of DMI fungicides to P. fijiensis urges for understanding of the underlying developmental mechanisms to ensure successful future control strategies based on similar and new chemistries. While resistance monitoring measures are generally applied in banana farms worldwide, the methods are outdated and key genetic information is hardly available, which translates into uncertainty and routine fungicide application rather than into decision support mechanisms. The aim of this thesis was, therefore, to elucidate the molecular mechanisms of reduced efficacy to DMI fungicides in P. fijiensis.

DMI fungicides selective pressure

For years, the DMI baseline sensitivity in most banana producing countries is continuously rising. Marín et al., (2003) reported an average EC_{50} for propiconazole of 0.15 mg.L⁻¹ with a maximum value of 0.5 mg.L⁻¹ in Costa Rican populations. In 2009, our study
revealed an increase in the propiconazole EC_{50} values to an average of 1.10 mg L⁻¹ with a maximum value of 1.53 mg.L⁻¹ for four resistant Costa Rican isolates (Chapter 3, (Díaz-Trujillo et al. 2016a)). A subsequent analysis of 107 P. fijiensis isolates from 2014 showed again an increase in resistance with an EC_{50} average of 5.8 mg.L⁻¹ and a maximum value of 18.4 mg.L⁻¹ for propiconazole (Chapter 2, (Chong et al. 2016b)). These data revealed an ~40fold increase of the EC_{50} over a decade, which was gradual and hence, predictable. Costa Rica has a long history of fungicide use in black Sigatoka management (Marín et al. 2003) and the DMI baseline sensitivity shift correlates with the increasing amounts of fungicides being used. The number of fungicide applications raised from 30 in the 90's up to 50 treatments by 2007 and are still rising (Lapeyre et al. 2010a). The results from the Costa Rican isolates are representative for the selective pressure role exerted by DMIs fungicides on the pathogen population. In this thesis we elaborated on the DMIs sensitivity baseline for P. fijiensis isolates representing populations from various countries. Unfortunately, documentation on the development of DMI sensitivity, in combination with the number of application is frequently lacking. Nonetheless, populations derived from countries with a (long) history of DMI applications are generally resistant. In contrast, P. fijiensis populations from areas without fungicide applications are generally sensitive. Exemplary are indigenous areas such as Bohol, Philippines, or the San Pablo area of Costa Rica as well as the sensitive populations from the most recently colonized areas, Martinique and Guadalupe (Guzmán et al. 2013; Ioos et al. 2011). This latter case raises questions about their origin. As stated in Chapter 2, in order for all isolates in these populations to be sensitive they should fit one of the two following hypotheses: (1) the islands were colonized by wild type (wt) P. fijiensis populations that had not undergone DMI selection pressure or (2) the islands were colonized by P. fijiensis populations that had undergone DMI selection pressure, but they reverted to wild type populations due to the lack of DMI selective pressure. The latter case supports the fitness costs

theory where DMI resistance is accompanied with a fitness penalty, which is rapidly lost in the absence of selective pressure. This phenomena was observed for *Magnaporthe oryzae* and *Cercospora beticola* but remained unnoticed for many others fungi (Hollomon 2015). Moreover, the isolates from Martinique and Guadalupe are closely related to the Latin American population, which might support hypothesis 2. However, in both island the selective pressure exist since DMI are used to control yellow Sigatoka. Besides, this population are also sensitive to other fungicides, namely strobilurins (QoI) and benzimidazoles (MBC) (data not shown) thus, the favoured hypothesis is that these islands were colonized by wt *P. fijiensis* isolates. We, therefore, consider the fitness hypothesis unlikely for *P. fijiensis*, particularly since we have identified wt strains in other non-sprayed areas such as San Carlos (Arango *et al.* 2016) in Costa Rica and Bohol in the Philippines as well as in Cameroon, Colombia, and Ecuador (Chapter 2). Nevertheless, it is worth mentioning that our research was limited to just a few isolates from these populations, hence analyses on more isolates and further genetic studies are required to conclusively elucidate this matter.

The role of selection exerted by DMI fungicides on *P. fijiensis* population is highlighted in Chapter 2 and 3 of this thesis in which we studied the genetic and phenotypic response of a global panel of *P. fijiensis* isolates to DMIs. The global panel strain from countries with a wide diversity in the intensity of DMI fungicide applications. This allowed us to compare the effects of fungicide application on DMI efficacy, i.e. the distribution of resistant and sensitive *P. fijiensis* strains and to analyse the underlying genetic background. Consequently, most resistant strains were collected from countries where banana production is important, which suffer from black Sigatoka disease and hence are exposed to a high fungicide application frequency. This information enables us now to predict, based on the number of fungicide application cycles and the country origin, the level of DMI sensitivity. We show that DMI resistance in *P. fijiensis* correlates with specific changes in the *Pfcyp51* gene.

CYP51 structure and DMI resistance

The accumulation of modifications in the CYP51 protein tends to confer reduced efficacy of DMI fungicides in several organisms (Cools et al. 2013). A high degree of polymorphisms in CYP51 was previously reported for *Tapesia acuformis* and *T. yallundae* (Albertini et al. 2003). We also identified a high degree of polymorphisms in P. fijiensis with 60 different *Pfcyp51* genotypes resulting in 28 different amino acid (aa) substitutions in the resulting protein. Among these, aa substitutions resulting in A19E, I70M, D71E, V260L, I264T, H380N, R418G, D460E, D460V, Y461N, Y461S, ΔY461 and G462D were hitherto unpublished in P. fijiensis. However, not all of these substitutions correlate with DMI resistance. Surprisingly, we identified sensitive isolates carrying three aa CYP51 modifications, which apparently might represent natural random mutations, although some could be compensatory substitutions. Substitutions T18I and A446S had an additive (EC_{50}) effect in tolerant and resistant isolates. Additive compensatory substitutions were nicely illustrated by aa changes in Zymoseptoria tritici - the Septoria tritici blotch pathogen of wheat - since the main substitution for fungicide resistance was enzymatically lethal as corroborated by complementation experiments in Saccharomyces cerevisiae (Becher & Wirsel 2012). Future studies in fungi showing reduced efficacy to DMIs should elaborate on the role of substitutions outside the catalytic core of the CYP51 protein.

The effect of DMI applications on genetic changes of *P. fijiensis* is exemplified by key mutations in the *Pfcyp51* gene. Especially CYP51 substitution A313G, and to a lesser extend Y136F, H380N, Y463D and D460V correlate with DMI resistance (Chapter 2). Equivalent substitutions in CYP51 of other fungi confirm their vital role in azole resistance

(Albertini et al. 2003; Cools et al. 2013; Délye et al. 1997; Lupetti et al. 2002). The importance of substitutions located in or near the core of CYP51 was highlighted by CYP51 modelling and fungicide docking experiments (Chapter 2). According to Mullins et al. (2011) DMI resistance due to modulation of the CYP51 enzyme occurs in the following order: (1) obstruction or loss of interaction due to residue substitution; (2) constriction of the binding cavity to block the access of azoles; and (3) enlargement of the binding cavity to prevent interactions between key residues and the active ingredient (Mullins et al. 2011). Interestingly, CYP51 modelling and propiconazole docking experiments confirmed all these options. Substitutions at positions 136, 313, 380, 381 affect the core of the protein in the substrate recognition site (SRS) and fulfil Mullins first statement. Modulations at positions 460 to 463, not located in the SRS, compromise the three-dimensional structure of the protein resulting in an affinity change due to significant distance and angle changes around position 524 to 526 (SRS6) (Chapter 2). Similar observations were made for the deletion of Y461 affecting the active site (Chapter 2). Position 125, at the entrance of the channel to the active site of the protein, was modified in all resistant strains, resulting in constriction of the binding cavity or enlargement of the binding cavity. Either affects the protein affinity for the active ingredient of the fungicide (Mullins et al. 2011). This knowledge can now be applied in protein modelling, anticipating on specific substitutions, and the effect on binding of azole fungicides and hence, act as a prediction tool in order to develop azole based compounds *de novo*.

Interestingly, the *P. fijiensis* reference strain CIRAD86 that was used to generate the first linkage map (Manzo-Sanchez *et al.* 2008) that was also used and improved in a recent whole genome sequencing project (Kema 2009), is the only strain among 268 isolates that encodes a valine instead of aspartic acid at position 106 in CYP51 (Chapter 2). Since South East Asia is the proposed centre of origin (Carlier *et al.* 1996; Halkett *et al.* 2010; Hayden *et al.* 2003; Rivas *et al.* 2004b) and CIRAD86 originates from Cameroon, we concluded that

substitution D106V is a rare event that exclusively occurred in CIRAD86 rather than the reverse substitution in all other strains. The proposed additive role of D106V, as stated in Chapter 2, is most likely a statistical artefact based on another (other) mutation(s) in the reference strain. Due to the fact that all resistant strains possess this variant, the statistical variance of V106D + A313G is, with 11.8, slightly higher than the threshold of 10. However, this is likely a statistical artefact as the interaction was preferred by the algorithm, probably by the presence of the resistant substitution A313G rather than V106D. This highlights two important issues: first, one should always consider biology for final decisions to avoid miss-interpretation based on probability; secondly, although the CIRAD86 genome has been a priceless tool for our studies, there is an urgent need for sequencing many more *P. fijiensis* isolates, preferably using strains from the centre of origin, to better understand overall genetic diversity.

Discovery of *Pfcyp51* promoter insertions and their role in reduced efficacy of DMIs

Whether aa substitutions are the main mechanism for reduced DMI efficacy is addressed in Chapter 3. For the first time we observed overexpression of the target Pfcyp51 gene, apparently through (repeated) insertions of a Pfcyp51 promoter localized sequence. The inserted sequences are composed of a particular repeat element (Chapter 2 and 3), which are widely shared among tolerant and resistant strains, whereas it was absent from all sensitive strains. The presence of these insertions and their number, positively correlate with DMIs fungicide resistance (Chapter 2). Since their discovery in Costa Rica populations (Chapter 3), other populations were identified with similar insertions (Chapter 2). In a previous study, the role of this mechanism was thought to be negligible since overexpression of the Pfcyp51 gene in propiconazole resistant isolates from Colombia was not observed (Cañas *et al.* 2009). There

are however, many possible reasons why overexpression was not (yet) observed: firstly, the propiconazole resistance level was still much lower than we observed for resistant strains (Chapter 2 and 3); and secondly, the Colombian set of isolates analysed by Cañas-Gutierrez (2009) was smaller. It is plausible that the frequency of strains, sampled in 2008, with insertions, was negligible or even not-existing (Cañas-Gutierrez 2009). In contrast, among the 2012 Colombian derived *P. fijiensis* strains, 24 out of 34 resistant strains contained a promoter insertion (70%). This rapid increase, between 2008 to 2012, in both EC₅₀ values and promoter insertion frequency correlated with the constant selection pressure of DMI fungicide applications with an average of 6.8 cycles per year (6.8 from a total of 30 fungicide applications) from 2008 to 2012 (Vicente Rey, Augura, personal communication). These data could be used to extrapolate the critical DMI selection pressure for the appearance of a particular resistant mechanism within a given population. Such a tool would be very useful for the management and improvement of diseases control strategies.

Inserts as observed in *Pfcyp51* promoters are commonly observed in other fungal species (Cools *et al.* 2012; Hamamoto *et al.* 2000; Ma *et al.* 2006; Mellado *et al.* 2007; Schnabel & Jones 2000; Snelders *et al.* 2012; Villani *et al.* 2016). Nevertheless, they differentiate greatly between species based on their size, sequence, position and nature. Clearly, they are the result of independent events, raising important questions about their origin. Some insertions are considered to be remains from transposable element activity. These can contain powerful promoter sequences whose footprints could be the observed insertions (Cools et al., 2013). The repeats identified in *P. fijiensis* can be categorized as mini-satellite like structures (>14 bp), as found by Espley et al. (2009) in the promoter of MYB10 overexpressed in red flesh apples (Espley *et al.* 2009). The expansion mechanism of mini-satellites is suggested to result from recombination (Espley *et al.* 2009). Nonetheless, mini-satellite like structures have been related to miniature inverted-repeat transposable elements

(Espley *et al.* 2009; Lu *et al.* 2008). Since the *Pfcyp51* gene is 8.7 kb away from the nearest recombination point (Chapter 4), it is unlikely that recombination is the key player in the *Pfcyp51* repeat element expansion and also, there is no clear evidence for miniature inverted-repeat transposable elements, and hence, the origin of these repeats remains unknown.

The P. fijiensis repeat element's central core is a palindromic motif. These motifs are frequently annotated as cis-elements, an important group of regulators in eukaryotes (Knox & Keller 2015). It is well known that many transcription factors (TF) bind palindromic sequences with high affinity (Narlikar & Hartemink 2006; Qian et al. 2006). Interestingly, we observed that these elements negatively regulate fungicide efficacy: an increasing number of repeat elements, particularly with the number of palindromic sequences, reduced the efficacy (Chapter 2 and 3). Finally, the promoter swapping transformation experiments described in Chapter 3 proved that the causality of these insertions: insertion in the *Pfcyp51* promoter both increased the gene's expression as well as azole resistance. This is consistent with observations in Venturia inaequalis where overexpression of the cyp51 confers differential resistance to difenoconazole (Villani et al. 2016). However, the increase of DMI resistance in the P. fijiensis mutants was not as high as in the resistant wt strain (Chapter 3) since that strain also possessed aa modulations in the target *Pfcyp51* gene. So, overexpression synergizes the effect of accompanying effective target site mutations. All these observations are consistent with results from Z. tritici, where promoter insertions were suggested to occur after target site mutations and also prevented further accumulation of such mutations as this would eventually compromise the enzymatic activity and stability of the protein (Leroux and Walker, 2011). Finally, in Chapter 2 the statistical analyses on the role of promoter insertions in reduced DMI efficacy revealed that they are not the main explanatory component, but important add-ons to key target site mutations.

One of the main upcoming questions for *P. fijiensis* is what molecular machinery drives this increase of repeat elements? Whole genome sequence methodology can shed light to their origin, but except for the palindromic sequence, no general lead was found. Therefore, we hypothesize that these palindromes are essential for further repeat amplification. One possible mechanism to study the role of the element and its palindromic core is DNA-protein hybridization. In particular, yeast one hybrid has been a useful DNA-protein hybridization system to find transcription factors (Ota *et al.* 2014). We could try using the *Pfcyp51* promoter as a capture probe in a genome-wide mapping of promoter-anchored interactions through HiCap methodologies for the identification of regulatory interactors as this is based on modified chromosome conformation capture followed by a sequence-capture of promoter containing fragments, resulting in a high-resolution map of promoter-anchored interactions (Sahlen *et al.* 2015). Finally, to elucidate more basic elements in fungal promoters, cap analysis of gene expression (CAGE) technology can be used to detect transcriptional start site(s) (TSS) and the expression levels by utilizing 5' cDNA tags and PCR (Kurosawa *et al.* 2011).

Classical genetic analysis to unequivocally identify and map genomic regions involved in DMIs resistance

The aim of Chapter 4 was to elucidate the genetic nature of reduced DMI efficacy by genetic mapping using segregating *P. fijiensis* populations from crosses between isolates with major differences in DMI sensitivity. We, therefore, generated, phenotyped and genotyped two mapping population and constructed two linkage maps using Diversity Array Technology (DArT) markers. As discussed earlier in Chapter 4, a gradual shift from sensitivity to resistance is usually based on the interaction of many genes, often referred to as quantitative or polygenic resistance (Dyer *et al.* 2000). The DMI resistance mechanism was characterized as polygenic 260

for *Candida albicans, A. fumigatus* and *Z. tritici* (Cools *et al.* 2013; Cowen 2008). Also, reduced DMI sensitivity for *P. fijiensis* in the field has been gradual in nature (Cañas *et al.* 2009; Marín *et al.* 2003). Nevertheless, the evidence presented in this thesis points at *Pfcyp51* as the single major gene involved and hence, the quantitative expression of the phenomenon seems to be largely due to the various modulations of the CYP51 protein and the binding of various active ingredients.

The first evidence of a monogenic cause in *P. fijiensis* was the correlation of the *Pfcyp51* changes with reduced DMIs efficacy as described in Chapter 2. The second evidence is the clear distinct 1:1 segregation for DMI sensitivity and analogous *Pfcyp51* modifications in the *P. fijiensis* mapping populations described in Chapter 4. Thirdly, the genetic maps revealed one genetic region harbouring *Pfcyp51* as the single most important candidate gene. Nonetheless, subtle variations were observed between individuals with the same *Pfcyp51* genotype configuration. We, therefore, cannot exclude modifying factors for DMI sensitivity, including physiological factors such as colony age, growth ratios and other stress factors.

Modernizing monitoring

Hitherto, DMI efficacy is monitored by germ tube lengths measurement and germination ratios of *P. fijiensis* ascospores. Though technically simple, it does not provide any insight in the underlying mechanisms and hence, DNA based methodologies are preferred to further precise and modernize monitoring strategies. Rapid molecular monitoring tools such as PCR-based technologies reduce the required timeframe for an adequate response to any disease. For DMI efficacy monitoring we could develop a quick molecular test focusing on the presence of important substitutions in PfCYP51, e.g. position 313, 136 and 463. We have shown that a simple PCR, which is based on the variable number of the insertions, indicates the presence of *Pfcyp51* promoter repeats, suggesting the potentially reducing sensitivity levels

in natural *P. fijiensis* populations (Chapter 3) for instance in Costa Rican populations (Díaz-Trujillo *et al.* 2016a). Ideally, such test should be run directly on leaf tissue, which would further the implementation of technology revealing the genomic basis of DMI resistance in *P. fijiensis* strains. The generation of the two genetic maps based on DMI sensitivity (Chapter 4) also contributed significantly to the identification of molecular markers and candidates genes involved in DMI sensitivity for further studies (Chong *et al.* 2016c). These should include quantification of DNA/RNA species enabling the ratio of resistant vs. wt genotype(s) in natural population (Singh & Mustapha 2013).

Concluding remarks

In conclusion, the proven monogenic basis of DMI sensitivity in *P. fijiensis* has an apparent quantitative phenotypic expression, which in many systems is considered to result from a polygenically controlled mechanism (Cools & Fraaije 2013; Cools *et al.* 2013; Dyer *et al.* 2000). How can we reconcile such a seemingly contrasting observation? Interestingly as noted in Chapter 2, each of the *Pfcyp51* mutations contributes to resistance, but does not confer full DMI resistance as it seems to depend on the balance between catalytic activity of the CYP51 protein and the active ingredient of the fungicide. Another phenomenon is that a particular substitution affects individual, or subsets of DMIs compounds, but is insufficient for cross-resistance to the whole class of fungicides (Cools et al., 2013), which was nicely illustrated in *Venturia inaequalis* with differential resistance to difenoconazole and myclobutanil (Villani *et al.* 2016). In theory, each (surviving) mutation in the CYP51 protein will be based on the interaction with the DMIs applied in the field. However, this is insufficient for full resistance against the array of fungicides.



Figure 1. Schematic representation of CYP51 interaction with DMI fungicides in *Pseudocercospora fijiensis* based on Cowen et al (2008) cyp51 illustration. A) Normal membrane integrity and ergosterol pathway. B) Scheme of the effect of DMI fungicides on the membrane integrity and the ergosterol pathway. Accumulation of 14 α -methylergosta-8,24(28)-dien-3 β , 6 α -diol will stop development and cause cell death (Lupetti *et al.* 2002; Shapiro *et al.* 2011). C) Modulated CYP51 reduces the affinity for the interaction with DMI fungicides and thereby their efficacy, hence increasing amounts of fungicide are needed for disease control. D) Increased expression of CYP51 overcomes increasing amounts of fungicides. This increment of enzymatic active units causes a synergistic effect with the reduced affinity towards the fungicide, resulting in a further amplification of resistance. In comparison with scenario (C) an increases of fungicide doses from ten times or more will be required for effective disease control (D).

The discovered *Pfcyp51* overexpression mechanism is the latest novelty in an important research area. Overexpression is unavoidable to maintain catalytic activity under the mutational pressure at and around the catalytic site (Figure 1). Finally, we hypothesize that in the near future additional mechanisms will appear, such as the increased exclusion of fungicides from the intracellular compartments as observed before in other DMI stressed fungi (Cowen 2008). Potentially, the occurrence of this mechanism in *P. fijiensis* might provoke a non-gradual increase in DMI resistance, which cannot be counteracted by increased fungicide

applications and hitherto practiced (Chapter 2). This stresses the need for novel mode of action fungicides (moa's) or control strategies to manage black Sigatoka disease in the future. The knowledge of the current distribution, evolution and impact of the resistance in the field is therefore an invaluable data source for the future control of this important banana disease.

References

- Aguilar-Barragan A, García-Torres AE, Odriozola-Casas O, *et al.* (2014) Chemical management in fungicide sensivity of *Mycosphaerella fijiensis* collected from banana fields in México. *Brazilian Journal of Microbiology* **45**, 359-364.
- Akins RA, Sobel JD (2009) Antifungal targets, mechanisms of action, and resistance in *Candida albicans*. 347-407.
- Albarrag AM, Anderson MJ, Howard SJ, *et al.* (2011) Interrogation of related clinical pan-azoleresistant *Aspergillus fumigatus* strains: G138C, Y431C, and G434C single nucleotide polymorphisms in *cyp51A*, upregulation of *cyp51A*, and integration and activation of transposon Atf1 in the *cyp51A* promoter. *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY* **55**, 5113-5121.
- Albertini C, Gredt M, Leroux P (2003) Polymorphism of 14α-demethylase gene (CYP51) in the cereal eyespot fungi Tapesia acuformis and *Tapesia yallundae*. *European Journal of Plant Pathology*, 117-128.
- Alvarez-Rueda N, Fleury A, Morio F, *et al.* (2011) Amino acid substitutions at the major insertion loop of *Candida albicans* Sterol 14α-Demethylase Are Involved in fluconazole resistance. *PLoS One* **6**, e21239.
- Amil AF, Heaney SP, Stanger C, Shaw MW (2007) Dynamics of QoI sensitivity in *Mycosphaerella fijiensis* in Costa Rica during 2000 to 2003. *Phytopathology* **97**, 1451-1457.
- Aouini L, Mirzadi Gohari, A., Ware, S.B., Van den Bosch, F., Helps, J., Alonso-Chavez, V., Seidl, M.F., Meijer, H.J.G., Schouten, H.J., Diaz-Trujillo, C., Ben M'Barek, S., Verstappen, E.C.P., de Wit, P.J.G.M., Thomma, B.P.H.J., and GHJ Kema. (2016) A paradigm shift: sex deals with biotic and abiotic threats in the fungal plant pathogen *Zymoseptoria tritici*. *Submitted to Nature Genetics*.
- Arango RE, Diaz C, Dhillon B, et al. (2016) Combating a global threat to a clonal crop: banana black Sigatoka pathogen *Pseudocercospora fijiensis* (synonym *Mycosphaerella fijiensis*) genomes reveal clues for disease control. *PloS Genetics*.
- Arias P, Dankers C, Liu P, Pilkauskas P (2003) The World Banana Economy, 1985–2002 (ed. Nations FaAOotU), Rome.
- Arzanlou M, Crous PW, Zwiers LH (2010) Evolutionary dynamics of mating-type loci of *Mycosphaerella spp.* occurring on banana. *Eukaryot Cell* **9**, 164-172.
- Arzanlou M, Groenewald JZ, Fullerton RA, *et al.* (2008) Multiple gene genealogies and phenotypic characters differentiate several novel species of *Mycosphaerella* and related anamorphs on banana. *Persoonia* **20**, 19-37.
- Bailey TL, Elkan C (1994) Fitting a Mixture Model by Expectation Maximization to Discover Motifs in Biopolymers, 28-36
- Beaglehole R, Irwin A, Prentice T (2003) The world health report 2003: shaping the future. World Health Organization, Geneva, Switzerland.
- Bean TP, Cools HJ, Lucas JA, *et al.* (2009) Sterol content analysis suggests altered eburicol 14alpha-demethylase (CYP51) activity in isolates of *Mycosphaerella graminicola* adapted to azole fungicides. *FEMS Microbiol Lett* **296**, 266-273.
- Becher R, Wirsel SG (2012) Fungal cytochrome P450 sterol 14α-demethylase (CYP51) and azole resistance in plant and human pathogens. *Applied Microbiology and Biotechnology* **95**, 825-840.
- Bennett RS, Arneson PA (2003) *Black Sigatoka of bananas and plantains* The American Phytopathological Society
- Blomme G, Eden-Green S, Mustaffa M, Nwauzoma B, Thangavelu R (2011) *Major disease of banana* CRC Press Taylor & Francis Group, United States of America.

- Bolton MD, Ebert MK, Faino L, *et al.* (2016) RNA-sequencing of *Cercospora beticola* DMIsensitive and -resistant isolates after treatment with tetraconazole identifies common and contrasting pathway induction. *Fungal Genet Biol* **92**, 1-13.
- Boogaerts M, Winston DJ, Bow EJ, *et al.* (2001) Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who Are receiving broad-spectrum antibacterial therapy. *Annals of Internal Medicine* **135** 412-422.
- Brauner A, Fridman O, Gefen O, Balaban NQ (2016) Distinguishing between resistance, tolerance and persistence to antibiotic treatment. *Nat Rev Microbiol* **14**, 320-330.
- Calvo CM, Romero RA, Guzmán M (1997) Inhibición del crecimiento del tubo germinativo de ascosporas de *Mycosphaerella fijiensis* resistentes y sensibles al propiconazole a diferentes tiempos de incubación. In: *Informe anual. Direccion de investigación y servicios agrícolas* (ed. CORBANA), p. 64, San José, Costa Rica.
- Cañas GP, Patiño LF, Arango ER, Arango R (2006) Molecular characterization of Benomylresistant isolates of *Mycosphaerella fijiensis*, collected in Colombia. *J. Phytopathology*, 403-409.
- Cañas GP, Velasquez MJA, Florez JMR, *et al.* (2009) Analysis of the CYP51 gene and encoded protein in propiconazole-resistant isolates of *Mycosphaerella fijiensis*. *Pest Manag Sci* **65**, 892-899.
- Carbone I, Kohn LM (1999) A method for designing primer sets for speciation studies in filamentous ascomycetes. *Mycologia* **91**, 553-556.
- Carlier J, Lebrun M, Zapater MF, Duboist C, Mourichon X (1996) Genetic structure of the global population of banana black leaf streak fungus, *Mycosphaerella fijiensis*. *Molecular Ecology* **5**, 499-510.
- Cartegni L, Wang J, Zhu Z, Zhang MQ, Krainer AR (2003) ESEfinder: a web resource to identify exonic splicing enhancers. *Nucleic Acids Research* **31**, 3568-3571.
- Chen C-K, Doyle PS, Yermalitskaya LV, *et al.* (2009) *Trypanosoma cruzi* CYP51 Inhibitor Derived from a *Mycobacterium tuberculosis* Screen Hit. *PLoS Neglected Tropical Diseases* **3**, e372.
- Chen CK, Leung SS, Guilbert C, et al. (2010) Structural characterization of CYP51 from *Trypanosoma cruzi* and *Trypanosoma brucei* bound to the antifungal drugs posaconazole and fluconazole. *PLoS Neglected Tropical Diseases* **4**, e651.
- Chong P, Arango R, Stergiopoulus I, et al. (2010) Analysis of azole fungicide resistance in Mycosphaerella fijiensis, causal agent of black Sigatoka. In: Proceedings of the 16th International Reinhardsbrunn Symposium on Modern Fungicides and Antifungal Compounds pp. 217 - 222.
- Chong P, Carr C, Murillo G, et al. (2016a) An historical treatise and critical review of black Sigatoka control in banana production. *In preparation*.
- Chong P, Essoh JN, Arango R, et al. (2016b) Global status and genetic dynamics associated to Azole Resistance in *Pseudocercospora fijiensis*. In preparation.
- Chong P, Vichou A, Schouten H, *et al.* (2016c) Genetic mapping resistance to 14α-demethylase inhibitor fungicides in the banana black Sigatoka pathogen *Pseudocercospora fijiensis* reveals *Pfcyp51* as a single explanatory factor. *In preparation*.
- Chowdhary A, Kathuria S, Xu J, Meis JF (2013) Emergence of Azole-Resistant Aspergillus fumigatus Strains due to Agricultural Azole Use Creates an Increasing Threat to Human Health. PLoS Pathog 9.
- Chung K-R, Daub ME, Kuchler K, Schüller C (2003) The CRG1 gene required for resistance to the singlet oxygen-generating cercosporin toxin in *Cercospora nicotianae* encodes a putative fungal transcription factor. *Biochemical and Biophysical Research Communications* **302**, 302-310.

- Churchill AC (2011a) *Mycosphaerella fijiensis*, the black leaf streak pathogen of banana: progress towards understanding pathogen biology and detection, disease development, and the challenges of control. *Mol Plant Pathol* **12**, 307-328.
- Churchill ACL (2011b) *Mycosphaerella fijiensis*, the black leaf streak pathogen of banana: progress towards understanding pathogen biology and detection, disease development, and the challenges of control. *Mol Plant Pathol* **12**, 307-328.
- Ciba-Geigy (1991) Tilt Thecnical Dossier (ed. Ltd. C-G), Basle, Switzerland.

Collins S (2014) Banana: staple food for 500 million people. CGIAR

http://dialogues.cgiar.org/blog/banana-staple-food-for-500-million-people/

- Conde-Ferraez L, Waalwijk C, Canto-Canche BB, *et al.* (2007) Isolation and characterization of the mating type locus of *Mycosphaerella fijiensis*, the causal agent of black leaf streak disease of banana. *Mol Plant Pathol* **8**, 111-120.
- Cook DC, Liu S, Edwards J, et al. (2013) Predicted economic impact of black Sigatoka on the Australian banana industry. *Crop Protection* **51**, 48-56.
- Cools HJ, Bayon C, Atkins S, Lucas JA, Fraaije BA (2012) Overexpression of the sterol 14αdemethylase gene (MgCYP51) in *Mycosphaerella graminicola* isolates confers a novel azole fungicide sensitivity phenotype. *Pest Manag Sci* **68**, 1034-1040.
- Cools HJ, Fraaije BA (2013) Update on mechanisms of azole resistance in *Mycosphaerella graminicola* and implications for future control. *Pest Manag Sci* **69**, 150-155.
- Cools HJ, Hawkins NJ, Fraaije BA (2013) Constraints on the evolution of azole resistance in plant pathogenic fungi. *Plant Pathology* **62**, 36-42.
- Cowen LE (2008) The evolution of fungal drug resistance: modulating the trajectory from genotype to phenotype. *Nat Rev Microbiol* **6**, 187-198.
- Crooks GE, Hon G, Chandonia J-M, Brenner SE (2004) WebLogo: A Sequence Logo Generator. *Genome Res* 14, 1188-1190.
- D'Hont A, Denoeud F, Aury JM, et al. (2012) The banana (*Musa acuminata*) genome and the evolution of monocotyledonous plants. *NATURE* **488**, 213-217.
- de Lapeyre de Bellaire L, Essoh Ngando, J., Abadie, C., Chabrier, C., Blanco, R., Lescot, T., Carlier, J. and Côte, F. (2009) Is chemical control of *Mycosphaerella* foliar diseases of bananas sustainable? . *Acta Horticulturae. (ISHS)* 828, 161-170.
- Dean R, Van Kan JA, Pretorius ZA, et al. (2012) The Top 10 fungal pathogens in molecular plant pathology. *Mol Plant Pathol* **13**, 414-430.
- Deighton FC (1976) Studies on Cercospora and allied genera. VI. Pseudocercospora Cif. and Cercoseptoria. *Petr. Mycol.* **140**, 1-168.
- Délye C, Laigret F, Corio-Costet MF (1997) A Mutation in the 14a-Demethylase Gene of *Uncinula necator* That Correlates with Resistance to a Sterol Biosynthesis Inhibitor. *Applied and Enviromental Microbiology* **63**, 2966–2970.
- Díaz-Trujillo C, Chong P, Cunha VCD, *et al.* (2016a) A new resistance mechanism to azole fungicides in the fungal banana black Sigatoka pathogen *Pseudocercospora fijiensis* is driven by increased expression of *Pfcyp51* through multiple promotor repeats. *In preparation*.
- Díaz-Trujillo C, Kobayashi AK, Zwiers L-H, *et al.* (2016b) Targeted and random genetic modification of mycelial tissue from the black Sigatoka pathogen *Pseudocercospora fijiensis* by *Agrobacterium tumefaciens*-mediated transformation. *J. Microbiol. Methods To be submitted*.
- Dilucca M, Cimini G, Semmoloni A, Deiana A, Giansanti A (2015) Codon Bias Patterns of E. coli's Interacting Proteins. *PLoS One* **10**, e0142127.

- Dyer PS, Hansen J, Delaney A, Lucas JA (2000) Genetic control of resistance to the sterol 14αdemethylase inhibitor fungicide prochloraz in the cereal eyespot pathogen *Tapesia yallundae*. *Applied and Environmental Microbiology* **66**, 4599-4604.
- Eberhart SA, Russell WA (1966) Stability parameters for comparing varieties. *Crop Science*, 36-40.
- Eddouzi J, Parker JE, Vale-Silva LA, *et al.* (2013) Molecular mechanisms of drug resistance in clinical *Candida* species isolated from Tunisian hospitals. *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY* **57**, 3182-3193.
- Ekesa B, Poulaert M, Davey MW, *et al.* (2012) Bioaccessibility of provitamin A carotenoids in bananas (*Musa spp.*) and derived dishes in African countries. *Food Chemestry* **133**, 1471-1477.
- Elshire RJ, Glaubitz JC, Sun Q, et al. (2011) A robust, simple genotyping-by-sequencing (GBS) approach for high diversity species. *PLoS One* **6**, e19379.
- Espley RV, Brendolise C, Chagné D, *et al.* (2009) Multiple Repeats of a Promoter Segment Causes Transcription Factor Autoregulation in Red Apples. *The Plant Cell* **21**, 168 - 183.
- Fahleson J, Nakyanzia M, Okoric P, et al. (2009) Genetic analysis of *Mycosphaerella fijiensis* in the Ugandan Lake Victoria region. *Plant Pathology* **58**, 888-897.
- FAO (2014a) Banana market review and banana Statistics 2012-2013 (ed. FAO).
- FAO (2014b) Food and Agriculture Organization of the United Nations, statistics division. http://data.fao.org/dataset?entryId=6983404e-4c24-434a-88e2-656eb68be453
- Fernández D, Torés JA, Vicente Ad, Pérez A (2010) *Fungicides: The Qol fungicides, the rise and fall of a successful class of agricultural fungicides* Odile Carisse.
- Finlay KW, Wilkinson GN (1963) The analysis of adaptation in a plant-breeding programme. Australian Journal of Agricultural Research **14**, 742-754.
- Fouré E (1985) Black leaf streak disease of banana and plantains (*Mycosphaerella fijiensis* Morelet). Study of the symptoms and stage of the disease in Gabon. *IRFA-CIRAD, París*.
- FRAC (2010) FRAC Recommendations for Fungicide Mixtures January 2010.
- FRAC (2013) FRAC Code List ©*2013: Fungicides sorted by mode of action (including FRAC Code numbering). *Fungicide Resistance Action Committee*, 1-10.
- FRAC (2015) Working groups fungicide. http://www.frac.info/working-group/banana-group
- Frith MC, Saunders NF, Kobe B, Bailey TL (2008) Discovering sequence motifs with arbitrary insertions and deletions. *PLoS Comput Biol* **4**, e1000071.
- Ganry J, Meyer JP (1972) La lutte contrôlée la Cercosporiose aux Antilles. Bases climatiques de L'avrtissement. *Fruits* **27**, 665-676.
- Goodwin SB, Kema GHJ (2014) The Genomes of *Mycosphaerella graminicola* and *M. fijiensis*. In: *Genomics of Plant-Associated Fungi: Monocot Pathogens* (eds. Dean RA, Lichens-Park A, Kole C), pp. 123-140.
- Goodwin SB, M'Barek SB, Dhillon B, *et al.* (2011) Finished genome of the fungal wheat pathogen *Mycosphaerella graminicola* reveals dispensome structure, chromosome plastici-ty and stealth pathogenesis *PLoS Genet* **7**.
- Grünwald NJ, Goodwin SB, Milgroom MG, Fry WE (2003) Analysis of genotypic diversity data for populations of microorganisms. *Analytical and Theoretical Plant Pathology* **93**, 738-746.
- Gullino ML, Tinivella F, Garibaldi A, et al. (2010) Mancozeb: Past, present, and future. *Plant Disease* **94**, 1076-1087.
- Guyot H, Guillé J (1954) Les formules fongicides huileuses pour le traitement de bananerais. *Fruits*, 289-292.
- Guzmán M (2007) Estrategias para el manejo de la resistencia de Mycosphaerella fijiensis Morelet, agente causal de la Sigatoka negra en banano, a fungicidas triazoles, Universidad de Costa Rica.

- Guzmán M, Orozco M, Pérez L (2013) Sigatoka leaf spot diseases of bananas: dispersion, impact and evolution of management strategies in Latin America-Caribbean region. XX Reunião Internacional da Associação para a Cooperação em Pesquisa e Desenvolvimento Integral das Musáceas (Bananas e Plátanos) 9 a 13 de setembro de 2013 - Fortaleza, CE, Brasil.
- Halkett F, Coste D, Platero GG, *et al.* (2010) Genetic discontinuities and disequilibria in recently established populations of the plant pathogenic fungus *Mycosphaerella fijiensis*. *Molecular Ecology* **19**, 3909-3923.
- Hamamoto H, Hasegawa K, Nakaune R, *et al.* (2000) Tandem repeat of a transcriptional enhancer upstream of the Sterol 14α-Demethylase gene (CYP51) in *Penicillium digitatum*. *Applied and Enviromental Microbiology* **66**, 3421–3426.
- Hargrove TY, Warwzak Z, Lamb DC, Guengerich FP, Lepesheva GI (2015) Structure-functional characterization of cytochrome P450 sterol alpha-demethylase (Cyp51B) from *Aspergillus Fumigatus* and molecular basis for the development of antifungal drugs. *THE JOURNAL OF BIOLOGICAL CHEMISTRY* **290**, 23916-23934.
- Hayden HL, Carlier J, Aitken EAB (2003) Genetic structure of *Mycosphaerella fijiensis* populations from Australia, Papua New Guinea and the Pacific Islands. *Plant Pathology*, 703-712.
- Hollomon DW (2015) Fungicide resistance: Facing the challenge. *Plant Protection Science* **51**, 170-176.
- INIBAP (1998) Bananas and food security. In: *Les productions bananières : un enjeu économique majeur pour la sécurité alimentaire* eds. C. Picq EF, Frison EA), Douala, Cameroon.
- Ioos R, Hubert J, Abadie C, *et al.* (2011) First Report of Black Sigatoka Disease in Banana Caused by *Mycosphaerella fijiensis* on Martinique Island *Plant Disease* **95**, 359.
- Johnson L, Johnson R, Akamatsu H, *et al.* (2001) Spontaneous loss of a conditionally dispensable chromosome from the Alternaria alternata apple pathotype leads to loss of toxin production and pathogenicity. *Curr Genet* **40**, 65-72.
- Kashino SS, Singer-Vermes LM, Calich VLG, Burger E (1990) Alterations in the pathogenicity of one *Paracoccidioides brasiliensis* isolate do not correlative with its in vitro growth. *Mycopathologia* **111** 173-180.
- Kema GHJ (2009) Sequencing the major *Mycosphaerella* pathogens of wheat and banana. *Acta Hort.* **828**, 147-152.
- Kema GHJ, Verstappen ECP, Todorova M, Waalwijk C (1996) Successful crosses and molecular tetrad and progeny analyses demonstrate heterothallism in *Mycosphaerella graminicola*. *Curr Genet* **30**, 251-258.
- Kilian A, Wenzl P, Huttner E, et al. (2012) Diversity arrays technology: a generic genome profiling technology on open platforms. *Methods in Molecular Biology* **888**, 67-89.
- Klein HH (1960) Control of *Cercospora* leaf spot of bananas with applications of oil spray based on the disease cycle. *Phytopathology* **50**, 488-490.
- Knight S, Wirz M, Amil A, Hall A, Shaw M (2002) The role of managing resistance to fungicides in maintaining the effectiveness of integrated strategies to control black leaf streak disease Workshop on Mycosphaerella leaf spot diseases
- Knox BP, Keller NP (2015) *Key players in the regulation of fungal secondary metabolism* Springer New York.
- Krokene P, Solheim H (2001) Loss of pathogenicity in the blue-stain fungus *Ceratocystis polonica*. *Plant Pathology*, 497-502.
- Kurosawa J, Nishiyori H, Hayashizaki Y (2011) Deep cap analysis of gene expression. *Methods Mol Biol* **687**, 147-163.
- Langhe ED, Vrydaghs L, Maret Pd, Perrier X, Denham T (2009) Why Bananas Matter: An introduction to the history of banana domestication. *Ethnobotany Research & Applications* **7**, 165-178.

- Lapeyre Ld, Abadie C, Carlier J, Ngando J, Kema GHJ (2010a) *Mycosphaerella* foliar diseases of bananas: towards an integrated protection (ed. ENDURE).
- Lapeyre Ld, Eric F, Abadie C, Carlier J (2010b) Black leaf streak disease is challenging the banana industry. *Fruits* **65**, 327-342.
- Latin R (2011) A practical guide to turfgrass fungicides The American Phytopathology
- Leach R (1946) Banana leaf spot (Mycosphaerella musicola) on the Gros Michel variety in Jamaica: Investigations on the aetiology of the disease and the principles of control by spraying The Government printer, Kingston, Jamaica.
- Lendenmann MH, Croll D, McDonald BA (2015) QTL mapping of fungicide sensitivity reveals novel genes and pleiotropy with melanization in the pathogen *Zymoseptoria tritici*. *Fungal Genet Biol*.
- Lepesheva GI, Waterman MR (2004) CYP51-the omnipotent P450. *Mol Cell Endocrinol* **215**, 165-170.
- Leroux P, Gredt M, Leroch M, Walker AS (2010) Exploring mechanisms of resistance to respiratory inhibitors in field strains of *Botrytis cinerea*, the causal agent of gray mold. *Appl Environ Microbiol* **76**, 6615-6630.
- Leroux P, Walker AS (2011) Multiple mechanisms account for resistance to sterol 14αdemethylation inhibitors in field isolates of *Mycosphaerella graminicola*. *Pest Manag Sci* **67**, 44-59.
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using Real-Time Quantitative PCR and the 2–ΔΔCT method. . *Methods* **25**, 402-408.
- Lloyd AT, Sharp PM (1991) Codon usage in Aspergillus nidulans. *Molecular Genetics and Genomics* **230**, 288-294.
- Long PG (1979) Banana black leaf streak disease (*Mycosphaerella fijiensis*) in western Samoa. *Transaction of the British mycological Society* **72**, 299-310.
- Lu K, Chai YR, Zhang K, *et al.* (2008) Cloning and characterization of phosphorus starvation inducible Brassica napus purple acid phosphatase 12 gene family, and imprinting of a recently evolved MITE-minisatellite twin structure. *Theor Appl Genet* **117**, 963-975.
- Lupetti A, Danesi R, Campa M, Tacca MD, Kelly S (2002) Molecular basis of resistance to azole antifungals. *TRENDS in Molecular Medicine* **8**, 76-81.
- Ma Z, Michailides TJ (2005) Advances in understanding molecular mechanisms of fungicide resistance and molecular detection of resistant genotypes in phytopathogenic fungi. *Crop Protection* **24**, 853-863.
- Ma Z, Proffer TJ, Jacobs JL, Sundin GW (2006) Overexpression of the 14α-demethylase target gene (*CYP51*) mediates fungicide resistance in *Blumeriella jaapii*. *APPLIED AND ENVIRONMENTAL MICROBIOLOGY* **72**, 2581-2585.
- Manzo-Sanchez G, Zapater MF, Luna-Martinez F, *et al.* (2008) Construction of a genetic linkage map of the fungal pathogen of banana *Mycosphaerella fijiensis*, causal agent of black leaf streak disease. *Curr Genet* **53**, 299 311.
- Marín DH, Romero RA, Guzmán M, Sutton TB (2003) Black Sigatoka: An increasing threat to banana cultivation. *Plant Disease* **87** 208-222.
- Martínez-Bolaños L, Téliz-Ortiz D, Rodríguez-Maciel JC, et al. (2012) Resistencia a fungicidas en poblaciones de Mycosphaerella fijiensis del sureste mexicano. Agrociencia 46, 707-717.
- Matthews GA, Baterman R, Miller P (2014) *Chemical control in integrated pest management, in: Pesticide application methods* John Wiley & Sons Oxford.
- Mellado E, Garcia-Effron G, Alcazar-Fuoli L, *et al.* (2007) A new *Aspergillus fumigatus* resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of *cyp51A* alterations. *ANTIMICROBIAL AGENTS AND CHEMOTHERAPY* **51**, 1897-1904.

- Meredith DS, Lawrence JS (1969) Black leaf streak disease of bananas (*Mycosphaerella fijiensis*): symtomps of disease in Hawaii, and notes of the causal fungus. *Transaction of the British mycological Society* **52**, 459-476.
- Mirzadi Gohari A, Ware SB, Wittenberg AH, et al. (2015) Effector discovery in the fungal wheat pathogen *Zymoseptoria tritici*. *Mol Plant Pathol* **16**, 931-945.
- Mitka M (2011) Animal antibiotic use. American Medical Association 306 1970.
- Monera OD, Sereda TJ, Zhou NE, Kay CM, Hodgesi RS (1995) Relationship of sidechain hydrophobicity and α -helical propensity on the stability of the single-stranded amphipathic α -helix. *Journal of Peptide Science* **1**, 319-329.
- Monk BC, Tomasiak TM, Keniya MV, *et al.* (2013) Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. *Proceedings of the National Academy of Sciences* **111**, 3865-3870.
- Morelet M (1969) Micromycetes du Var et d'ailleurs (2me Note). Ann. Société Sci. Nat. Archeol Toulon Var **21**, 104-106.
- Morio F, Loge C, Besse B, Hennequin C, Le Pape P (2010) Screening for amino acid substitutions in the *Candida albicans* Erg11 protein of azole-susceptible and azole-resistant clinical isolates: new substitutions and a review of the literature. *Diagn Microbiol Infect Dis* 66, 373-384.
- Mullins JG, Parker JE, Cools HJ, et al. (2011) Molecular modelling of the emergence of azole resistance in *Mycosphaerella graminicola*. *PLoS One* **6**, e20973.
- Narlikar L, Hartemink AJ (2006) Sequence features of DNA binding sites reveal structural class of associated transcription factor. *Bioinformatics* **22**, 157-163.
- Ordoñez N, Seidl MF, Waalwijk C, et al. (2015) Worse comes to worst: Bananas and Panama Disease--When plant and pathogen clones meet. *PLoS Pathog* **11**, e1005197.
- Ota K, Feng SY, Ito T (2014) Detecting protein-DNA interactions using a modified yeast onehybrid system. *Methods Mol Biol* **1164**, 39-50.
- Peláez JE, Vásquez LE, Díaz TJ, et al. (2006) Use of a micro title plate dilution assay to measure activity of antifungal compounds against *Mycosphaerella Fijiensis*, Morelet. *Revista Facultad Nacional de Agronomía. Medellín* **59**, 3425-3433.
- Perea I, Rodríguez-Arango E, Márquez E, Arango R (2005) Genetic diversity of Colombian isolates of *Mycosphaerella fijensis* Morelet based on microsatellite markers. *InfoMusa* **14**, 18-21.
- Pereira SI, Figueiredo PI, Barros AS, *et al.* (2014) Changes in the metabolome of lettuce leaves due to exposure to mancozeb pesticide. *Food Chem* **154**, 291-298.
- Peres NAR, Souza NL, Peever TL, Timmer LW (2014) Benomyl sensitivity of isolates of *Colletotrichum acutatum* and *C. gloeosporioides* from citrus. *The American Phytopathological Society* **88**, 125-130.
- Pérez L (2006) Manejo convencional y alternativo de la Sigatoka negra en bananos: Estado actual y persepectivas In: *Fitosanidad*, pp. 55-72.
- Perrier X, De Langhe E, Donohue M, et al. (2011) Multidisciplinary perspectives on banana (*Musa spp.*) domestication. *Proc Natl Acad Sci U S A* **108**, 11311-11318.
- Pietila MP, Vohra PK, Sanyal B, et al. (2006) Cloning and characterization of CYP51 from Mycobacterium avium. Am J Respir Cell Mol Biol **35**, 236-242.
- Ploetz R (2000) Black Sigatoka. Pesticide Outlook, 19-23.
- Ploetz RC, Kema GH, Ma LJ (2015) Impact of diseases on export and smallholder production of banana. Annual Review of Phytopathology.
- Qian J, Lin J, Zack DJ (2006) Characterization of Binding Sites of Eukaryotic Transcription Factors. *Genomics, Proteomics & Bioinformatics* **4**, 67-79.

- R-Development-Core-Team (2008) *R: A language and environment for statistical computing.* R Foundation for Statistical Computing, Vienna, Austria.
- Ramsay JO (1988) Monotone regressions splines in action. Statistical Science 3, 425-441.
- Rhodes PL (1964) A new banana disease in Fiji. *Commonwealth Phytopathological News* **10**, 38-41.
- Rieux A, Soubeyrand S, Bonnot F, *et al.* (2014) Long-distance wind-dispersal of spores in a fungal plant pathogen: estimation of anisotropic dispersal kernels from an extensive field experiment. *PLoS One* **9**, e103225.
- Risède J-M, Lescot T, Cabrera JC, *et al.* (2010) Challenging short and mid-term strategies to reduce the use of pesticides in banana production. (ed. ENDURE).
- Rivas G, Zapater MF, Abadie C, Carlier J (2004a) Contribuciones de la genética de poblaciones de *Mycosphaerella fijiensis* al entendimiento y manejo de la Sigatoka negra en los Trópicos. In: XVI REUNIÓN INTERNACIONAL ACORBAT 2004, Mexico.
- Rivas GG, Zapater MF, Abadie C, Carlier J (2004b) Founder effects and stochastic dispersal at the continental scale of the fungal pathogen of bananas *Mycosphaerella fijiensis*. *Molecular Ecology* **13**, 471-482.
- Robert S, Ravigne V, Zapater MF, Abadie C, Carlier J (2012) Contrasting introduction scenarios among continents in the worldwide invasion of the banana fungal pathogen *Mycosphaerella fijiensis*. *Molecular Ecology* **21**, 1098-1114.
- Rodríguez CM, Raigosa N, Conde L, *et al.* (2006) Variation in electrophoretic karyotype among Mexican isolates of *Mycosphaerella fijiensis*. *Canadian Journal of Plant Pathology* **28**, 236-241.
- Romero CR (1999) Origin and distribution of fungicide resistant strains of *M. fijiensis* in banana plantations in Costa Rica. In: *Banana Breeding and Biotechnology: Commodity advances through banana improvement project research* (ed. Bank TW). Presley and P. George, Washington DC.
- Romero RA, Sutton TB (1997) Sensitivity of Mycosphaerella fijiensis, causal agent of black Sigatoka of Banana, to Propiconazole. Phytopathology. **87**, 96-100.
- Sahlen P, Abdullayev I, Ramskold D, et al. (2015) Genome-wide mapping of promoter-anchored interactions with close to single-enhancer resolution. *Genome Biol* **16**, 156.
- Saleh D, Milazzo J, Adreit H, Tharreau D, Fournier E (2012) Asexual reproduction induces a rapid and permanent loss of sexual reproduction capacity in the rice fungal pathogen *Magnaporthe oryzae*: results of in vitro experimental evolution assays. *BMC Evol Biol* **12**, 42.
- Scalliet G, Bowler J, Luksch T, *et al.* (2012) Mutagenesis and functional studies with succinate dehydrogenase inhibitors in the wheat pathogen *Mycosphaerella graminicola*. *PLoS One* **7**, e35429.
- Schnabel G, Jones AL (2000) The 14a-Demethylase (CYP51A1) Gene is Overexpressed in *Venturia inaequalis* Strains Resistant to Myclobutanil. *Genetics and Resistance*.
- Sepúlveda L, Torres J (2016) Lack of cross resistance between pyraclostrobin and azoxystrobin in Mycosphaerella fijiensis. In: VI Congreso Internacional sobre banano CORBANA y XXI Reunión internacional ACORBAT (ed. ACORBAT). ACORBAT, Miami, Florida.
- Sereda TJ, Mant CT, Sonnichsen FD, Hodges RS (1994) Reversed-phase chromatography of synthetic amphipathic α-helical peptides as a model for ligand/receptor interactions effect of changing hydrophobic environment on the relative hydrophilicity/hydrophobicity of amino acid side- chains. *Journal of Chromatography* **A 676** 139-153.
- Shapiro RS, Robbins N, Cowen LE (2011) Regulatory circuitry governing fungal development, drug resistance, and disease. *Microbiol Mol Biol Rev* **75**, 213-267.

- Shively G, Hao J (2012) A review of agriculture, food security and human nutrition issues in Uganda, p. 28. Purdue University, Department of Aricultural Economics.
- Sierotzki H, Parisi S, Steinfeld U, *et al.* (2000) Mode of resistance to respiration inhibitors at the cytochrome bc1 enzyme complex of *Mycosphaerella fijiensis* field isolates. *Pest Manag Sci*, 833-841.
- Singh P, Mustapha A (2013) Multiplex TaqMan(R) detection of pathogenic and multi-drug resistant *Salmonella*. Int J Food Microbiol **166**, 213-218.
- Snelders E, Camps SM, Karawajczyk A, *et al.* (2012) Triazole fungicides can induce crossresistance to medical triazoles in *Aspergillus fumigatus*. *PLoS One* **7**, e31801.
- Stam P (1993) Construction of integrated genetic linkage maps by means of a new computer package: JOINMAP. *The Plant Journal* **3**, 739-744.
- Stammler G, Cordero J, Koch A, Semar M, Schlehuber S (2009) Role of the Y134F mutation in *cyp51* and overexpression of *cyp51* in the sensitivity response of *Puccinia triticina* to epoxiconazole. *Crop Protection* **28**, 891-897.
- Stergiopoulos I, Cordovez V, Okmen B, *et al.* (2014) Positive selection and intragenic recombination contribute to high allelic diversity in effector genes of *Mycosphaerella fijiensis,* causal agent of the black leaf streak disease of banana. *Mol Plant Pathol* **15**, 447-460.
- Stergiopoulos I, van den Burg HA, Okmen B, *et al.* (2010) Tomato Cf resistance proteins mediate recognition of cognate homologous effectors from fungi pathogenic on dicots and monocots. *Proc Natl Acad Sci U S A* **107**, 7610-7615.
- Stergiopoulos I, Zwiers L-H, Waard MAD (2002) Secretion of natural and synthetic toxic compounds from filamentous fungi by membrane transporters of the ATP-binding cassette and major facilitator superfamily. *European Journal of Plant Pathology* **108**, 719-734.
- Stover RH (1962) Intercontinental spread of banana leaf spot (*Mycosphaerela musicola* Leach). *Trop. Agric. Trin.* **39**, 327-338.
- Stover RH (1990) Sigatoka leaf spots: Thirty years of changing control strategies 1959 -1989. In: *INIBAP poceedings international worshop* (ed. Fullerton RA), pp. 66-74. INIBAP, San José, Costa Rica.
- Stover RH, Simmonds NW (1987) Bananas, 3rd. Edition edn. Wiley.
- Strushkevich N, Usanov SA, Park H (To be publish) *Crystal structure of human lanosterol* 14alpha-demethylase (CYP51) in complex with econazole.
- Sun X, Xu Q, Ruan R, *et al.* (2013) PdMLE1, a specific and active transposon acts as a promoter and confers *Penicillium digitatum* with DMI resistance. *Environ Microbiol Rep* **5**, 135-142.
- Thurkral SK, Eisen A, Young ET (1991) Two monomers of yeast transcription factor ADR1 bind a palindromic sequence symmetrically to activate ADH2 expression. *MOLECULAR AND CELLULAR BIOLOGY* **11**, 1566-1577.
- Trotta E (2013) Selection on codon bias in yeast: a transcriptional hypothesis. *Nucleic Acids Research* **41**, 9382-9395.
- Unno T, Han D, Jang J, *et al.* (2010) High diversity and abundance of antibiotic-resistant Escherichia coli isolated from humans and farm animal hosts in Jeonnam Province, South Korea. *Sci Total Environ* **408**, 3499-3506.
- van Wendel de Joode B, Barbeau B, Bouchard MF, et al. (2016) Manganese concentrations in drinking water from villages near banana plantations with aerial mancozeb spraying in Costa Rica: Results from the Infants' Environmental Health Study (ISA). Environ Pollut 215, 247-257.

- Vega H (2011) The banana sector in Ecuador. Trade. Supply chain. U.S. Cooperation. In: *Global Agriculture Information Network (GAIN) Report* (ed. Service UFA). USDA Foreign Agriculture Service Quito.
- Verweij PE, Kema GHJ, B BZ, Melchers WJ (2013) Triazole fungicides and the selection of resistance to medical triazoles in the opportunistic mould *Aspergillus fumigatus*. *Pest Manag Sci* **69**, 165-170.
- Verweij PE, Snelders E, Kema GHJ, Mellado E, Melchers WJG (2009) Azole resistance in *Aspergillus fumigatus*: a side-eff ect of environmental fungicide use? *The Lancet* **9**, 789-795.
- Villani SM, Hulvey J, Hily JM, Cox KD (2016) Overexpression of the CYP51A1 Gene and Repeated Elements are Associated with Differential Sensitivity to DMI Fungicides in *Venturia inaequalis*. *Phytopathology* **106**, 562-571.
- Vincellin P (2014) Some principles of fungicide resistance. Agriculture & Natural Resources.
- Waalwijk C, Mendes O, Verstappen ECP, Waard MAD, Kema GHJ (2002) Isolation and characterisation of the mating-type ideomorphs from the wheat septoria leaf blotch fungus *Mycosphaerella graminicola*. *Fungal Genet Biol* **35** 277-286.
- Ware S, Trujillo CD, Kema G, Lee Tvd, Waard M (2006) *Aspects of sexual reproduction in Mycosphaerella species on wheat and barley: genetic studies on specificity, mapping, and fungicide resistant*, Wageningen University and Research
- Warrilow AG, Parker JE, Kelly DE, Kelly SL (2013) Azole affinity of sterol 14alpha-demethylase (CYP51) enzymes from *Candida albicans* and *Homo sapiens*. *ANTIMICROBIAL AGENTS* AND CHEMOTHERAPY **57**, 1352-1360.
- Wittenberg AHJ, Lee TAJVd, M'Barek SB, *et al.* (2009) Meiosis drives extraordinary genome plasticity in the haploid fungal plant pathogen *Mycosphaerella graminicola*. *PLoS One* **4** 1-10.
- Wong M-H, Crous PW, Henderson J, Groenewald JZ, Drenth A (2012) *Phyllosticta* species associated with freckle disease of banana. *Fungal Diversity* **56**, 173-187.
- Wyand RA, Brown JK (2005) Sequence variation in the CYP51 gene of Blumeria graminis associated with resistance to sterol demethylase inhibiting fungicides. *Fungal Genet Biol* **42**, 726-735.
- Yang CW, Chang YT, Chao WL, *et al.* (2014) An investigation of total bacterial communities, culturable antibiotic-resistant bacterial communities and integrons in the river water environments of Taipei city. *J Hazard Mater* **277**, 159-168.
- Zadoks JC, Schein RD (1979) *Epidemiology and Plant Disease Management* Oxford University Press, New York.
- Zandjanakou-Tachin M, Vroh-Bi I, Ojiambo PS, *et al.* (2009) Identification and genetic diversity of *Mycosphaerella* species on banana and plantain in Nigeria. *Plant Pathology* **58**, 536-546.
- Zeitoun M, Allan T, Al Aulaqi N, Jabarin A, Laamrani H (2012) Water demand management in Yemen and Jordan: addressing power and interests. *The Geographical Journal* **178**, 54-66.
- Zhang L, Skolnick J (1998) What should the Z-score of native protein structures be? *Protein Science* **7**, 1201-1207.
- Zwiers L-H (2002) ABC transporters of the wheat pathogen Mycosphaerella graminicola, Wageningen University & Research.

Summary

Pseudocercospora fijiensis is the causal agent of black Sigatoka which is the most serious leaf defoliation disease on Musa spp. (bananas and plantains). Many plantain and banana species are susceptible to black Sigatoka including the exporting Cavendish cultivars. Leaf defoliation results in significant yield loses and premature ripening of banana fruit, which is a serious problem for the banana exporting industry. The main control measure of black Sigatoka involves frequent fungicide application with a very high environmental and economic burden. Among these fungicides, the azole chemical family is one of the most frequently used fungicides for the control of the disease. Azole fungicides belong to the sterol demethylation-inhibitors (DMIs) that target the lanosterol 14α -demethylase enzyme (CYP51). One of the major problems in black Sigatoka control has been the excessive and unplanned use of the DMI fungicide applications in many banana farms worldwide. This uncurbed use of the fungicide resulted in DMI resistance in pathogen population. Over time, resistance levels have increased to such an extent that the number of fungicide application cycles is now near maximum level. The reduction of sensitivity in P. fijiensis to currently used DMIs has been gradual in nature, suggesting a polygenic control (Cañas et al. 2009). Nevertheless, genetic evidence described in this thesis suggests that *Pfcyp51* is the single major factor responsible for the sensitivity loss in the field. Our study is the first global analysis of DMI fungicide resistance in P. fijiensis, provides a lead to understand DMI sensitivity reduction, enables the development of better black Sigatoka management strategies, but also calls for more sustainable solutions of this unparalleled banana threat.

Chapter 1 describes the importance of the banana fruit as commodity and staple food worldwide and the impact of black Sigatoka on its cultivation. It introduces the subject of the thesis, the problem of the resistance to DMIs in the control of black Sigatoka and describes lifestyle features of the causal agent *P. fijiensis*, the history of fungicide control of the disease,

the impact that DMI fungicides exerted in the population of this species and concludes with the set-up of the thesis.

Chapter 2 provides an historical treatise of black Sigatoka management – primarily in Costa Rica – including the strategies that were developed and applied. It concludes with a critical evaluation of the current practice and the required changes.

Chapter 3 describes an extensive worldwide phenotypic and genotypic survey of *P*. *fijiensis* resistance to DMI fungicides. The sensitivity of a set of 592 field isolates collected from various banana production zones in Colombia, Costa Rica, the Dominican Republic, Ecuador, the Philippines, Guadalupe, Martinique and Cameroon was tested. The sequence analyses of the 14 α -demethylase enzyme CYP51 encoding the *Pfcyp51* gene in 266 isolates showed a wide suite of modulations. Insertions of a 19 base pairs (bp) element found in the promoter region of the *Pfcyp51* gene were described and the correlation between these changes in the *Pfcyp51* gene and promoter and the increase in azole resistance was established. In addition, the contribution of the main CYP51 amino acid substitutions through the elucidation of seven in silico protein models was evaluated.

Chapter 4 describes the *de-novo* identification of a 19 bp element found in the promoter region of the *Pfcyp51* gene. Evidence strongly suggested that insertion of this element in the promoter - up to 6 copies - of resistant strains causes over expression of the *Pfcyp51* gene in comparison to strains that contain one element. PCR based assays were used to analyse the presence of the repeat element in four *P. fijiensis* populations of Costa Rica and some isolates from Ecuador, Africa and South East Asia. Promoter swap transformation experiments were used to analyse the role of the repeat element in the expression of the *Pfcyp51* gene. This identified the repeat element as a novel component that, together with mutations in the *Pfcyp51* open reading frame, are responsible for higher levels of resistance against azole fungicides.

Chapter 5 describes the generation of two F_1 *P. fijiensis* progenies for the construction of two genetic maps that identifies the region encoding for DMI fungicide resistance using DArTseq technology. Full agreement was found between the genetic markers in either population, underlining the robustness of the approach. This genetic tool was essential to identify the genetic region that determines the resistant to DMI fungicides in the species and strongly supports the hypothesis that the *Pfcyp51* gene is the single major determinant of

resistance towards DMI fungicides in *P. fijiensis*. The mapped region comprises 250,660 bp and contains 53 putative genes, including the *Pfcyp51* gene, which is the most plausible candidate as the driving molecular force for the resistance to DMI fungicides based on our and others' findings.

Chapter 6 discusses the experimental outcomes obtained in the thesis and describes them in a broader framework. It highlights the compelling evidence that modulation of the promoter and the coding gene sequence of *Pfcyp51* correlate with the observed azole sensitivity. Finally, the impact and implications of these findings are discussed for future disease control strategies.

Resumen

Pseudocercospora fijiensis es el agente causal de la Sigatoka negra, la enfermedad foliar más grave de Musa spp. (bananos y plátanos). Muchas especies de plátano y banano son susceptibles a la Sigatoka negra incluyendo los cultivares de exportación Cavendish. La defoliación que causa la enfermedad resulta en una reducción significativa de la producción y la maduración prematura de la fruta, que es un serio problema para la industria exportadora de banano. La principal medida de control de la enfermedad implica la aplicación frecuente de fungicidas con un impacto ambiental y económico muy alto. Entre los fungicidas usados para el control de la enfermedad, los triazoles son uno de los fungicidas más utilizados. Los azoles pertenecen al grupo de compuestos inhibidores de la des-metilación del esterol (DMIs). Estos fungicidas pertenecientes al grupo DMI que actúan directamente en la inhibición de la enzima lanosterol 14 α -desmetilasa (CYP51). Uno de los principales problemas en el control de la Sigatoka negra ha sido el uso excesivo y no planificado de las aplicaciones de fungicidas DMI en muchas fincas de banano alrededor del mundo. Este uso desordenado de los fungicidas ha dado lugar a la aparición de resistencia a los DMI en las poblaciones del patógeno. Con el tiempo, los niveles de resistencia han aumentado a tal medida que el número de ciclos de aplicación de fungicidas están cerca del nivel máximo. La pérdida de sensibilidad de P. *fijiensis* a los DMI que se utilizan actualmente ha sido gradual, esto aparentemente sugeriría que la resistencia a los DMI es de naturaleza poligénica. Sin embargo, la evidencia genética encontrada en esta tesis sugiere que el gen cyp51 es el principal y único responsable de la pérdida de sensibilidad en el campo. Este estudio es el primer análisis global de la resistencia a los fungicidas DMI en P. fijiensis y; ofrece pistas para entender la reducción de la sensibilidad a los DMI. La información obtenida en este trabajo nos permitirá el desarrollo de mejores estrategias de manejo de la Sigatoka negra, pero al mismo tiempo nos muestra la necesidad de la búsqueda de soluciones más sostenibles para lidiar con esta amenaza sin precedentes al cultivo del banano.

El **capítulo 1** describe la importancia de la fruta del banano como bien de exportación y como alimento básico a nivel mundial, mostrándonos el impacto que la Sigatoka negra ejerce en su cultivo. Nos introduce el tema de la tesis, el problema de la resistencia a DMIs en el control de la Sigatoka negra. Describe las características del estilo de vida del agente causal *P. fijiensis*, la historia del control de la enfermedad y el impacto que ejercen los fungicidas DMI en la población de la especie y concluye mostrando la estructura de la tesis.

El **capítulo 2** provee una disertación histórica del manejo de la Sigatoka negra – principalmente en Costa Rica – incluyendo las estrategias que han sido desarrolladas y aplicadas a través del tiempo. Concluye con una evaluación critica del presente manejo de la enfermedad y de los cambios que se necesitan para futuro.

El **capítulo 3** Describe un análisis fenotípico y genotípico mundial de la resistencia de *P. fijiensis* a los fungicidas DMIs. En el capítulo 2 se examinó la sensibilidad de un conjunto de 592 aislados del campo recogidos de diferentes zonas de producción bananera en Colombia, Costa Rica, República Dominicana, Ecuador, Filipinas, Guadalupe, Martinica y Camerún. El análisis de la secuencia del gen *Pfcyp51* que codifica la enzima 14 α -desmetilasa CYP51 en 266 aislamientos mostraron una amplia gama de variaciones. Se describe también las inserciones de un elemento de 19 pares de bases (pb) que se descubrió en la región promotora del gen *Pfcyp51*. Se estableció la correlación entre los cambios en el *gen Pfcyp51* y su promotor con el aumento de la resistencia a los azoles. Además, se evaluó la contribución de las principales sustituciones en los aminoácidos de la CYP51 a través de la elucidación de 7 modelos computacionales de proteínas.

El **capítulo 4** describe por primera vez la identificación de un elemento de 19 pares de bases (pb) en la región promotora del gen *Pfcyp51*. La evidencia sugiere fuertemente que insertos de hasta 6 copias de este elemento en el promotor de cepas resistentes proporcionar sobre-expresión al gen en comparación con las cepas que contienen un elemento. Ensayos basados en PCR se utilizaron para analizar la presencia del elemento repetido en cuatro poblaciones de *P. fijiensis* de Costa Rica y en algunos aislados de Ecuador, África y el Sudeste Asiático. Experimentos de transformación de intercambio del promotor se utilizaron para analizar el papel de este elemento repetido en la expresión del gen *Pfcyp51*. Estos experimentos nos permitieron identificar a este nuevo elemento repetido como un componente que junto con las mutaciones en la región codificante del *Pfcyp51* son responsables de niveles superiores de resistencia contra los fungicidas azólicos.

El **capítulo 5** describe la generación de dos progenies F1 de *P. fijiensis* para la construcción de dos mapas genéticos basados en la resistencia a los fungicidas DMI. La tecnología DArTseq se utilizó para generar un mapa de ligamiento genético para ambas poblaciones. Se encontró total acuerdo entre los marcadores genéticos de ambas poblaciones, lo que subraya la solidez del enfoque. Esta herramienta genética fue esencial para identificar la región genética que determina la resistencia a los fungicidas DMI en la especie y apoya

firmemente la hipótesis de que el gen cyp51 es el único importante determinante de la resistencia a fungicidas DMI en *P. fijiensis*. Esta región genética de 250.660 pb contiene 53 genes putativos que incluyen el gen cyp51 que base en los hallazgos de otros autores y los nuestros es el candidato más plausible como la fuerza molecular que determina la resistencia a los fungicidas DMIs.

El **capítulo 6** analiza los resultados experimentales obtenidos en la tesis y los describe desde una perspectiva más amplia. Este capítulo resalta la evidencia convincente de que la modulación de la secuencia del promotor y la región codificante del gen *cyp51* se correlaciona con la perdida de sensibilidad observada en azoles. Finalmente, se discute el impacto y las implicaciones de estos hallazgos en las futuras estrategias para el control de enfermedades.

Samenvatting

Pseudocercospora fijiensis is de veroorzaker van black Sigatoka (of zwarte blad strepenziekte), de schadelijkste bladvlekkenziekte van het geslacht Musa dat ook bananen en bakbananen omvat. Vele soorten zijn vatbaar voor black Sigatoka, inclusief de "Cavendish" export variëteiten. Bladschade veroorzaakt belangrijke opbrengstverliezen en vroegtijdige afrijping van bananen, een belangrijke schadepost voor de exportindustrie. De belangrijkste beheersmethode voor black Sigatoka betreft het frequent bespuiten van plantages met fungiciden die een grote milieukundige en economische belasting vormen. Onder deze fungiciden omvat de chemische familie van de azolen de meest gebruikte werkzame stoffen om de ziekte te bestrijden. Azolen vallen onder de sterol demethylase remmers (DMIs) die het 14α demethylase enzym (CYP51) blokkeren. Eén van de grootste problemen bij de bestrijding van black Sigatoka vormt de buitensporige en regelmatige toepassing van fungiciden op vele bananenplantages rondom de wereld. Het ongebreidelde gebruik van fungiciden heeft bijgedragen aan het ontstaan van populaties met een hoog niveau van DMI-resistentie. Gedurende de tijd is deze resistentie zodanig toegenomen dat het maximum aantal toepassingen in bereikt. Het verlies van gevoeligheid voor DMIs in P. fijiensis is gradueel ontstaan en dat geeft de indruk van een eigenschap die polygeen wordt gereguleerd. Desniettegenstaande blijkt in dit proefschrift dat het Pfcyp51 gen uitsluitend verantwoordelijk is voor dit verlies onder veldomstandigheden. Onze studie omvat de eerste wereldwijde analyse van fungicideresistentie tegen DMIs in *P. fijiensis*, voorziet in een leidend principe om deze ontwikkeling te begrijpen, maakt het daarmee mogelijk om betere beheerstrategieën voor black Sigatoka te ontwerpen en roept op tot een duurzame oplossing voor deze ongeëvenaarde bedreiging van de bananenteelt.

In **Hoofdstuk 1** wordt het belang van banaan als fruit en voedselgewas beschreven alsmede het effect van black Sigatoka op de wereldwijde teelt van banaan en wordt het thema van dit proefschrift omschreven: fungicide resistentie tegen DMIs. Het beschrijft de levenscyclus en kenmerken van het pathogene organisme *P. fijiensis*, alsmede de geschiedenis van het gebruik van fungiciden en het effect van DMIs op natuurlijke populaties van de soort en wordt afgesloten met de opzet van het proefschrift.

In Hoofdstuk 2 wordt een historisch overzicht beschreven van de bestrijding van black Sigatoka – met name in Costa Rica - en welke strategieën daarbij werden ontwikkeld en ingezet. Het sluit af met een kritische analyse van deze praktijk en de gewenste veranderingen.

Hoofdstuk 3 beschrijft een uitvoerige wereldwijde phenotypering en genotypering van resistentie tegen DMIs in *P. fijiensis*. De gevoeligheid van 592 veldisolaten - afkomstig uit verschillende productiegebieden in Colombia, Costa Rica, de Dominicaanse Republiek, Ecuador, de Filippijnen, Guadeloupe, Martinique en Kameroen – tegen DMIs werd bepaald. Uit sequentieanalyses van het gen dat het 14α -demethylase enzym CYP51 codeert, *Pfcyp51*, in 266 isolaten komt een grote variatie naar voren. Daarbij werden ook inserties van een 19 bp fragment in de promotor van het gen gevonden en beschreven. De correlatie tussen deze veranderingen in de promotor en de toenemende resistentie tegen azolen was daarbij een opvallende constatering. Daarnaast werd het effect van de modulering van het CYP51 eiwit door diverse mutaties geëvalueerd door gebruik te maken van *in-silico* eiwitmodellen.

Hoofdstuk 4 beschrijft een *de-novo* identificatie van een 19 bp element dat werd gevonden in de promotor van het Pfcyp51 gen. De meervoudige - tot zes kopieën - insertie van dit fragment in de promotor in resistente stammen leidt tot overexpressie van het Pfcyp51 gen in vergelijking met isolaten die slecht één fragment in de promotor hebben. Een op PCR gebaseerde test werd gebruikt om de aanwezigheid van deze fragmenten in veldpopulaties uit Costa Rica en enige isolaten uit Ecuador, Afrika en Zuidoost Azië te onderzoeken. Transformatie experimenten waarbij de promotoren tussen gevoelige en resistente isolaten werden omgewisseld demonstreerden de rol van promotorinserties in de expressie van het Pfcyp51 gen. Hiermee werd het geïnserteerde fragment als een nieuwe component van fungicideresistentie beschreven dat tezamen met mutaties in het coderende Pfcyp51 gebied verantwoordelijk is voor de toenemende fungicideresistentie tegen azolen.

Hoofdstuk 5 beschrijft het maken van twee F_1 populaties van *P. fijiensis* die werden gebruikt om twee genetisch kaarten te maken van het gebied dat codeert voor DMI-fungicideresistentie en dat met DArT-technologie werd gekarteerd. Daarbij werd een volledige overeenkomst geconstateerd tussen de merkers in beide populaties die de robuustheid van de gehanteerde methoden onderstreepte. Deze benadering was essentieel om het gebied dat DMI-resistentie codeert in kaart te brengen en bevestigde de hypothese dat het *Pfcyp51* gen de bepalende factor is voor DMI-fungicideresistentie in *P. fijiensis*. Het gekarteerde gebied omvat 250,660 bp en bevat 53 mogelijke genen, waaronder *Pfcyp51*, als de belangrijkste kandidaat en de drijvende kracht achter de resistentie tegen DMIs in ons onderzoek en dat van anderen.

Hoofdstuk 6 is een algemene discussie over de uitkomsten van dit onderzoek en beschrijft deze in een breder kader. Hierbij wordt op overtuigende wijze aangetoond dat modulering van de promotor en het coderende gebied van *Pfcyp51* bepalend is voor en correleert met de waargenomen gevoeligheid voor azolen. Tenslotte worden het effect en de implicaties van dit onderzoek bediscussieerd ten aanzien van toekomstige beheersstrategieën van de ziekte.

Acknowledgements

For many reasons the writing of this thesis has been one of the biggest challenges in my life. There are always mixed feelings when you end a major chapter in your life. On the one hand, there is great joy for the accomplishments of the goals, the new friends made in this way and the satisfaction for the hard work well done. On the other hand, there are always sacrifices that you made and anxiety about the future. With all these remarks, I also acknowledge the fact that finishing this journey was only possible with the help and support of many people.

Firstly, I would like to thank a special person that is always holding my hand through my life, my father, my friend and my God, Jehovah. He has given me life and all the good things I can be proud of, my family and friends. Without him nothing would be possible. It has been a difficult journey and my faith in him has given me an anchor to take the right paths.

I want to thank my family for their great effort and sacrifice. I would like to express my profound gratitude to them. To my lovely wife Adriana who has accompany me day by day facing the challenges of living abroad with limited funds and in a new culture. Thank you Adriana for your patience and support, your kindness and love. We faced the great dilemma that a PhD abroad can be for the family. The reward for our sacrifices not only resulted in the way of a career achievement but also with the blessing of a new life, our beloved baby daughter Abigail. I want to express my love and gratitude to my parents Pedro and Camelia. Without your support it would have been impossible to finish my PhD. From start to the end of this journey you have been there for me (and us!). Thank you very much and we will always love you. I would like also to thanks my brother Pedro and my sister-in-law Karen for their lovely support and care. For always being a source of encouragement and an emotional anchor, we love you guys.

I would like to express my special thanks for the help and support to my promotor Prof. Dr. Ir. Ing. Gert Kema. Thank you for giving me the opportunity to be part of the banana group. This has been the most exciting research in my life (so far) and a key stone in my career development. I want to thank you for your guidance and encouragement throughout the complications of the PhD process. I deeply appreciate your patience and time helping me and others with our personal and professional needs. You give to us a good example of hard work and balance by being a successful and well recognized scientist and at the same time a humble person. I will miss our regular theological and philosophical debates, but hope that we will have the opportunity to continue collaborating together in future research. God bless you and your family. I hope we will see each other soon "Amigo".

I would like to express my profound appreciations and gratitude to my former home institute director Dr. Esther Peralta. Dear Esther, thank you for your trust in me and for your kind support. None of this would have been possible without you. I hope that with the accomplishment of my PhD and those of my colleagues from the Centro de Investigaciones Biotecnológicas del Ecuador (CIBE), we can fulfil your dream of forming a renowned high-standard scientific research center in Ecuador. You have been as a second mother to me, to us. You always supported me throughout my career and personal life. I have the dearest memories of our friendship and the kindness you have shown to me and my family. I hope that someday I can repay all the effort and support you have given me and make you proud. To my daily supervisor Dr. Harold Meijer. Dear Harold, thank you very much for your help and support with the completion of this thesis. Writing is one of the most difficult jobs in science and without your contribution and guidance it would have been an impossible task. Thank you for showing kindness and patience with me during our discussions and your consistency throughout the experimental and editorial work. I would like also to thank Drs. Gabriel Scalliet and Helge Sierotzski for facilitating Syngenta's financial contribution to this research and for their expert support. Thank you for giving me constructive scientific and experimental advices. Your support and guidance have been invaluable for the accomplishment of this thesis. I look forward to a continued collaboration with all of you in the future.

Undoubtedly, this work would have been impossible to accomplish without the technical and scientific support of Marga van Gent-Pelzer, Els Verstappen and Odette Mendes. I deeply appreciate your kind support in the laboratory/greenhouse and your guidance during the different aspects of my experiments. I enjoyed very much our nice conversations during lunch time and your kindness to me and my family when Abigail was born. Thanks also to Marion Notermans and Ineke de Vries for their support with all the administration. Dear Pieter Vereijken and Paul Keizer, thank you for your patience and support with the heavy task of data analyses. I have learned a lot from both of you.

Finally, I would like to give an especial recognition to my colleagues and friends from both the banana group at Wageningen UR and CIBE. Thank you very much my friend Caucasella Díaz. You have been my partner in the good and bad moments of working with *P. fijiensis*. I appreciated your true friendship and loyalty. Although working on the same topic, there was never a spirit of competition or envy between us. We worked hard together and we finally did it together. May God bless you and your family. I wish you the best in your career and personal life. My dear friend Lamia Aouini, thank you for your friendship, your support and help with the scientific work. You have been a true friend for me and my wife and a real aunty for Abby. She always remembers her aunty "L'Mamiamia". I also want to thank my oldest friend in the group, Nadia Ordoñez. Nadia you also have supported and helped me with my work and personal life. To you, my family and I want to give our deepest appreciation and love. My deep appreciation also goes to Aikaterini Vichou, Amir Mirzadi, Anibal Meza, Carla Maté Goldar, Fernando García, Janna Beckerman, María Isabel Jiménez, María Jama, Omar Ruiz, Sarrah Ben M'Barek, Steve Goodwin, Tatiana Chavez and Thijs Bouten. My family and I thank you guys for your friendship, advices and support during this journey.

About the author

Pablo Antonio Chong Aguirre was born in 1977 in Guayaquil, Guayas, Ecuador. After completing high school in physics and mathematics in 1995, he began his studies at La Escuela Superior Politécnica del Litoral (ESPOL Polytechnic University) in Guayaquil and obtained his BSc degree in Marine Aquaculture in 2001 and his MSc degree in Biotechnology in 2007. In 2001 he started his research career as a junior researcher in the Plant Pathology department at the Centro de Investigaciones Biotecnológicas del Ecuador (CIBE, Ecuadorian Centre for Biotechnology Research), where he became head of the Molecular Biology department in 2007 and head of the Plant Pathology department from 2009 to 2012. In 2010 he was awarded a scholarship from the Secretaría de Educación Superior, Ciencia, Tecnología e Innovación (SENESCYT, Ministry of Science, Technology and Innovation) of the Ecuadorian government and a scholarship from ESPOL Polytechnic University. These allowed him to perform his PhD research abroad. In September 2012, he started his program in the group of Prof. Dr. Ir. Ing. Gert H.J. Kema at Wageningen University and Research, Plant Research International and the Laboratory of Phytopathology on the analysis of fungicide resistance in *Pseudocercospora fijiensis*, the causal agent of the banana black Sigatoka disease. This dissertation summarizes the research results of his PhD program on the origin, versatility and distribution of resistance mechanisms to DMI fungicides in P. fijiensis. After returning to Ecuador in 2016 he will continue his work as invited Professor of Biology and head of the Molecular Biology department at CIBE-ESPOL.

List of publications:

- An historical treatise and critical review of black Sigatoka control in banana production. Pablo Chong, Claudiana Carr, Gilberth Murillo, Mauricio Guzmán, Jorge Sandoval and Gerrit H.J. Kema. (to be submitted).
- Global analysis of reduced sensitivity to azole fungicides in the banana black Sigatoka pathogen *Pseudocercospora fijiensis*. Pablo Chong, Josué Ngando Essoh, Rafael Arango, L. C. Paul Keizer, Ioannis Stergiopoulos, Michael F. Seidl, Mauricio Guzman, Jorge Sandoval, Paul E. Verweij, Gabriel Scalliet, Helge Sierotzski, Luc de Lapeyre de Bellaire, Pedro W. Crous, Jean Carlier, Sandrine Cros, Harold J. G. Meijer, Esther Lilia Peralta1 and Gert H. J. Kema. (to be submitted).
- A new resistance mechanism to azole fungicides in the fungal banana black Sigatoka pathogen *Pseudocercospora fijiensis* is driven by increased expression of *Pfcyp51* through multiple promoter repeats. Caucasella Díaz-Trujillo*, Pablo Chong*, Viviane Cordovez, Mauricio Guzman, Pierre J.G.M. De Wit, Ioannis Stergiopoulos, Harold J. G. Meijer, Rafael E. Arango Isaza, Gabriel Scalliet, Helge Sierotzki, Esther Lilia Peralta and Gerrit H. J. Kema. (to be submitted).
- Genetic mapping of resistance to 14α-demethylase inhibitor fungicides in the banana black Sigatoka pathogen *Pseudocercospora fijiensis* reveals *Pfcyp51* as a single explanatory factor. Pablo Chong, Aikaterini Vichou, Henk Schouten, Harold J. G. Meijer, Rafael Arango and Gert H. J. Kema. (to be submitted).
- Brote de *Eacles imperialis* (Lepidóptera: *Saturniidae*) en Cultivos de Cacao y Frutales en Milagro Ecuador Jorge Rafael Paredes Montero, Esther Lilia Peralta García, Pablo Antonio Chong Aguirre. Revista Tecnológica ESPOL – RTE, Vol. 23, N. 1, 13-19, (Diciembre, 2010).
- "Análisis del Polimorfismo de 21 Genotipos de Musa spp., Mediante el Uso de Marcadores Microsatélites" Christian Abraham Romero Bonifaz, Pablo Antonio Chong Aguirre Revista Tecnológica ESPOL – RTE, Vol. 22, N. 1, 1-6, (septiembre, 2009).
- "Diversidad Genética de Poblaciones de *Mycosphaerella fijiensis* Provenientes de Haciendas Bananeras con Manejo Orgánico y Convencional" Chong Pablo. Revista tecnológica de la ESPOL, Vol. 20, N. 1, 215 222, (octubre, 2007), ISSN: 0257-1749.
- Identificación de los genes Mat 1-1 y Mat 1-2 del hongo *Mycosphaerella fijiensis*, agente causal de la Sigatoka negra, para su cruce en laboratorio. Tesis de grado para la obtención del título de Biólogo al Sr. Julio A. Bonilla Jaime, Director de tesis: Pablo Chong Aguirre, Esther Lilia Peralta. Facultad de Ingeniería Marítimo y Ciencias del Mar, Escuela Superior Politécnica del Litoral. (22/05/2009)
- "Análisis Genético de la Resistencia A Triazoles En Aislados de *Mycosphaerella fijiensis* Para Poblaciones De Ecuador". Tesis de grado para la obtención del título de Bióloga a la Srta. Tatiana Paola Chávez Navarrete, Director de tesis: Pablo Chong Aguirre. Facultad de Ingeniería Marítimo y Ciencias del Mar, Escuela Superior Politécnica del Litoral. (22/06/2012).

*Equal contribution
			Education certificate
	I	Education Statement of the Graduate School	The Graduate School
		Experimental Plant Sciences	SCIENCES
lssued to: Date: Group: University:		Pablo Antonio Chong Aguirre 31 October 2016 Laboratory of Phytopathology & BU Biointeractions and Plant Health Wageningen University & Research	
1) \$	Start-up p	hase	date
•	First prese	entation of your project	
	Mycosphae	erella fijiensis population and fungicide resistance analyses	Oct 26, 2009
►	Writing or	rewriting a project proposal	
	Fungicide I	Resistance in Mycosphaerella fijiensis	Jun 30, 2010
►	Writing a	review or book chapter	
►	MSc cours	xes s	
	Laborator	y use of isotopes	
		Subtotal Start-up Phase	4.5 credits*
2) 5	Scientific	Exposure	date
•	FPS PhD	student davs	
-	EPS PhD S	Student day. Amsterdam University	Nov 31, 2012
	EPS PhD S	Student day, Leiden University	Nov 29, 2013
	EPS them	e symposia	
	EPS Them	e 2 symposium 'Interactions between Plants and Biotic Agents' and 'Willie Commelin	Fab 25, 2014
	Scholten D	ay', Amsterdam University	Feb 25, 2014
	EPS Them	e 4 symposium 'Genome Biology', Amsterdam University	Dec 14, 2015
►	NWO Lunt	eren days and other National Platforms	
►	Seminars	(series), workshops and symposia	
	ESPOL Cie	encia 2010	Jan 21, 2010
	29th Meetin	ng of the Fusarium working group of the Koninklijke Nederlandse Planteziektenkundige	Oct 29, 2014
	vereniging		
•	Seminar p	ius	
►	Internatio	nal symposia and congresses	Nev 08 12 2010
			Nov 08-12, 2010
	17th Reinh	ONGRESU INTERNACIONAL DE BIOTECNOLOGIA Y BIODIVERSIDAD (ECUADO)	Way 20-31, 2012
1	(Germany)	and share symposian on wodon i angiolado and Anniangar compoundo, i neuhoniola	May 21-25, 2013
1	FRAC mee	ting 2014 (Germany)	Feb 04-05, 2014
	Presentati	ons	
1	ESPOL Cie	encia 2010 (Talk))	Jan 21, /2010
1	ACORBAT	2010 (Talk)	Nov 08, 2010
1	PRIMER C	ONGRESO INTERNACIONAL DE BIOTECNOLOGÍA Y BIODIVERSIDAD (Talk)	May 29, 2012
1	17th Reinh	ardsbrunn Symposium on Modern Fungicides and Antifungal Compounds (Talk)	May 21-25, 2013
1	FRAC mee	ting 2014 (Talk)	Feb 04-05, 2014
►	IAB interv	ew	
1	Meeting wi	th a member of the International Advisory Board of EPS	Nov 14, 2012
►	Excursion	S	10.0
		Subtotal Scientific Exposure	12.0 credits^
3) I	n-Depth S	Studies	<u>date</u>
	EPS cours	es or other PhD courses	
1	Course Bas	sic statistics	May 26,27, Jun 04,05,06, 2014
1	-		

	Course Basic statistics	May 26,27, Jun 04,05,06, 2014
	Course Bioinformatic	Aug 27-31, 2012
	Course Transcription Factor and Transcriptional Regulation	Dec 17-19, 2013
	Course Mixed model based genetic analysis in GenStat: from QTL mapping and association mapping to genomic prediction	Sep 02- 04, 2013
►	Journal club	
	Member of a literature discussion group at ESPOL	2010-2012
	Member of a literature discussion group at PRI-WUR	2012-2014
►	Individual research training	
	Purdue USDA training	Apr-May 2011
	Subtotal In-Depth Studies	10.9 credits*
_		
4	Personal development	date

►	Skill training courses		
	Course Techniques for Writing and Presenting a Scientific Paper		Dec 10-13, 2013
	Course Project Management		Mar 19, Apr 02, 29, 2014
	Course Scientific Writing		Apr 08- Jun 18, 2015
►	Organisation of PhD students day, course or conference		
	Membership of Board, Committee or PhD council		
		Subtotal Personal Development	3.9 credits*

TOTAL NUMBER OF CREDIT POINTS* 31.3

Herewith the Graduate School declares that the PhD candidate has complied with the educational requirements set by the Educational Committee of EPS which comprises of a minimum total of 30 ECTS

* A credit represents a normative study load of 28 hours of study.

This research was conducted at the laboratory of Plant Research International of Wageningen University and was financially supported by the Ecuadorian government through the "Secretaría de Educación Superior, Ciencia Tecnología e Innovación" (SENESCYT), the Ecuadorian University "Escuela Superior Politécnica del Litoral" (ESPOL) and Syngenta AG, Stain, Switzerland.

Cover and layout design: Angela Cárdenas Gómez

Printed by: Wohrmann Print Service, Zutphen, NL